US5223409A
(en)
*
|
1988-09-02 |
1993-06-29 |
Protein Engineering Corp. |
Directed evolution of novel binding proteins
|
US5534617A
(en)
*
|
1988-10-28 |
1996-07-09 |
Genentech, Inc. |
Human growth hormone variants having greater affinity for human growth hormone receptor at site 1
|
US5688666A
(en)
*
|
1988-10-28 |
1997-11-18 |
Genentech, Inc. |
Growth hormone variants with altered binding properties
|
EP0368684B2
(de)
*
|
1988-11-11 |
2004-09-29 |
Medical Research Council |
Klonierung von Immunglobulin sequenzen aus den variabelen Domänen.
|
US7413537B2
(en)
|
1989-09-01 |
2008-08-19 |
Dyax Corp. |
Directed evolution of disulfide-bonded micro-proteins
|
US5427908A
(en)
*
|
1990-05-01 |
1995-06-27 |
Affymax Technologies N.V. |
Recombinant library screening methods
|
US5723286A
(en)
|
1990-06-20 |
1998-03-03 |
Affymax Technologies N.V. |
Peptide library and screening systems
|
GB9015198D0
(en)
*
|
1990-07-10 |
1990-08-29 |
Brien Caroline J O |
Binding substance
|
US6916605B1
(en)
*
|
1990-07-10 |
2005-07-12 |
Medical Research Council |
Methods for producing members of specific binding pairs
|
US7063943B1
(en)
|
1990-07-10 |
2006-06-20 |
Cambridge Antibody Technology |
Methods for producing members of specific binding pairs
|
GB9206318D0
(en)
*
|
1992-03-24 |
1992-05-06 |
Cambridge Antibody Tech |
Binding substances
|
DK0585287T3
(da)
*
|
1990-07-10 |
2000-04-17 |
Cambridge Antibody Tech |
Fremgangsmåde til fremstilling af specifikke bindingsparelementer
|
US7084260B1
(en)
|
1996-10-10 |
2006-08-01 |
Genpharm International, Inc. |
High affinity human antibodies and human antibodies against human antigens
|
US7041871B1
(en)
|
1995-10-10 |
2006-05-09 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
US5770429A
(en)
*
|
1990-08-29 |
1998-06-23 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
US6893845B1
(en)
|
1990-09-28 |
2005-05-17 |
Applied Molecular Evolution, Inc. |
Surface expression libraries of heteromeric receptors
|
WO1992006191A1
(en)
*
|
1990-09-28 |
1992-04-16 |
Protein Engineering Corporation |
Proteinaceous anti-dental plaque agents
|
DK0564531T3
(da)
*
|
1990-12-03 |
1998-09-28 |
Genentech Inc |
Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber
|
ES2287206T3
(es)
|
1991-03-01 |
2007-12-16 |
Dyax Corporation |
Proceso para el desarrollo de mini-proteinas de union.
|
IE921169A1
(en)
|
1991-04-10 |
1992-10-21 |
Scripps Research Inst |
Heterodimeric receptor libraries using phagemids
|
US5871907A
(en)
|
1991-05-15 |
1999-02-16 |
Medical Research Council |
Methods for producing members of specific binding pairs
|
US6225447B1
(en)
|
1991-05-15 |
2001-05-01 |
Cambridge Antibody Technology Ltd. |
Methods for producing members of specific binding pairs
|
US6492160B1
(en)
|
1991-05-15 |
2002-12-10 |
Cambridge Antibody Technology Limited |
Methods for producing members of specific binding pairs
|
US6800738B1
(en)
|
1991-06-14 |
2004-10-05 |
Genentech, Inc. |
Method for making humanized antibodies
|
LU91067I2
(fr)
|
1991-06-14 |
2004-04-02 |
Genentech Inc |
Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
|
WO1994004679A1
(en)
*
|
1991-06-14 |
1994-03-03 |
Genentech, Inc. |
Method for making humanized antibodies
|
DE4122599C2
(de)
|
1991-07-08 |
1993-11-11 |
Deutsches Krebsforsch |
Phagemid zum Screenen von Antikörpern
|
WO1993006213A1
(en)
*
|
1991-09-23 |
1993-04-01 |
Medical Research Council |
Production of chimeric antibodies - a combinatorial approach
|
ES2136092T3
(es)
*
|
1991-09-23 |
1999-11-16 |
Medical Res Council |
Procedimientos para la produccion de anticuerpos humanizados.
|
US5733731A
(en)
*
|
1991-10-16 |
1998-03-31 |
Affymax Technologies N.V. |
Peptide library and screening method
|
US5270170A
(en)
*
|
1991-10-16 |
1993-12-14 |
Affymax Technologies N.V. |
Peptide library and screening method
|
US5872215A
(en)
*
|
1991-12-02 |
1999-02-16 |
Medical Research Council |
Specific binding members, materials and methods
|
EP2224006A1
(de)
*
|
1991-12-02 |
2010-09-01 |
MedImmune Limited |
Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken
|
DK1696031T3
(da)
|
1991-12-02 |
2010-08-02 |
Medimmune Ltd |
Fremstilling af anti-autoantigener fra antistofsegmentrepertoirer og præsentere på fag
|
PT1024191E
(pt)
*
|
1991-12-02 |
2008-12-22 |
Medical Res Council |
Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
|
WO1993019172A1
(en)
*
|
1992-03-24 |
1993-09-30 |
Cambridge Antibody Technology Limited |
Methods for producing members of specific binding pairs
|
US6765087B1
(en)
|
1992-08-21 |
2004-07-20 |
Vrije Universiteit Brussel |
Immunoglobulins devoid of light chains
|
ATE427968T1
(de)
|
1992-08-21 |
2009-04-15 |
Univ Bruxelles |
Immunoglobuline ohne leichtkette
|
AU685753B2
(en)
*
|
1992-09-04 |
1998-01-29 |
Scripps Research Institute, The |
Phagemids coexpressing a surface receptor and a surface heterologous protein
|
WO1994007921A1
(en)
*
|
1992-09-25 |
1994-04-14 |
Commonwealth Scientific And Industrial Research Organisation |
Target binding polypeptide
|
US6936464B1
(en)
|
1992-10-02 |
2005-08-30 |
Cancer Research Technology Limited |
Immune responses to fusion proteins
|
GB9220808D0
(en)
*
|
1992-10-02 |
1992-11-18 |
Medical Res Council |
Antibody genes
|
GB9225453D0
(en)
|
1992-12-04 |
1993-01-27 |
Medical Res Council |
Binding proteins
|
US5837242A
(en)
*
|
1992-12-04 |
1998-11-17 |
Medical Research Council |
Multivalent and multispecific binding proteins, their manufacture and use
|
US6955900B1
(en)
|
1993-02-02 |
2005-10-18 |
The Scripps Research Institute |
Methods for producing polypeptide binding sites, monoclonal antibodies and compositions thereof
|
CA2115811A1
(en)
*
|
1993-02-17 |
1994-08-18 |
Claus Krebber |
A method for in vivo selection of ligand-binding proteins
|
EP0614989A1
(de)
*
|
1993-02-17 |
1994-09-14 |
MorphoSys AG |
Verfahren für in vivo Selektion von Ligandenbindende Proteine
|
US6027884A
(en)
*
|
1993-06-17 |
2000-02-22 |
The Research Foundation Of The State University Of New York |
Thermodynamics, design, and use of nucleic acid sequences
|
JPH09503759A
(ja)
|
1993-09-22 |
1997-04-15 |
メディカル リサーチ カウンシル |
抗体のリターゲッティング
|
DK145493D0
(da)
*
|
1993-12-23 |
1993-12-23 |
Dako As |
Antistof
|
ES2247204T3
(es)
|
1994-01-31 |
2006-03-01 |
Trustees Of Boston University |
Bancos de anticuerpos policlonales.
|
US20060078561A1
(en)
*
|
1994-01-31 |
2006-04-13 |
The Trustees Of Boston University |
Polyclonal antibody libraries
|
US5516637A
(en)
*
|
1994-06-10 |
1996-05-14 |
Dade International Inc. |
Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
|
US6576236B1
(en)
|
1994-07-01 |
2003-06-10 |
Dana Farber Cancer Institute |
Methods for stimulating T cell responses by manipulating a common cytokine receptor γ chain
|
US6010861A
(en)
*
|
1994-08-03 |
2000-01-04 |
Dgi Biotechnologies, Llc |
Target specific screens and their use for discovering small organic molecular pharmacophores
|
US7597886B2
(en)
*
|
1994-11-07 |
2009-10-06 |
Human Genome Sciences, Inc. |
Tumor necrosis factor-gamma
|
US7820798B2
(en)
*
|
1994-11-07 |
2010-10-26 |
Human Genome Sciences, Inc. |
Tumor necrosis factor-gamma
|
AUPO591797A0
(en)
|
1997-03-27 |
1997-04-24 |
Commonwealth Scientific And Industrial Research Organisation |
High avidity polyvalent and polyspecific reagents
|
US7060808B1
(en)
*
|
1995-06-07 |
2006-06-13 |
Imclone Systems Incorporated |
Humanized anti-EGF receptor monoclonal antibody
|
ES2176484T3
(es)
*
|
1995-08-18 |
2002-12-01 |
Morphosys Ag |
Bancos de proteinas/(poli)peptidos.
|
US6706484B1
(en)
|
1995-08-18 |
2004-03-16 |
Morphosys Ag |
Protein/(poly)peptide libraries
|
GB9518731D0
(en)
|
1995-09-13 |
1995-11-15 |
Innes John Centre |
Flowering genes
|
PT1568772E
(pt)
*
|
1995-09-21 |
2010-04-14 |
Genentech Inc |
Variantes da hormona do crescimento humana
|
US7368111B2
(en)
|
1995-10-06 |
2008-05-06 |
Cambridge Antibody Technology Limited |
Human antibodies specific for TGFβ2
|
US6090382A
(en)
|
1996-02-09 |
2000-07-18 |
Basf Aktiengesellschaft |
Human antibodies that bind human TNFα
|
US6537776B1
(en)
|
1999-06-14 |
2003-03-25 |
Diversa Corporation |
Synthetic ligation reassembly in directed evolution
|
US7888466B2
(en)
|
1996-01-11 |
2011-02-15 |
Human Genome Sciences, Inc. |
Human G-protein chemokine receptor HSATU68
|
SE506771C2
(sv)
*
|
1996-02-06 |
1998-02-09 |
Gotpat 105 Ab |
Fusionsprotein, bakteriofag uttryckande proteinet, dessas användning samt hybridoma celler och monoklonaler producerade av cellerna
|
AU2527397A
(en)
*
|
1996-03-13 |
1997-10-01 |
Protein Design Labs, Inc. |
Fas ligand fusion proteins and their uses
|
GB9712818D0
(en)
*
|
1996-07-08 |
1997-08-20 |
Cambridge Antibody Tech |
Labelling and selection of specific binding molecules
|
BR9711844A
(pt)
|
1996-10-01 |
2000-01-18 |
Geron Corp |
Preparação de proteìna isolada, substancialmente pura ou recombinante, proteìna de trt isolada, substancialmente pura ou recombinante protéina de trt isolada, substancialmente pura ou recombinante, protéina de trt isolada ou uma sua variante, ou um seu fragmento, polinucleotìdeo, sintético, substancialmente puro ou recombinante, ácido nucléico isolado, codificando uma proteìna de trt, vetor de expressão, célula transfectada, animal não-humano, ou sua progênie, animal não-humano transgênico, anticorpo ou seu fragmento de ligação, anticorpo, especificamente imunorreativo sob condições imunologicamente reativas, para uma proteìna de trt ou seu fragmento imunogênico, processos de determinar se um composto ou tratamento é um modulador de uma atividade ou expressão de trt, de determinar se um composto de teste é um modulador de uma atividade de trt, de preparar telomerase recombinante, de detectar um produto genético de trt em uma amostra, de detectar a presença de pelo menos uma célula humana positiva de telomerase em uma amostra biológica compreendendo células humanas, de diagnosticar uma condição relacionada com a telomerase em um mamìfero, para aumentar a capacidade proliferativa de uma célula de vertebrado in vitro, para detectar a presença de yuma sequência de polinucleotìdeo codificando pelo menos uma parte de uma trt em uma amostra bilógica, para produzir um polinucleotìdeo, para detectar a expressão ou presença de uma trt em uma amostra biológica, usos de ummpolinucleotìdeo, de um agente que aumenta a expressão ou atividade de uma trt, de um inibidor da expressão ou atividade de telomerase de uma proteìna, variante ou fragmento, composição farmacêutica, polipeptìdeo substancialmente purificado, sequência de polinucleotìdeo isolado, complexo de telomerase, composição, telomerase substancialmente pura, polipeptìdeo de trt isolado, ácido nucléico isolado.
|
US7883872B2
(en)
*
|
1996-10-10 |
2011-02-08 |
Dyadic International (Usa), Inc. |
Construction of highly efficient cellulase compositions for enzymatic hydrolysis of cellulose
|
US5811381A
(en)
*
|
1996-10-10 |
1998-09-22 |
Mark A. Emalfarb |
Cellulase compositions and methods of use
|
GB9701425D0
(en)
|
1997-01-24 |
1997-03-12 |
Bioinvent Int Ab |
A method for in vitro molecular evolution of protein function
|
US6497874B1
(en)
*
|
1997-02-05 |
2002-12-24 |
Maardh Sven |
Recombinant phages
|
ES2285768T5
(es)
|
1997-04-16 |
2011-12-22 |
Millennium Pharmaceuticals, Inc. |
Proteínas crsp (proteínas segregadas ricas en cisteína), moléculas de ácido nucleico que codifican para las mismas y uso.
|
US6342369B1
(en)
|
1997-05-15 |
2002-01-29 |
Genentech, Inc. |
Apo-2-receptor
|
US20040241759A1
(en)
*
|
1997-06-16 |
2004-12-02 |
Eileen Tozer |
High throughput screening of libraries
|
CA2297070A1
(en)
*
|
1997-08-01 |
1999-02-11 |
Morphosys Ag |
Novel method and phage for the identification of nucleic acid sequences encoding members of a multimeric (poly)peptide complex
|
GB9717192D0
(en)
|
1997-08-13 |
1997-10-22 |
Innes John Centre Innov Ltd |
Genetic control of plant growth and development
|
US6342220B1
(en)
|
1997-08-25 |
2002-01-29 |
Genentech, Inc. |
Agonist antibodies
|
GB9718455D0
(en)
|
1997-09-02 |
1997-11-05 |
Mcgregor Duncan P |
Chimeric binding peptide library screening method
|
US6562599B1
(en)
|
1997-09-02 |
2003-05-13 |
Sumitomo Pharmaceuticals Company, Limited |
Single-stranded antibody against hepatitis B virus core protein, gene thereof, and therapeutic agent for hepatitis B containing these
|
WO1999015897A1
(en)
*
|
1997-09-19 |
1999-04-01 |
Chiron Corporation |
Subtractive protein screening for gene identification
|
GB9722131D0
(en)
|
1997-10-20 |
1997-12-17 |
Medical Res Council |
Method
|
EP1025220B1
(de)
|
1997-10-21 |
2007-01-03 |
The University Court Of The University Of Glasgow |
Jmy, mit-aktivator für p300/cbp, dafür kodierendenucleinsäure und deren verwendungen
|
US6355244B1
(en)
|
1997-11-17 |
2002-03-12 |
University Of Kentucky Research Foundation |
Methods and compositions for the treatment of psoriasis
|
US7964192B1
(en)
|
1997-12-02 |
2011-06-21 |
Janssen Alzheimer Immunotherapy |
Prevention and treatment of amyloidgenic disease
|
TWI239847B
(en)
|
1997-12-02 |
2005-09-21 |
Elan Pharm Inc |
N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
|
US7179892B2
(en)
|
2000-12-06 |
2007-02-20 |
Neuralab Limited |
Humanized antibodies that recognize beta amyloid peptide
|
US20080050367A1
(en)
|
1998-04-07 |
2008-02-28 |
Guriq Basi |
Humanized antibodies that recognize beta amyloid peptide
|
US6759243B2
(en)
|
1998-01-20 |
2004-07-06 |
Board Of Trustees Of The University Of Illinois |
High affinity TCR proteins and methods
|
EP1965213A3
(de)
|
1998-02-04 |
2009-07-15 |
Invitrogen Corporation |
Microarrays und ihre Verwendungen
|
EP1093457B8
(de)
|
1998-03-19 |
2011-02-02 |
Human Genome Sciences, Inc. |
Der gemeinsamen gamma-kette ähnlicher zytokinrezeptor
|
US20030224001A1
(en)
*
|
1998-03-19 |
2003-12-04 |
Goldstein Neil I. |
Antibody and antibody fragments for inhibiting the growth of tumors
|
EP0947582A1
(de)
*
|
1998-03-31 |
1999-10-06 |
Innogenetics N.V. |
Eine Polypeptidstruktur zur Verwendung als Gerüst
|
US7163682B2
(en)
|
1998-04-13 |
2007-01-16 |
The Forsyth Institute |
Glucan binding protein and glucosyltransferase immunogens
|
US7056517B2
(en)
|
1998-04-13 |
2006-06-06 |
The Forsyth Institute |
Glucosyltransferase immunogens
|
GB2379933B
(en)
*
|
1998-05-13 |
2003-07-09 |
Domantis Ltd |
Selection system for phagemids using proteolytically sensitive helper phage
|
EP1078051B1
(de)
*
|
1998-05-13 |
2007-12-12 |
Domantis Limited |
Phagen-display-selektionssystem für korrekt gefaltete proteine
|
ZA200007412B
(en)
*
|
1998-05-15 |
2002-03-12 |
Imclone Systems Inc |
Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
|
GB9810756D0
(en)
|
1998-05-19 |
1998-07-15 |
Angeletti P Ist Richerche Bio |
Mimotopes of hypervariable region 1 of the e2 glycoprotein of hcv and uses thereof
|
ES2331901T3
(es)
|
1998-06-12 |
2010-01-19 |
Genentech, Inc. |
Anticuerpos monoclonales, anticuerpos que reaccionan de forma cruzada y procedimiento para la produccion de los mismos.
|
US7153655B2
(en)
*
|
1998-06-16 |
2006-12-26 |
Alligator Bioscience Ab |
Method for in vitro molecular evolution of protein function involving the use of exonuclease enzyme and two populations of parent polynucleotide sequence
|
US6846655B1
(en)
|
1998-06-29 |
2005-01-25 |
Phylos, Inc. |
Methods for generating highly diverse libraries
|
US6335428B1
(en)
*
|
1998-07-23 |
2002-01-01 |
The United States Of America As Represented By The Department Of Health And Human Services |
Agents that bind to and inhibit human cytochrome P450 1A2
|
US6323325B1
(en)
|
1998-07-23 |
2001-11-27 |
The United States Of America As Represented By The Department Of Health And Human Services |
Agents that bind to and inhibit human cytochrome P450 2A6
|
CA2334170A1
(en)
|
1998-07-27 |
2000-02-10 |
Genentech, Inc. |
Improved transformation efficiency in phage display through modification of a coat protein
|
ES2237159T3
(es)
*
|
1998-10-06 |
2005-07-16 |
Mark Aaron Emalfarb |
Sistema de transformacion en el campo de los hongos micoticos filamentosos en chrysosporium.
|
US6420110B1
(en)
|
1998-10-19 |
2002-07-16 |
Gpc Biotech, Inc. |
Methods and reagents for isolating biologically active peptides
|
US6667176B1
(en)
|
2000-01-11 |
2003-12-23 |
Geron Corporation |
cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells
|
US7112661B1
(en)
*
|
1998-10-30 |
2006-09-26 |
The Research Foundation Of State University Of New York |
Variable heavy chain and variable light chain regions of antibodies to human platelet glycoprotein Ib alpha
|
PT1133558E
(pt)
|
1998-11-27 |
2007-01-31 |
Ucb Sa |
Composições e métodos para aumentar a mineralização óssea
|
EP2357192A1
(de)
|
1999-02-26 |
2011-08-17 |
Human Genome Sciences, Inc. |
Menschliches alpha-Endokin und Verfahren zu seiner Verwendung
|
WO2000050443A2
(en)
|
1999-02-26 |
2000-08-31 |
Millennium Pharmaceutcals, Inc. |
Secreted proteins and uses thereof
|
US6914128B1
(en)
|
1999-03-25 |
2005-07-05 |
Abbott Gmbh & Co. Kg |
Human antibodies that bind human IL-12 and methods for producing
|
AR043274A1
(es)
|
1999-03-25 |
2005-07-27 |
Abbott Gmbh & Co Kg |
Anticuerpos humanos que enlazan a il-12 humana y metodos para producirlos
|
US7883704B2
(en)
|
1999-03-25 |
2011-02-08 |
Abbott Gmbh & Co. Kg |
Methods for inhibiting the activity of the P40 subunit of human IL-12
|
DE19915057A1
(de)
|
1999-04-01 |
2000-10-19 |
Forschungszentrum Borstel |
Monoklonale Antikörper gegen das humane Mcm3 Protein, Verfahren zu ihrer Herstellung und ihre Verwendung
|
GB9908195D0
(en)
|
1999-04-09 |
1999-06-02 |
Microbiological Res Authority |
Treatment of intracellular infection
|
EP1169473B1
(de)
|
1999-04-14 |
2006-11-22 |
THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES |
Hochsensitiver nachweis von biomolekülen mittels "phage display"
|
US6492497B1
(en)
|
1999-04-30 |
2002-12-10 |
Cambridge Antibody Technology Limited |
Specific binding members for TGFbeta1
|
AU782994C
(en)
*
|
1999-05-14 |
2006-08-24 |
Imclone Llc |
Treatment of refractory human tumors with epidermal growth factor receptor antagonists
|
AU777005B2
(en)
|
1999-05-15 |
2004-09-30 |
University Of California, San Diego |
Protein A based binding domains with desirable activities
|
US7163686B1
(en)
|
1999-05-15 |
2007-01-16 |
The Regents Of The University Of California |
Protein A based binding domains with desirable activities
|
EP2067788B1
(de)
*
|
1999-05-18 |
2015-07-22 |
Dyax Corp. |
FAB-Fragmentbibliotheken und Verwendungsverfahren dafür
|
US20020102613A1
(en)
*
|
1999-05-18 |
2002-08-01 |
Hoogenboom Hendricus Renerus Jacobus Mattheus |
Novel Fab fragment libraries and methods for their use
|
UA81216C2
(en)
|
1999-06-01 |
2007-12-25 |
|
Prevention and treatment of amyloid disease
|
US6262265B1
(en)
|
1999-06-18 |
2001-07-17 |
Microgenics Corporation |
Non-hydrolyzable analogs of heroin metabolites suitable for use in immunoassay
|
US20040001826A1
(en)
*
|
1999-06-30 |
2004-01-01 |
Millennium Pharmaceuticals, Inc. |
Glycoprotein VI and uses thereof
|
US7291714B1
(en)
|
1999-06-30 |
2007-11-06 |
Millennium Pharmaceuticals, Inc. |
Glycoprotein VI and uses thereof
|
CA2347973C
(en)
|
1999-07-20 |
2010-06-22 |
Morphosys Ag |
Novel methods for displaying (poly)peptides/proteins on bacteriophage particles via disulfide bonds
|
WO2001014557A1
(en)
|
1999-08-23 |
2001-03-01 |
Dana-Farber Cancer Institute, Inc. |
Pd-1, a receptor for b7-4, and uses therefor
|
CA2382587A1
(en)
|
1999-08-23 |
2001-03-01 |
Chugai Seiyaku Kabushiki Kaisha |
Hm1.24 antigen expression potentiators
|
US7297478B1
(en)
|
2000-09-22 |
2007-11-20 |
Large Scale Biology Corporation |
Creation of variable length and sequence linker regions for dual-domain or multi-domain molecules
|
DK1224222T3
(da)
|
1999-10-12 |
2010-05-17 |
Chemocentryx Inc |
Chemokinreceptor
|
US20060073509A1
(en)
*
|
1999-11-18 |
2006-04-06 |
Michael Kilpatrick |
Method for detecting and quantitating multiple subcellular components
|
EP1235906B8
(de)
*
|
1999-11-26 |
2008-01-23 |
BASF Plant Science GmbH |
Verfahren zur mutagenese von nukleotidsequenzen aus pflanzen, algen, oder pilzen
|
WO2001039722A2
(en)
|
1999-11-30 |
2001-06-07 |
Mayo Foundation For Medical Education And Research |
B7-h1, a novel immunoregulatory molecule
|
ES2283340T3
(es)
|
1999-12-30 |
2007-11-01 |
President And Fellows Of Harvard College |
Metodos referentes a la modulacion de la actividad del subconjunto de celulas th2 mediante modulacion de la actividad de xbp-1.
|
CN1461310B
(zh)
|
2000-02-10 |
2013-06-12 |
雅培制药有限公司 |
结合人白介素-18的抗体及制备和使用方法
|
EP1259601A2
(de)
*
|
2000-02-22 |
2002-11-27 |
Ahuva Nissim |
Chimäre und tcr phagen-display-bibliotheken, chimäre und tcr reagentien und anwendungsmethoden
|
AU2001234125A1
(en)
*
|
2000-02-22 |
2001-09-03 |
Medical And Biological Laboratories Co., Ltd. |
Antibody library
|
GB2360282A
(en)
*
|
2000-03-17 |
2001-09-19 |
Bioinvent Int Ab |
Making and using micro-arrays of biological materials
|
EP1274720A4
(de)
|
2000-04-12 |
2004-08-18 |
Human Genome Sciences Inc |
Albumin enthaltende fusionsproteine
|
US20010041349A1
(en)
*
|
2000-04-17 |
2001-11-15 |
Andrew Patron |
Protein expression system arrays and use in biological screening
|
ES2393535T3
(es)
*
|
2000-04-17 |
2012-12-26 |
Dyax Corp. |
Nuevos métodos para construir bibliotecas de paquetes genéticos que presentan de forma colectiva los miembros de una familia diversa de péptidos, polipéptidos o proteínas
|
US8288322B2
(en)
|
2000-04-17 |
2012-10-16 |
Dyax Corp. |
Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries
|
WO2001081375A2
(en)
*
|
2000-04-24 |
2001-11-01 |
Yale University |
Dna & protein binding miniature proteins
|
US7495070B2
(en)
*
|
2000-04-24 |
2009-02-24 |
Yale University |
Protein binding miniature proteins
|
US6458589B1
(en)
|
2000-04-27 |
2002-10-01 |
Geron Corporation |
Hepatocyte lineage cells derived from pluripotent stem cells
|
US7030219B2
(en)
|
2000-04-28 |
2006-04-18 |
Johns Hopkins University |
B7-DC, Dendritic cell co-stimulatory molecules
|
WO2001084149A2
(en)
|
2000-04-29 |
2001-11-08 |
University Of Iowa Research Foundation |
Diagnostics and therapeutics for macular degeneration-related disorders
|
EP1714661A3
(de)
|
2000-05-19 |
2012-03-14 |
The Center for Blood Research, INC. |
Verfahren zur Diagnose und Behandlung von hämostatischen Störungen durch Modulation der P-Selectin Aktivität
|
US20030031675A1
(en)
|
2000-06-06 |
2003-02-13 |
Mikesell Glen E. |
B7-related nucleic acids and polypeptides useful for immunomodulation
|
JP2004502412A
(ja)
|
2000-06-08 |
2004-01-29 |
ザ センター フォー ブラッド リサーチ インコーポレーティッド |
免疫グロブリンを介した再灌流障害を抑制するための方法および組成物
|
EP2431054A3
(de)
|
2000-06-15 |
2013-03-06 |
Human Genome Sciences, Inc. |
Menschlicher Tumornekrosefaktor Delta und Ypsilon
|
AU6842701A
(en)
|
2000-06-16 |
2002-01-14 |
Human Genome Sciences Inc |
Antibodies that immunospecifically bind to blys
|
US20020115068A1
(en)
*
|
2000-06-23 |
2002-08-22 |
Ian Tomlinson |
Matrix screening method
|
US20020055110A1
(en)
*
|
2000-06-23 |
2002-05-09 |
Ian Tomlinson |
Matrix screening method
|
CA2414331C
(en)
|
2000-06-28 |
2011-11-29 |
Genetics Institute, Llc. |
Pd-l2 molecules: novel pd-1 ligands and uses therefor
|
UY26807A1
(es)
|
2000-06-29 |
2002-01-31 |
Abbott Lab |
Anticuerpos de especificidad doble y métodos para la elaboración y el uso de los mismos
|
WO2002028893A2
(en)
|
2000-07-14 |
2002-04-11 |
Cropdesign N.V. |
Plant cyclin-dependent kinase inhibitors
|
US20020019004A1
(en)
*
|
2000-08-03 |
2002-02-14 |
Albert Orfao |
Method for isolating molecules, cells and other particles which are specifically bound to a large particle
|
AU9500201A
(en)
*
|
2000-08-09 |
2002-02-18 |
Imclone Systems Inc |
Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists
|
AU2001287000A1
(en)
|
2000-09-01 |
2002-03-13 |
The Center For Blood Research, Inc. |
Modified polypeptides stabilized in a desired conformation and methods for producing same
|
GB0022748D0
(en)
|
2000-09-15 |
2000-11-01 |
Allied Therapeutics Ltd |
Reducing the content of cells in a biological sample
|
GB0022978D0
(en)
|
2000-09-19 |
2000-11-01 |
Oxford Glycosciences Uk Ltd |
Detection of peptides
|
US6673580B2
(en)
*
|
2000-10-27 |
2004-01-06 |
Genentech, Inc. |
Identification and modification of immunodominant epitopes in polypeptides
|
JP2004515233A
(ja)
|
2000-11-01 |
2004-05-27 |
イルーシス セラポーティクス,インコーポレーテッド |
タンパク質トランススプライシングによる二重特異性分子の作製方法
|
US7666995B2
(en)
|
2000-11-03 |
2010-02-23 |
Pestka Biomedical Laboratories |
Interferons, uses and compositions related thereto
|
EP2316976A1
(de)
|
2000-11-28 |
2011-05-04 |
Wyeth LLC |
Expressionsanalyse von FKBP Nukleinsäuren und Polypeptiden, die zur Diagnose und Behandlung von Prostatakrebs geeignet sind
|
EP2338512A1
(de)
|
2000-11-28 |
2011-06-29 |
MedImmune, LLC |
Verfahren zur Verabreichung/Dosierung von Anti-RSV-Antikörpern zur Prophylaxe und Behandlung
|
US7037652B2
(en)
|
2000-11-28 |
2006-05-02 |
Wyeth |
Expression analysis of KIAA nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
|
US7396917B2
(en)
*
|
2000-12-05 |
2008-07-08 |
Alexion Pharmaceuticals, Inc. |
Rationally designed antibodies
|
DE60136656D1
(de)
|
2000-12-05 |
2009-01-02 |
Alexion Pharma Inc |
Rationell entworfene Antikörper
|
US20040253242A1
(en)
*
|
2000-12-05 |
2004-12-16 |
Bowdish Katherine S. |
Rationally designed antibodies
|
TWI255272B
(en)
|
2000-12-06 |
2006-05-21 |
Guriq Basi |
Humanized antibodies that recognize beta amyloid peptide
|
AU2002220275A1
(en)
*
|
2000-12-08 |
2002-06-18 |
The Board Of Trustees Of The University Of Illinois |
Mutated class ii major histocompatibility proteins
|
PT1355919E
(pt)
|
2000-12-12 |
2011-03-02 |
Medimmune Llc |
Moléculas com semivida longa, composições que as contêm e suas utilizações
|
US6958213B2
(en)
|
2000-12-12 |
2005-10-25 |
Alligator Bioscience Ab |
Method for in vitro molecular evolution of protein function
|
AU2002249854B2
(en)
|
2000-12-18 |
2007-09-20 |
Dyax Corp. |
Focused libraries of genetic packages
|
JP4986370B2
(ja)
|
2000-12-22 |
2012-07-25 |
マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ |
Rgmおよびそのモジュレーターの用途
|
US20020086292A1
(en)
|
2000-12-22 |
2002-07-04 |
Shigeaki Harayama |
Synthesis of hybrid polynucleotide molecules using single-stranded polynucleotide molecules
|
US7132510B2
(en)
|
2000-12-29 |
2006-11-07 |
Bio-Technology General (Israel) Ltd. |
Specific human antibodies for selective cancer therapy
|
ATE464322T1
(de)
|
2001-01-05 |
2010-04-15 |
Pfizer |
Antikörper gegen den rezeptor für den insulinähnlichen wachstumsfaktor i
|
EP2067486A1
(de)
|
2001-01-31 |
2009-06-10 |
Biogen Idec Inc. |
Verwendung von CD23 Antagonisten zur Behandlung von neoplastischen Erkrankungen
|
WO2002062850A2
(en)
*
|
2001-02-02 |
2002-08-15 |
Millennium Pharmaceuticals, Inc. |
Hybrid antibodies and uses thereof
|
PT1733736E
(pt)
*
|
2001-02-07 |
2015-06-11 |
Wilex Ag |
Método de produção de anticorpos recombinantes contra tumores
|
US7931897B2
(en)
|
2001-02-07 |
2011-04-26 |
Chugai Seiyaku Kabushiki Kaisha |
Therapeutic agent for hematopoietic tumors
|
JP2005503116A
(ja)
|
2001-02-09 |
2005-02-03 |
ヒューマン ジノーム サイエンシーズ, インコーポレイテッド |
ヒトgタンパク質ケモカインレセプター(ccr5)hdgnr10
|
CA2438680A1
(en)
|
2001-02-23 |
2002-09-06 |
Dsm Ip Assets B.V. |
Genes encoding proteolytic enzymes from aspargilli
|
AU2002250236A1
(en)
*
|
2001-03-02 |
2002-09-19 |
Medimmune, Inc. |
Cd2 antagonists for treatment of autoimmune or inflammatory disease
|
ES2360205T3
(es)
|
2001-03-02 |
2011-06-01 |
Agennix Ag |
Sistema de ensayo de tres híbridos.
|
US20080008704A1
(en)
*
|
2001-03-16 |
2008-01-10 |
Mark Rubin |
Methods of treating colorectal cancer with anti-epidermal growth factor antibodies
|
US8231878B2
(en)
*
|
2001-03-20 |
2012-07-31 |
Cosmo Research & Development S.P.A. |
Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
|
US8981061B2
(en)
|
2001-03-20 |
2015-03-17 |
Novo Nordisk A/S |
Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
|
US20090081199A1
(en)
*
|
2001-03-20 |
2009-03-26 |
Bioxell S.P.A. |
Novel receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
|
CA2342376C
(en)
*
|
2001-03-20 |
2013-11-12 |
Marco Colonna |
A receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
|
CA2440676A1
(en)
|
2001-03-22 |
2002-10-03 |
Abbott Gmbh & Co. Kg |
Transgenic animals expressing antibodies specific for genes of interest and uses thereof
|
BR0208637A
(pt)
|
2001-04-02 |
2004-12-07 |
Wyeth Corp |
Pd-1, um receptor para b7-4, e usos dos mesmos
|
UA80091C2
(en)
|
2001-04-02 |
2007-08-27 |
Chugai Pharmaceutical Co Ltd |
Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
|
CA2442801A1
(en)
*
|
2001-04-02 |
2002-10-10 |
Idec Pharmaceutical Corporation |
Recombinant antibodies coexpressed with gntiii
|
EP1249499A1
(de)
*
|
2001-04-10 |
2002-10-16 |
Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. |
Verfahren und Vorrichtung zur Bestimmung und Selektion von Molekül-Molekül-Wechselwirkungen
|
ATE470676T1
(de)
|
2001-04-13 |
2010-06-15 |
Human Genome Sciences Inc |
Anti-vegf-2 antikörper
|
EP1572868A4
(de)
|
2001-04-16 |
2007-04-04 |
Wyeth Corp |
Neue, polypeptidantigene codierende offene leseraster aus streptococcus pneumoniae und verwendungen davon
|
ES2552281T3
(es)
|
2001-05-11 |
2015-11-26 |
Ludwig Institute For Cancer Research Ltd. |
Proteínas de unión específica y usos de las mismas
|
US20100056762A1
(en)
|
2001-05-11 |
2010-03-04 |
Old Lloyd J |
Specific binding proteins and uses thereof
|
US20110313230A1
(en)
|
2001-05-11 |
2011-12-22 |
Terrance Grant Johns |
Specific binding proteins and uses thereof
|
WO2002094376A2
(en)
*
|
2001-05-22 |
2002-11-28 |
Duke University |
Compositions and methods for promoting or inhibiting ndpk
|
AU2002310046A1
(en)
*
|
2001-05-22 |
2002-12-03 |
Duke University |
Compositions and methods for inhibiting metastasis
|
DE60229846D1
(de)
|
2001-05-22 |
2008-12-24 |
Merck & Co Inc |
Beta-secretase-substrat und seine verwendung
|
CN100594935C
(zh)
|
2001-05-25 |
2010-03-24 |
人体基因组科学有限公司 |
免疫特异性结合trail受体的抗体
|
US6441163B1
(en)
|
2001-05-31 |
2002-08-27 |
Immunogen, Inc. |
Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
|
US6989452B2
(en)
*
|
2001-05-31 |
2006-01-24 |
Medarex, Inc. |
Disulfide prodrugs and linkers and stabilizers useful therefor
|
US20060239533A1
(en)
*
|
2001-06-04 |
2006-10-26 |
Triantafyllos Tafas |
Method for detecting infectious agents using computer controlled automated image analysis
|
CA2868614A1
(en)
|
2001-06-08 |
2002-12-08 |
Abbott Laboratories (Bermuda) Ltd. |
Methods of administering anti-tnf.alpha. antibodies
|
AU2002322388A1
(en)
|
2001-06-22 |
2003-01-08 |
E.I. Du Pont De Nemours And Company |
Defensin polynucleotides and methods of use
|
GB0115841D0
(en)
|
2001-06-28 |
2001-08-22 |
Medical Res Council |
Ligand
|
US6867189B2
(en)
|
2001-07-26 |
2005-03-15 |
Genset S.A. |
Use of adipsin/complement factor D in the treatment of metabolic related disorders
|
US6833441B2
(en)
|
2001-08-01 |
2004-12-21 |
Abmaxis, Inc. |
Compositions and methods for generating chimeric heteromultimers
|
JP2005507870A
(ja)
*
|
2001-08-13 |
2005-03-24 |
ユニバーシティ・オブ・サザン・カリフォルニア |
低毒性のインターロイキン−2突然変異体
|
US20040142325A1
(en)
|
2001-09-14 |
2004-07-22 |
Liat Mintz |
Methods and systems for annotating biomolecular sequences
|
WO2003031611A2
(en)
*
|
2001-10-05 |
2003-04-17 |
Cangene Corporation |
Phagemid display system
|
US6894149B2
(en)
|
2001-10-11 |
2005-05-17 |
Protein Design Labs, Inc. |
Anti-HLA-DA antibodies and the methods of using thereof
|
WO2003035839A2
(en)
*
|
2001-10-24 |
2003-05-01 |
Dgi Biotechnologies, Inc. |
Target specific screening andits use for identifying target binders
|
AU2002337312A1
(en)
|
2001-10-25 |
2003-05-06 |
Medical Research Council |
Molecules
|
US7175983B2
(en)
|
2001-11-02 |
2007-02-13 |
Abmaxis, Inc. |
Adapter-directed display systems
|
AR039067A1
(es)
|
2001-11-09 |
2005-02-09 |
Pfizer Prod Inc |
Anticuerpos para cd40
|
AU2002359568B2
(en)
|
2001-12-03 |
2008-02-21 |
Alexion Pharmaceuticals, Inc. |
Hybrid antibodies
|
US7858297B2
(en)
|
2001-12-18 |
2010-12-28 |
Centre National De La Recherche Scientifique Cnrs |
Chemokine-binding protein and methods of use
|
WO2003051917A2
(en)
|
2001-12-18 |
2003-06-26 |
Endocube Sas |
Novel death associated proteins of the thap family and related par4 pathways involved in apoptosis control
|
AU2002359721A1
(en)
|
2001-12-19 |
2003-07-09 |
Bristol-Myers Squibb Company |
Pichia pastoris formate dehydrogenase and uses therefor
|
GB0130543D0
(en)
|
2001-12-20 |
2002-02-06 |
Univ Cambridge Tech |
Human antibodies and their use
|
CA2841097A1
(en)
|
2001-12-21 |
2003-07-24 |
Human Genome Sciences, Inc. |
Albumin and g-csf fusion proteins
|
US20080194481A1
(en)
|
2001-12-21 |
2008-08-14 |
Human Genome Sciences, Inc. |
Albumin Fusion Proteins
|
EP1456237A2
(de)
*
|
2001-12-21 |
2004-09-15 |
Vlaams Interuniversitair Instituut voor Biotechnologie vzw. |
Methode zur klonierung von sequenzen aus den variablen domänen
|
EP2075256A2
(de)
|
2002-01-14 |
2009-07-01 |
William Herman |
Gezielte Liganden
|
US20060046249A1
(en)
*
|
2002-01-18 |
2006-03-02 |
Fei Huang |
Identification of polynucleotides and polypetide for predicting activity of compounds that interact with protein tyrosine kinase and or protein tyrosine kinase pathways
|
US7094579B2
(en)
|
2002-02-13 |
2006-08-22 |
Xoma Technology Ltd. |
Eukaryotic signal sequences for prokaryotic expression
|
DK1475101T3
(da)
|
2002-02-14 |
2011-01-10 |
Chugai Pharmaceutical Co Ltd |
Antistof-holdige farmaceutiske opløsninger
|
SI2336184T1
(sl)
|
2002-02-25 |
2015-04-30 |
Biogen Idec Ma Inc. |
Dajanje sredstev za zdravljenje vnetij
|
DE60329020D1
(de)
|
2002-03-01 |
2009-10-08 |
Siemens Healthcare Diagnostics |
Assays zur überwachung von krebspatienten auf grundlage der spiegel des analyten für die extrazelluläre domäne (ecd) des epidermalen wachstumsfaktor-rezeptors (egfr), allein oder in kombination mit anderen analyten, in proben von körperflüssigkeiten
|
US20030180819A1
(en)
*
|
2002-03-01 |
2003-09-25 |
Carney Walter P. |
Assays for cancer patient monitoring based on levels of analyte components of the plasminogen activator system in body fluid samples
|
JP2005526506A
(ja)
|
2002-03-04 |
2005-09-08 |
イムクローン システムズ インコーポレイティド |
Kdrに特異的なヒト抗体及びその利用
|
AU2003217976A1
(en)
|
2002-03-07 |
2003-09-22 |
The Forsyth Institute |
Immunogenicity of glucan binding protein
|
US7141653B2
(en)
|
2002-03-29 |
2006-11-28 |
Schering Corporation |
Human monoclonal antibodies to interleukin-5
|
CA2480052A1
(en)
*
|
2002-04-01 |
2003-10-16 |
Human Genome Sciences, Inc. |
Antibodies that specifically bind to gmad
|
GB0207533D0
(en)
|
2002-04-02 |
2002-05-08 |
Oxford Glycosciences Uk Ltd |
Protein
|
US7745192B2
(en)
|
2002-04-03 |
2010-06-29 |
Venomics Pty Limited |
Prothrombin activating protein
|
EP1499352A4
(de)
|
2002-04-12 |
2006-10-11 |
Medimmune Inc |
Rekombinante anti-interleukin-9-antikörper
|
US8030461B2
(en)
|
2002-04-15 |
2011-10-04 |
Chugai Seiyaku Kabushiki Kaisha |
Methods for constructing scDb libraries
|
ATE459880T1
(de)
|
2002-04-17 |
2010-03-15 |
Deutsches Krebsforsch |
Verfahren zum screening einer substanz zur modulierung der wnt -signalkaskade.
|
US20030206898A1
(en)
|
2002-04-26 |
2003-11-06 |
Steven Fischkoff |
Use of anti-TNFalpha antibodies and another drug
|
CA2486147A1
(en)
|
2002-05-17 |
2003-11-27 |
Protein Design Labs, Inc. |
Treatment of crohn's disease or psoriasis using anti-inteferon gamma antibodies
|
ATE356871T1
(de)
*
|
2002-05-17 |
2007-04-15 |
Alligator Bioscience Ab |
Eine methode zur in vitro molekularen evolution der proteinfunktion
|
WO2003097825A2
(en)
|
2002-05-21 |
2003-11-27 |
Dsm Ip Assets B.V. |
Novel phospholipases and uses thereof
|
WO2003102136A2
(en)
|
2002-05-30 |
2003-12-11 |
Human Genome Sciences, Inc. |
Antibodies that specifically bind to neurokinin b
|
EP2305710A3
(de)
|
2002-06-03 |
2013-05-29 |
Genentech, Inc. |
Synthetische Antikörperphagenbibliotheken
|
NZ556507A
(en)
|
2002-06-03 |
2010-03-26 |
Genentech Inc |
Synthetic antibody phage libraries
|
US7304128B2
(en)
*
|
2002-06-04 |
2007-12-04 |
E.I. Du Pont De Nemours And Company |
Carbon nanotube binding peptides
|
AU2003274463B2
(en)
*
|
2002-06-10 |
2009-10-29 |
University Of Rochester |
Gene differentially expressed in breast and bladder cancer and encoded polypeptides
|
US7425618B2
(en)
|
2002-06-14 |
2008-09-16 |
Medimmune, Inc. |
Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
|
US9028822B2
(en)
|
2002-06-28 |
2015-05-12 |
Domantis Limited |
Antagonists against TNFR1 and methods of use therefor
|
US20060002935A1
(en)
|
2002-06-28 |
2006-01-05 |
Domantis Limited |
Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
|
AU2002368055B2
(en)
|
2002-06-28 |
2008-09-18 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Method of treating autoimmune diseases with interferon-beta and IL-2R antagonist
|
US7696320B2
(en)
|
2004-08-24 |
2010-04-13 |
Domantis Limited |
Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
|
US9321832B2
(en)
|
2002-06-28 |
2016-04-26 |
Domantis Limited |
Ligand
|
AU2003247869C1
(en)
|
2002-07-15 |
2009-12-24 |
Board Of Regents, The University Of Texas System |
Selected antibodies binding to anionic phospholipids and aminophospholipids and their use in treating viral infections and cancer
|
USRE47770E1
(en)
|
2002-07-18 |
2019-12-17 |
Merus N.V. |
Recombinant production of mixtures of antibodies
|
ATE514717T1
(de)
|
2002-07-18 |
2011-07-15 |
Merus B V |
Rekombinante produktion von antikörpermischungen
|
PT1944322E
(pt)
|
2002-07-19 |
2015-07-01 |
Abbvie Biotechnology Ltd |
Tratamento de distúrbios relacionados com tnf-alfa
|
US7250551B2
(en)
|
2002-07-24 |
2007-07-31 |
President And Fellows Of Harvard College |
Transgenic mice expressing inducible human p25
|
US7794716B2
(en)
|
2002-07-25 |
2010-09-14 |
Glenveigh Pharmaceuticals, Llc |
Antibody composition and passive immunization against pregnancy-induced hypertension
|
US7390898B2
(en)
|
2002-08-02 |
2008-06-24 |
Immunogen Inc. |
Cytotoxic agents containing novel potent taxanes and their therapeutic use
|
PT1534736E
(pt)
|
2002-08-10 |
2010-09-07 |
Univ Yale |
Antagonistas do receptor nogo
|
US20040067532A1
(en)
|
2002-08-12 |
2004-04-08 |
Genetastix Corporation |
High throughput generation and affinity maturation of humanized antibody
|
CA2495725C
(en)
*
|
2002-08-13 |
2013-06-25 |
Haptogen Ltd |
Methods for the treatment of an infectious bacterial disease with an anti-lactone or lactone derived signal molecules antibody
|
JP4459810B2
(ja)
|
2002-08-14 |
2010-04-28 |
マクロジェニクス,インコーポレーテッド |
FcγRIIB特異的抗体とその利用法
|
WO2004018660A2
(en)
|
2002-08-19 |
2004-03-04 |
Dsm Ip Assets B.V. |
Novel lipases and uses thereof
|
WO2004018505A1
(en)
|
2002-08-20 |
2004-03-04 |
Yeda Research And Development Co. Ltd. |
Akap84 and its use for visualization of biological structures
|
EP2311978A1
(de)
|
2002-08-20 |
2011-04-20 |
Millennium Pharmaceuticals, Inc. |
Zusammensetzungen, Kits und Verfahren zur Identifizierung, Beurteilung, Vorbeugung und Therapie von Gebärmutterhalskrebs
|
WO2004019966A1
(ja)
|
2002-08-27 |
2004-03-11 |
Chugai Seiyaku Kabushiki Kaisha |
タンパク質溶液製剤の安定化方法
|
WO2004030613A2
(en)
|
2002-09-04 |
2004-04-15 |
University Of Louisville Research Foundation, Inc. |
Cancer therapy using beta glucan and antibodies
|
US8557743B2
(en)
|
2002-09-05 |
2013-10-15 |
Dyax Corp. |
Display library process
|
CN1688198A
(zh)
|
2002-09-10 |
2005-10-26 |
金克克国际有限公司 |
使用高浓度糖混合物诱导基因表达
|
KR101119448B1
(ko)
|
2002-09-11 |
2012-03-15 |
추가이 세이야쿠 가부시키가이샤 |
단백질 정제 방법
|
US9535076B2
(en)
|
2002-09-12 |
2017-01-03 |
The Regents Of The University Of California |
Methods and compositions for eliciting an amyloid-selective immune response
|
US7432351B1
(en)
|
2002-10-04 |
2008-10-07 |
Mayo Foundation For Medical Education And Research |
B7-H1 variants
|
DE60336406D1
(de)
|
2002-10-16 |
2011-04-28 |
Purdue Pharma Lp |
Antikörper, die an zellassoziiertes ca 125/0722p binden, und verfahren zu deren anwendung
|
TW200509968A
(en)
|
2002-11-01 |
2005-03-16 |
Elan Pharm Inc |
Prevention and treatment of synucleinopathic disease
|
US8506959B2
(en)
|
2002-11-01 |
2013-08-13 |
Neotope Biosciences Limited |
Prevention and treatment of synucleinopathic and amyloidogenic disease
|
ATE466885T1
(de)
|
2002-11-15 |
2010-05-15 |
Novartis Vaccines & Diagnostic |
Methoden zur verhinderung und behandlung von krebs-metastasierung und mit krebs-metastasierung einhergehendem knochenverlust
|
AU2004204095B2
(en)
|
2003-01-07 |
2009-07-30 |
Dyax Corporation |
Kunitz domain library
|
JP2006524039A
(ja)
|
2003-01-09 |
2006-10-26 |
マクロジェニクス,インコーポレーテッド |
変異型Fc領域を含む抗体の同定および作製ならびにその利用法
|
AU2004205631A1
(en)
*
|
2003-01-16 |
2004-08-05 |
Genentech, Inc. |
Synthetic antibody phage libraries
|
ATE431423T1
(de)
*
|
2003-01-21 |
2009-05-15 |
Chugai Pharmaceutical Co Ltd |
Verfahren zum screening der leichten kette eines antikörpers
|
JP2006518997A
(ja)
*
|
2003-01-21 |
2006-08-24 |
ブリストル−マイヤーズ スクイブ カンパニー |
新規アシルコエンザイムa:モノアシルグリセロールアシルトランスフェラーゼ−3(mgat3)をコードするポリヌクレオチドおよびその用途
|
CA2514125A1
(en)
|
2003-01-24 |
2004-08-12 |
Elan Pharmaceuticals, Inc. |
Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents
|
EA200501197A1
(ru)
*
|
2003-01-27 |
2006-04-28 |
Байоджен Айдек Ма Инк. |
Композиции и способы для лечения злокачественной опухоли с применением igsf9 и liv - 1
|
DE10303974A1
(de)
|
2003-01-31 |
2004-08-05 |
Abbott Gmbh & Co. Kg |
Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
|
EP1947116B1
(de)
|
2003-02-10 |
2017-06-21 |
2-BBB Medicines B.V. |
Differenziell exprimierte Nukleinsäuren der Blut-Hirnschranke bei einer Entzündung
|
CA2515779A1
(en)
|
2003-02-14 |
2004-09-02 |
The Curators Of The University Of Missouri |
Contraceptive method and compositions related to proteasomal interference
|
ES2457538T3
(es)
|
2003-02-20 |
2014-04-28 |
Seattle Genetics, Inc. |
Conjugados de anticuerpo anti-CD70-fármaco y su uso para el tratamiento de cánder y trastornos inmunológicos
|
US20040180387A1
(en)
|
2003-03-13 |
2004-09-16 |
Fujirebio Diagnostics, Inc. |
Detection of urinary mesothelin-/megakaryocyte potentiating factor-related peptides for assessment of ovarian cancer
|
BRPI0408315A
(pt)
|
2003-03-14 |
2006-03-07 |
Wyeth Corp |
anticorpo isolado, composição farmacêutica, ácido nucleico isolado, vetor de expressão, célula hospedeira, métodos de produzir um anticorpo, de gerar um anticorpo ou fragmento de ligação de antìgeno, de regular uma resposta imune, de tratar ou prevenir um distúrbio associado com célula imune em um paciente, de tratar ou prevenir um distúrbio hiperproliferativo em um paciente, e, kit de diagnóstico
|
PT2248899E
(pt)
|
2003-03-19 |
2015-09-23 |
Biogen Ma Inc |
Proteína de ligação do receptor nogo
|
US20080081841A1
(en)
|
2003-03-20 |
2008-04-03 |
Badache Ali |
Materials and Methods for Modulating Cell Motility
|
EP1622941A2
(de)
*
|
2003-03-20 |
2006-02-08 |
ImClone Systems Incorporated |
Methode zur produktion von anti-egfr antikörpern
|
US7294701B2
(en)
*
|
2003-04-02 |
2007-11-13 |
Technion Research & Development Foundation Ltd. |
Antibody fragment capable of modulating multidrug resistance and compositions and kits and methods using same
|
US7354584B2
(en)
|
2003-04-11 |
2008-04-08 |
Medimmune, Inc. |
Recombinant IL-9 antibodies
|
US7321065B2
(en)
*
|
2003-04-18 |
2008-01-22 |
The Regents Of The University Of California |
Thyronamine derivatives and analogs and methods of use thereof
|
US20040208876A1
(en)
|
2003-04-18 |
2004-10-21 |
Kim Kyung Jin |
Monoclonal antibodies to hepatocyte growth factor
|
GB2401040A
(en)
|
2003-04-28 |
2004-11-03 |
Chugai Pharmaceutical Co Ltd |
Method for treating interleukin-6 related diseases
|
CA2524305C
(en)
|
2003-05-01 |
2015-12-08 |
Imclone Systems Incorporated |
Fully human antibodies directed against the human insulin-like growth factor-1 receptor
|
TWI353991B
(en)
|
2003-05-06 |
2011-12-11 |
Syntonix Pharmaceuticals Inc |
Immunoglobulin chimeric monomer-dimer hybrids
|
PT1624891E
(pt)
|
2003-05-06 |
2010-01-05 |
Syntonix Pharmaceuticals Inc |
Proteínas quiméricas de factor de coagulação-fc destinadas ao tratamento da hemofilia
|
US7709610B2
(en)
|
2003-05-08 |
2010-05-04 |
Facet Biotech Corporation |
Therapeutic use of anti-CS1 antibodies
|
US20050025763A1
(en)
|
2003-05-08 |
2005-02-03 |
Protein Design Laboratories, Inc. |
Therapeutic use of anti-CS1 antibodies
|
US8088387B2
(en)
|
2003-10-10 |
2012-01-03 |
Immunogen Inc. |
Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
|
US20090005257A1
(en)
|
2003-05-14 |
2009-01-01 |
Jespers Laurent S |
Process for Recovering Polypeptides that Unfold Reversibly from a Polypeptide Repertoire
|
US20050014932A1
(en)
|
2003-05-15 |
2005-01-20 |
Iogenetics, Llc |
Targeted biocides
|
US7358331B2
(en)
|
2003-05-19 |
2008-04-15 |
Elan Pharmaceuticals, Inc. |
Truncated fragments of alpha-synuclein in Lewy body disease
|
PT1633189T
(pt)
|
2003-05-19 |
2017-10-04 |
Prothena Biosciences Ltd |
Fragmentos truncados de alfa-sinucleína em doença com corpos de lewy
|
SI3524611T1
(sl)
|
2003-05-20 |
2021-05-31 |
Immunogen, Inc. |
Izboljšana citotoksična sredstva, ki vsebujejo nove majtanzinoide
|
US9708410B2
(en)
|
2003-05-30 |
2017-07-18 |
Janssen Biotech, Inc. |
Anti-tissue factor antibodies and compositions
|
US20100069614A1
(en)
|
2008-06-27 |
2010-03-18 |
Merus B.V. |
Antibody producing non-human mammals
|
EP2395016A3
(de)
|
2003-05-30 |
2012-12-19 |
Merus B.V. |
Entwurf und Verwendung von gepaarten unterschiedlichen Regionen von spezifisch bindenden Molekülen
|
US20040248109A1
(en)
*
|
2003-06-09 |
2004-12-09 |
Lawrence Greenfield |
Methods for selecting protein binding moieties
|
WO2005004794A2
(en)
|
2003-06-09 |
2005-01-20 |
Alnylam Pharmaceuticals Inc. |
Method of treating neurodegenerative disease
|
US8597911B2
(en)
|
2003-06-11 |
2013-12-03 |
Chugai Seiyaku Kabushiki Kaisha |
Process for producing antibodies
|
DE602004028249D1
(de)
|
2003-06-18 |
2010-09-02 |
Chugai Pharmaceutical Co Ltd |
Fucosetransporter
|
US8153410B2
(en)
|
2003-07-07 |
2012-04-10 |
Fox Chase Cancer Center |
Alternate morpheein forms of allosteric proteins as a target for the development of bioactive molecules
|
US20060162014A1
(en)
|
2003-07-07 |
2006-07-20 |
Jaffe Eileen K |
Alternate morpheeins of allosteric proteins as a target for the development of bioactive molecules
|
US20050058658A1
(en)
*
|
2003-07-15 |
2005-03-17 |
Barros Research Institute |
Compositions and methods for immunotherapy of human immunodeficiency virus (HIV)
|
AU2004259727A1
(en)
|
2003-07-15 |
2005-02-03 |
Barros Research Institute |
Compositions and methods for immunotherapy of cancer and infectious diseases.
|
GB0407315D0
(en)
*
|
2003-07-15 |
2004-05-05 |
Cambridge Antibody Tech |
Human antibody molecules
|
ES2383328T3
(es)
|
2003-07-25 |
2012-06-20 |
Amgen, Inc |
Métodos relacionados con LDCAM y CRTAM
|
US7727752B2
(en)
|
2003-07-29 |
2010-06-01 |
Life Technologies Corporation |
Kinase and phosphatase assays
|
US7758859B2
(en)
|
2003-08-01 |
2010-07-20 |
Genentech, Inc. |
Anti-VEGF antibodies
|
US20050106667A1
(en)
*
|
2003-08-01 |
2005-05-19 |
Genentech, Inc |
Binding polypeptides with restricted diversity sequences
|
HN2004000285A
(es)
|
2003-08-04 |
2006-04-27 |
Pfizer Prod Inc |
ANTICUERPOS DIRIGIDOS A c-MET
|
EP1652923B1
(de)
|
2003-08-08 |
2011-10-12 |
Perseus Proteomics Inc. |
Bei krebs überexprimiertes gen
|
JP2007511738A
(ja)
|
2003-08-08 |
2007-05-10 |
ジーンニュース インコーポレーテッド |
変形性関節症のバイオマーカー及びその使用
|
ES2458636T3
(es)
|
2003-08-18 |
2014-05-06 |
Medimmune, Llc |
Humanización de anticuerpos
|
US7046714B2
(en)
*
|
2003-09-10 |
2006-05-16 |
Intel Corporation |
Method and apparatus for Raman ring resonator based laser/wavelength converter
|
AR045563A1
(es)
|
2003-09-10 |
2005-11-02 |
Warner Lambert Co |
Anticuerpos dirigidos a m-csf
|
MXPA06003402A
(es)
|
2003-10-07 |
2006-06-27 |
Millennium Pharm Inc |
Moleculas de acidos nucleicos y proteinas para la identificacion, evaluacion, prevencion y tratamiento de cancer de ovario.
|
IL158287A0
(en)
|
2003-10-07 |
2004-05-12 |
Yeda Res & Dev |
Antibodies to nik, their preparation and use
|
DK1673475T3
(da)
|
2003-10-10 |
2010-07-19 |
Deutsches Krebsforsch |
Sammensætninger til diagnose og terapi af sygdomme, som er forbundet med aberrant ekspression af futriner (R-Spondiner) og/eller Wnt
|
CN1882602B
(zh)
|
2003-10-10 |
2011-02-09 |
阿尔卡米亚肿瘤股份有限公司 |
在疾病治疗中乙酰透明质酸合成的调节和降解
|
JP4443568B2
(ja)
*
|
2003-10-15 |
2010-03-31 |
エフ.ホフマン−ラ ロシュ アーゲー |
乳癌に対するマーカーとしてのタンパク質ascの使用
|
ATE506077T1
(de)
|
2003-10-16 |
2011-05-15 |
Imclone Llc |
Fibroblasten-wachstumsfaktor-1-hemmer und behandlungsverfahren dafür
|
US7329725B1
(en)
*
|
2003-10-29 |
2008-02-12 |
Nastech Pharmaceutical Company Inc. |
Phage displayed Trp cage ligands
|
GB0325836D0
(en)
*
|
2003-11-05 |
2003-12-10 |
Celltech R&D Ltd |
Biological products
|
EP1697415A1
(de)
|
2003-11-12 |
2006-09-06 |
Biogen Idec MA Inc. |
Polypeptidvarianten, die an den neonatal-fc-receptor (fcrn) binden, dimere fc-bindende proteine und damit in zusammenhang stehende verfahren
|
US20050100965A1
(en)
|
2003-11-12 |
2005-05-12 |
Tariq Ghayur |
IL-18 binding proteins
|
US20070269428A1
(en)
|
2003-11-21 |
2007-11-22 |
Celltech R&D Limited |
Method for the Treatment of Multiple Sclerosis by Inhibiting Il-17 Activity
|
CA2544577C
(en)
|
2003-12-01 |
2013-01-08 |
Dako Denmark A/S |
Methods and compositions for immuno-histochemical detection
|
AU2004296184B2
(en)
*
|
2003-12-04 |
2010-12-16 |
Vaccinex, Inc. |
Methods of killing tumor cells by targeting internal antigens exposed on apoptotic tumor cells
|
EP2418220B1
(de)
|
2003-12-10 |
2017-08-02 |
E. R. Squibb & Sons, L.L.C. |
Interferon-Alpha-Antikörper und deren Verwendungen
|
PT1691837E
(pt)
|
2003-12-10 |
2012-08-27 |
Medarex Inc |
Anticorpos ip-10 e suas utilizações
|
TW200530269A
(en)
|
2003-12-12 |
2005-09-16 |
Chugai Pharmaceutical Co Ltd |
Anti-Mpl antibodies
|
DK1711528T3
(da)
|
2003-12-23 |
2012-08-20 |
Genentech Inc |
Behandling af cancer med hidtil ukendte anti-il 13 monoklonale antistoffer
|
GB0329825D0
(en)
|
2003-12-23 |
2004-01-28 |
Celltech R&D Ltd |
Biological products
|
WO2005061532A1
(es)
*
|
2003-12-23 |
2005-07-07 |
Berthet Francois Xavier |
Composiciones y procedimientos para detectar infección patógena
|
EP1704166B1
(de)
|
2004-01-07 |
2015-04-29 |
Novartis Vaccines and Diagnostics, Inc. |
M-csf spezifischer monoclonaler antikörper und dessen verwendungen
|
DK2177537T3
(da)
|
2004-01-09 |
2011-12-12 |
Pfizer |
Antistoffer til MAdCAM
|
DK1737971T3
(da)
|
2004-01-20 |
2017-11-13 |
Merus Nv |
Blandinger af bindingsproteiner
|
US20060014211A1
(en)
|
2004-01-21 |
2006-01-19 |
Fujirebio Diagnostics, Inc. |
Detection of mesothelin-/megakaryocyte potentiating factor-related peptides for assessment of the peritoneum and the peritoneal cavity
|
GB0401876D0
(en)
|
2004-01-28 |
2004-03-03 |
Vereniging Het Nl Kanker I |
New use for cancer antigen
|
BRPI0507026A
(pt)
|
2004-02-09 |
2007-04-17 |
Human Genome Sciences Inc |
proteìnas de fusão de albumina
|
AU2005212369B2
(en)
|
2004-02-10 |
2011-06-23 |
Musc Foundation For Research Development |
Inhibition of factor B, the alternative complement pathway and methods related thereto
|
DE602005018325D1
(de)
|
2004-02-19 |
2010-01-28 |
Genentech Inc |
Antikörper mit korrigierten cdr
|
ATE498010T1
(de)
|
2004-03-01 |
2011-02-15 |
Immune Disease Inst Inc |
Natürliche igm-antikörper und inhibitoren davon
|
JP4734319B2
(ja)
|
2004-03-19 |
2011-07-27 |
イムクローン・リミテッド・ライアビリティ・カンパニー |
ヒト抗上皮成長因子受容体抗体
|
KR100882249B1
(ko)
|
2004-03-24 |
2009-02-06 |
트리패스 이미징, 인코포레이티드 |
자궁경부 질환의 검사 방법 및 조성물
|
WO2005097184A2
(en)
|
2004-03-26 |
2005-10-20 |
Human Genome Sciences, Inc. |
Antibodies against nogo receptor
|
GB0407008D0
(en)
|
2004-03-27 |
2004-04-28 |
Haptogen Ltd |
Methods for inducing rapid cell death (autolysis) in infectious bacteria
|
CN1961003B
(zh)
|
2004-03-31 |
2013-03-27 |
健泰科生物技术公司 |
人源化抗TGF-β抗体
|
TWI439284B
(zh)
|
2004-04-09 |
2014-06-01 |
Abbvie Biotechnology Ltd |
用於治療TNFα相關失調症之多重可變劑量療法
|
US7785903B2
(en)
|
2004-04-09 |
2010-08-31 |
Genentech, Inc. |
Variable domain library and uses
|
EP1745149A4
(de)
|
2004-04-15 |
2008-08-06 |
Univ Florida |
Neurale proteine als biomarker für eine verletzung des nervensystems und andere neurale störungen
|
ES2442386T3
(es)
|
2004-04-23 |
2014-02-11 |
Bundesrepublik Deutschland Letztvertreten Durch Das Robert Koch-Institut Vertreten Durch Seinen Pr |
Método para el tratamiento de condiciones mediadas por células T por la disminución de las células positivas de ICOS in vivo.
|
GB0410627D0
(en)
|
2004-05-12 |
2004-06-16 |
Scancell Ltd |
Specific binding members
|
GB0410958D0
(en)
|
2004-05-15 |
2004-06-16 |
Haptogen Ltd |
Methods for reducing biofilm formation in infectious bacteria
|
AU2005244980B2
(en)
*
|
2004-05-19 |
2011-09-15 |
E. R. Squibb & Sons, L.L.C. |
Chemical linkers and conjugates thereof
|
RU2402548C2
(ru)
|
2004-05-19 |
2010-10-27 |
Медарекс, Инк. |
Химические линкеры и их конъюгаты
|
CA2567623C
(en)
|
2004-05-26 |
2012-04-03 |
Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung E.V. |
Isolation of allergen-specific immunoglobulin genes from human b-cells of atopic subjects
|
EA012622B1
(ru)
|
2004-06-01 |
2009-10-30 |
Домэнтис Лимитед |
Биспецифичные гибридные антитела с увеличенным периодом полувыведения из сыворотки
|
WO2005118635A2
(en)
|
2004-06-03 |
2005-12-15 |
Novimmune S.A. |
Anti-cd3 antibodies and methods of use thereof
|
NZ551782A
(en)
|
2004-06-03 |
2010-03-26 |
Athlomics Pty Ltd |
Agents and methods for diagnosing stress
|
WO2005123048A2
(en)
|
2004-06-21 |
2005-12-29 |
Proteome Sciences Plc |
Screening methods using c-abl, fyn and syk in combination with tau protein
|
KR20150041193A
(ko)
|
2004-06-21 |
2015-04-15 |
메다렉스, 엘.엘.시. |
인터페론 알파 수용체 1 항체 및 그의 용도
|
GB0414054D0
(en)
|
2004-06-23 |
2004-07-28 |
Owen Mumford Ltd |
Improvements relating to automatic injection devices
|
PT1776136E
(pt)
|
2004-06-24 |
2012-12-05 |
Biogen Idec Inc |
Tratamento de estados que envolvem desmielinização
|
EP2322554A1
(de)
|
2004-06-30 |
2011-05-18 |
Domantis Limited |
Zusammensetzung die ein anti-TNF-alpha Domainantiköper enthält zur Behandlung von Rheumatoide Arthritis
|
ES2563491T3
(es)
*
|
2004-07-06 |
2016-03-15 |
Bioren, LLC |
Bibliotecas universales de anticuerpos
|
US7973134B2
(en)
|
2004-07-07 |
2011-07-05 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in anaplastic large cell lymphoma signaling pathways
|
US6986264B1
(en)
*
|
2004-07-15 |
2006-01-17 |
Carrier Corporation |
Economized dehumidification system
|
BRPI0513200A
(pt)
|
2004-07-16 |
2008-04-29 |
Pfizer Prod Inc |
uso de um anticorpo anti-igf-1r na preparação de um medicamento para tratamento combinado para malignidades não-hematológicas
|
US7342093B2
(en)
|
2004-07-23 |
2008-03-11 |
University Of Massachusetts |
Compounds that inhibit Hsp90 protein-protein interactions with IAP proteins
|
PL1781321T3
(pl)
|
2004-08-02 |
2014-07-31 |
Zenyth Operations Pty Ltd |
Sposób leczenia raka zawierający antagonistę VEGF-B
|
US7846438B2
(en)
|
2004-08-03 |
2010-12-07 |
Biogen Idec Ma Inc. |
Methods of promoting neurite outgrowth with soluble TAJ polypeptides
|
WO2006135382A2
(en)
|
2004-08-04 |
2006-12-21 |
Chemocentryx, Inc. |
Enzymatic activities in chemokine-mediated inflammation
|
EP1623996A1
(de)
*
|
2004-08-06 |
2006-02-08 |
Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts |
Verbessertes Verfahren zur Auswahl eines Proteins von einer Bibliothek
|
EA013752B1
(ru)
|
2004-08-09 |
2010-06-30 |
Элан Фармасьютикалз, Инк. |
Предупреждение и лечение синуклеинопатических и амилоидогенных заболеваний
|
ITRM20040406A1
(it)
*
|
2004-08-10 |
2004-11-10 |
Bait Biotecnologie Applicate Italiane Srl |
Complesso in grado di rilevare un analita, procedimento per la sua preparazione e usi di esso.
|
SI2322556T1
(sl)
|
2004-09-03 |
2016-02-29 |
Genentech, Inc. |
Humanizirani antagonisti proti beta7 in njihove uporabe
|
EP1797176A2
(de)
*
|
2004-09-09 |
2007-06-20 |
University of Washington |
All-trans-retinol:all-trans-13,14-dihydroretinol-saturase und verfahren zu ihrer verwendung
|
FI20041204A0
(fi)
|
2004-09-16 |
2004-09-16 |
Riikka Lund |
Menetelmät immuunivälitteisiin sairauksiin liittyvien uusien kohdegeenien hyödyntämiseksi
|
US7563443B2
(en)
|
2004-09-17 |
2009-07-21 |
Domantis Limited |
Monovalent anti-CD40L antibody polypeptides and compositions thereof
|
AU2005286770A1
(en)
|
2004-09-21 |
2006-03-30 |
Medimmune, Llc |
Antibodies against and methods for producing vaccines for respiratory syncytial virus
|
GB0421838D0
(en)
|
2004-09-30 |
2004-11-03 |
Congenia S R L |
Cancer markers
|
US7935790B2
(en)
|
2004-10-04 |
2011-05-03 |
Cell Singaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in T-cell receptor signaling pathways
|
PL1810026T3
(pl)
|
2004-10-06 |
2018-08-31 |
Mayo Foundation For Medical Education And Research |
B7-H1 i PD-1 w leczeniu raka nerkowokomórkowego
|
RU2401842C2
(ru)
|
2004-10-08 |
2010-10-20 |
Домантис Лимитед |
Антагонисты и способы их применения
|
WO2006047417A2
(en)
|
2004-10-21 |
2006-05-04 |
University Of Florida Research Foundation, Inc. |
Detection of cannabinoid receptor biomarkers and uses thereof
|
EP2465872A3
(de)
|
2004-10-25 |
2012-12-19 |
Merck Sharp & Dohme Corporation |
Anti-ADDL-Antikörper und ihre Verwendungen
|
CA2585717A1
(en)
|
2004-10-27 |
2006-05-04 |
Medimmune Inc. |
Modulation of antibody specificity by tailoring the affinity to cognate antigens
|
WO2006050257A2
(en)
*
|
2004-10-29 |
2006-05-11 |
Massachusetts Institute Of Tecchnology |
Detection of ion channel or receptor activity
|
JP2008518609A
(ja)
|
2004-11-09 |
2008-06-05 |
フィロゲン エスピーエー |
テネイシンcに対する抗体
|
EP2377555A3
(de)
|
2004-11-18 |
2011-11-23 |
Imclone LLC |
Antikörper gegen den vaskulären endothelialen Wachstumsfaktorrezeptor-1
|
GB0426146D0
(en)
|
2004-11-29 |
2004-12-29 |
Bioxell Spa |
Therapeutic peptides and method
|
AU2005322410B2
(en)
|
2004-11-30 |
2011-11-10 |
Amgen Fremont Inc. |
Antibodies directed to GPNMB and uses thereof
|
GB0521621D0
(en)
|
2005-10-24 |
2005-11-30 |
Domantis Ltd |
Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases
|
EP1841796A2
(de)
|
2004-12-02 |
2007-10-10 |
Domantis Limited |
Bispezifische domänen-antikörper gegen serum albumin und glp-1 oder pyy
|
US7517870B2
(en)
|
2004-12-03 |
2009-04-14 |
Fondazione Telethon |
Use of compounds that interfere with the hedgehog signaling pathway for the manufacture of a medicament for preventing, inhibiting, and/or reversing ocular diseases related with ocular neovascularization
|
AU2005313026B2
(en)
|
2004-12-06 |
2011-09-08 |
Kyowa Hakko Kirin Co., Ltd. |
Human monoclonal antibodies to influenza M2 protein and methods of making and using same
|
AR052051A1
(es)
|
2004-12-15 |
2007-02-28 |
Neuralab Ltd |
Anticuerpos ab humanizados usados en mejorar la cognicion
|
US7807789B2
(en)
|
2004-12-21 |
2010-10-05 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in EGFR-signaling pathways
|
JPWO2006067847A1
(ja)
|
2004-12-22 |
2008-06-12 |
中外製薬株式会社 |
フコーストランスポーターの機能が阻害された細胞を用いた抗体の作製方法
|
PL1835922T3
(pl)
*
|
2004-12-22 |
2009-10-30 |
Merck Serono Sa |
Terapia skojarzona stwardnienia rozsianego
|
US7850960B2
(en)
|
2004-12-30 |
2010-12-14 |
University Of Washington |
Methods for regulation of stem cells
|
EP2311880A3
(de)
|
2005-01-05 |
2011-07-27 |
Biogen Idec MA Inc. |
Cripto-bindende Moleküle
|
GT200600031A
(es)
|
2005-01-28 |
2006-08-29 |
|
Formulacion anticuerpo anti a beta
|
EP2520669A3
(de)
|
2005-02-07 |
2013-02-27 |
GeneNews Inc. |
Biomarker für milde Arthrose und Verwendungen davon
|
CN101163502A
(zh)
|
2005-02-08 |
2008-04-16 |
根茨美公司 |
针对TGFβ的抗体
|
US7811572B2
(en)
|
2005-08-24 |
2010-10-12 |
Immunogen, Inc. |
Process for preparing purified drug conjugates
|
EP1853322B1
(de)
|
2005-02-11 |
2014-06-25 |
ImmunoGen, Inc. |
Verfahren zur herstellung von maytansinoid-antikörper-konjugaten
|
US20110166319A1
(en)
*
|
2005-02-11 |
2011-07-07 |
Immunogen, Inc. |
Process for preparing purified drug conjugates
|
CN103920142A
(zh)
|
2005-02-14 |
2014-07-16 |
爱荷华大学研究基金会 |
治疗和诊断年龄相关性黄斑变性的方法和试剂
|
AU2006214121B9
(en)
|
2005-02-15 |
2013-02-14 |
Duke University |
Anti-CD19 antibodies and uses in oncology
|
US8211430B2
(en)
*
|
2005-03-04 |
2012-07-03 |
Curedm Group Holdings, Llc |
Methods and pharmaceutical compositions for treating type 1 diabetes mellitus and other conditions
|
US20090142338A1
(en)
*
|
2005-03-04 |
2009-06-04 |
Curedm, Inc. |
Methods and Compositions for Treating Type 1 and Type 2 Diabetes Mellitus and Related Conditions
|
JP5153613B2
(ja)
|
2005-03-18 |
2013-02-27 |
メディミューン,エルエルシー |
抗体のフレームワーク・シャッフル
|
JP2008532559A
(ja)
|
2005-03-19 |
2008-08-21 |
メディカル リサーチ カウンシル |
ウイルス感染の治療及び予防又は治療及び予防の改善
|
EA037929B1
(ru)
|
2005-03-23 |
2021-06-08 |
Генмаб А/С |
Антитела к cd38 человека и их применение
|
PT2343320T
(pt)
|
2005-03-25 |
2018-01-23 |
Gitr Inc |
Anticorpos anti-gitr e as suas utilizações
|
EP3050963B1
(de)
|
2005-03-31 |
2019-09-18 |
Chugai Seiyaku Kabushiki Kaisha |
Verfahren zur herstellung von polypeptiden durch regulierung der anordnung
|
WO2006106903A1
(ja)
|
2005-03-31 |
2006-10-12 |
Chugai Seiyaku Kabushiki Kaisha |
sc(Fv)2構造異性体
|
GB0506912D0
(en)
|
2005-04-05 |
2005-05-11 |
Celltech R&D Ltd |
Biological products
|
US7714016B2
(en)
*
|
2005-04-08 |
2010-05-11 |
Medarex, Inc. |
Cytotoxic compounds and conjugates with cleavable substrates
|
US20090099340A1
(en)
*
|
2007-10-12 |
2009-04-16 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
|
EP1868650B1
(de)
|
2005-04-15 |
2018-10-03 |
MacroGenics, Inc. |
Kovalente diabodies und ihre verwendung
|
US20060269556A1
(en)
*
|
2005-04-18 |
2006-11-30 |
Karl Nocka |
Mast cell activation using siglec 6 antibodies
|
EP1871418B1
(de)
|
2005-04-19 |
2014-03-19 |
Seattle Genetics, Inc. |
Humanisierte, anti-cd70-bindende wirkstoffe und ihre verwendung
|
CN101163719A
(zh)
|
2005-04-22 |
2008-04-16 |
伊莱利利公司 |
TGFβ1特异性抗体
|
MX2007013217A
(es)
|
2005-04-25 |
2008-03-11 |
Pfizer |
Anticuerpos contra miostatina.
|
UA95775C2
(uk)
|
2005-04-26 |
2011-09-12 |
Пфайзер Инк. |
Антитіло, яке специфічно зв'язується з р-кадгерином
|
US7595380B2
(en)
|
2005-04-27 |
2009-09-29 |
Tripath Imaging, Inc. |
Monoclonal antibodies and methods for their use in the detection of cervical disease
|
US7592429B2
(en)
|
2005-05-03 |
2009-09-22 |
Ucb Sa |
Sclerostin-binding antibody
|
WO2006121852A2
(en)
|
2005-05-05 |
2006-11-16 |
Duke University |
Anti-cd19 antibody therapy for autoimmune disease
|
KR101498834B1
(ko)
|
2005-05-09 |
2015-03-05 |
오노 야꾸힝 고교 가부시키가이샤 |
예정 사멸 인자 1(pd-1)에 대한 인간 모노클로날 항체, 및 항-pd-1 항체를 단독 사용하거나 기타 면역 요법제와 병용한 암 치료 방법
|
NZ627177A
(en)
|
2005-05-16 |
2016-02-26 |
Abbvie Biotechnology Ltd |
Use of tnf inhibitor for treatment of erosive polyarthritis
|
NZ563263A
(en)
|
2005-05-17 |
2010-04-30 |
Univ Connecticut |
Composition and methods for immunomodulation in an organism
|
CA2726759C
(en)
|
2005-05-25 |
2016-02-16 |
Curedm Group Holdings, Llc |
Human proislet peptide, derivatives and analogs thereof, and methods of using same
|
ES2548700T3
(es)
|
2005-05-26 |
2015-10-20 |
The Regents Of The University Of Colorado, A Body Corporate |
Inhibición de la vía alternativa del complemento para el tratamiento de lesión cerebral traumática, lesión de médula espinal y afecciones relacionadas
|
DK1888113T3
(da)
|
2005-05-27 |
2014-09-01 |
Biogen Idec Inc |
Tweak-bindende antistoffer
|
US7875465B2
(en)
|
2005-05-31 |
2011-01-25 |
Canon Kabushiki Kaisha |
Target substance capturing molecule
|
WO2006129843A2
(en)
|
2005-05-31 |
2006-12-07 |
Canon Kabushiki Kaisha |
Bispecific capturing molecule
|
JP2006333825A
(ja)
*
|
2005-06-03 |
2006-12-14 |
Canon Inc |
標的物質捕捉用タンパク質の製造方法及びその構成材料の選択方法
|
KR101360671B1
(ko)
|
2005-06-10 |
2014-02-07 |
추가이 세이야쿠 가부시키가이샤 |
sc(Fv)2를 함유하는 의약조성물
|
KR101367544B1
(ko)
|
2005-06-10 |
2014-02-26 |
추가이 세이야쿠 가부시키가이샤 |
메글루민을 함유하는 단백질 제제의 안정화제, 및 그의이용
|
WO2006138739A2
(en)
*
|
2005-06-17 |
2006-12-28 |
Tolerx, Inc. |
Ilt3 binding molecules and uses therefor
|
WO2006138553A2
(en)
|
2005-06-17 |
2006-12-28 |
Wyeth |
Methods of purifying fc region containing proteins
|
KR20080025174A
(ko)
|
2005-06-23 |
2008-03-19 |
메디뮨 인코포레이티드 |
응집 및 단편화 프로파일이 최적화된 항체 제제
|
CN103172739A
(zh)
*
|
2005-06-30 |
2013-06-26 |
Abbvie公司 |
Il-12/p40结合蛋白
|
JP5142458B2
(ja)
*
|
2005-06-30 |
2013-02-13 |
キヤノン株式会社 |
標的物質捕捉分子、標的物質捕捉用の素子、これらを用いた標的物質検出用の装置及びキット、並びに、標的物質の検出方法
|
HUE026039T2
(en)
|
2005-07-01 |
2016-05-30 |
Squibb & Sons Llc |
Human monoclonal antibodies programmed for death ligand 1 (PD-L1)
|
US20090264305A1
(en)
|
2005-07-07 |
2009-10-22 |
Athlomics Pty Ltd. |
Polynucleotide Marker Genes and their Expression, for Diagnosis of Endotoxemia
|
WO2007008604A2
(en)
*
|
2005-07-08 |
2007-01-18 |
Bristol-Myers Squibb Company |
Single nucleotide polymorphisms associated with dose-dependent edema and methods of use thereof
|
SI1904104T1
(sl)
|
2005-07-08 |
2013-12-31 |
Biogen Idec Ma Inc. |
Protitelesa SP35 in njihova uporaba
|
WO2007016285A2
(en)
|
2005-07-28 |
2007-02-08 |
Novartis Ag |
M-csf specific monoclonal antibody and uses thereof
|
DE602006014691D1
(de)
|
2005-08-02 |
2010-07-15 |
Xbiotech Inc |
DIAGNOSE, BEHANDLUNG UND PRÄVENTION VON GEFÄSSERKRANKUNGEN MITTELS IL-1alpha-AUTOANTIKÖRPERN
|
EP1920057A4
(de)
|
2005-08-03 |
2009-03-18 |
Grains Res & Dev Corp |
Polysaccharid-synthasen
|
PT2573114T
(pt)
|
2005-08-10 |
2016-07-13 |
Macrogenics Inc |
Identificação e manipulação de anticorpos com regiões fc variantes e métodos de utilização dos mesmos
|
JP2009504685A
(ja)
*
|
2005-08-15 |
2009-02-05 |
アラーナ・テラピューティクス・リミテッド |
新世界霊長類フレームワーク領域を用いる設計された抗体
|
NZ594784A
(en)
|
2005-08-18 |
2013-06-28 |
Genmab As |
Therapy with CD4 binding peptides and radiation
|
CN103450359B
(zh)
|
2005-08-19 |
2018-07-24 |
惠氏有限责任公司 |
抗gdf-8的拮抗剂抗体以及在als和其他gdf-8-相关病症治疗中的用途
|
US7612181B2
(en)
*
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
US20090215992A1
(en)
*
|
2005-08-19 |
2009-08-27 |
Chengbin Wu |
Dual variable domain immunoglobulin and uses thereof
|
EP2500357A3
(de)
|
2005-08-19 |
2012-10-24 |
Abbott Laboratories |
Immunglobuline mit zweifacher variabler Domäne und ihre Verwendung
|
US20070202512A1
(en)
*
|
2005-08-19 |
2007-08-30 |
Bristol-Myers Squibb Company |
Human single nucleotide polymorphisms associated with dose-dependent weight gain and methods of use thereof
|
KR20140053410A
(ko)
|
2005-08-19 |
2014-05-07 |
아보트 러보러터리즈 |
이원 가변 도메인 면역글로불린 및 이의 용도
|
US20070041905A1
(en)
|
2005-08-19 |
2007-02-22 |
Hoffman Rebecca S |
Method of treating depression using a TNF-alpha antibody
|
US20100151495A9
(en)
*
|
2005-08-31 |
2010-06-17 |
Cell Signaling Technolgy, Inc. |
Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
|
WO2007027906A2
(en)
*
|
2005-08-31 |
2007-03-08 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in leukemia signaling pathways
|
KR101536506B1
(ko)
|
2005-09-07 |
2015-07-14 |
암젠 프레몬트 인코포레이티드 |
액티빈 수용체 유사 키나제-1에 대한 인간 모노클로날 항체
|
US8945573B2
(en)
|
2005-09-08 |
2015-02-03 |
The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. |
Targeted identification of immunogenic peptides
|
WO2007030560A2
(en)
|
2005-09-08 |
2007-03-15 |
Philadelphia Health & Education Corporation, D/B/A Drexel University College Of Medicine |
Identification of modulators of serine protease inhibitor kazal and their use as anti-cancer and anti-viral agents
|
EP1926757B1
(de)
*
|
2005-09-14 |
2012-02-22 |
UCB Pharma, S.A. |
Antikörper-kammpolymer-konjugat
|
WO2007035716A2
(en)
|
2005-09-16 |
2007-03-29 |
Raptor Pharmaceutical Inc. |
Compositions comprising receptor-associated protein (rap) variants specific for cr-containing proteins and uses thereof
|
CA2623652C
(en)
|
2005-09-26 |
2013-11-26 |
Medarex, Inc. |
Antibody-drug conjugates and methods of use
|
NZ566395A
(en)
|
2005-09-26 |
2012-03-30 |
Medarex Inc |
Human monoclonal antibodies to CD70
|
JP2009510002A
(ja)
|
2005-09-30 |
2009-03-12 |
アボット ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト |
反発誘導分子(rgm)タンパク質ファミリーのタンパク質の結合ドメイン、及びその機能的断片、及びそれらの使用
|
BRPI0617378B8
(pt)
|
2005-10-14 |
2022-09-20 |
Chugai Pharmaceutical Co Ltd |
Uso de um inibidor de il-6 para produzir uma composição farmacêutica para suprimir dano a um ilhota transplantada depois do transplante de ilhota; e aperfeiçoar a viabilidade de uma ilhota em um transplante de ilhota
|
GB0521139D0
(en)
|
2005-10-18 |
2005-11-23 |
Univ Sheffield |
Therapeutic agent
|
CN102260742A
(zh)
|
2005-10-21 |
2011-11-30 |
基因信息股份有限公司 |
用于使生物标志产物水平与疾病相关联的方法和装置
|
KR101239051B1
(ko)
|
2005-10-21 |
2013-03-04 |
추가이 세이야쿠 가부시키가이샤 |
심장질환 치료제
|
PE20080036A1
(es)
|
2005-10-21 |
2008-03-06 |
Novartis Ag |
Anticuerpos humanos para la interleucina-13 (il13)
|
JP5602365B2
(ja)
|
2005-10-25 |
2014-10-08 |
ザ・ジョンズ・ホプキンス・ユニバーシティ |
マルファン症候群及び関連疾患を治療するための方法及び組成物。
|
DK1940789T3
(da)
|
2005-10-26 |
2012-03-19 |
Medarex Inc |
Fremgangsmåder og forbindelser til fremstilling af CC-1065-analoger
|
WO2007051077A2
(en)
|
2005-10-28 |
2007-05-03 |
The Regents Of The University Of California |
Methods and compounds for lymphoma cell detection and isolation
|
BRPI0618085A2
(pt)
|
2005-11-01 |
2011-08-16 |
Abbott Biotech Ltd |
processos e kits para diagnóstico de espondilite ancilosante usando biomarcadores
|
US20070099246A1
(en)
*
|
2005-11-03 |
2007-05-03 |
Sandy John D |
Antibodies, assays and kits to quantitate cartilage destruction
|
EP1959979A4
(de)
|
2005-11-04 |
2010-01-27 |
Biogen Idec Inc |
Verfahren zur förderung des axonen-wachstums und des überlebens dopaminergischer neuronen
|
EP3299027A1
(de)
|
2005-11-04 |
2018-03-28 |
Genentech, Inc. |
Verwendung von komplementweginhibitoren zur behandlung von augenkrankheiten
|
AU2006311661B2
(en)
|
2005-11-07 |
2011-05-26 |
The Scripps Research Institute |
Compositions and methods for controlling tissue factor signaling specificity
|
EP2465870A1
(de)
|
2005-11-07 |
2012-06-20 |
Genentech, Inc. |
Bindepolypeptide mit verschiedenartigen und übereinstimmenden hypervariablen VH/VL-Sequenzen
|
UA96139C2
(uk)
*
|
2005-11-08 |
2011-10-10 |
Дженентек, Інк. |
Антитіло до нейропіліну-1 (nrp1)
|
WO2007059404A2
(en)
|
2005-11-10 |
2007-05-24 |
Medarex, Inc. |
Duocarmycin derivatives as novel cytotoxic compounds and conjugates
|
WO2007059166A2
(en)
|
2005-11-14 |
2007-05-24 |
Weber Georg F |
Peptide sequence that promotes tumor invasion
|
US8128934B2
(en)
|
2005-11-14 |
2012-03-06 |
Ribomic, Inc. |
Method for treatment or prevention of disease associated with functional disorder of regulatory T cell
|
AR057582A1
(es)
|
2005-11-15 |
2007-12-05 |
Nat Hospital Organization |
Agentes para suprimir la induccion de linfocitos t citotoxicos
|
AU2006318580A1
(en)
*
|
2005-11-21 |
2007-05-31 |
Merck Serono Sa |
Compositions and methods of producing hybrid antigen binding molecules and uses thereof
|
TWI461436B
(zh)
|
2005-11-25 |
2014-11-21 |
Kyowa Hakko Kirin Co Ltd |
人類cd134(ox40)之人類單株抗體及其製造及使用方法
|
TW200803894A
(en)
|
2005-11-25 |
2008-01-16 |
Univ Keio |
Prostate cancer therapeutic agents
|
US20070122413A1
(en)
|
2005-11-28 |
2007-05-31 |
Sivakumar Pallavur V |
Il-21 antagonists
|
JP5475994B2
(ja)
|
2005-11-30 |
2014-04-16 |
アッヴィ・インコーポレイテッド |
抗Aβグロブロマー抗体、その抗原結合部分、対応するハイブリドーマ、核酸、ベクター、宿主細胞、前記抗体を作製する方法、前記抗体を含む組成物、前記抗体の使用及び前記抗体を使用する方法。
|
EP2410335A1
(de)
|
2005-11-30 |
2012-01-25 |
Massachusetts Institute of Technology (MIT) |
Biosensor zur Erkennung von Krankheitserregern
|
RS53270B2
(sr)
|
2005-11-30 |
2018-05-31 |
Abbvie Deutschland |
Monoklonalna antitela protiv amiloidnog beta proteina i njihova upotreba
|
US9829494B2
(en)
|
2005-12-01 |
2017-11-28 |
Adrenomed Ag |
Methods of treatment using ADM antibodies
|
EP1965827B1
(de)
|
2005-12-02 |
2015-02-25 |
Biogen Idec MA Inc. |
Behandlung von entmyelinisierenden erkrankungen
|
RU2470941C2
(ru)
|
2005-12-02 |
2012-12-27 |
Дженентек, Инк. |
Связывающие полипептиды и их применения
|
EP1973951A2
(de)
*
|
2005-12-02 |
2008-10-01 |
Genentech, Inc. |
Bindende polypeptide mit eingeschränkten diversitätssequenzen
|
JP5512128B2
(ja)
|
2005-12-08 |
2014-06-04 |
メダレックス・リミテッド・ライアビリティ・カンパニー |
フコシルgm1に対するヒトモノクローナル抗体および抗フコシルgm1を使用するための方法
|
WO2007066082A1
(en)
|
2005-12-09 |
2007-06-14 |
Ucb Pharma S.A. |
Antibody molecules having specificity for human il-6
|
DOP2006000277A
(es)
|
2005-12-12 |
2007-08-31 |
Bayer Pharmaceuticals Corp |
Anticuerpos anti mn y métodos para su utilización
|
US10183986B2
(en)
|
2005-12-15 |
2019-01-22 |
Industrial Technology Research Institute |
Trimeric collagen scaffold antibodies
|
US8014957B2
(en)
|
2005-12-15 |
2011-09-06 |
Fred Hutchinson Cancer Research Center |
Genes associated with progression and response in chronic myeloid leukemia and uses thereof
|
US20070264687A1
(en)
|
2005-12-15 |
2007-11-15 |
Min-Yuan Chou |
Recombinant triplex scaffold-based polypeptides
|
US7632498B2
(en)
|
2005-12-19 |
2009-12-15 |
Tripath Imaging, Inc. |
MCM6 and MCM7 monoclonal antibodies and methods for their use in the detection of cervical disease
|
EP1803814A1
(de)
|
2005-12-27 |
2007-07-04 |
SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. |
Methode zur Verbesserung der Antikörperselektionskapazität in einer Phagen-Display-Bibliothek
|
EP1977763A4
(de)
|
2005-12-28 |
2010-06-02 |
Chugai Pharmaceutical Co Ltd |
Antikörper-enthaltende stabilisierende zubereitung
|
WO2007084568A2
(en)
|
2006-01-17 |
2007-07-26 |
Health Research, Inc. |
Heteroduplex tracking assay
|
WO2009051846A2
(en)
|
2007-10-18 |
2009-04-23 |
Cell Signaling Technology, Inc. |
Translocation and mutant ros kinase in human non-small cell lung carcinoma
|
US20120208824A1
(en)
|
2006-01-20 |
2012-08-16 |
Cell Signaling Technology, Inc. |
ROS Kinase in Lung Cancer
|
BRPI0706750A2
(pt)
|
2006-01-25 |
2011-04-05 |
Univ Erasmus Medical Ct |
geração de anticorpos de cadeia pesada em animais transgênicos
|
ES2550099T3
(es)
|
2006-01-27 |
2015-11-04 |
Biogen Ma Inc. |
Antagonistas del receptor Nogo
|
EP2363711A1
(de)
|
2006-01-27 |
2011-09-07 |
Tripath Imaging, Inc. |
Verfahren zur Identifizierung von Patienten mit erhöhter Wahrscheinlichkeit des Auftretens eines Ovarialkarzinoms und Zusammensetzungen dafür
|
AU2007208678B2
(en)
|
2006-01-27 |
2013-01-10 |
Chugai Seiyaku Kabushiki Kaisha |
Therapeutic agents for diseases involving choroidal neovascularization
|
US20080038761A1
(en)
*
|
2006-01-30 |
2008-02-14 |
Invitrogen Corporation |
Compositions and methods for detecting and quantifying toxic substances in disease states
|
US20070175313A1
(en)
*
|
2006-01-31 |
2007-08-02 |
Kevin Vandervliet |
MP3 player holder assembly
|
EP1987064A4
(de)
*
|
2006-02-01 |
2010-04-07 |
Arana Therapeutics Ltd |
Domänen-antikörper-konstrukt
|
WO2007120975A2
(en)
|
2006-02-13 |
2007-10-25 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Variants in complement regulatory genes predict age-related macular degeneration
|
US7704953B2
(en)
*
|
2006-02-17 |
2010-04-27 |
Mdrna, Inc. |
Phage displayed cell binding peptides
|
TW200744634A
(en)
|
2006-02-21 |
2007-12-16 |
Wyeth Corp |
Methods of using antibodies against human IL-22
|
TWI417301B
(zh)
|
2006-02-21 |
2013-12-01 |
Wyeth Corp |
對抗人類介白素-22(il-22)之抗體及其用途
|
DK2495327T3
(da)
|
2006-03-03 |
2017-01-02 |
Promis Neurosciences Inc |
Fremgangsmåder og sammensætninger til at behandle og opdage sygdomme fremkaldt af fejlfoldet SOD1
|
EP2650306A1
(de)
|
2006-03-06 |
2013-10-16 |
Aeres Biomedical Limited |
Humanisierte Anti-CD22-Antikörper und ihre Verwendung bei der Behandlung von Krebs, Transplantationen und Autoimmunerkrankungen
|
EP2010569A4
(de)
|
2006-03-20 |
2009-09-09 |
Xoma Technology Ltd |
Für gastrin spezifische humane antikörper, materialien und methoden
|
ES2424468T3
(es)
|
2006-03-27 |
2013-10-02 |
Medimmune Limited |
Miembro de unión para el receptor GM-CSF
|
CA2646048A1
(en)
|
2006-03-30 |
2007-11-08 |
Novartis Ag |
Compositions and methods of use for antibodies of c-met
|
EP3345616A1
(de)
|
2006-03-31 |
2018-07-11 |
Chugai Seiyaku Kabushiki Kaisha |
Antikörpermodifizierungsverfahren zur reinigung von bispezifischem antikörper
|
IN2014DN10515A
(de)
|
2006-03-31 |
2015-08-21 |
Chugai Pharmaceutical Co Ltd |
|
JP5514539B2
(ja)
|
2006-03-31 |
2014-06-04 |
メダレックス・リミテッド・ライアビリティ・カンパニー |
ヒト抗体の調製に用いるためのキメラ抗体を発現するトランスジェニック動物
|
AR059922A1
(es)
|
2006-04-01 |
2008-05-07 |
Galaxy Biotech Llc |
Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
|
NZ596517A
(en)
|
2006-04-05 |
2013-06-28 |
Abbott Biotech Ltd |
Antibody purification
|
WO2007118214A2
(en)
|
2006-04-07 |
2007-10-18 |
The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services |
Antibody compositions and methods for treatment of neoplastic disease
|
EP2025346B1
(de)
|
2006-04-07 |
2016-08-10 |
Osaka University |
Mittel zur förderung der muskelregeneration
|
EP2708242A3
(de)
|
2006-04-10 |
2014-03-26 |
Abbott Biotechnology Ltd |
Anwendungen und Zusammensetzungen zur Behandlung von Morbus Bechterew
|
CA2564435A1
(en)
|
2006-04-10 |
2007-10-10 |
Abbott Biotechnology Ltd. |
Methods for monitoring and treating intestinal disorders
|
EP2007426A4
(de)
|
2006-04-10 |
2010-06-16 |
Abbott Biotech Ltd |
Anwendungen und zusammensetzungen zur behandlung von psoriasis-arthritis
|
US20100080794A1
(en)
|
2006-04-14 |
2010-04-01 |
Takashi Tsuji |
Mutant polypeptide having effector function
|
US8784810B2
(en)
|
2006-04-18 |
2014-07-22 |
Janssen Alzheimer Immunotherapy |
Treatment of amyloidogenic diseases
|
TWI395754B
(zh)
|
2006-04-24 |
2013-05-11 |
Amgen Inc |
人類化之c-kit抗體
|
WO2007127335A2
(en)
*
|
2006-04-27 |
2007-11-08 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in atm and atr kinase signaling pathways
|
US7702468B2
(en)
|
2006-05-03 |
2010-04-20 |
Population Diagnostics, Inc. |
Evaluating genetic disorders
|
US10522240B2
(en)
|
2006-05-03 |
2019-12-31 |
Population Bio, Inc. |
Evaluating genetic disorders
|
EP2420832A1
(de)
|
2006-05-04 |
2012-02-22 |
Abmaxis, Inc. |
Artenübergreifende und Mehrartenanzeigesysteme
|
EP2016101A2
(de)
*
|
2006-05-09 |
2009-01-21 |
Genentech, Inc. |
Bindung von polypeptiden mit optimierten gerüsten
|
JP2009537147A
(ja)
|
2006-05-15 |
2009-10-29 |
シー レーン バイオテクノロジーズ, エルエルシー |
インフルエンザウイルスに対する中和抗体
|
GB0611116D0
(en)
|
2006-06-06 |
2006-07-19 |
Oxford Genome Sciences Uk Ltd |
Proteins
|
WO2010123874A1
(en)
|
2009-04-20 |
2010-10-28 |
Oxford Biotherapeutics Ltd. |
Antibodies specific to cadherin-17
|
ES2429407T3
(es)
|
2006-06-08 |
2013-11-14 |
Chugai Seiyaku Kabushiki Kaisha |
Agente preventivo o remedio para enfermedades inflamatorias
|
SG10201504662WA
(en)
|
2006-06-14 |
2015-07-30 |
Macrogenics Inc |
Methods For The Treatment Of Autoimmune Disorders Using Immunosuppressive Monoclonal Antibodies With Reduced Toxicity
|
US7777008B2
(en)
*
|
2006-06-19 |
2010-08-17 |
Tolerx, Inc. |
ILT3 binding molecules and uses therefor
|
EP2076281A4
(de)
|
2006-06-23 |
2010-03-03 |
Aegis Therapeutics Inc |
Stabilisierende alkylglykosid-zusammensetzungen und ihre verfahren
|
WO2008019199A2
(en)
|
2006-06-26 |
2008-02-14 |
Macrogenics, Inc. |
FCγRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
|
US7572618B2
(en)
|
2006-06-30 |
2009-08-11 |
Bristol-Myers Squibb Company |
Polynucleotides encoding novel PCSK9 variants
|
AU2007269791B2
(en)
|
2006-06-30 |
2013-10-03 |
Abbvie Biotechnology Ltd |
Automatic injection device
|
AU2007269714A1
(en)
|
2006-07-03 |
2008-01-10 |
Charles David Adair |
Composition for modulating the expression of cell adhesion molecules
|
ES2372709T3
(es)
|
2006-07-05 |
2012-01-25 |
Catalyst Biosciences, Inc. |
Procedimientos de cribado de proteasas y proteasas identificadas por los mismos.
|
TW200808351A
(en)
|
2006-07-13 |
2008-02-16 |
Chugai Pharmaceutical Co Ltd |
Cell death-inducing agents
|
EA020324B1
(ru)
*
|
2006-07-18 |
2014-10-30 |
Санофи-Авентис |
АНТИТЕЛА К РЕЦЕПТОРУ ЭФРИНА EphA2 И ИХ ПРИМЕНЕНИЕ
|
EP2047862B9
(de)
|
2006-07-21 |
2013-04-10 |
Chugai Seiyaku Kabushiki Kaisha |
Mittel zur behandlung von nierenerkrankungen
|
SI2511301T1
(en)
|
2006-08-04 |
2018-05-31 |
MedImmune Limited, |
Human antibodies to ERBB 2
|
EP2420252A1
(de)
|
2006-08-04 |
2012-02-22 |
Novartis AG |
EPHB3-spezifischer Antikörper und Verwendungen davon
|
US7939636B2
(en)
|
2006-08-11 |
2011-05-10 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in c-Src signaling pathways
|
JP5244785B2
(ja)
|
2006-08-11 |
2013-07-24 |
小野薬品工業株式会社 |
ストローマ由来因子−1(sdf−1)に対するモノクローナル抗体
|
JP5235881B2
(ja)
|
2006-08-11 |
2013-07-10 |
シーエスエル、リミテッド |
肺疾患病態の処理
|
EP3111955B1
(de)
|
2006-08-14 |
2019-01-23 |
Chugai Seiyaku Kabushiki Kaisha |
Diagnose und behandlung von krebs mittels anti-desmoglein-3 antikörper
|
JP5517619B2
(ja)
|
2006-08-18 |
2014-06-11 |
ノバルティス アーゲー |
Prlr特異的抗体およびその使用
|
EP2057271A2
(de)
|
2006-08-22 |
2009-05-13 |
University of Copenhagen |
An der glucosinolat-biosynthese beteiligte flavin-monooxygenasen und transkriptionsfaktoren
|
SG170032A1
(en)
|
2006-08-28 |
2011-04-29 |
Kyowa Hakko Kirin Co Ltd |
Antagonistic human light-specific human monoclonal antibodies
|
US20090258442A1
(en)
*
|
2006-08-31 |
2009-10-15 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
|
GB0617429D0
(en)
|
2006-09-05 |
2006-10-18 |
Electrophoretics Ltd |
Markers of renal transplant rejection and renal damage
|
MX2009002418A
(es)
|
2006-09-05 |
2009-04-23 |
Medarex Inc |
Anticuerpos para las proteinas morfogenicas oseas y receptores de estas y metodos para su uso.
|
SG174782A1
(en)
|
2006-09-08 |
2011-10-28 |
Abbott Lab |
Interleukin - 13 binding proteins
|
US20100297103A1
(en)
|
2006-09-14 |
2010-11-25 |
Medical & Biological Laboratories Co., Ltd. |
Antibody having enhanced adcc activity and method for production thereof
|
CA2664740C
(en)
|
2006-09-26 |
2021-11-16 |
Genmab A/S |
Combination treatment of cd38-expressing tumors
|
AU2007302626B2
(en)
|
2006-09-28 |
2013-09-26 |
The Macfarlane Burnet Institute For Medical Research And Public Health Limited |
A method of diagnosis and kit therefor
|
PT2486941T
(pt)
|
2006-10-02 |
2017-05-30 |
Squibb & Sons Llc |
Anticorpos humanos que ligam a cxcr4 e utilizações dos mesmos
|
JP2010506839A
(ja)
|
2006-10-12 |
2010-03-04 |
ワイス エルエルシー |
乳光の低減を伴う方法および組成物
|
TWI414531B
(zh)
*
|
2006-10-12 |
2013-11-11 |
Genentech Inc |
淋巴毒素α之抗體
|
CN103396486A
(zh)
|
2006-10-12 |
2013-11-20 |
中外制药株式会社 |
使用抗ereg抗体的癌症的诊断和治疗
|
AU2007313300A1
(en)
|
2006-10-16 |
2008-04-24 |
Medimmune, Llc. |
Molecules with reduced half-lives, compositions and uses thereof
|
GB0620729D0
(en)
|
2006-10-18 |
2006-11-29 |
Ucb Sa |
Biological products
|
EP1914242A1
(de)
|
2006-10-19 |
2008-04-23 |
Sanofi-Aventis |
Neue Antikörper gegen CD38 zur Behandlung von Krebs
|
DK2068922T3
(da)
|
2006-10-19 |
2012-10-08 |
Csl Ltd |
Anti-IL-13Ralfa1-antistoffer samt deres anvendelser
|
PL2829551T3
(pl)
|
2006-10-19 |
2018-04-30 |
Csl Limited |
Antagonisty przeciwciała o wysokim powinowactwie wobec receptora alfa 1 interleukiny-13
|
US9023993B2
(en)
|
2006-10-20 |
2015-05-05 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-cancer agent comprising anti-HB-EGF antibody as active ingredient
|
EP3040347A3
(de)
|
2006-10-20 |
2016-09-21 |
Chugai Seiyaku Kabushiki Kaisha |
Pharmazeutische zusammensetzung mit anti-hb-egf-antikörper als wirkstoff
|
US7846434B2
(en)
|
2006-10-24 |
2010-12-07 |
Trubion Pharmaceuticals, Inc. |
Materials and methods for improved immunoglycoproteins
|
JP5401319B2
(ja)
|
2006-11-03 |
2014-01-29 |
ワイス・エルエルシー |
細胞培養における解糖阻害物質
|
EP1921142A1
(de)
*
|
2006-11-07 |
2008-05-14 |
Cytos Biotechnology AG |
Auswahl von menschlichen monoklonalen Antikörpern unter Verwendung von eukaryontischem Zell-Display
|
EP2087007A2
(de)
|
2006-11-09 |
2009-08-12 |
Irm Llc |
Agonistische trkb-antikörper und ihre verwendung
|
US20110294782A1
(en)
|
2006-11-10 |
2011-12-01 |
Massachusetts Institute Of Technology |
Small molecule pak inhibitors
|
NZ577085A
(en)
|
2006-11-15 |
2012-06-29 |
Medarex Inc |
Human monoclonal antibodies to btla and methods of use
|
AU2007323799B2
(en)
|
2006-11-15 |
2013-07-18 |
Eli Lilly And Company |
Anti-TSG101 antibodies and their uses for treatment of viral infections
|
WO2008064306A2
(en)
*
|
2006-11-22 |
2008-05-29 |
Curedm, Inc. |
Methods and compositions relating to islet cell neogenesis
|
US7488807B2
(en)
|
2006-11-22 |
2009-02-10 |
3M Innovative Properties Company |
Antibody with protein A selectivity
|
CA2683287A1
(en)
|
2006-11-27 |
2008-12-18 |
Patrys Limited |
Novel glycosylated peptide target in neoplastic cells
|
US8455626B2
(en)
|
2006-11-30 |
2013-06-04 |
Abbott Laboratories |
Aβ conformer selective anti-aβ globulomer monoclonal antibodies
|
TW200831528A
(en)
|
2006-11-30 |
2008-08-01 |
Astrazeneca Ab |
Compounds
|
SI2662091T1
(sl)
|
2006-12-01 |
2019-01-31 |
Novartis Ag |
Protitelesa proti P-selektinu in postopki za njihovo uporabo za zdravljenje vnetnih bolezni
|
CN103172743B
(zh)
|
2006-12-01 |
2015-04-08 |
梅达雷克斯有限责任公司 |
结合cd22的人抗体及其用途
|
US8455622B2
(en)
|
2006-12-01 |
2013-06-04 |
Seattle Genetics, Inc. |
Variant target binding agents and uses thereof
|
US8637244B2
(en)
|
2006-12-05 |
2014-01-28 |
Decode Genetics Ehf. |
Genetic markers for risk management of atrial fibrillation, atrial flutter, and stroke
|
CN101678100A
(zh)
|
2006-12-06 |
2010-03-24 |
米迪缪尼有限公司 |
治疗系统性红斑狼疮的方法
|
KR101519672B1
(ko)
|
2006-12-07 |
2015-05-29 |
노파르티스 아게 |
Ephb3에 대한 길항제 항체
|
US20080139790A1
(en)
*
|
2006-12-08 |
2008-06-12 |
Jennings Philip A |
Chimeric antibodies
|
WO2008073914A2
(en)
|
2006-12-10 |
2008-06-19 |
Dyadic International Inc. |
Expression and high-throughput screening of complex expressed dna libraries in filamentous fungi
|
US9862956B2
(en)
|
2006-12-10 |
2018-01-09 |
Danisco Us Inc. |
Expression and high-throughput screening of complex expressed DNA libraries in filamentous fungi
|
CL2007003622A1
(es)
|
2006-12-13 |
2009-08-07 |
Medarex Inc |
Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales.
|
EP2103628A4
(de)
|
2006-12-14 |
2012-02-22 |
Forerunner Pharma Res Co Ltd |
Monoklonaler anti-claudin-3-antikörper und die behandlung und diagnose von krebs unter dessen verwendung
|
AU2007333098A1
(en)
|
2006-12-14 |
2008-06-19 |
Medarex, Inc. |
Human antibodies that bind CD70 and uses thereof
|
TWI419904B
(zh)
|
2006-12-18 |
2013-12-21 |
Genentech Inc |
拮抗劑抗-notch3抗體及其用於預防及治療notch3相關疾病之用途
|
RU2554747C9
(ru)
|
2006-12-20 |
2015-10-20 |
Ксома (Сша) Ллс |
Способы лечения il-1бета-зависимых заболеваний
|
US9127064B2
(en)
|
2006-12-21 |
2015-09-08 |
Novo Nordisk A/S |
Antibodies against human NKG2D and uses thereof
|
US20080171344A1
(en)
*
|
2006-12-22 |
2008-07-17 |
Kapsner Kenneth P |
Methods, Kits and Materials for Diagnosing Disease States by Measuring Isoforms or Proforms of Myeloperoxidase
|
WO2008083169A2
(en)
|
2006-12-26 |
2008-07-10 |
The Johns Hopkins University |
Compositions and methods for the treatment of immunologic disorders
|
WO2008083239A2
(en)
|
2006-12-27 |
2008-07-10 |
The Johns Hopkins University |
Compositions and methods for stimulating an immune response
|
JP5623747B2
(ja)
|
2006-12-27 |
2014-11-12 |
エモリー ユニバーシティ |
感染症および腫瘍を処置するための組成物および方法
|
US7989173B2
(en)
|
2006-12-27 |
2011-08-02 |
The Johns Hopkins University |
Detection and diagnosis of inflammatory disorders
|
TWI412367B
(zh)
|
2006-12-28 |
2013-10-21 |
Medarex Llc |
化學鏈接劑與可裂解基質以及其之綴合物
|
US8324350B2
(en)
*
|
2006-12-29 |
2012-12-04 |
Abbott Laboratories |
Dual-specific IL-1α/IL-1β antibodies
|
JP5618172B2
(ja)
|
2007-01-05 |
2014-11-05 |
国立大学法人東京大学 |
抗prg−3抗体を用いる癌の診断および治療
|
NZ577976A
(en)
|
2007-01-09 |
2011-12-22 |
Biogen Idec Inc |
Sp35 antibodies and uses thereof
|
US8128926B2
(en)
|
2007-01-09 |
2012-03-06 |
Biogen Idec Ma Inc. |
Sp35 antibodies and uses thereof
|
CA2675340C
(en)
|
2007-01-11 |
2018-07-31 |
Philipps-Universitaet Marburg |
Diagnosis and treatment of alzheimer's and other neurodementing diseases
|
WO2008088823A2
(en)
|
2007-01-16 |
2008-07-24 |
Abbott Laboratories |
Methods for treating psoriasis
|
CL2008000188A1
(es)
|
2007-01-23 |
2008-07-18 |
Chugai Pharmaceutical Co Ltd |
Agente para suprimir la reaccion de rechazo cronica que comprende como ingrediente activo un inhibidor de il-6; y uso del inhibidor de il-6.
|
EP2114983B8
(de)
|
2007-02-07 |
2015-02-18 |
The Regents of the University of Colorado, A Body Corporate |
Axl-tyrosinkinasehemmer sowie verfahren zu ihrer herstellung und verwendung
|
MX2009008461A
(es)
|
2007-02-07 |
2009-08-17 |
Decode Genetics Ehf |
Variantes geneticas que contribuyen a riesgo de cancer de prostata.
|
RU2009133784A
(ru)
|
2007-02-09 |
2011-03-20 |
Дженентек, Инк. (Us) |
АНТИ-Robo4-АНТИТЕЛА И ИХ ПРИМЕНЕНИЯ
|
AR065368A1
(es)
|
2007-02-15 |
2009-06-03 |
Astrazeneca Ab |
Anticuerpos para moleculas de ige
|
US8685666B2
(en)
*
|
2007-02-16 |
2014-04-01 |
The Board Of Trustees Of Southern Illinois University |
ARL-1 specific antibodies and uses thereof
|
US8114606B2
(en)
|
2007-02-16 |
2012-02-14 |
The Board Of Trustees Of Southern Illinois University |
ARL-1 specific antibodies
|
PT2129396E
(pt)
|
2007-02-16 |
2013-11-18 |
Merrimack Pharmaceuticals Inc |
Anticorpos contra erbb3 e suas utilizações
|
AU2008218542B2
(en)
|
2007-02-21 |
2014-06-26 |
Decode Genetics Ehf. |
Genetic susceptibility variants associated with cardiovascular disease
|
KR20090122439A
(ko)
|
2007-02-21 |
2009-11-30 |
메다렉스, 인코포레이티드 |
단일 아미노산을 갖는 화학적 링커 및 이의 접합체
|
PT2118300E
(pt)
|
2007-02-23 |
2015-09-22 |
Univ California |
Prevenção e tratamento da doença sinucleinopática e amiloidogénica
|
PL2583978T3
(pl)
|
2007-02-23 |
2016-07-29 |
Prothena Biosciences Ltd Co |
Profilaktyka i leczenie chorób synukleinopatycznych i amyloidogennych
|
EP2121745A2
(de)
|
2007-02-26 |
2009-11-25 |
Oxford Genome Sciences (UK) Limited |
Proteine
|
WO2008104803A2
(en)
|
2007-02-26 |
2008-09-04 |
Oxford Genome Sciences (Uk) Limited |
Proteins
|
WO2008105560A1
(ja)
|
2007-02-27 |
2008-09-04 |
Forerunner Pharma Research Co., Ltd. |
抗grp78抗体を有効成分として含む医薬組成物
|
EP2124952A2
(de)
|
2007-02-27 |
2009-12-02 |
Abbott GmbH & Co. KG |
Verfahren zur behandlung von amyloidosen
|
EP1972639A3
(de)
|
2007-03-07 |
2008-12-03 |
Cell Signaling Technology, Inc. |
Reagenzien zur Erkennung von Proteinphosphorylierung in Karzinom-Signalwegen
|
CL2008000719A1
(es)
|
2007-03-12 |
2008-09-05 |
Univ Tokushima Chugai Seiyaku |
Agente terapeutico para cancer resistente a agentes quimioterapeuticos que comprende un anticuerpo que reconoce hla de clase i como ingrediente activo; composicion farmaceutica que comprende dicho anticuerpo; y metodo para tratar cancer resistente a
|
CN103641908A
(zh)
|
2007-03-22 |
2014-03-19 |
赫普泰雅治疗有限公司 |
突变的g蛋白偶联受体及其选择方法
|
BRPI0809042B1
(pt)
|
2007-03-22 |
2021-08-31 |
Biogen Ma Inc. |
Proteína de ligação a cd154 isolada, seu uso, e composição
|
US20090068684A1
(en)
*
|
2007-03-26 |
2009-03-12 |
Cell Signaling Technology, Inc. |
Serine and threoninephosphorylation sites
|
US20080238709A1
(en)
*
|
2007-03-28 |
2008-10-02 |
Faramarz Vaziri |
One-way communication apparatus with dynamic key generation
|
RU2476442C2
(ru)
|
2007-03-29 |
2013-02-27 |
Эббот Лэборетриз |
Кристаллические антитела против il-12 человека
|
WO2008121615A2
(en)
|
2007-03-30 |
2008-10-09 |
Medimmune, Inc. |
Antibody formulation
|
BRPI0809989B8
(pt)
|
2007-04-02 |
2021-05-25 |
Philogen Spa |
usos de um anticorpo ou fragmento de ligação a antígeno do mesmo que se liga a isoforma extradomínio-a (ed-a) de fibronectina e/ou ao ed-a de fibronectina
|
MX2009010765A
(es)
|
2007-04-02 |
2009-10-26 |
Amgen Fremont Inc |
Anticuerpos anti-ige.
|
US7807168B2
(en)
*
|
2007-04-10 |
2010-10-05 |
Vaccinex, Inc. |
Selection of human TNFα specific antibodies
|
NZ579985A
(en)
|
2007-04-13 |
2012-02-24 |
Catalyst Biosciences Inc |
Modified factor vii polypetides and uses thereof
|
GB0707505D0
(en)
|
2007-04-18 |
2007-05-30 |
Medical Res Council |
Antibodies against il-25
|
US7977462B2
(en)
|
2007-04-19 |
2011-07-12 |
Cell Signaling Technology, Inc. |
Tyrosine phosphorylation sites
|
EP1983003A3
(de)
|
2007-04-19 |
2009-03-11 |
Peter Hornbeck |
Tyrosinphosphorylationsstellen und spezifische Antikörper
|
EP1983002A3
(de)
|
2007-04-19 |
2009-03-11 |
Peter Hornbeck |
Tyrosinphosphorylations-Stellen und spezifische Antikörper
|
US20090053831A1
(en)
|
2007-05-01 |
2009-02-26 |
Cell Signaling Technology, Inc. |
Tyrosine phosphorylation sites
|
PT2164868E
(pt)
|
2007-05-04 |
2015-08-04 |
Technophage Investigaçao E Desenvolvimento Em Biotecnologia Sa |
Domínios variáveis de anticorpos de coelho manipulados e suas utilizações
|
EP2703011A3
(de)
|
2007-05-07 |
2014-03-26 |
MedImmune, LLC |
Anti-Icos-Antikörper und ihre Verwendung bei der Behandlung von Krebs, Transplantationen und Autoimmunerkrankungen
|
AU2008255027B2
(en)
|
2007-05-14 |
2013-10-03 |
Astrazeneca Ab |
Methods of reducing eosinophil levels
|
KR101523788B1
(ko)
|
2007-05-17 |
2015-06-26 |
제넨테크, 인크. |
뉴로필린 단편 및 뉴로필린-항체 복합체의 결정 구조
|
MX2009012722A
(es)
|
2007-05-25 |
2009-12-11 |
Decode Genetics Ehf |
Variantes geneticas sobre chr 5p12 y 10q26 como marcadores para el uso en la evaluacion del riesgo, diagnostico, pronostico y tratamiento del cancer de mama.
|
JP5117765B2
(ja)
|
2007-05-28 |
2013-01-16 |
国立大学法人 東京大学 |
抗robo1抗体を含むpet用腫瘍診断剤
|
US20090175847A1
(en)
*
|
2007-05-30 |
2009-07-09 |
Abbott Laboratories |
Humanized antibodies to ab (20-42) globulomer and uses thereof
|
US20090232801A1
(en)
*
|
2007-05-30 |
2009-09-17 |
Abbot Laboratories |
Humanized Antibodies Which Bind To AB (1-42) Globulomer And Uses Thereof
|
US7709215B2
(en)
|
2007-06-01 |
2010-05-04 |
Cytonics Corporation |
Method for diagnosing and treating acute joint injury
|
GB0724331D0
(en)
|
2007-12-13 |
2008-01-23 |
Domantis Ltd |
Compositions for pulmonary delivery
|
CA2688434A1
(en)
|
2007-06-06 |
2008-12-11 |
Domantis Limited |
Polypeptides, antibody variable domains and antagonists
|
US8999337B2
(en)
|
2007-06-11 |
2015-04-07 |
Abbvie Biotechnology Ltd. |
Methods for treating juvenile idiopathic arthritis by inhibition of TNFα
|
US8138313B2
(en)
|
2007-06-15 |
2012-03-20 |
Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts |
Treatment of tumors using specific anti-L1 antibody
|
KR101799337B1
(ko)
|
2007-06-21 |
2017-12-20 |
마크로제닉스, 인크. |
공유결합형 디아바디 및 이것의 사용
|
CN101801413A
(zh)
|
2007-07-12 |
2010-08-11 |
托勒克斯股份有限公司 |
采用gitr结合分子的联合疗法
|
EP2170946A2
(de)
|
2007-07-13 |
2010-04-07 |
The Johns Hopkins University |
B7-dc-varianten
|
KR101486615B1
(ko)
|
2007-07-16 |
2015-01-28 |
제넨테크, 인크. |
항-cd79b 항체 및 면역접합체 및 사용 방법
|
ES2528922T3
(es)
|
2007-07-16 |
2015-02-13 |
Genentech, Inc. |
Anticuerpos anti-CD79b humanizados e inmunoconjugados y métodos de uso
|
CA2691218C
(en)
|
2007-07-25 |
2018-04-24 |
Philogen S.P.A. |
An antigen associated with lung cancers and lymphomas
|
JP5424330B2
(ja)
|
2007-07-26 |
2014-02-26 |
国立大学法人大阪大学 |
インターロイキン6受容体阻害剤を有効成分とする眼炎症疾患治療剤
|
PT2182983E
(pt)
|
2007-07-27 |
2014-09-01 |
Janssen Alzheimer Immunotherap |
Tratamento de doenças amiloidogénicas com anticorpos anti-abeta humanizados
|
WO2009054873A2
(en)
|
2007-08-02 |
2009-04-30 |
Novimmune S.A. |
Anti-rantes antibodies and methods of use thereof
|
AU2008299784B9
(en)
|
2007-08-02 |
2015-06-18 |
Gilead Biologics, Inc. |
LOX and LOXL2 inhibitors and uses thereof
|
US20100273722A1
(en)
*
|
2007-08-06 |
2010-10-28 |
Yale University |
Modified miniature proteins
|
JP5588866B2
(ja)
|
2007-08-10 |
2014-09-10 |
メダレックス エル.エル.シー. |
Hco32およびhco27、ならびに関連実施例
|
JP5485152B2
(ja)
|
2007-08-15 |
2014-05-07 |
バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
単一特異性および多特異性抗体ならびに使用方法
|
ES2403904T3
(es)
|
2007-08-21 |
2013-05-22 |
Morphosys Ag |
Métodos para la formación de enlaces disulfuro
|
US8865875B2
(en)
|
2007-08-22 |
2014-10-21 |
Medarex, L.L.C. |
Site-specific attachment of drugs or other agents to engineered antibodies with C-terminal extensions
|
RU2015147300A
(ru)
|
2007-08-29 |
2019-01-11 |
Санофи-Авентис |
Гуманизированные антитела к cxcr5, их производные и их применение
|
SG185940A1
(en)
*
|
2007-08-30 |
2012-12-28 |
Curedm Group Holdings Llc |
Compositions and methods of using proislet peptides and analogs thereof
|
NZ583966A
(en)
|
2007-08-30 |
2012-04-27 |
Daiichi Sankyo Co Ltd |
Anti-epha2 antibody
|
EP2190469B1
(de)
|
2007-09-04 |
2015-02-25 |
Compugen Ltd. |
Polypeptide und polynukleotide und ihre verwendung als zielmolekül zur herstellung von arzneimitteln und biologika
|
GB0717337D0
(en)
|
2007-09-06 |
2007-10-17 |
Ucb Pharma Sa |
Method of treatment
|
CA2736661A1
(en)
*
|
2007-09-07 |
2009-03-12 |
Dyadic International, Inc. |
Novel fungal enzymes
|
US8877688B2
(en)
|
2007-09-14 |
2014-11-04 |
Adimab, Llc |
Rationally designed, synthetic antibody libraries and uses therefor
|
DK3124497T3
(da)
|
2007-09-14 |
2020-05-11 |
Adimab Llc |
Rationelt designede syntetiske antistofbiblioteker og anvendelser deraf
|
CL2008002775A1
(es)
|
2007-09-17 |
2008-11-07 |
Amgen Inc |
Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
|
ES2624450T3
(es)
|
2007-09-18 |
2017-07-14 |
Dako Denmark A/S |
Método rápido y sensible para la detección de dianas biológicas
|
CA2700701C
(en)
|
2007-09-26 |
2020-12-29 |
Chugai Seiyaku Kabushiki Kaisha |
Method of modifying isoelectric point of antibody via amino acid substitution in cdr
|
CA2700714C
(en)
|
2007-09-26 |
2018-09-11 |
Ucb Pharma S.A. |
Dual specificity antibody fusions
|
US8383114B2
(en)
|
2007-09-27 |
2013-02-26 |
Amgen Inc. |
Pharmaceutical formulations
|
EP2584043A3
(de)
|
2007-09-28 |
2013-10-02 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-Glypican-3-Antikörper mit verbesserter Kinetik in Plasma
|
BR122019021238B8
(pt)
|
2007-10-02 |
2021-07-27 |
Chugai Pharmaceutical Co Ltd |
uso de um inibidor do receptor da interleucina-6 (il-6) no tratamento da doença do enxerto versus hospedeiro (gvhd)
|
US8470560B2
(en)
|
2007-10-03 |
2013-06-25 |
The United States Of America As Represented By The Secretary Of The Army |
CR-2 binding peptide P28 as molecular adjuvant for DNA vaccines
|
EP2205971A4
(de)
*
|
2007-10-04 |
2011-03-30 |
Bionomics Ltd |
Endothelzellen-marker und verwendungen davon
|
EP2206727B1
(de)
|
2007-10-11 |
2015-04-01 |
Daiichi Sankyo Company, Limited |
AUF DAS OSTEOCLAST-RELATED PROTEIN Siglec-15 ZIELENDER ANTIKÖRPER
|
AR068767A1
(es)
|
2007-10-12 |
2009-12-02 |
Novartis Ag |
Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina
|
ES2499391T5
(es)
|
2007-10-15 |
2021-12-22 |
Chugai Pharmaceutical Co Ltd |
Método para la producción de anticuerpos
|
EP2050764A1
(de)
|
2007-10-15 |
2009-04-22 |
sanofi-aventis |
Neues polyvalentes bispezifisches Antikörperformat und Verwendung
|
JO3076B1
(ar)
|
2007-10-17 |
2017-03-15 |
Janssen Alzheimer Immunotherap |
نظم العلاج المناعي المعتمد على حالة apoe
|
EA201000603A1
(ru)
|
2007-10-23 |
2010-12-30 |
Новартис Аг |
ПРИМЕНЕНИЕ АНТИТЕЛ К TrkB ДЛЯ ЛЕЧЕНИЯ РЕСПИРАТОРНЫХ НАРУШЕНИЙ
|
EP2230300A4
(de)
|
2007-10-24 |
2012-08-08 |
Otsuka Chemical Holdings Co Ltd |
Polypeptid mit verbesserter effektorfunktion
|
WO2009055656A2
(en)
|
2007-10-26 |
2009-04-30 |
Centocor, Inc. |
Vectors, host cells, and methods of production and uses
|
SI2209805T1
(sl)
|
2007-10-30 |
2017-11-30 |
Philogen S.P.A. |
Antigen, povezan z revmatoidnim artritisom
|
CA2704809A1
(en)
|
2007-11-01 |
2009-05-07 |
University Of Iowa Research Foundation |
Rca locus analysis to assess susceptibility to amd and mpgnii
|
PE20091163A1
(es)
|
2007-11-01 |
2009-08-09 |
Wyeth Corp |
Anticuerpos para gdf8
|
ES2560532T3
(es)
|
2007-11-02 |
2016-02-19 |
Novartis Ag |
Moléculas y métodos de modulación de la proteína 6 relacionada con el receptor de lipoproteína de baja densidad (LRP6)
|
CA2703705A1
(en)
|
2007-11-05 |
2009-05-14 |
Medimmune, Llc |
Methods of treating scleroderma
|
ES2445755T3
(es)
|
2007-11-07 |
2014-03-05 |
Celldex Therapeutics, Inc. |
Anticuerpos que se unen a células dendríticas y epiteliales humanas 205 (DEC-205)
|
WO2009063970A1
(ja)
|
2007-11-14 |
2009-05-22 |
Forerunner Pharma Research Co., Ltd. |
抗gpr49抗体を用いる癌の診断および治療
|
EP3381445B1
(de)
|
2007-11-15 |
2023-10-25 |
Amgen Inc. |
Wässrige antikörperformulierung mit stabilisierung durch antioxidantien zur parenteralen verabreichung
|
SG188134A1
(en)
|
2007-11-15 |
2013-03-28 |
Chugai Pharmaceutical Co Ltd |
Monoclonal antibody capable of binding to anexelekto, and use thereof
|
EP3115469B1
(de)
|
2007-11-19 |
2020-04-29 |
Celera Corporation |
Lungenkrebsmarker und verwendungen davon
|
US20090203043A1
(en)
|
2007-11-21 |
2009-08-13 |
Peter Hornbeck |
Protein phosphorylation by basophilic serine/threonine kinases in insulin signaling pathways
|
AR069393A1
(es)
|
2007-11-21 |
2010-01-20 |
Imclone Systems Inc |
Inhibicion del receptor para la proteina estimulante del macrofago (ron) y metodos para el tratamiento del mismo
|
WO2009070642A1
(en)
|
2007-11-28 |
2009-06-04 |
Medimmune, Llc |
Protein formulation
|
UY31504A1
(es)
|
2007-11-30 |
2009-07-17 |
|
Construcciones de union de antigenos
|
US8697360B2
(en)
|
2007-11-30 |
2014-04-15 |
Decode Genetics Ehf. |
Genetic variants on CHR 11Q and 6Q as markers for prostate and colorectal cancer predisposition
|
TWI468417B
(zh)
|
2007-11-30 |
2015-01-11 |
Genentech Inc |
抗-vegf抗體
|
WO2009072598A1
(ja)
|
2007-12-05 |
2009-06-11 |
Chugai Seiyaku Kabushiki Kaisha |
掻痒症治療剤
|
ES2834741T3
(es)
|
2007-12-05 |
2021-06-18 |
Chugai Pharmaceutical Co Ltd |
Anticuerpo anti-NR10 y uso del mismo
|
GB0724051D0
(en)
|
2007-12-08 |
2008-01-16 |
Medical Res Council |
Mutant proteins and methods for producing them
|
EP2241333A1
(de)
|
2007-12-12 |
2010-10-20 |
National Cancer Center |
Therapeutisches mittel gegen mll-leukämie und moz-leukämie, dessen ziel der m-csf-rezeptor ist, und seine anwendung
|
EP2594590B1
(de)
|
2007-12-14 |
2014-11-12 |
Bristol-Myers Squibb Company |
Verfahren zur Herstellung von Bindungsmolekülen für den humanen OX40-Rezeptor
|
RU2559782C2
(ru)
|
2007-12-17 |
2015-08-10 |
Марфл Аб |
Набор для детекции спор, происходящих из микобактерий
|
AU2008343085B2
(en)
|
2007-12-20 |
2015-03-12 |
Xoma (Us) Llc |
Methods for the treatment of gout
|
GB0724860D0
(en)
|
2007-12-20 |
2008-01-30 |
Heptares Therapeutics Ltd |
Screening
|
EP2235058A2
(de)
|
2007-12-21 |
2010-10-06 |
Amgen, Inc |
Anti-amyloid-antikörper und ihre verwendung
|
MX343594B
(es)
|
2007-12-21 |
2016-11-11 |
Medimmune Ltd |
Miembros de union para receptor alfa de interleucina-4 (il-4ra) - 173.
|
US8092804B2
(en)
|
2007-12-21 |
2012-01-10 |
Medimmune Limited |
Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
|
WO2009082485A1
(en)
|
2007-12-26 |
2009-07-02 |
Vaccinex, Inc. |
Anti-c35 antibody combination therapies and methods
|
PE20091174A1
(es)
|
2007-12-27 |
2009-08-03 |
Chugai Pharmaceutical Co Ltd |
Formulacion liquida con contenido de alta concentracion de anticuerpo
|
NZ586875A
(en)
|
2007-12-28 |
2012-10-26 |
Elan Pharm Inc |
Treatment and prophylaxis of amyloidosis with an antibody that binds a specific epitope of human amyloid A peptide
|
GB0800277D0
(en)
|
2008-01-08 |
2008-02-13 |
Imagination Tech Ltd |
Video motion compensation
|
WO2009087978A1
(ja)
|
2008-01-11 |
2009-07-16 |
The University Of Tokyo |
抗cldn6抗体
|
AU2009203350B2
(en)
|
2008-01-11 |
2014-03-13 |
Gene Techno Science Co., Ltd. |
Humanized anti-alpha9 integrin antibodies and the uses thereof
|
CA2711736A1
(en)
|
2008-01-18 |
2009-07-23 |
Medimmune, Llc |
Cysteine engineered antibodies for site-specific conjugation
|
ES2500066T3
(es)
|
2008-01-25 |
2014-09-30 |
Amgen, Inc |
Anticuerpos frente a ferroportina y métodos de uso
|
WO2009097128A1
(en)
*
|
2008-01-29 |
2009-08-06 |
Ludwig Institute For Cancer Research Ltd. |
Membrane transporter napi2b (slc34a2) epitope for antibody therapy, antibodies directed thereto, and target for cancer therapy
|
TWI607019B
(zh)
|
2008-01-31 |
2017-12-01 |
建南德克公司 |
抗-cd79b抗體及免疫共軛物及使用方法
|
EP2240203B1
(de)
|
2008-02-05 |
2014-04-09 |
Bristol-Myers Squibb Company |
Alpha-5-beta-1-antikörper und ihre verwendungen
|
EP2250279B1
(de)
|
2008-02-08 |
2016-04-13 |
MedImmune, LLC |
Anti-ifnar1-antikörper mit reduzierter fc-ligandenaffinität
|
GB0802474D0
(en)
|
2008-02-11 |
2008-03-19 |
Heptares Therapeutics Ltd |
Mutant proteins and methods for selecting them
|
EP2245153A4
(de)
*
|
2008-02-13 |
2011-06-22 |
Dyax Corp |
Verbesserte verfahren zur herstellung spezifischer bindungspaare
|
US8828657B2
(en)
|
2008-02-14 |
2014-09-09 |
Decode Genetics Ehf. |
Susceptibility variants for lung cancer
|
BRPI0906060A2
(pt)
|
2008-02-28 |
2015-12-01 |
3M Innovative Properties Co |
anticorpos isolados, métodos de preparo de um anticorpo anti-clostridium difficile, composição e método para a detecção da presença de um esporo de clostridium difficile em uma amostra
|
US8962803B2
(en)
|
2008-02-29 |
2015-02-24 |
AbbVie Deutschland GmbH & Co. KG |
Antibodies against the RGM A protein and uses thereof
|
US20090220991A1
(en)
*
|
2008-02-29 |
2009-09-03 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in leukemia signaling pathways
|
EP2098536A1
(de)
|
2008-03-05 |
2009-09-09 |
4-Antibody AG |
Isolation und Identifikation antigen- oder ligandenspezifischer Bindungsproteine
|
US7951370B2
(en)
|
2008-03-12 |
2011-05-31 |
Imclone Llc |
Anti-TYRP1 antibodies
|
US9873957B2
(en)
|
2008-03-13 |
2018-01-23 |
Dyax Corp. |
Libraries of genetic packages comprising novel HC CDR3 designs
|
BR122012027456A2
(pt)
|
2008-03-14 |
2015-07-14 |
Allergan Inc |
Composição farmacêutica compreendendo sorotipo de neurotoxina botulínica a
|
TW201513883A
(zh)
|
2008-03-18 |
2015-04-16 |
Abbvie Inc |
治療牛皮癬的方法
|
WO2009118300A1
(en)
|
2008-03-25 |
2009-10-01 |
Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Treating cancer by down-regulating frizzled-4 and/or frizzled-1
|
EP2698380A1
(de)
|
2008-03-28 |
2014-02-19 |
Sea Lane Biotechnologies, LLC |
Neutralisierung von Molekülen in Virusantigene
|
MX348362B
(es)
|
2008-03-31 |
2017-06-07 |
Genentech Inc * |
Composiciones y metodos para tratar y diagnosticar asma.
|
EP2274450A2
(de)
|
2008-04-01 |
2011-01-19 |
Decode Genetics EHF |
Suszeptibilitätsvarianten bei peripherer arterienkrankheit und bauchschlagader-aneurysma
|
EP3045475B1
(de)
|
2008-04-02 |
2017-10-04 |
MacroGenics, Inc. |
Bcr-komplex-spezifische antikorper und verfahren zu ihrer verwendung
|
DK2247304T3
(en)
|
2008-04-02 |
2016-09-26 |
Macrogenics Inc |
Her2 / neu-specific antibodies and methods of use thereof
|
CL2009000647A1
(es)
|
2008-04-04 |
2010-06-04 |
Chugai Pharmaceutical Co Ltd |
Composicion farmaceutica para tratar o prevenir cancer hepatico que comprende una combinacion de un agente quimioterapeutico y un anticuerpo anti-glipicano 3; agente para atenuar un efecto secundario que comprende dicho anticuerpo; metodo para tratar o prevenir un cancer hepatico de un sujeto.
|
CA2718975A1
(en)
|
2008-04-10 |
2009-10-15 |
Cell Signaling Technology, Inc. |
Compositions and methods for detecting egfr mutations in cancer
|
MY159553A
(en)
|
2008-04-11 |
2017-01-13 |
Seattle Genetics Inc |
Detection and treatment of pancreatic, ovarian and other cancers
|
SG189775A1
(en)
|
2008-04-11 |
2013-05-31 |
Chugai Pharmaceutical Co Ltd |
Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
|
CA2721093A1
(en)
|
2008-04-11 |
2009-10-15 |
Merrimack Pharmaceuticals, Inc. |
Human serum albumin linkers and conjugates thereof
|
GB0807413D0
(en)
|
2008-04-23 |
2008-05-28 |
Ucb Pharma Sa |
Biological products
|
JP5780951B2
(ja)
|
2008-04-24 |
2015-09-16 |
ダイアックス コーポレーション |
新規のhccdr1、cdr2、およびcdr3設計、ならびに新規のlccdr1、cdr2、およびcdr3設計を含む、遺伝子パッケージのライブラリ
|
AU2009238897B2
(en)
|
2008-04-24 |
2015-03-19 |
Gene Techno Science Co., Ltd. |
Humanized antibodies specific for amino acid sequence RGD of an extracellular matrix protein and the uses thereof
|
US20090269786A1
(en)
*
|
2008-04-25 |
2009-10-29 |
The Board Of Trustees Of The University Of Illinois |
RHO1-Gamma Amino Butyric Acid C Receptor-Specific Antibodies
|
KR102072896B1
(ko)
|
2008-04-25 |
2020-02-03 |
다이액스 코포레이션 |
Fcrn에 대한 항체 및 이들의 용도
|
US9029508B2
(en)
|
2008-04-29 |
2015-05-12 |
Abbvie Inc. |
Dual variable domain immunoglobulins and uses thereof
|
DK2281006T3
(da)
|
2008-04-30 |
2017-11-06 |
Immunogen Inc |
Tværbindingsmidler og anvendelser deraf
|
CA2722600C
(en)
|
2008-05-01 |
2014-01-21 |
Amgen Inc. |
Anti-hepcidin antibodies and methods of use
|
ES2458541T3
(es)
|
2008-05-02 |
2014-05-06 |
Seattle Genetics, Inc. |
Métodos y composiciones para elaborar anticuerpos y derivados de anticuerpos con fucosilación del núcleo reducida
|
EP2711021B1
(de)
|
2008-05-02 |
2016-03-09 |
BliNK Therapeutics Limited |
Produkte und Verfahren zur Stimulation einer Immunantwort
|
CN102089430B
(zh)
|
2008-05-09 |
2015-02-04 |
Abbvie公司 |
针对渐进性糖化终极产物受体(rage)的抗体及其用途
|
SG176464A1
(en)
|
2008-05-09 |
2011-12-29 |
Agency Science Tech & Res |
Diagnosis and treatment of kawasaki disease
|
MX2010012368A
(es)
*
|
2008-05-16 |
2010-12-06 |
Genentech Inc |
Uso de biomarcadores para evaluar un tratamiento contra trastornos inflamatorios gastrointestinales con antagonistas de beta7-integrina.
|
US20090291073A1
(en)
*
|
2008-05-20 |
2009-11-26 |
Ward Keith W |
Compositions Comprising PKC-theta and Methods for Treating or Controlling Ophthalmic Disorders Using Same
|
EP2599793A1
(de)
|
2008-05-29 |
2013-06-05 |
Nuclea Biotechnologies, Inc. |
Anti-Phosphor-AKT-Antikörper
|
BRPI0912035A2
(pt)
|
2008-05-29 |
2017-05-23 |
Galaxy Biotech Llc |
anticorpo monoclonal, composição farmacêutica, uso de uma composição farmacêutica, mab de camundongo na forma quimérica ou humanizada, e, anticorpo humanizado
|
AR071891A1
(es)
|
2008-05-30 |
2010-07-21 |
Imclone Llc |
Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano)
|
WO2009147781A1
(ja)
|
2008-06-02 |
2009-12-10 |
国立大学法人東京大学 |
抗がん剤
|
CN102112494A
(zh)
|
2008-06-03 |
2011-06-29 |
雅培制药有限公司 |
双重可变结构域免疫球蛋白及其用途
|
EP3002299A1
(de)
|
2008-06-03 |
2016-04-06 |
AbbVie Inc. |
Dual-variable- domain-immunglobuline und ihre verwendungen
|
ES2675730T3
(es)
|
2008-06-04 |
2018-07-12 |
Macrogenics, Inc. |
Anticuerpos con unión alterada a FcRn y métodos de uso de los mismos
|
TW201503898A
(zh)
|
2008-06-05 |
2015-02-01 |
Chugai Pharmaceutical Co Ltd |
神經浸潤抑制劑
|
NZ589795A
(en)
|
2008-06-16 |
2013-02-22 |
Patrys Ltd |
Use of LM-1 antibody which binds to NONO/nmt55 protein to prevent metastasis
|
KR20110038047A
(ko)
|
2008-06-20 |
2011-04-13 |
고꾸리츠 다이가꾸 호우징 오까야마 다이가꾸 |
산화 LDL/β2GPI복합체에 대한 항체 및 그 용도
|
JP2011527565A
(ja)
|
2008-07-07 |
2011-11-04 |
ディコーデ ジェネテクス イーエイチエフ |
乳癌のリスクアセスメントのための遺伝的変異
|
EP2310049A4
(de)
|
2008-07-08 |
2013-06-26 |
Abbvie Inc |
Prostaglandin-e2 bindende proteine und ihre verwendung
|
KR20110031369A
(ko)
|
2008-07-08 |
2011-03-25 |
아보트 러보러터리즈 |
프로스타글란딘 e2 이원 가변 도메인 면역글로불린 및 이의 용도
|
MX2011000236A
(es)
|
2008-07-08 |
2011-02-24 |
Oncomed Pharm Inc |
Agentes de union a notch y antagonistas y metodos de uso de los mismos.
|
EP2315779A2
(de)
|
2008-07-09 |
2011-05-04 |
Biogen Idec MA Inc. |
Antikörper gegen lingo oder fragmente davon enthaltende zusammensetzungen
|
JP5675608B2
(ja)
|
2008-07-18 |
2015-02-25 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
Cd28結合のための一価組成物および使用方法
|
US8148088B2
(en)
*
|
2008-07-18 |
2012-04-03 |
Abgent |
Regulation of autophagy pathway phosphorylation and uses thereof
|
EP2316030B1
(de)
|
2008-07-25 |
2019-08-21 |
Wagner, Richard W. |
Proteinscreeningverfahren
|
WO2010010469A2
(en)
*
|
2008-07-25 |
2010-01-28 |
Abbott Gmbh & Co. Kg |
Abeta (x-38..43) oligomers, and processes, compositions, and uses thereof
|
EP2815766B1
(de)
|
2008-08-05 |
2017-07-05 |
Novartis AG |
Zusammensetzungen und Verfahren für auf das Komplementprotein C5 gerichtete Antikörper
|
US9580513B2
(en)
|
2008-08-08 |
2017-02-28 |
Agency For Science, Technology And Research (A*Star) |
VHZ for diagnosis and treatment of cancers
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
MX2011001409A
(es)
|
2008-08-14 |
2011-03-29 |
Cephalon Australia Pty Ltd |
Anticuerpos anti-il-12/il-23.
|
WO2010028347A2
(en)
|
2008-09-05 |
2010-03-11 |
President & Fellows Of Harvard College |
Continuous directed evolution of proteins and nucleic acids
|
US8163497B2
(en)
|
2008-09-07 |
2012-04-24 |
Glyconex Inc. |
Anti-extended type I glycosphingolipid antibody, derivatives thereof and use
|
CA2735716A1
(en)
|
2008-09-12 |
2010-03-18 |
Dako Denmark A/S |
Prostate cancer biomarker
|
CN102224254A
(zh)
|
2008-09-23 |
2011-10-19 |
哈佛大学校长及研究员协会 |
Sirt4及其用途
|
JP2012504939A
(ja)
|
2008-09-23 |
2012-03-01 |
ワイス・エルエルシー |
架橋結合タンパク質による活性化シグナルの産生を予測するための方法
|
US8313942B2
(en)
|
2008-09-26 |
2012-11-20 |
Wyeth Llc |
Compatible display vector systems
|
HUE030807T2
(en)
|
2008-09-26 |
2017-05-29 |
Dana Farber Cancer Inst Inc |
Human anti-PD-1, anti-PD-L1 and anti-PD-L2 antibodies and their applications
|
GB0817891D0
(en)
|
2008-09-30 |
2008-11-05 |
Medical Res Council |
Antibodies against il-25
|
WO2010040073A1
(en)
|
2008-10-03 |
2010-04-08 |
Xoma Technology Ltd. |
Novel triple tag sequences and methods of use thereof
|
EP2346532B1
(de)
*
|
2008-10-07 |
2020-10-07 |
Bracco Suisse SA |
Target-konstrukt mit einem anti-polymer-antikörper und an diesen bindende mikrovesikel
|
DK3335728T3
(da)
|
2008-10-10 |
2020-02-24 |
Childrens Medical Center |
Biokemisk stabiliseret hiv-1 env-trimervaccine
|
CA2740440A1
(en)
|
2008-10-14 |
2010-04-22 |
Dyax Corp. |
Use of igf-ii/igf-iie binding proteins for the treatment and prevention of systemic sclerosis-associated pulmonary fibrosis
|
BRPI0920027A2
(pt)
|
2008-10-20 |
2015-10-06 |
Abbott Lab |
isolamento e purificação de anticorpos usando cromatografia de afinidade a proteína a
|
US20120251502A1
(en)
|
2008-10-24 |
2012-10-04 |
The Government of the US as Represented by the Secretary of the Dept. of health |
Human Ebola Virus Species and Compositions and Methods Thereof
|
MX345226B
(es)
|
2008-10-29 |
2017-01-20 |
Ablynx Nv |
Formulaciones de moleculas de union a antigeno de dominio sencillo.
|
ES2631507T3
(es)
|
2008-10-29 |
2017-08-31 |
China Synthetic Rubber Corporation |
Procedimientos y agentes para el diagnóstico y tratamiento del carcinoma hepatocelular
|
CA2739352C
(en)
|
2008-10-29 |
2021-07-13 |
Wyeth Llc |
Methods for purification of single domain antigen binding molecules
|
US9067981B1
(en)
|
2008-10-30 |
2015-06-30 |
Janssen Sciences Ireland Uc |
Hybrid amyloid-beta antibodies
|
PT2350304T
(pt)
|
2008-10-31 |
2017-03-23 |
Janssen Biotech Inc |
Antagonistas do recetor de tipo toll 3
|
US8298533B2
(en)
|
2008-11-07 |
2012-10-30 |
Medimmune Limited |
Antibodies to IL-1R1
|
US8628927B2
(en)
|
2008-11-07 |
2014-01-14 |
Sequenta, Inc. |
Monitoring health and disease status using clonotype profiles
|
US9528160B2
(en)
|
2008-11-07 |
2016-12-27 |
Adaptive Biotechnolgies Corp. |
Rare clonotypes and uses thereof
|
US8748103B2
(en)
|
2008-11-07 |
2014-06-10 |
Sequenta, Inc. |
Monitoring health and disease status using clonotype profiles
|
WO2010052288A1
(en)
|
2008-11-07 |
2010-05-14 |
Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research |
Teneurin and cancer
|
US9506119B2
(en)
|
2008-11-07 |
2016-11-29 |
Adaptive Biotechnologies Corp. |
Method of sequence determination using sequence tags
|
CN102272327B
(zh)
|
2008-11-07 |
2015-11-25 |
赛昆塔公司 |
通过序列分析监测状况的方法
|
BRPI0917315B8
(pt)
|
2008-11-07 |
2021-05-25 |
Galaxy Biotech Llc |
anticorpo monoclonal, seu uso e composição farmacêutica o compreendendo
|
WO2010054007A1
(en)
|
2008-11-07 |
2010-05-14 |
Fabrus Llc |
Combinatorial antibody libraries and uses thereof
|
US9365901B2
(en)
|
2008-11-07 |
2016-06-14 |
Adaptive Biotechnologies Corp. |
Monitoring immunoglobulin heavy chain evolution in B-cell acute lymphoblastic leukemia
|
EP2358392B1
(de)
|
2008-11-12 |
2019-01-09 |
MedImmune, LLC |
Antikörper-formulierung
|
EP2189539B2
(de)
|
2008-11-21 |
2018-06-13 |
Chimera Biotec GmbH |
Konjugatkomplexe zum Analytnachweis
|
US20110229471A1
(en)
|
2008-11-26 |
2011-09-22 |
Cedars-Sinai Medical Center |
Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease
|
RU2011121042A
(ru)
|
2008-11-26 |
2013-01-10 |
Файв Прайм Терапеутикс, Инк. |
Композиции и способы регулирования экспрессии коллагена и актина гладких мышц посредством serpine2
|
HUE028582T2
(en)
|
2008-11-28 |
2016-12-28 |
Univ Emory |
Method for determining the efficacy of PD-1 antagonists
|
GB0822011D0
(en)
|
2008-12-02 |
2009-01-07 |
Queen Mary & Westfield College |
Treatment
|
EP2370092A1
(de)
|
2008-12-03 |
2011-10-05 |
Research Development Foundation |
Modulierung von olfml-3-vermittelter angiogenese
|
EP2373692A4
(de)
*
|
2008-12-04 |
2013-11-20 |
Abbvie Inc |
Immunglobuline mit zweifacher variabler domäne und ihre verwendung
|
EP2364326B1
(de)
|
2008-12-05 |
2018-07-04 |
Glaxo Group Limited |
Verfahren zur selektion proteaseresistenter polypeptide
|
CN102300874B
(zh)
|
2008-12-08 |
2015-08-05 |
卡姆普根有限公司 |
Tmem154多肽和多核苷酸及其作为产生药物和生物制品的药物靶标的用途
|
TWI686405B
(zh)
|
2008-12-09 |
2020-03-01 |
建南德克公司 |
抗pd-l1抗體及其於增進t細胞功能之用途
|
EA201100943A1
(ru)
|
2008-12-16 |
2012-05-30 |
Новартис Аг |
Системы дрожжевого дисплея
|
JP5734201B2
(ja)
|
2008-12-19 |
2015-06-17 |
マクロジェニクス,インコーポレーテッド |
共有結合型ダイアボディ及びその使用
|
MX2011006908A
(es)
|
2008-12-26 |
2011-10-06 |
Univ Tokio |
Diagnosis y tratamiento del cancer utilizando el anticuerpo anti-lgr7.
|
US20120003235A1
(en)
|
2008-12-31 |
2012-01-05 |
Biogen Idec Ma Inc. |
Anti-lymphotoxin antibodies
|
WO2010078950A2
(en)
|
2009-01-07 |
2010-07-15 |
Philogen S.P.A. |
Antigens associated with endometriosis, psoriatic arthritis and psoriasis
|
US9181315B2
(en)
|
2009-01-08 |
2015-11-10 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for induced brown fat differentiation
|
GB0900425D0
(en)
|
2009-01-12 |
2009-02-11 |
Ucb Pharma Sa |
Biological products
|
CA2749572A1
(en)
|
2009-01-14 |
2010-07-22 |
Iq Therapeutics Bv |
Combination antibodies for the treatment and prevention of disease caused by bacillus anthracis and related bacteria and their toxins
|
WO2010083456A1
(en)
|
2009-01-15 |
2010-07-22 |
Imdaptive Inc. |
Adaptive immunity profiling and methods for generation of monoclonal antibodies
|
EP2389195B1
(de)
|
2009-01-20 |
2015-05-20 |
Homayoun H. Zadeh |
Antikörpervermittelte knochenregeneration
|
US20120058131A1
(en)
|
2009-01-21 |
2012-03-08 |
Oxford Biotherapeutics Ltd |
Pta089 protein
|
US20100260752A1
(en)
|
2009-01-23 |
2010-10-14 |
Biosynexus Incorporated |
Opsonic and protective antibodies specific for lipoteichoic acid of gram positive bacteria
|
JP5755149B2
(ja)
|
2009-01-26 |
2015-07-29 |
エレクトロフォレティクス リミテッドElectrophoretics Limited |
方法
|
JP2012516153A
(ja)
*
|
2009-01-29 |
2012-07-19 |
アボット・ラボラトリーズ |
Il−1結合タンパク質
|
US20110165063A1
(en)
*
|
2009-01-29 |
2011-07-07 |
Abbott Laboratories |
Il-1 binding proteins
|
WO2010087702A1
(en)
|
2009-01-30 |
2010-08-05 |
Stichting Katholieke Universiteit |
TET2 gene as a marker for diagnosing a myelodysuplastic syndrome (MDS) or an acute myeloid leukemia (AML) and determining the prognosis in a subject
|
WO2010087927A2
(en)
|
2009-02-02 |
2010-08-05 |
Medimmune, Llc |
Antibodies against and methods for producing vaccines for respiratory syncytial virus
|
MX368362B
(es)
|
2009-02-05 |
2019-09-30 |
Immunogen Inc |
Derivados novedosos de benzodiacepina.
|
US20120165340A1
(en)
|
2009-02-11 |
2012-06-28 |
Ludwing Institute For Cancer Research Ltd. |
Pten phosphorylation-driven resistance to cancer treatment and altered patient prognosis
|
EP2881402B1
(de)
|
2009-02-12 |
2017-05-10 |
Cell Signaling Technology, Inc. |
Expression mutanter ROS bei menschlichem Leberkrebs
|
WO2010093993A2
(en)
|
2009-02-12 |
2010-08-19 |
Human Genome Sciences, Inc. |
Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance
|
PL2398498T3
(pl)
*
|
2009-02-17 |
2019-03-29 |
Ucb Biopharma Sprl |
Cząsteczki przeciwciał swoiste wobec ludzkiego OX40
|
JP5721639B2
(ja)
|
2009-02-19 |
2015-05-20 |
ダコ・デンマーク・エー/エス |
分子標的の検出のための方法と化合物
|
WO2010097394A1
(en)
|
2009-02-24 |
2010-09-02 |
Glaxo Group Limited |
Multivalent and/or multispecific rankl-binding constructs
|
WO2010097386A1
(en)
|
2009-02-24 |
2010-09-02 |
Glaxo Group Limited |
Antigen-binding constructs
|
US8030026B2
(en)
|
2009-02-24 |
2011-10-04 |
Abbott Laboratories |
Antibodies to troponin I and methods of use thereof
|
EP2401298A1
(de)
|
2009-02-24 |
2012-01-04 |
Glaxo Group Limited |
Antigenbindende konstrukte
|
GB0903325D0
(en)
|
2009-02-26 |
2009-04-08 |
Univ Aberdeen |
Antibody molecules
|
EP2403880A1
(de)
|
2009-03-05 |
2012-01-11 |
Tripath Imaging, Inc. |
Monoklonale antikörper gegen matrixmetalloproteinase-7 (mmp-7) und verfahren zu ihrer verwendung beim nachweis von eierstockkrebs
|
RU2015132478A
(ru)
|
2009-03-05 |
2015-12-10 |
Эббви Инк. |
Связывающие il-17 белки
|
US8420084B2
(en)
|
2009-03-05 |
2013-04-16 |
Medarex, Inc. |
Fully human antibodies specific to CADM1
|
US20110311521A1
(en)
|
2009-03-06 |
2011-12-22 |
Pico Caroni |
Novel therapy for anxiety
|
AU2010221188A1
(en)
|
2009-03-06 |
2011-10-20 |
Tripath Imaging, Inc. |
Glycodelin monoclonal antibodies and methods for their use in the detection of ovarian cancer
|
WO2010104208A1
(en)
|
2009-03-10 |
2010-09-16 |
Gene Techno Science Co., Ltd. |
Generation, expression and characterization of the humanized k33n monoclonal antibody
|
GB0904214D0
(en)
|
2009-03-11 |
2009-04-22 |
Ucb Pharma Sa |
Biological products
|
GB0904321D0
(en)
|
2009-03-12 |
2009-04-22 |
Cambridge Entpr Ltd |
Modulation of T-cell mediated immune responses
|
CA2753894C
(en)
|
2009-03-13 |
2017-12-05 |
Allergan, Inc. |
Immuno-based retargeted endopeptidase activity assays
|
JP2010210772A
(ja)
|
2009-03-13 |
2010-09-24 |
Dainippon Screen Mfg Co Ltd |
液晶表示装置の製造方法
|
ES2486673T3
(es)
|
2009-03-19 |
2014-08-19 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Uso de NKp46 para prevenir la diabetes tipo I
|
US20120121591A1
(en)
|
2009-03-20 |
2012-05-17 |
Amgen Inc. |
SELECTIVE AND POTENT PEPTIDE INHIBITORS OF Kv1.3
|
WO2010111702A1
(en)
|
2009-03-27 |
2010-09-30 |
The Research Foundation Of State University Of New York |
Methods for preventing and treating angioedema
|
AU2010234849B2
(en)
|
2009-03-30 |
2017-06-22 |
Mount Sinai School Of Medicine |
Influenza virus vaccines and uses thereof
|
BRPI1012676A2
(pt)
|
2009-04-01 |
2016-04-05 |
Genentech Inc |
anticorpos anti-fcrh5 e imunoconjugados e métodos de uso
|
EP2414543B1
(de)
|
2009-04-03 |
2016-10-12 |
Decode Genetics EHF |
Genetische marker zur risikobewertung von vorhofflimmern und apoplexie
|
GB0905972D0
(en)
|
2009-04-06 |
2009-05-20 |
Medical Res Council |
Antibodies against IL-17BR
|
NZ596218A
(en)
|
2009-04-08 |
2013-07-26 |
Olle Hernell |
Bssl antagonists for treatment of inflammatory diseases
|
MX343049B
(es)
|
2009-04-09 |
2016-10-21 |
Daiichi Sankyo Co Ltd |
Anticuerpo anti-lectina similar a inmunoglobulina de union a acido sialico-15.
|
ES2571235T3
(es)
|
2009-04-10 |
2016-05-24 |
Kyowa Hakko Kirin Co Ltd |
Procedimiento para el tratamiento de un tumor sanguíneo que utiliza el anticuerpo anti-TIM-3
|
EP2241323A1
(de)
|
2009-04-14 |
2010-10-20 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Tenascin-W und Hirnkrebs
|
RU2595379C2
(ru)
|
2009-04-16 |
2016-08-27 |
АббВай Биотерапеутикс Инк. |
АНТИТЕЛА ПРОТИВ TNF-α И ИХ ПРИМЕНЕНИЯ
|
US20120052064A1
(en)
|
2009-04-17 |
2012-03-01 |
Yuuki Ito |
Anti-hgf antibody combinational cancer therapies
|
US9062116B2
(en)
|
2009-04-23 |
2015-06-23 |
Infinity Pharmaceuticals, Inc. |
Anti-fatty acid amide hydrolase-2 antibodies and uses thereof
|
US8741581B2
(en)
|
2009-04-27 |
2014-06-03 |
Technion Research And Development Foundation Ltd. |
Markers for cancer detection
|
MX2011011338A
(es)
|
2009-04-27 |
2012-04-19 |
Novartis Ag |
Composiciones y metodos de uso para anticuerpos terapeuticos especificos para la subunidad beta1 del receptor de il-12.
|
PT2426148E
(pt)
|
2009-04-27 |
2015-10-26 |
Kyowa Hakko Kirin Co Ltd |
Anticorpo anti-rá-il-3 para se utilizar no tratamento de tumores do sangue
|
EP3275900A1
(de)
|
2009-04-27 |
2018-01-31 |
Novartis AG |
Zusammensetzungen und verfahren zur förderung des muskelwachstums
|
MX2011011541A
(es)
|
2009-04-29 |
2012-02-28 |
Abbott Biotech Ltd |
Dispositivo de inyeccion automatico.
|
ES2495367T3
(es)
|
2009-04-29 |
2014-09-17 |
The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. |
Anticuerpos monoclonales de ERG
|
SG175396A1
(en)
|
2009-04-29 |
2011-12-29 |
Centocor Ortho Biotech Inc |
Toll-like receptor 3 antagonists
|
CA2760642A1
(en)
|
2009-05-01 |
2010-11-04 |
The University Of Tokyo |
Anti-cadherin antibody
|
PT2448970E
(pt)
|
2009-05-04 |
2014-10-20 |
Abbvie Res B V |
Anticorpos contra factor de crescimento nervoso (ngf) com estabilidade in vivo melhorada
|
EP2427203B1
(de)
|
2009-05-05 |
2018-10-17 |
Novimmune S.A. |
Anti-il-17f-antikörper und deren verwendung
|
EP2270053A1
(de)
|
2009-05-11 |
2011-01-05 |
U3 Pharma GmbH |
Humanisierte AXL-Antikörper
|
BRPI1011195B1
(pt)
|
2009-05-20 |
2020-10-13 |
Novimmune S.A |
métodos para produzir uma coleção de ácidos nucleicos
|
EP2435475B1
(de)
|
2009-05-26 |
2018-10-17 |
Icahn School of Medicine at Mount Sinai |
Mittels zyklischer verabreichung erzeugte monoklonale antikörper gegen influenzavirus und ihre anwendung
|
JP5804521B2
(ja)
|
2009-05-29 |
2015-11-04 |
モルフォシス・アー・ゲー |
コレクション及びその使用方法
|
US20120141501A1
(en)
|
2009-05-29 |
2012-06-07 |
Forerunner Pharma Research Co. Ltd |
Pharmaceutical Composition Containing Antagonist of EGF Family Ligand as Component
|
RU2765240C2
(ru)
|
2009-06-03 |
2022-01-27 |
Иммьюноджен, Инк. |
Способы конъюгации
|
EP2261242A1
(de)
|
2009-06-10 |
2010-12-15 |
Universite Catholique De Louvain |
Aspartat-N-Acetyltransferaseenzym, Diagnoseverfahren und therapeutisches Verfahren
|
SG10201403327WA
(en)
|
2009-06-17 |
2014-10-30 |
Abbvie Biotherapeutics Inc |
Anti-vegf antibodies and their uses
|
MX2012000121A
(es)
|
2009-06-22 |
2012-03-07 |
Medimmune Llc |
Regiones fc modificadas para la conjugacion especifica del sitio.
|
GB0910725D0
(en)
|
2009-06-22 |
2009-08-05 |
Heptares Therapeutics Ltd |
Mutant proteins and methods for producing them
|
WO2010151632A1
(en)
|
2009-06-25 |
2010-12-29 |
Bristol-Myers Squibb Company |
Protein purifacation by caprylic acid (octanoic acid ) precipitation
|
EP2446052B1
(de)
|
2009-06-25 |
2018-08-08 |
Fred Hutchinson Cancer Research Center |
Verfahren zur messung der adaptiven immunität
|
EP2272979A1
(de)
|
2009-06-30 |
2011-01-12 |
Centre National de la Recherche Scientifique (CNRS) |
Verfahren zum Testen einer Person, die eine Prädisposition für Krebs aufzuweisen scheint
|
WO2011000543A1
(en)
|
2009-06-30 |
2011-01-06 |
Philochem Ag |
Murine antibody display library
|
EP2451487A1
(de)
|
2009-07-09 |
2012-05-16 |
F. Hoffmann-La Roche AG |
In-vivo-bildgebung von tumorvaskulatur
|
CA2767360A1
(en)
|
2009-07-10 |
2011-01-13 |
Decode Genetics Ehf. |
Genetic markers associated with risk of diabetes mellitus
|
US9217157B2
(en)
|
2009-07-27 |
2015-12-22 |
Icahn School Of Medicine At Mount Sinai |
Recombinant influenza viruses and uses thereof
|
EP2459585A1
(de)
|
2009-07-30 |
2012-06-06 |
Mount Sinai School of Medicine |
Influenzaviren und ihre verwendung
|
CN102596220A
(zh)
|
2009-07-31 |
2012-07-18 |
韦恩州立大学 |
单磷酸化的脂质a衍生物
|
SG178190A1
(en)
|
2009-07-31 |
2012-03-29 |
Shin Maeda |
Cancer metastasis inhibitor
|
US9259476B2
(en)
|
2009-07-31 |
2016-02-16 |
Wayne State University |
Monophosphorylated lipid A derivatives
|
DK2464664T3
(da)
|
2009-08-13 |
2016-01-18 |
Crucell Holland Bv |
Antistoffer mod humant respiratorisk syncytialvirus (rsv) og fremgangsmåder til anvendelse deraf
|
CN102574917A
(zh)
|
2009-08-17 |
2012-07-11 |
株式会社未来创药研究所 |
含有抗hb-egf抗体作为有效成分的药物组合物
|
WO2011021146A1
(en)
|
2009-08-20 |
2011-02-24 |
Pfizer Inc. |
Osteopontin antibodies
|
GB0914691D0
(en)
|
2009-08-21 |
2009-09-30 |
Lonza Biologics Plc |
Immunoglobulin variants
|
EP2292266A1
(de)
|
2009-08-27 |
2011-03-09 |
Novartis Forschungsstiftung, Zweigniederlassung |
Behandlung von Krebs durch Modulation von Copine III
|
CN102741288B
(zh)
|
2009-08-29 |
2015-08-19 |
Abbvie公司 |
治疗用dll4结合蛋白
|
AU2010286361A1
(en)
|
2009-08-31 |
2012-03-15 |
Amplimmune, Inc. |
Methods and compositions for the inhibition of transplant rejection
|
JP2013503607A
(ja)
|
2009-09-01 |
2013-02-04 |
アボット・ラボラトリーズ |
二重可変ドメイン免疫グロブリンおよびその使用
|
US20110059111A1
(en)
|
2009-09-01 |
2011-03-10 |
Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center |
Mammalian receptors as targets for antibody and active vaccination therapy against mold infections
|
WO2011029823A1
(en)
|
2009-09-09 |
2011-03-17 |
Novartis Ag |
Monoclonal antibody reactive with cd63 when expressed at the surface of degranulated mast cells
|
WO2011030107A1
(en)
|
2009-09-10 |
2011-03-17 |
Ucb Pharma S.A. |
Multivalent antibodies
|
WO2011032181A2
(en)
*
|
2009-09-14 |
2011-03-17 |
Dyax Corp. |
Libraries of genetic packages comprising novel hc cdr3 designs
|
EP2477654A4
(de)
|
2009-09-14 |
2013-01-23 |
Abbott Lab |
Verfahren zur behandlung von schuppenflechte
|
WO2011032204A1
(en)
|
2009-09-15 |
2011-03-24 |
Csl Limited |
Treatment of neurological conditions
|
US20120302737A1
(en)
|
2009-09-16 |
2012-11-29 |
Genentech, Inc. |
Coiled coil and/or tether containing protein complexes and uses thereof
|
EP3009455A1
(de)
|
2009-09-16 |
2016-04-20 |
Immunomedics Inc. |
Klasse-i-anti-cea-antikörper und verwendungen davon
|
EP2478101A1
(de)
|
2009-09-16 |
2012-07-25 |
Stichting Het Nederlands Kanker Instituut |
Fra-1-zielgene als wirkstofftargets zur behandlung von krebs
|
US20110189183A1
(en)
|
2009-09-18 |
2011-08-04 |
Robert Anthony Williamson |
Antibodies against candida, collections thereof and methods of use
|
EP2305717A1
(de)
|
2009-09-21 |
2011-04-06 |
Koninklijke Nederlandse Akademie van Wetenschappen |
Hemmung von TNIK zur Behandlung von Darmkrebs
|
WO2011036118A1
(en)
|
2009-09-22 |
2011-03-31 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Treating cancer by modulating mex-3
|
WO2011037983A1
(en)
|
2009-09-23 |
2011-03-31 |
Medarex, Inc. |
Cation exchange chromatography
|
TW201118166A
(en)
|
2009-09-24 |
2011-06-01 |
Chugai Pharmaceutical Co Ltd |
HLA class I-recognizing antibodies
|
US8926976B2
(en)
|
2009-09-25 |
2015-01-06 |
Xoma Technology Ltd. |
Modulators
|
EP2480572B1
(de)
|
2009-09-25 |
2019-01-30 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Neutralisierende antikörper gegen hiv-1 und ihre verwendung
|
WO2011036555A1
(en)
|
2009-09-25 |
2011-03-31 |
University Of Oslo |
Multivalent phage display systems and methods
|
GB201005063D0
(en)
|
2010-03-25 |
2010-05-12 |
Ucb Pharma Sa |
Biological products
|
WO2011038301A2
(en)
|
2009-09-25 |
2011-03-31 |
Xoma Technology Ltd. |
Screening methods
|
US20110076232A1
(en)
|
2009-09-29 |
2011-03-31 |
Ludwig Institute For Cancer Research |
Specific binding proteins and uses thereof
|
BR112012007160A2
(pt)
|
2009-09-30 |
2018-03-13 |
Harvard College |
metodos para modulacao da autofagia por meio da modulacao d eprodutos genicos inibidores da autofagia
|
WO2011040973A2
(en)
|
2009-10-02 |
2011-04-07 |
Ludwig Institute For Cancer Research Ltd. |
Tnf-immunoconjugates with fibroblast activation protein antibodies and methods and uses thereof
|
EP2483316A1
(de)
|
2009-10-02 |
2012-08-08 |
Ludwig Institute for Cancer Research Ltd. |
Anti-fibroblastenaktivierungsprotein-antikörper, verfahren und verwendung
|
UY32914A
(es)
|
2009-10-02 |
2011-04-29 |
Sanofi Aventis |
Anticuerpos que se usan específicamente al receptor epha2
|
JP2013506709A
(ja)
|
2009-10-06 |
2013-02-28 |
イミュノジェン・インコーポレーテッド |
有効なコンジュゲートおよび親水性リンカー
|
DK2486141T3
(en)
|
2009-10-07 |
2018-04-23 |
Macrogenics Inc |
FC-REGION-CONTAINING POLYPEPTIDES THAT PROVIDE IMPROVED EFFECTOR FUNCTION BASED ON CHANGES OF THE SCOPE OF FUCOSYLATION AND PROCEDURES FOR THEIR USE
|
US20120231004A1
(en)
|
2009-10-13 |
2012-09-13 |
Oxford Biotherapeutic Ltd. |
Antibodies
|
AR078651A1
(es)
|
2009-10-15 |
2011-11-23 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
WO2011045352A2
(en)
|
2009-10-15 |
2011-04-21 |
Novartis Forschungsstiftung |
Spleen tyrosine kinase and brain cancers
|
MX341136B
(es)
|
2009-10-20 |
2016-08-09 |
Abbvie Inc |
Aislamiento y purificacion de los anticuerpos anti-il-13 al usar la cromatografia de afinidad con proteina a.
|
CN104714007B
(zh)
|
2009-10-20 |
2017-04-12 |
丹麦达科有限公司 |
单个靶实体的免疫化学检测
|
GB0922434D0
(en)
|
2009-12-22 |
2010-02-03 |
Ucb Pharma Sa |
antibodies and fragments thereof
|
GB0922435D0
(en)
|
2009-12-22 |
2010-02-03 |
Ucb Pharma Sa |
Method
|
US20110098862A1
(en)
|
2009-10-27 |
2011-04-28 |
ExxonMobil Research Engineering Company Law Department |
Multi-stage processes and control thereof
|
US9234037B2
(en)
|
2009-10-27 |
2016-01-12 |
Ucb Biopharma Sprl |
Method to generate antibodies to ion channels
|
CN102781963B
(zh)
|
2009-10-27 |
2018-02-16 |
Ucb医药有限公司 |
功能修饰性NAv1.7抗体
|
EP2493929B1
(de)
|
2009-10-28 |
2017-08-16 |
AbbVie Biotherapeutics Inc. |
Anti-egfr-antikörper und deren verwendungen
|
UY32979A
(es)
|
2009-10-28 |
2011-02-28 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
US20120213801A1
(en)
|
2009-10-30 |
2012-08-23 |
Ekaterina Gresko |
Phosphorylated Twist1 and cancer
|
EA029283B1
(ru)
|
2009-10-30 |
2018-03-30 |
Янссен Байотек, Инк. |
Антагонисты il-17a
|
TW201121568A
(en)
*
|
2009-10-31 |
2011-07-01 |
Abbott Lab |
Antibodies to receptor for advanced glycation end products (RAGE) and uses thereof
|
US20120282177A1
(en)
|
2009-11-02 |
2012-11-08 |
Christian Rohlff |
ROR1 as Therapeutic and Diagnostic Target
|
EP2496600A1
(de)
|
2009-11-04 |
2012-09-12 |
Fabrus LLC |
Verfahren zur optimierung von antikörpern auf der basis von affinitätsreifung
|
JP2013509874A
(ja)
|
2009-11-04 |
2013-03-21 |
エラスムス ユニバーシティ メディカル センター ロッテルダム |
新脈管形成を調節する為の新規化合物及びこれらの化合物を使用する処置方法
|
US20110165648A1
(en)
|
2009-11-04 |
2011-07-07 |
Menno Van Lookeren Campagne |
Co-crystal structure of factor D and anti-factor D antibody
|
CN102640001A
(zh)
|
2009-11-05 |
2012-08-15 |
诺瓦提斯公司 |
预测纤维化进展的生物标记物
|
EP2496604B1
(de)
|
2009-11-06 |
2017-08-23 |
IDEXX Laboratories, Inc. |
Antikörper gegen hunde-cd20
|
CA2780024A1
(en)
|
2009-11-11 |
2011-05-19 |
Gentian As |
Immunoassay for assessing related analytes of different origin
|
CA3061784C
(en)
|
2009-11-13 |
2023-09-26 |
Dana-Farber Cancer Institute, Inc. |
Compositions, kits, and methods for the diagnosis, prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1
|
GB0920127D0
(en)
|
2009-11-17 |
2009-12-30 |
Ucb Pharma Sa |
Antibodies
|
HUE035508T2
(en)
|
2009-11-17 |
2018-05-02 |
Squibb & Sons Llc |
Procedures for Increased Protein Production
|
EP2325311A1
(de)
|
2009-11-18 |
2011-05-25 |
Pierre Fabre Medicament |
Neuer Phagenanzeigevektor
|
GB0920324D0
(en)
|
2009-11-19 |
2010-01-06 |
Ucb Pharma Sa |
Antibodies
|
MX2012005864A
(es)
|
2009-11-20 |
2012-08-31 |
Amgen Inc |
Proteinas de enlace al antígeno anti-orai 1 y usos de las mismas.
|
WO2011067711A2
(en)
|
2009-12-01 |
2011-06-09 |
Compugen Ltd |
Novel heparanase splice variant
|
EP2510001B1
(de)
|
2009-12-08 |
2015-12-02 |
AbbVie Deutschland GmbH & Co KG |
Monoklonale antikörper gegen das rgm-a-protein zur behandlung von degenerationen der retinalen nervenfaserschicht
|
IN2012DN04908A
(de)
|
2009-12-09 |
2015-09-25 |
Inst Nat Sante Rech Med |
|
WO2011084496A1
(en)
|
2009-12-16 |
2011-07-14 |
Abbott Biotherapeutics Corp. |
Anti-her2 antibodies and their uses
|
WO2011075185A1
(en)
|
2009-12-18 |
2011-06-23 |
Oligasis |
Targeted drug phosphorylcholine polymer conjugates
|
CA2785587A1
(en)
|
2009-12-23 |
2011-06-30 |
4-Antibody Ag |
Binding members for human cytomegalovirus
|
US9005579B2
(en)
|
2010-01-05 |
2015-04-14 |
Contrafect Corporation |
Methods and compositions for enhanced immunological therapy and targeting of gram-positive bacteria
|
ES2688093T3
(es)
|
2010-01-06 |
2018-10-30 |
Dyax Corp. |
Proteínas de unión a calicreína plasmática
|
GB201000467D0
(en)
|
2010-01-12 |
2010-02-24 |
Ucb Pharma Sa |
Antibodies
|
MX2012008085A
(es)
|
2010-01-13 |
2012-09-12 |
Oncomed Pharm Inc |
Agentes de union notch1 y metodos de uso de los mismos.
|
WO2011088163A1
(en)
|
2010-01-14 |
2011-07-21 |
President And Fellows Of Harvard College |
Methods for modulating skeletal remodeling and patterning by modulating shn2 activity, shn3 activity, or shn2 and shn3 activity in combination
|
TWI505838B
(zh)
|
2010-01-20 |
2015-11-01 |
Chugai Pharmaceutical Co Ltd |
Stabilized antibody solution containing
|
AU2011207210A1
(en)
|
2010-01-22 |
2012-08-16 |
Dana-Farber Cancer Institute, Inc. |
Compositions,kits, and methods for identification, assessment, prevention, and therapy of metabolic disorders
|
EP2530109A4
(de)
|
2010-01-29 |
2013-08-28 |
Toray Industries |
Harzfolie auf polymilchsäurebasis
|
WO2011097301A2
(en)
|
2010-02-02 |
2011-08-11 |
Abbott Biotechnology Ltd. |
METHODS AND COMPOSITIONS FOR PREDICTING RESPONSIVENESS TO TREATMENT WITH TNF-α INHIBITOR
|
TWI518325B
(zh)
|
2010-02-04 |
2016-01-21 |
自治醫科大學 |
對alk抑制劑具有先抗性或後抗性癌症的識別、判斷和治療
|
EP2354244A1
(de)
|
2010-02-04 |
2011-08-10 |
Stichting Top Institute Food and Nutrition |
MBL2 als Marker für die leberspezifische Insulinresistenz
|
EP2354245A1
(de)
|
2010-02-04 |
2011-08-10 |
Stichting Top Institute Food and Nutrition |
MBL2 als Marker für die hepatische PPAR-Aktivität
|
WO2011097511A1
(en)
|
2010-02-05 |
2011-08-11 |
The United States Of America, As Represented By The Secretary Department Of Health & Human Services |
REGULATORY B CELLS (tBREGS) AND THEIR USE
|
MX2012009318A
(es)
|
2010-02-10 |
2012-09-07 |
Novartis Ag |
Metodos y compuestos para el crecimiento muscular.
|
US8815211B2
(en)
|
2010-02-10 |
2014-08-26 |
Fujifilm Ri Pharma Co., Ltd. |
Radioactive metal-labeled anti-cadherin antibody
|
NZ601743A
(en)
|
2010-02-12 |
2014-11-28 |
Oncomed Pharm Inc |
Methods for identifying and isolating cells expressing a polypeptide
|
WO2011103330A2
(en)
|
2010-02-17 |
2011-08-25 |
The Johns Hopkins University |
Novel phosphorylation of cardiac troponin i as a monitor for cardiac injury
|
KR20120132506A
(ko)
|
2010-02-18 |
2012-12-05 |
마운트 시나이 스쿨 오브 메디슨 |
인플루엔자 바이러스 질환의 예방 및 치료에 사용되는 백신
|
KR20190114019A
(ko)
|
2010-02-24 |
2019-10-08 |
이뮤노젠 아이엔씨 |
엽산염 수용체 1 항체와 면역접합체 및 이들의 용도
|
RU2016146198A
(ru)
|
2010-03-02 |
2018-12-19 |
Эббви Инк. |
Терапевтические dll4-связывающие белки
|
EP2544688B1
(de)
|
2010-03-02 |
2016-09-07 |
President and Fellows of Harvard College |
Verfahren und zusammensetzungen zur behandlung des angelman-syndroms
|
JP5889181B2
(ja)
|
2010-03-04 |
2016-03-22 |
中外製薬株式会社 |
抗体定常領域改変体
|
US20130004519A1
(en)
|
2010-03-05 |
2013-01-03 |
Ruth Chiquet-Ehrismann |
Smoci, tenascin-c and brain cancers
|
SG183542A1
(en)
|
2010-03-12 |
2012-10-30 |
Immunogen Inc |
Cd37-binding molecules and immunoconjugates thereof
|
ES2575160T3
(es)
|
2010-03-15 |
2016-06-24 |
The Board Of Trustees Of The University Of Illinois |
Inhibidores de las interacciones que unen la subunidad alfa de la beta integrina-proteína G
|
BR112012023895A2
(pt)
|
2010-03-17 |
2016-11-29 |
Abbott Res Bv |
composições de anti-fator de crescimento do nervo (ngf)
|
US10706955B2
(en)
|
2010-03-23 |
2020-07-07 |
Iogenetics, Llc |
Bioinformatic processes for determination of peptide binding
|
WO2011117653A1
(en)
|
2010-03-25 |
2011-09-29 |
Ucb Pharma S.A. |
Disulfide stabilized dvd-lg molecules
|
GB201005064D0
(en)
|
2010-03-25 |
2010-05-12 |
Ucb Pharma Sa |
Biological products
|
CA2794483C
(en)
|
2010-03-26 |
2020-07-07 |
Trustees Of Dartmouth College |
Vista regulatory t cell mediator protein, vista binding agents and use thereof
|
US10745467B2
(en)
|
2010-03-26 |
2020-08-18 |
The Trustees Of Dartmouth College |
VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
|
US20150231215A1
(en)
|
2012-06-22 |
2015-08-20 |
Randolph J. Noelle |
VISTA Antagonist and Methods of Use
|
TW201138821A
(en)
|
2010-03-26 |
2011-11-16 |
Roche Glycart Ag |
Bispecific antibodies
|
AU2011235220B2
(en)
|
2010-03-30 |
2016-03-10 |
Mount Sinai School Of Medicine |
Influenza virus vaccines and uses thereof
|
DK2552961T3
(en)
|
2010-03-30 |
2018-03-05 |
Janssen Biotech Inc |
HUMANIZED IL-25 ANTIBODIES
|
TWI667346B
(zh)
|
2010-03-30 |
2019-08-01 |
中外製藥股份有限公司 |
促進抗原消失之具有經修飾的FcRn親和力之抗體
|
EP2558498B1
(de)
|
2010-04-13 |
2016-10-12 |
Celldex Therapeutics, Inc. |
Humane cd27-bindende antikörper und ihre verwendung
|
CA2796339C
(en)
|
2010-04-15 |
2020-03-31 |
Abbott Laboratories |
Amyloid-beta binding proteins
|
WO2011131611A1
(en)
|
2010-04-19 |
2011-10-27 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Modulating xrn1
|
EP2380909A1
(de)
|
2010-04-26 |
2011-10-26 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
An Brustkrebs beteiligtes Protein PTK-7
|
MX340696B
(es)
|
2010-04-30 |
2016-07-21 |
Alexion Pharma Inc |
Anticuerpos anti-c5a y metodos para usar los anticuerpos.
|
JP2013533211A
(ja)
|
2010-05-04 |
2013-08-22 |
メリマック ファーマシューティカルズ インコーポレーティッド |
上皮成長因子受容体(egfr)に対する抗体およびその使用
|
WO2011140151A1
(en)
|
2010-05-04 |
2011-11-10 |
Dyax Corp. |
Antibodies against epidermal growth factor receptor (egfr)
|
US9290573B2
(en)
|
2010-05-06 |
2016-03-22 |
Novartis Ag |
Therapeutic low density lipoprotein-related protein 6 (LRP6) multivalent antibodies
|
AU2011249783B9
(en)
|
2010-05-06 |
2014-11-06 |
Novartis Ag |
Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (LRP6) antibodies
|
IL208820A0
(en)
|
2010-10-19 |
2011-01-31 |
Rachel Teitelbaum |
Biologic female contraceptives
|
WO2011141823A2
(en)
|
2010-05-14 |
2011-11-17 |
Orega Biotech |
Methods of treating and/or preventing cell proliferation disorders with il-17 antagonists
|
CN102946903B
(zh)
|
2010-05-14 |
2014-11-26 |
安进公司 |
高浓度抗体制剂
|
ES2635594T3
(es)
|
2010-05-14 |
2017-10-04 |
Abbvie Inc. |
Proteínas de unión a IL-1
|
GB201008541D0
(en)
|
2010-05-21 |
2010-07-07 |
Univ Geneve |
Diagnostic methods
|
WO2011149051A1
(ja)
|
2010-05-28 |
2011-12-01 |
中外製薬株式会社 |
抗腫瘍t細胞応答増強剤
|
JP5904552B2
(ja)
|
2010-05-28 |
2016-04-13 |
国立研究開発法人国立がん研究センター |
膵癌治療剤
|
AU2011261161A1
(en)
|
2010-06-01 |
2013-01-10 |
Ludwig Institute For Cancer Research Limited |
Antibodies directed to the unprocessed receptor tyrosine kinase c-Met
|
PT2575884T
(pt)
|
2010-06-03 |
2018-10-31 |
Abbvie Biotechnology Ltd |
Utilizações e composições para o tratamento de hidradenite supurativa (hs)
|
US9499813B2
(en)
|
2010-06-10 |
2016-11-22 |
President And Fellows Of Harvard College |
Systems and methods for amplification and phage display
|
US20130089538A1
(en)
|
2010-06-10 |
2013-04-11 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute forBiomedical Researh |
Treating cancer by modulating mammalian sterile 20-like kinase 3
|
CA2802631C
(en)
|
2010-06-14 |
2019-12-17 |
Lykera Biomed Sa |
S100a4 antibodies and therapeutic uses thereof
|
MX2012014838A
(es)
|
2010-06-16 |
2013-02-07 |
Abbvie Inc |
Comparacion de las muestras de proteina.
|
EP4269563A3
(de)
|
2010-06-19 |
2024-01-10 |
Memorial Sloan-Kettering Cancer Center |
Anti-gd2-antikörper
|
EP3327035A1
(de)
|
2010-06-22 |
2018-05-30 |
Precision Biologics Inc. |
Für dickdarm- und bauchspeicheldrüsenkrebs spezifische antigene und antikörper
|
ES2706913T3
(es)
|
2010-06-25 |
2019-04-01 |
Univ Aston |
Glucoproteínas que tienen propiedades de movilización de lípidos y usos terapéuticos de las mismas
|
EP2588107A1
(de)
|
2010-07-01 |
2013-05-08 |
Takeda Pharmaceutical Company Limited |
Kombination aus einem cmet-hemmer und einem antikörper gegen hgf und/oder cmet
|
WO2012004565A1
(en)
|
2010-07-06 |
2012-01-12 |
Robert White |
Cancer biomarker brf1
|
EP2591005A2
(de)
|
2010-07-06 |
2013-05-15 |
Aveo Pharmaceuticals, Inc. |
Anti-ron-antikörper
|
BR112013000341A2
(pt)
|
2010-07-07 |
2017-09-26 |
Tubitak |
estruturas de anticorpos recombinantes ligando-se e bloqueando o crescimento da atividade vascular endotelial de fator 2 (vegfr-2/kdr)
|
WO2012006500A2
(en)
|
2010-07-08 |
2012-01-12 |
Abbott Laboratories |
Monoclonal antibodies against hepatitis c virus core protein
|
UY33492A
(es)
|
2010-07-09 |
2012-01-31 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
KR20130120439A
(ko)
|
2010-07-09 |
2013-11-04 |
제넨테크, 인크. |
항-뉴로필린 항체 및 사용 방법
|
WO2012006552A1
(en)
|
2010-07-09 |
2012-01-12 |
Exelixis, Inc. |
Combinations of kinase inhibitors for the treatment of cancer
|
TW201217526A
(en)
|
2010-07-09 |
2012-05-01 |
Biogen Idec Hemophilia Inc |
Chimeric clotting factors
|
JP5744196B2
(ja)
|
2010-07-09 |
2015-07-08 |
クルセル ホランド ベー ヴェー |
抗ヒト呼吸器多核体ウイルス(rsv)抗体および使用の方法
|
BR112013000796B1
(pt)
|
2010-07-14 |
2021-08-31 |
Merck Sharp & Dohme Corp |
Anticorpo isolado ou um fragmento de ligação ao antígeno, composição farmacêutica, métodos para inibir a montagem de ligantes difusíveis derivados de ß-amiloide, para inibir a fosforilação de proteína tau em ser202/thr205, para identificar um suposto agente terapêutico, para detectar ligantes difusíveis derivados de ß-amiloide e para diagnosticar uma doença associada aos ligantes difusíveis derivados de ß-amiloide, e, kit para detectar ligantes difusíveis derivados de ß-amiloide
|
US20120100166A1
(en)
|
2010-07-15 |
2012-04-26 |
Zyngenia, Inc. |
Ang-2 Binding Complexes and Uses Thereof
|
JP6266343B2
(ja)
|
2010-07-16 |
2018-01-24 |
アディマブ, エルエルシー |
抗体ライブラリー
|
CN103119062A
(zh)
|
2010-07-16 |
2013-05-22 |
埃博灵克斯股份有限公司 |
修饰的单结构域抗原结合分子及其应用
|
MX345300B
(es)
|
2010-07-30 |
2017-01-24 |
Novartis Ag * |
Moléculas andamio de fibronectina y bibliotecas de las mismas.
|
CA2807127C
(en)
|
2010-08-02 |
2019-02-12 |
Leslie S. Johnson |
Covalent diabodies and uses thereof
|
CN103392182B
(zh)
|
2010-08-02 |
2017-07-04 |
众有生物有限公司 |
用于发现遗传疾病中致病突变的系统和方法
|
NZ607480A
(en)
|
2010-08-03 |
2014-10-31 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
WO2012019024A2
(en)
|
2010-08-04 |
2012-02-09 |
Immunogen, Inc. |
Her3-binding molecules and immunoconjugates thereof
|
WO2012019061A2
(en)
|
2010-08-05 |
2012-02-09 |
Stem Centrx, Inc. |
Novel effectors and methods of use
|
US20120101108A1
(en)
|
2010-08-06 |
2012-04-26 |
Cell Signaling Technology, Inc. |
Anaplastic Lymphoma Kinase In Kidney Cancer
|
SG187787A1
(en)
|
2010-08-10 |
2013-03-28 |
Amgen Inc |
Dual function in vitro target binding assay for the detection of neutralizing antibodies against target antibodies
|
EP2420250A1
(de)
|
2010-08-13 |
2012-02-22 |
Universitätsklinikum Münster |
Anti-Syndecan-4-Antikörper
|
JP2013537416A
(ja)
|
2010-08-13 |
2013-10-03 |
メディミューン リミテッド |
変異型Fc領域を含むモノマーポリペプチド及び使用方法
|
JP6147665B2
(ja)
|
2010-08-14 |
2017-06-14 |
アッヴィ・インコーポレイテッド |
アミロイドベータ結合タンパク質
|
WO2012022734A2
(en)
|
2010-08-16 |
2012-02-23 |
Medimmune Limited |
Anti-icam-1 antibodies and methods of use
|
PL2606361T3
(pl)
|
2010-08-17 |
2017-02-28 |
Stichting Katholieke Universiteit |
Nowy sposób diagnozowania gorączki q z użyciem komórkowego oznaczenia immunologicznego
|
JP6121903B2
(ja)
|
2010-08-19 |
2017-04-26 |
ゾエティス・ベルジャム・エス・アー |
抗ngf抗体およびその使用
|
GB201014033D0
(en)
|
2010-08-20 |
2010-10-06 |
Ucb Pharma Sa |
Biological products
|
DK2606070T3
(en)
|
2010-08-20 |
2017-03-27 |
Novartis Ag |
Antibodies for the epidermal growth factor receptor 3 (HER3)
|
EP2608803A4
(de)
|
2010-08-26 |
2014-01-15 |
Abbvie Inc |
Immunglobuline mit zweifacher variabler domäne und ihre verwendung
|
KR20140018837A
(ko)
|
2010-08-27 |
2014-02-13 |
스템 센트알엑스 인코포레이티드 |
노텀 단백질 조절 인자 및 사용 방법
|
SG10201506909PA
(en)
|
2010-09-01 |
2015-10-29 |
Genzyme Corp |
Treatment of myocardial infarction using tgf - beta antagonists
|
US20130224192A1
(en)
|
2010-09-02 |
2013-08-29 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Method for the prognosis of the progression of cancer
|
US9458231B2
(en)
|
2010-09-03 |
2016-10-04 |
Stemcentrx, Inc. |
Modulators and methods of use
|
RU2013115927A
(ru)
|
2010-09-10 |
2014-10-20 |
Апексиджен, Инк. |
АНТИТЕЛА ПРОТИВ ИЛ-1β И СПОСОБЫ ПРИМЕНЕНИЯ
|
US20130171159A1
(en)
|
2010-09-10 |
2013-07-04 |
Brian Arthur Hemmings |
Phosphorylated twist1 and metastasis
|
EP2616100B1
(de)
|
2010-09-17 |
2016-08-31 |
Compugen Ltd. |
Zusammensetzungen und verfahren zur behandlung von wirkstoffresistentem multiplem myelom
|
DK2616090T3
(da)
|
2010-09-17 |
2023-09-18 |
Takeda Pharmaceuticals Co |
Stabilisering af immunoglobuliner gennem vandig formulering med histidin ved svag syre til neutral ph
|
AU2011305754B2
(en)
|
2010-09-20 |
2015-11-05 |
Abbvie Inc. |
Purification of antibodies using simulated moving bed chromatography
|
DK2619584T3
(en)
|
2010-09-21 |
2017-01-09 |
Stichting Katholieke Univ |
New method for the diagnosis of Lyme disease using a cellular immunological tests
|
SG188591A1
(en)
|
2010-09-22 |
2013-04-30 |
Amgen Inc |
Carrier immunoglobulins and uses thereof
|
EP2622091B1
(de)
|
2010-09-23 |
2019-03-13 |
Precision Biologics, Inc. |
Peptidomimetika gegen darm- und bauchspeicheldrüsenkrebs
|
EP3223014B1
(de)
|
2010-09-24 |
2018-12-05 |
Full Spectrum Genetics, Inc. |
Verfahren zur analyse von bindungsinteraktionen
|
CA2812389C
(en)
|
2010-09-27 |
2019-12-31 |
John Kehoe |
Antibodies binding human collagen ii
|
KR102595129B1
(ko)
|
2010-09-29 |
2023-10-31 |
어젠시스 인코포레이티드 |
191p4d12 단백질에 결합하는 항체 약물 컨쥬게이트(adc)
|
WO2012044921A1
(en)
|
2010-10-01 |
2012-04-05 |
St. Jude Children's Research Hospital |
Methods and compositions for typing molecular subgroups of medulloblastoma
|
US8525237B1
(en)
|
2010-10-04 |
2013-09-03 |
The Regents Of The University Of California |
Electrically conductive polymer nanowires with incorporated viruses
|
JP2013543384A
(ja)
|
2010-10-05 |
2013-12-05 |
ノバルティス アーゲー |
抗−il12rベータ1抗体ならびに自己免疫性および炎症性疾患の処置おけるその使用
|
GB201016864D0
(en)
|
2010-10-06 |
2010-11-17 |
Univ Aston |
Therapeutic methods
|
SG189322A1
(en)
|
2010-10-13 |
2013-05-31 |
Janssen Biotech Inc |
Human oncostatin m antibodies and methods of use
|
NZ624752A
(en)
|
2010-10-19 |
2015-11-27 |
Mayo Foundation |
Human antibodies and diagnostic and therapeutic uses thereof for the treatment of neurological disease
|
WO2012052391A1
(en)
|
2010-10-19 |
2012-04-26 |
Glaxo Group Limited |
Polypeptide with jmjd3 catalytic activity
|
EP2629801B3
(de)
|
2010-10-22 |
2019-11-27 |
Seattle Genetics, Inc. |
Synergiewirkung zwischen auristatin-basierten antikörper-wirkstoffkonjugaten und hemmern des pi3k-akt-mtor-signalwegs
|
US20130337470A1
(en)
|
2010-10-25 |
2013-12-19 |
Biogen Idec Ma Inc. |
METHODS FOR DETERMINING DIFFERENCES IN ALPHA-4 INTEGRIN ACTIVITY BY CORRELATING DIFFERENCES IN sVCAM AND/OR sMadCAM LEVELS
|
AU2011323784A1
(en)
|
2010-10-25 |
2013-05-30 |
Regents Of The University Of Minnesota |
Therapeutic composition for treatment of glioblastoma
|
NZ623347A
(en)
|
2010-10-29 |
2014-07-25 |
Daiichi Sankyo Co Ltd |
Novel anti-dr5 antibody
|
PT2634194T
(pt)
|
2010-10-29 |
2018-10-19 |
Perseus Proteomics Inc |
Anticorpos anti-cdh3 possuidores de elevada capacidade de internalização
|
SG10201407036YA
(en)
|
2010-11-05 |
2014-12-30 |
Transbio Ltd |
Markers of Endothelial Progenitor Cells and Uses Thereof
|
US10180426B2
(en)
|
2010-11-08 |
2019-01-15 |
Dako Denmark A/S |
Quantification of single target molecules in histological samples
|
EP2640366A2
(de)
|
2010-11-15 |
2013-09-25 |
Exelixis, Inc. |
Benzoxazepine als pi3k/mtor-hemmer sowie verfahren zur ihrer verwendung und herstellung
|
EP2640367A2
(de)
|
2010-11-15 |
2013-09-25 |
Exelixis, Inc. |
Benzoxazepine als pi3k/mtor-hemmer sowie verfahren zur ihrer verwendung und herstellung
|
EP2640738A1
(de)
|
2010-11-15 |
2013-09-25 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Antimykotische wirkstoffe
|
US20140199682A1
(en)
|
2010-11-17 |
2014-07-17 |
Sea Lane Biotechnologies, Llc |
Influenza neutralizing agents
|
WO2012068463A2
(en)
|
2010-11-18 |
2012-05-24 |
Beth Israel Deaconess Medicall Center, Inc. |
Methods of treating obesity by inhibiting nicotinamide n-methyl transferase (nnmt)
|
MX353795B
(es)
|
2010-11-19 |
2018-01-30 |
Morphosys Ag |
Coleccion y metodos para su uso.
|
AR084141A1
(es)
|
2010-11-19 |
2013-04-24 |
Imai Toshio |
Anticuerpos neutralizadores anti-ccl20
|
WO2012071509A2
(en)
|
2010-11-24 |
2012-05-31 |
Exelixis, Inc. |
Benzoxazepines as inhibitors of p13k/mtor and methods of their use and manufacture
|
EP2643353A1
(de)
|
2010-11-24 |
2013-10-02 |
Novartis AG |
Multispezifische moleküle
|
EA201390611A1
(ru)
|
2010-11-24 |
2014-01-30 |
Глаксо Груп Лимитед |
Мультиспецифические антигенсвязывающие белки, направленные на hgf
|
CN103328632A
(zh)
|
2010-11-30 |
2013-09-25 |
中外制药株式会社 |
与多分子的抗原重复结合的抗原结合分子
|
EP4303237A3
(de)
|
2010-11-30 |
2024-03-27 |
Chugai Seiyaku Kabushiki Kaisha |
Zytotoxizitätsinduzierendes therapeutikum
|
CA2817161C
(en)
|
2010-12-06 |
2019-04-02 |
Dako Denmark A/S |
Combined histological stain
|
RU2608646C2
(ru)
|
2010-12-06 |
2017-01-23 |
Сиэтл Генетикс, Инк. |
Гуманизированные антитела к LIV-1 и их применение для лечения рака
|
TWI585106B
(zh)
|
2010-12-08 |
2017-06-01 |
艾伯維史坦森特瑞斯有限責任公司 |
新穎調節劑及其使用方法
|
EP2465928A1
(de)
|
2010-12-16 |
2012-06-20 |
Academisch Medisch Centrum bij de Universiteit van Amsterdam |
Behandlung von Th17-vermittelten Krankheiten
|
BR112013015508B1
(pt)
|
2010-12-20 |
2022-04-05 |
Medimmune Limited |
Molécula de anticorpo para il-18 humana, domínio vh isolado e domínio vl isolado, composição, uso de uma molécula de anticorpo ou do domínio vh isolado e do domínio vl isolado, molécula de ácido nucleico isolada, célula hospedeira procariótica recombinante, método para produzir um anticorpo, e método in vitro para medir il-18 em uma amostra de um indivíduo
|
US9029502B2
(en)
|
2010-12-20 |
2015-05-12 |
The Regents Of The University Of Michigan |
Inhibitors of the epidermal growth factor receptor-heat shock protein 90 binding interaction
|
WO2012121775A2
(en)
|
2010-12-21 |
2012-09-13 |
Abbott Laboratories |
Dual variable domain immunoglobulins and uses thereof
|
TW201307388A
(zh)
|
2010-12-21 |
2013-02-16 |
Abbott Lab |
Il-1結合蛋白
|
CN103429261A
(zh)
|
2010-12-22 |
2013-12-04 |
塞法隆澳大利亚股份有限公司 |
半寿期改进的修饰抗体
|
JP6088438B2
(ja)
|
2010-12-22 |
2017-03-01 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
連続的定向進化
|
WO2012085064A1
(en)
|
2010-12-23 |
2012-06-28 |
Roche Diagnostics Gmbh |
Detection of a posttranslationally modified polypeptide by a bi-valent binding agent
|
WO2012085069A2
(en)
|
2010-12-23 |
2012-06-28 |
Roche Diagnostics Gmbh |
Detection of a polypeptide dimer by a bivalent binding agent
|
WO2012085113A1
(en)
|
2010-12-23 |
2012-06-28 |
Roche Diagnostics Gmbh |
Binding agent
|
SG191153A1
(en)
|
2010-12-23 |
2013-07-31 |
Hoffmann La Roche |
Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
|
EP2658971A1
(de)
|
2010-12-28 |
2013-11-06 |
XOMA Technology Ltd. |
Zelloberflächendisplay mit pdz-domänen
|
EP2658869B1
(de)
|
2010-12-30 |
2019-06-12 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antigenbindende formate zur verwendung in therapeutischen behandlungen oder diagnosetests
|
US10208349B2
(en)
|
2011-01-07 |
2019-02-19 |
Ucb Biopharma Sprl |
Lipocalin 2 as a biomarker for IL-17 inhibitor therapy efficacy
|
GB201100282D0
(en)
|
2011-01-07 |
2011-02-23 |
Ucb Pharma Sa |
Biological methods
|
KR101950306B1
(ko)
|
2011-01-14 |
2019-02-20 |
유씨비 바이오파마 에스피알엘 |
Il-17a 및 il-17f에 결합하는 항체 분자
|
EP2663579B1
(de)
|
2011-01-14 |
2017-04-26 |
The Regents of the University of California |
Therapeutische antikörper gegen das protein ror-1 und verfahren zu ihrer verwendung
|
EA201370161A1
(ru)
|
2011-01-18 |
2013-12-30 |
Амген Инк. |
НОКАУТНЫЕ ПО Na1.7 МЫШИ И ИХ ПРИМЕНЕНИЕ
|
WO2012103141A1
(en)
|
2011-01-24 |
2012-08-02 |
Abbott Biotechnology Ltd. |
Automatic injection devices having overmolded gripping surfaces
|
EP2668210B1
(de)
|
2011-01-26 |
2020-06-17 |
Celldex Therapeutics, Inc. |
Anti-kit-antikörper und ihre verwendungen
|
US9732143B2
(en)
|
2011-02-03 |
2017-08-15 |
Xoma Technology Ltd. |
Methods and materials for enhancing functional protein expression in bacteria
|
US9956236B2
(en)
|
2011-02-07 |
2018-05-01 |
Cornell University |
Methods for increasing immune responses using agents that directly bind to and activate IRE-1
|
GB201102189D0
(en)
|
2011-02-08 |
2011-03-23 |
King S College London |
Materials and methods relating to cardiovascular imaging
|
KR101667096B1
(ko)
|
2011-02-10 |
2016-10-18 |
로슈 글리카트 아게 |
돌연변이 인터루킨-2 폴리펩티드
|
CA2824252A1
(en)
|
2011-02-10 |
2012-08-16 |
Roche Glycart Ag |
Improved immunotherapy
|
EP3666289A1
(de)
|
2011-02-15 |
2020-06-17 |
ImmunoGen, Inc. |
Zytotoxische benzodiazepinderivate
|
SA112330278B1
(ar)
|
2011-02-18 |
2015-10-09 |
ستيم سينتركس، انك. |
مواد ضابطة جديدة وطرق للاستخدام
|
WO2012110824A1
(en)
|
2011-02-18 |
2012-08-23 |
Astrazeneca Ab |
Binding agents with specificity for a nucleic acid modification
|
WO2012133782A1
(ja)
|
2011-03-30 |
2012-10-04 |
中外製薬株式会社 |
抗原結合分子の血漿中滞留性と免疫原性を改変する方法
|
SG192945A1
(en)
|
2011-02-25 |
2013-09-30 |
Chugai Pharmaceutical Co Ltd |
Fcgriib-specific fc antibody
|
CA2828000A1
(en)
|
2011-03-01 |
2012-09-07 |
Amgen Inc. |
Bispecific binding agents
|
PE20140627A1
(es)
|
2011-03-02 |
2014-05-30 |
Berg Llc |
Ensayos interrogatorios basados en celulas y usos de los mismos
|
US8753634B2
(en)
|
2011-03-03 |
2014-06-17 |
Apexigen, Inc. |
Anti-IL-6 receptor antibodies and methods of use
|
US9383364B2
(en)
|
2011-03-07 |
2016-07-05 |
University Of Louisville Research Foundation, Inc. |
Predictive marker of DNMT1 inhibitor therapeutic efficacy and methods of using the marker
|
ES2666301T3
(es)
|
2011-03-09 |
2018-05-03 |
Cell Signaling Technology, Inc. |
Métodos y reactivos para crear anticuerpos monoclonales
|
CA2827759C
(en)
|
2011-03-10 |
2018-10-16 |
Omeros Corporation |
Generation of anti-fn14 monoclonal antibodies by ex-vivo accelerated antibody evolution
|
US20120238730A1
(en)
|
2011-03-15 |
2012-09-20 |
Abbott Laboratories |
Integrated approach to the isolation and purification of antibodies
|
JP2014510730A
(ja)
|
2011-03-16 |
2014-05-01 |
サノフイ |
デュアルv領域抗体様タンパク質の使用
|
WO2012128810A1
(en)
|
2011-03-23 |
2012-09-27 |
Abbott Laboratories |
Methods and systems for the analysis of protein samples
|
CA2830538C
(en)
|
2011-03-25 |
2020-05-12 |
Amgen Inc. |
Anti - sclerostin antibody crystals and formulations thereof
|
SG193997A1
(en)
|
2011-03-29 |
2013-11-29 |
Immunogen Inc |
Process for manufacturing conjugates of improved homogeneity
|
TR201902180T4
(tr)
|
2011-03-29 |
2019-03-21 |
Immunogen Inc |
Tek adimli bi̇r i̇şlem i̇le maytansi̇noi̇d anti̇kor konjugatlarinin hazirlanmasi
|
AU2012237287B2
(en)
|
2011-03-30 |
2016-09-08 |
Ablynx Nv |
Methods of treating immune disorders with single domain antibodies against TNF-alpha
|
US9777332B2
(en)
|
2011-03-31 |
2017-10-03 |
St. Jude Children's Research Hospital |
Methods and compositions for identifying minimal residual disease in acute lymphoblastic leukemia
|
MX356426B
(es)
|
2011-04-04 |
2018-05-29 |
Univ Iowa Res Found |
Metodos para mejorar inmunogenicidad de vacuna.
|
WO2012139045A1
(en)
|
2011-04-08 |
2012-10-11 |
Gilead Biologics, Inc. |
Methods and compositions for normalization of tumor vasculature by inhibition of loxl2
|
US20120328567A1
(en)
|
2011-04-08 |
2012-12-27 |
Steven Bushnell |
Biomarkers predictive of therapeutic responsiveness to ifnb and uses thereof
|
WO2012142164A1
(en)
|
2011-04-12 |
2012-10-18 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Human monoclonal antibodies that bind insulin-like growth factor (igf) i and ii
|
AU2012241373B2
(en)
|
2011-04-15 |
2016-06-09 |
Compugen Ltd. |
Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
|
EP2700652B1
(de)
|
2011-04-18 |
2018-12-19 |
The University of Tokyo |
Diagnose und behandlung von krebs mittels anti-itm2a-antikörpern
|
CA2832907C
(en)
|
2011-04-19 |
2020-07-14 |
Dako Denmark A/S |
New method for enzyme-mediated signal amplification
|
DK2699264T3
(en)
|
2011-04-20 |
2018-06-25 |
Medimmune Llc |
ANTIBODIES AND OTHER MOLECULES BINDING B7-H1 AND PD-1
|
LT2703486T
(lt)
|
2011-04-25 |
2018-05-25 |
Daiichi Sankyo Company, Limited |
Anti-b7-h3 antikūnas
|
US9062106B2
(en)
|
2011-04-27 |
2015-06-23 |
Abbvie Inc. |
Methods for controlling the galactosylation profile of recombinantly-expressed proteins
|
JP6125489B2
(ja)
|
2011-04-29 |
2017-05-10 |
アペクシジェン, インコーポレイテッド |
抗cd40抗体および使用方法
|
EA201892619A1
(ru)
|
2011-04-29 |
2019-04-30 |
Роше Гликарт Аг |
Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
|
WO2012153707A1
(ja)
|
2011-05-09 |
2012-11-15 |
株式会社ペルセウスプロテオミクス |
トランスフェリン受容体を特異的に認識できる抗体
|
CN103842383B
(zh)
|
2011-05-16 |
2017-11-03 |
健能隆医药技术(上海)有限公司 |
多特异性fab融合蛋白及其使用方法
|
GB201108272D0
(en)
|
2011-05-17 |
2011-06-29 |
Cambridge Entpr Ltd |
Methods relating to HCMV infected cells
|
KR102030531B1
(ko)
|
2011-05-21 |
2019-10-10 |
마크로제닉스, 인크. |
탈면역화된 혈청-결합 도메인 및 혈청 반감기를 연장하기 위한 그것의 용도
|
CN103857699B
(zh)
|
2011-05-24 |
2016-08-31 |
泽恩格尼亚股份有限公司 |
多价和单价多特异性复合物及其用途
|
AR086543A1
(es)
|
2011-05-25 |
2014-01-08 |
Bg Medicine Inc |
Inhibidores de galectina-3 y metodos de uso de los mismos, composicion farmaceutica
|
JP6342325B2
(ja)
|
2011-05-25 |
2018-06-13 |
イナート・ファルマ・ソシエテ・アノニムInnate Pharma Pharma S.A. |
炎症性障害の治療のための抗kir抗体
|
PL2726510T3
(pl)
|
2011-05-27 |
2023-05-29 |
F.Hoffmann-La Roche Ag |
Kierowanie podwójne
|
US20140255405A1
(en)
|
2011-05-27 |
2014-09-11 |
Dutalys |
Removal of Monomeric Targets
|
AU2012262007B2
(en)
|
2011-06-02 |
2017-06-22 |
Takeda Pharmaceutical Company Limited |
Fc receptor binding proteins
|
US8691231B2
(en)
|
2011-06-03 |
2014-04-08 |
Merrimack Pharmaceuticals, Inc. |
Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies
|
US8569462B2
(en)
|
2011-06-03 |
2013-10-29 |
Xoma Technology Ltd. |
Antibodies specific for TGF-beta and methods for treating thereof
|
US9181553B2
(en)
|
2011-06-06 |
2015-11-10 |
Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Method of treatment of breast cancers over-expressing the SHP2 signature genes
|
WO2012170740A2
(en)
|
2011-06-07 |
2012-12-13 |
University Of Hawaii |
Biomarker of asbestos exposure and mesothelioma
|
WO2012170742A2
(en)
|
2011-06-07 |
2012-12-13 |
University Of Hawaii |
Treatment and prevention of cancer with hmgb1 antagonists
|
AU2012266363A1
(en)
|
2011-06-10 |
2014-01-09 |
Corimmun Gmbh |
Binding compounds to human beta1-adrenoreceptor (beta1-AR) and their use in the measurement of auto-anti-beta1-AR antibodies
|
WO2012170807A2
(en)
|
2011-06-10 |
2012-12-13 |
Medimmune, Llc |
Anti-pseudomonas psl binding molecules and uses thereof
|
WO2012172495A1
(en)
|
2011-06-14 |
2012-12-20 |
Novartis Ag |
Compositions and methods for antibodies targeting tem8
|
AU2012271413B2
(en)
|
2011-06-17 |
2017-07-13 |
President And Fellows Of Harvard College |
Frizzled 2 as a target for therapeutic antibodies in the treatment of cancer
|
US8685401B2
(en)
|
2011-06-17 |
2014-04-01 |
Adrian Harris |
Methods of enhancing the response to radiation in tumor therapy using anti-DLL4 antibodies
|
MX350954B
(es)
|
2011-06-21 |
2017-09-26 |
Immunogen Inc |
Derivados de maitansinoides novedosos con enlazador de peptido y conjugados de estos.
|
SI2723769T2
(sl)
|
2011-06-23 |
2022-09-30 |
Ablynx Nv |
Tehnike za napovedovanje, zaznavanje in zmanjševanje nespecifične motnje proteina v testih, ki vključujejo domene imunoglobulina z eno spremenljivko
|
CA3142288A1
(en)
|
2011-06-23 |
2012-12-27 |
Ablynx Nv |
Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
|
EP4350345A2
(de)
|
2011-06-23 |
2024-04-10 |
Ablynx N.V. |
Verfahren zur vorhersage, erkennung und reduzierung von aspezifischer proteininterferenz in tests mit variablen immunglobulin-einzeldomänen
|
AU2012275841A1
(en)
|
2011-06-27 |
2014-01-16 |
The Jackson Laboratory |
Methods and compositions for treatment of cancer and autoimmune disease
|
WO2013003625A2
(en)
|
2011-06-28 |
2013-01-03 |
Oxford Biotherapeutics Ltd. |
Antibodies
|
WO2013001369A2
(en)
|
2011-06-28 |
2013-01-03 |
Oxford Biotherapeutics Ltd. |
Therapeutic and diagnostic target
|
CA2836855C
(en)
|
2011-06-30 |
2020-07-14 |
Compugen Ltd. |
Polypeptides and uses thereof for treatment of autoimmune disorders and infection
|
CA2839539C
(en)
|
2011-06-30 |
2021-06-08 |
Chugai Seiyaku Kabushiki Kaisha |
Heterodimerized polypeptide
|
US9365651B2
(en)
|
2011-07-01 |
2016-06-14 |
Novartis Ag |
Method for treating metabolic disorders by administration of an anti-ActRIIB antibody
|
AU2012283039A1
(en)
|
2011-07-13 |
2014-01-30 |
Abbvie Inc. |
Methods and compositions for treating asthma using anti-IL-13 antibodies
|
GB201112056D0
(en)
|
2011-07-14 |
2011-08-31 |
Univ Leuven Kath |
Antibodies
|
MX349198B
(es)
|
2011-07-15 |
2017-07-18 |
Oncomed Pharmaceuticals Inc * |
Agentes que se unen a las proteinas de r-espondinas (rspo) y usos de los mismos.
|
WO2013010955A1
(en)
|
2011-07-15 |
2013-01-24 |
Morphosys Ag |
Antibodies that are cross-reactive for macrophage migration inhibitory factor (mif) and d-dopachrome tautomerase (d-dt)
|
WO2013012733A1
(en)
|
2011-07-15 |
2013-01-24 |
Biogen Idec Ma Inc. |
Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto
|
EP2548891A1
(de)
|
2011-07-18 |
2013-01-23 |
Universiteit Maastricht |
Humaner monoklonaler Antikörper gegen die Gamma-Untereinheit des Acetylcholin-Rezeptors zur Verwendung bei der Behandlung von Rhabdomyosarkom
|
US9574005B2
(en)
|
2011-07-19 |
2017-02-21 |
Chugai Seiyaku Kabushiki Kaisha |
Stable Protein-containing preparation containing argininamide or analogous compound thereof
|
WO2013015821A1
(en)
|
2011-07-22 |
2013-01-31 |
The Research Foundation Of State University Of New York |
Antibodies to the b12-transcobalamin receptor
|
US9120858B2
(en)
|
2011-07-22 |
2015-09-01 |
The Research Foundation Of State University Of New York |
Antibodies to the B12-transcobalamin receptor
|
EA028886B1
(ru)
|
2011-07-27 |
2018-01-31 |
Глаксо Груп Лимитед |
ОТДЕЛЬНЫЕ ВАРИАБЕЛЬНЫЕ ДОМЕНЫ ПРОТИВ VEGF, СЛИТЫЕ С Fc-ДОМЕНАМИ
|
EP2739311B9
(de)
|
2011-08-04 |
2018-09-19 |
Amgen Inc. |
Verfahren zur behandlung von knochenleitungsdefekten
|
US8663637B2
(en)
|
2011-08-05 |
2014-03-04 |
Research Development Foundation |
Methods and compositions for modulation of Olfml3 mediated angiogenesis
|
US9102724B2
(en)
|
2011-08-12 |
2015-08-11 |
Omeros Corporation |
Anti-FZD10 monoclonal antibodies and methods for their use
|
US9676854B2
(en)
|
2011-08-15 |
2017-06-13 |
Medimmune, Llc |
Anti-B7-H4 antibodies and their uses
|
EP3321286B1
(de)
|
2011-08-23 |
2021-01-06 |
Roche Glycart AG |
Bispezifische antigenbindende moleküle zur t-zellen-aktivierung
|
WO2013026837A1
(en)
|
2011-08-23 |
2013-02-28 |
Roche Glycart Ag |
Bispecific t cell activating antigen binding molecules
|
WO2013026835A1
(en)
|
2011-08-23 |
2013-02-28 |
Roche Glycart Ag |
Fc-free antibodies comprising two fab fragments and methods of use
|
BR112014004213A2
(pt)
|
2011-08-23 |
2017-06-20 |
Found Medicine Inc |
novas moléculas de fusão kif5b-ret e usos das mesmas
|
JP6101205B2
(ja)
|
2011-08-23 |
2017-03-22 |
中外製薬株式会社 |
抗腫瘍活性を有する新規な抗ddr1抗体
|
BR112014004168A2
(pt)
|
2011-08-23 |
2017-12-12 |
Roche Glycart Ag |
anticorpo biespecífico, composição farmacêutica, uso do anticorpo biespecífico, célula hospedeira procariótica ou eucariótica, método de produção de anticorpo e invenção
|
SG2014008577A
(en)
|
2011-08-23 |
2014-04-28 |
Roche Glycart Ag |
Bispecific antigen binding molecules
|
US20130058947A1
(en)
|
2011-09-02 |
2013-03-07 |
Stem Centrx, Inc |
Novel Modulators and Methods of Use
|
EP2753697A1
(de)
|
2011-09-05 |
2014-07-16 |
ETH Zürich |
Biosynthetischer gencluster zur herstellung von peptid- bzw. protein-analoga
|
US10018630B2
(en)
|
2011-09-07 |
2018-07-10 |
Chugai Seiyaku Kabushiki Kaisha |
Cancer stem cell isolation
|
CA2848074A1
(en)
|
2011-09-09 |
2013-03-14 |
Medimmune Limited |
Anti-siglec-15 antibodies and uses thereof
|
US10385475B2
(en)
|
2011-09-12 |
2019-08-20 |
Adaptive Biotechnologies Corp. |
Random array sequencing of low-complexity libraries
|
WO2013039471A1
(en)
|
2011-09-12 |
2013-03-21 |
Janssen Biotech Inc. |
Toll-like receptor 3 antagonists for the treatment of metabolic and cardiovascular diseases
|
US8969519B2
(en)
|
2011-09-13 |
2015-03-03 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for brown fat induction and activity using FNDC5
|
EP2771349B1
(de)
|
2011-09-16 |
2020-02-26 |
Iogenetics, LLC. |
Bioinformatikverfahren zur bestimmung von peptidbindungen
|
GB201116092D0
(en)
|
2011-09-16 |
2011-11-02 |
Bioceros B V |
Antibodies and uses thereof
|
WO2013043729A1
(en)
|
2011-09-20 |
2013-03-28 |
Mount Sinai School Of Medicine |
Influenza virus vaccines and uses thereof
|
IN2014CN02113A
(de)
|
2011-09-21 |
2015-05-29 |
Fujirebio Kk |
|
HUE061002T2
(hu)
|
2011-09-23 |
2023-04-28 |
Mereo Biopharma 5 Inc |
VEGF/DLL4-kötõ ágensek és alkalmazásaik
|
RU2628089C2
(ru)
|
2011-09-26 |
2017-08-14 |
Филоген С.П.А. |
Комбинированная терапия иммуноцитокинами
|
KR102492584B1
(ko)
|
2011-09-30 |
2023-01-27 |
추가이 세이야쿠 가부시키가이샤 |
표적 항원에 대한 면역응답을 유도하는 항원 결합 분자
|
KR102528622B1
(ko)
|
2011-09-30 |
2023-05-04 |
추가이 세이야쿠 가부시키가이샤 |
이온 농도 의존성 결합 분자 라이브러리
|
TW201817744A
(zh)
|
2011-09-30 |
2018-05-16 |
日商中外製藥股份有限公司 |
具有促進抗原清除之FcRn結合域的治療性抗原結合分子
|
EP3939996A1
(de)
|
2011-09-30 |
2022-01-19 |
Chugai Seiyaku Kabushiki Kaisha |
Antigenbindende moleküle zur förderung der zersetzung von antigenen mit mehreren biologischen aktivitäten
|
TW201726745A
(zh)
|
2011-09-30 |
2017-08-01 |
中外製藥股份有限公司 |
促進抗原消失的抗原結合分子
|
JP6271251B2
(ja)
|
2011-10-05 |
2018-01-31 |
中外製薬株式会社 |
糖鎖受容体結合ドメインを含む抗原の血漿中からの消失を促進する抗原結合分子
|
EP2764370B1
(de)
|
2011-10-06 |
2017-09-13 |
The Board of Trustees of the University of Illionis |
Myosinbindendes protein-c zur verwendung bei verfahren im zusammenhang mit diastolischer herzinsuffizienz
|
EP2766394B1
(de)
|
2011-10-10 |
2017-11-22 |
Medimmune Limited |
Behandlung von rheumatoider arthritis
|
US10221454B2
(en)
|
2011-10-10 |
2019-03-05 |
The Hospital For Sick Children |
Methods and compositions for screening and treating developmental disorders
|
JP2014530816A
(ja)
|
2011-10-14 |
2014-11-20 |
ノバルティスアーゲー |
Wnt経路関連疾患のための抗体および方法
|
CA2853088C
(en)
|
2011-10-21 |
2018-03-13 |
Adaptive Biotechnologies Corporation |
Quantification of adaptive immune cell genomes in a complex mixture of cells
|
TW201323440A
(zh)
|
2011-10-24 |
2013-06-16 |
Abbvie Inc |
抗骨硬化素(sclerostin)之免疫結合物
|
WO2013063114A1
(en)
|
2011-10-24 |
2013-05-02 |
Abbvie Inc. |
Immunobinders directed against tnf
|
EP3603671A3
(de)
|
2011-10-28 |
2020-07-29 |
Chugai Seiyaku Kabushiki Kaisha |
Krebstammzellenspezifisches molekül
|
KR102398736B1
(ko)
|
2011-10-31 |
2022-05-16 |
추가이 세이야쿠 가부시키가이샤 |
중쇄와 경쇄의 회합이 제어된 항원 결합 분자
|
AU2012332588B2
(en)
|
2011-11-01 |
2017-09-07 |
Bionomics, Inc. |
Methods of blocking cancer stem cell growth
|
WO2013067057A1
(en)
|
2011-11-01 |
2013-05-10 |
Bionomics, Inc. |
Anti-gpr49 antibodies
|
WO2013067060A1
(en)
|
2011-11-01 |
2013-05-10 |
Bionomics, Inc. |
Anti-gpr49 antibodies
|
JP2014533247A
(ja)
|
2011-11-01 |
2014-12-11 |
バイオノミクス インコーポレイテッド |
抗体および癌を治療する方法
|
JP6117225B2
(ja)
|
2011-11-02 |
2017-04-19 |
アペクシジェン, インコーポレイテッド |
抗kdr抗体およびその使用方法
|
US10527526B2
(en)
|
2011-11-03 |
2020-01-07 |
Tripath Imaging, Inc. |
Methods and compositions for preparing samples for immunostaining
|
EP2773779B1
(de)
|
2011-11-04 |
2020-10-14 |
Population Bio, Inc. |
Verfahren und zusammensetzungen zur diagnose, prognose und behandlung neurologischer erkrankungen
|
EP2776065B1
(de)
|
2011-11-07 |
2020-08-05 |
MedImmune Limited |
Kombinationstherapien mit anti-pseudomonas-psl- und pcrv-bindenden molekülen
|
US20140294732A1
(en)
|
2011-11-08 |
2014-10-02 |
Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute |
Early diagnostic of neurodegenerative diseases
|
WO2013068902A1
(en)
|
2011-11-08 |
2013-05-16 |
Pfizer Inc. |
Methods of treating inflammatory disorders using anti-m-csf antibodies
|
WO2013068431A1
(en)
|
2011-11-08 |
2013-05-16 |
Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research |
New treatment for neurodegenerative diseases
|
WO2013071233A1
(en)
|
2011-11-10 |
2013-05-16 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Methods for detecting infectious agents and a novel virus detected thereby
|
EP2776466B1
(de)
|
2011-11-11 |
2017-08-23 |
UCB Biopharma SPRL |
Albuminbindende antikörper und bindungsfragmenten davon
|
SG10201801919QA
(en)
|
2011-11-16 |
2018-04-27 |
Adrenomed Ag |
Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for prevention or reduction of organ dysfunction or organ failure in a patient having a chronic or acute disease or acute condition
|
ES2617211T3
(es)
|
2011-11-16 |
2017-06-15 |
Sphingotec Gmbh |
Ensayos de adrenomedulina y métodos para determinar la adrenomedulina madura
|
JP6321544B2
(ja)
|
2011-11-16 |
2018-05-09 |
アドレノメト アクチェンゲゼルシャフト |
慢性若しくは急性疾患又は急性病態に罹患している患者の死亡リスクを低減するための抗アドレノメデュリン(ADM)抗体、抗ADM抗体フラグメント又は抗ADM非Ig足場
|
JP6224608B2
(ja)
|
2011-11-16 |
2017-11-01 |
アドレノメト アクチェンゲゼルシャフト |
血液循環を安定化させるための、患者の急性疾患又は急性病態の治療法における使用に向けた、抗アドレノメデュリン(ADM)抗体、抗ADM抗体フラグメント又は抗ADM非Ig足場
|
SG10201802054TA
(en)
|
2011-11-16 |
2018-05-30 |
Adrenomed Ag |
Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for regulating the fluid balance in a patient having a chronic or acute disease
|
PL2594588T3
(pl)
|
2011-11-16 |
2014-11-28 |
Adrenomed Ag |
Przeciwciało przeciwko adrenomedulinie (ADM) lub fragment przeciwciała anty-ADM lub szkielet białkowy niestanowiący Ig anty-ADM do zastosowania w terapii
|
EP2797957B1
(de)
|
2011-11-23 |
2019-06-19 |
MedImmune, LLC |
Her3-spezifische bindungsmoleküle und verwendungen davon
|
RU2739792C1
(ru)
|
2011-11-30 |
2020-12-28 |
Чугаи Сейяку Кабусики Кайся |
Содержащий лекарственное средство переносчик в клетку для формирования иммунного комплекса
|
AU2012346861A1
(en)
|
2011-11-30 |
2014-06-19 |
AbbVie Deutschland GmbH & Co. KG |
Methods and compositions for determining responsiveness to treatment with a tnf-alpha inhibitor
|
CN108341873B
(zh)
|
2011-12-05 |
2022-03-25 |
诺华股份有限公司 |
表皮生长因子受体3(her3)的抗体
|
EA201491107A1
(ru)
|
2011-12-05 |
2014-11-28 |
Новартис Аг |
Антитела к рецептору эпидермального фактора роста 3 (her3), направленные на домен ii her3
|
US9824179B2
(en)
|
2011-12-09 |
2017-11-21 |
Adaptive Biotechnologies Corp. |
Diagnosis of lymphoid malignancies and minimal residual disease detection
|
US9499865B2
(en)
|
2011-12-13 |
2016-11-22 |
Adaptive Biotechnologies Corp. |
Detection and measurement of tissue-infiltrating lymphocytes
|
US9518128B2
(en)
|
2011-12-14 |
2016-12-13 |
Janssen Pharmaceuticals, Inc. |
Thrombin-binding antibody molecules
|
GB201121513D0
(en)
|
2011-12-14 |
2012-01-25 |
Cambridge Entpr Ltd |
Thrombin-binding antibody molecules and uses thereof
|
US9636398B2
(en)
|
2011-12-14 |
2017-05-02 |
AbbVie Deutschland GmbH & Co. KG |
Composition and method for the diagnosis and treatment of iron-related disorders
|
AU2012352168C1
(en)
|
2011-12-14 |
2018-01-25 |
AbbVie Deutschland GmbH & Co. KG |
Composition and method for the diagnosis and treatment of iron-related disorders
|
US20150017157A1
(en)
|
2011-12-19 |
2015-01-15 |
Xoma (Us) Llc |
Methods for treating acne
|
AU2012359039B2
(en)
|
2011-12-20 |
2017-08-24 |
Janssen Biotech, Inc. |
Anti-PHF-tau antibodies and their uses
|
BR112014015111A2
(pt)
|
2011-12-21 |
2017-06-13 |
Novartis Ag |
composições e processos para anticorpos que se direcionam ao fator p
|
EP2794653B1
(de)
|
2011-12-23 |
2019-03-13 |
Pfizer Inc |
Konstante regionen gentechnisch hergestellter antikörper für stellenspezifische konjugation sowie verfahren und verwendungen dafür
|
SG11201403718YA
(en)
|
2011-12-28 |
2014-07-30 |
Amgen Inc |
Method of treating alveolar bone loss through the use of anti-sclerostin antibodies
|
TWI593705B
(zh)
|
2011-12-28 |
2017-08-01 |
Chugai Pharmaceutical Co Ltd |
Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient
|
EP2797955A2
(de)
|
2011-12-30 |
2014-11-05 |
AbbVie Inc. |
Immunglobuline mit zweifacher variabler domäne gegen il-13 und/oder il-17
|
EP2800583A1
(de)
|
2012-01-02 |
2014-11-12 |
Novartis AG |
Cdcp1 und brustkrebs
|
GB201200259D0
(en)
|
2012-01-09 |
2012-02-22 |
Ohlin Per M |
Novel therapies
|
JP6247226B2
(ja)
|
2012-01-10 |
2017-12-13 |
バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. |
血液脳関門を越える治療分子の輸送の向上
|
GB201201332D0
(en)
|
2012-01-26 |
2012-03-14 |
Imp Innovations Ltd |
Method
|
PL2807192T3
(pl)
|
2012-01-27 |
2019-02-28 |
Abbvie Deutschland |
Kompozycja oraz sposób diagnostyki i leczenia chorób związanych ze zwyrodnieniem neurytów
|
MX2014009289A
(es)
|
2012-02-01 |
2015-09-08 |
Compugen Ltd |
Anticuerpos c1orf32 y usos de los mismos para el tratamiento del cancer.
|
CA2863564A1
(en)
|
2012-02-03 |
2013-08-08 |
Medimmune Limited |
Process for reducing antibody aggregate levels and antibodies produced thereby
|
MX366965B
(es)
|
2012-02-03 |
2019-07-31 |
Hoffmann La Roche |
Moleculas de anticuerpos biespecificos con celulas t transfectadas por antigeno y su uso en medicina.
|
CN104271757B
(zh)
|
2012-02-06 |
2020-06-09 |
印希彼有限公司 |
Cd47抗体及其使用方法
|
DK2812452T3
(da)
|
2012-02-09 |
2020-06-29 |
Population Bio Inc |
Fremgangsmåder og sammensætninger til screening og behandling af udviklingsforstyrrelser
|
US20150210763A1
(en)
|
2012-02-09 |
2015-07-30 |
Chugai Seiyaku Kabushiki Kaisha |
MODIFIED Fc REGION OF ANTIBODY
|
JP6336400B2
(ja)
|
2012-02-10 |
2018-06-06 |
フィロジカ リミテッドPhylogica Limited |
標的タンパク質上の相互作用部位を特性決定する方法
|
CA2864092C
(en)
|
2012-02-10 |
2021-06-29 |
Seattle Genetics, Inc. |
Detection and treatment of cd30+ cancers
|
JP6486686B2
(ja)
|
2012-02-10 |
2019-03-20 |
ジェネンテック, インコーポレイテッド |
単鎖抗体及び他のヘテロ多量体
|
US9550830B2
(en)
|
2012-02-15 |
2017-01-24 |
Novo Nordisk A/S |
Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
|
DK2814842T3
(en)
|
2012-02-15 |
2018-12-10 |
Novo Nordisk As |
ANTIBODIES BINDING PEPTIDOGLYCAN RECOGNITION PROTEIN 1
|
WO2013120553A1
(en)
|
2012-02-15 |
2013-08-22 |
Novo Nordisk A/S |
Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (trem-1)
|
GB201203071D0
(en)
|
2012-02-22 |
2012-04-04 |
Ucb Pharma Sa |
Biological products
|
US20150201588A1
(en)
|
2012-02-22 |
2015-07-23 |
Amgen Inc. |
Autologous Mammalian Models Derived from Induced Pluripotent Stem Cells and Related Methods
|
GB201203051D0
(en)
|
2012-02-22 |
2012-04-04 |
Ucb Pharma Sa |
Biological products
|
EP2817338B1
(de)
|
2012-02-24 |
2017-07-26 |
AbbVie Stemcentrx LLC |
Dll3-modulatoren und verwendungsverfahren
|
JP6138108B2
(ja)
|
2012-02-24 |
2017-05-31 |
中外製薬株式会社 |
FcγRIIBを介して抗原の消失を促進する抗原結合分子
|
JP6302847B2
(ja)
|
2012-03-05 |
2018-03-28 |
アダプティヴ バイオテクノロジーズ コーポレーション |
頻度が一致したサブユニットからの、対をなす免疫受容体鎖の決定
|
EP2825200A4
(de)
|
2012-03-15 |
2015-08-26 |
Janssen Biotech Inc |
Menschliche anti-cd27-antikörper, verfahren und verwendungen
|
WO2013138518A1
(en)
|
2012-03-15 |
2013-09-19 |
Omeros Corporation |
Composition and method for diversification of target sequences
|
WO2013140393A1
(en)
|
2012-03-21 |
2013-09-26 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Peptides derived from the d1 - domain of nkp46
|
CA2866185C
(en)
|
2012-03-23 |
2021-04-06 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Pathogenic phlebovirus isolates and compositions and methods of use
|
US9592289B2
(en)
|
2012-03-26 |
2017-03-14 |
Sanofi |
Stable IgG4 based binding agent formulations
|
SG10201702842SA
(en)
|
2012-03-27 |
2017-06-29 |
Genentech Inc |
Methods of prognosing, diagnosing and treating idiopathic pulmonary fibrosis
|
US10041950B2
(en)
|
2012-03-27 |
2018-08-07 |
Ventana Medical Systems, Inc. |
Signaling conjugates and methods of use
|
WO2013147153A1
(ja)
|
2012-03-29 |
2013-10-03 |
株式会社未来創薬研究所 |
抗lamp5抗体およびその利用
|
US20150266961A1
(en)
|
2012-03-29 |
2015-09-24 |
Novartis Forschungsstiftung, Zweigniederlassung, Fridrich Miescher Institute |
Inhibition of interleukin-8 and/or its receptor cxcr1 in the treatment of her2/her3-overexpressing breast cancer
|
CN104321430A
(zh)
|
2012-03-30 |
2015-01-28 |
第一三共株式会社 |
新颖的抗-siglec-15抗体
|
BR112014024537A2
(pt)
|
2012-04-02 |
2017-08-08 |
Berg Llc |
métodos para identificar moduladores de um sistema biológico, de um processo de doença, e de angiogênese
|
WO2013151649A1
(en)
|
2012-04-04 |
2013-10-10 |
Sialix Inc |
Glycan-interacting compounds
|
KR20150003251A
(ko)
|
2012-04-04 |
2015-01-08 |
가부시키가이샤 페르세우스 프로테오믹스 |
항 cdh3(p-카드헤린) 항체의 약물 콘쥬게이트
|
US9714298B2
(en)
|
2012-04-09 |
2017-07-25 |
Daiichi Sankyo Company, Limited |
Anti-FGFR2 antibodies and methods of use thereof for treating cancer
|
NZ701278A
(en)
|
2012-04-17 |
2016-12-23 |
Mayo Foundation |
Human antibodies and specific binding sequences thereof for use in stroke and ischemia or ischemic conditions
|
WO2013158859A1
(en)
|
2012-04-18 |
2013-10-24 |
Cell Signaling Technology, Inc. |
Egfr and ros1 in cancer
|
WO2013158275A1
(en)
|
2012-04-20 |
2013-10-24 |
Abbvie Inc. |
Cell culture methods to reduce acidic species
|
WO2013158279A1
(en)
|
2012-04-20 |
2013-10-24 |
Abbvie Inc. |
Protein purification methods to reduce acidic species
|
US9067990B2
(en)
|
2013-03-14 |
2015-06-30 |
Abbvie, Inc. |
Protein purification using displacement chromatography
|
US9248181B2
(en)
|
2012-04-20 |
2016-02-02 |
Merus B.V. |
Methods and means for the production of Ig-like molecules
|
US9181572B2
(en)
|
2012-04-20 |
2015-11-10 |
Abbvie, Inc. |
Methods to modulate lysine variant distribution
|
CN104768973B
(zh)
|
2012-04-27 |
2019-01-22 |
第一三共株式会社 |
抗robo4抗体
|
US9212227B2
(en)
|
2012-04-30 |
2015-12-15 |
Janssen Biotech, Inc. |
ST2L antibody antagonists for the treatment of ST2L-mediated inflammatory pulmonary conditions
|
WO2013166290A1
(en)
|
2012-05-04 |
2013-11-07 |
Abbvie Biotherapeutics Inc. |
P21 biomarker assay
|
PL2831276T3
(pl)
|
2012-05-08 |
2016-10-31 |
|
Kompozycje i sposób oznaczania i kalibracji dla odchylenia amplifikacji w reakcjach multipleksowej pcr
|
WO2013173364A2
(en)
|
2012-05-14 |
2013-11-21 |
Biogen Idec Ma Inc. |
Lingo-2 antagonists for treatment of conditions involving motor neurons
|
MX362497B
(es)
|
2012-05-15 |
2019-01-21 |
Eisai Inc |
Un anticuerpo que se une específicamente al receptor alfa del folato y usos del mismo.
|
US20130309223A1
(en)
|
2012-05-18 |
2013-11-21 |
Seattle Genetics, Inc. |
CD33 Antibodies And Use Of Same To Treat Cancer
|
WO2013177118A2
(en)
|
2012-05-21 |
2013-11-28 |
Abbvie Inc. |
Novel purification of non-human antibodies using protein a affinity chromatography
|
WO2013177386A1
(en)
|
2012-05-24 |
2013-11-28 |
Abbvie Biotherapeutics Inc. |
Biomarkers for predicting response to tweak receptor (tweakr) agonist therapy
|
EP2855521A4
(de)
|
2012-05-24 |
2016-03-02 |
Mountgate Group Ltd |
Zusammensetzungen und verfahren in zusammenhang mit der vorbeugung und behandlung von tollwutinfektion
|
WO2013176754A1
(en)
|
2012-05-24 |
2013-11-28 |
Abbvie Inc. |
Novel purification of antibodies using hydrophobic interaction chromatography
|
WO2013180200A1
(ja)
|
2012-05-30 |
2013-12-05 |
中外製薬株式会社 |
標的組織特異的抗原結合分子
|
EP3892638A1
(de)
|
2012-05-30 |
2021-10-13 |
Chugai Seiyaku Kabushiki Kaisha |
Antigenbindende moleküle zur beseitigung von aggregierten antigenen
|
KR20150018604A
(ko)
|
2012-06-06 |
2015-02-23 |
온코메드 파마슈티칼스, 인크. |
히포 경로를 조절하는 결합제 및 그의 용도
|
JP6629069B2
(ja)
|
2012-06-06 |
2020-01-15 |
ゾエティス・エルエルシー |
イヌ化抗ngf抗体およびその方法
|
US11142563B2
(en)
|
2012-06-14 |
2021-10-12 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule containing modified Fc region
|
AU2013277051B2
(en)
|
2012-06-22 |
2018-06-07 |
King's College London |
Novel VISTA-Ig constructs and the use of VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
|
US9890215B2
(en)
|
2012-06-22 |
2018-02-13 |
King's College London |
Vista modulators for diagnosis and treatment of cancer
|
SG11201408554QA
(en)
|
2012-06-22 |
2015-02-27 |
Cytomx Therapeutics Inc |
Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof
|
WO2014001325A1
(en)
|
2012-06-27 |
2014-01-03 |
F. Hoffmann-La Roche Ag |
Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof
|
RU2639287C2
(ru)
|
2012-06-27 |
2017-12-20 |
Ф. Хоффманн-Ля Рош Аг |
Способ отбора и получения высокоселективных и мультиспецифичных нацеливающих групп с заданными свойствами, включающих по меньшей мере две различные связывающие группировки, и их применения
|
CA2871386A1
(en)
|
2012-06-27 |
2014-01-03 |
F. Hoffmann-La Roche Ag |
Method for the selection and production of tailor-made, selective and multi-specific therapeutic molecules comprising at least two different targeting entities and uses thereof
|
WO2014001557A1
(en)
|
2012-06-28 |
2014-01-03 |
Ucb Pharma S.A. |
A method for identifying compounds of therapeutic interest
|
EP2866831A1
(de)
|
2012-06-29 |
2015-05-06 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Behandlung von krankheiten durch modulation einer spezifischen isoform von mkl1
|
UY34887A
(es)
|
2012-07-02 |
2013-12-31 |
Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware |
Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
|
US20150184154A1
(en)
|
2012-07-05 |
2015-07-02 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Resear |
New treatment for neurodegenerative diseases
|
CN104619342A
(zh)
|
2012-07-05 |
2015-05-13 |
Ucb医药有限公司 |
骨疾病的治疗
|
WO2014006115A1
(en)
|
2012-07-06 |
2014-01-09 |
Novartis Ag |
Combination of a phosphoinositide 3-kinase inhibitor and an inhibitor of the il-8/cxcr interaction
|
UY34905A
(es)
|
2012-07-12 |
2014-01-31 |
Abbvie Inc |
Proteínas de unión a il-1
|
BR112015000660A8
(pt)
|
2012-07-13 |
2022-03-15 |
Childrens Hospital Philadelphia |
uso de uma terapia de primeira linha e uma terapia de segunda linha para tratamento de um paciente possuindo uma doença, desordem ou condição associada com uma expressão elevada de um antígeno de tumor, e de uma composição para reduzir ou evitar um efeito adverso associado com a administração de uma célula geneticamente modificada para expressar um car.
|
GB201213652D0
(en)
|
2012-08-01 |
2012-09-12 |
Oxford Biotherapeutics Ltd |
Therapeutic and diagnostic target
|
EP3613765A1
(de)
|
2012-08-03 |
2020-02-26 |
Dana-Farber Cancer Institute, Inc. |
Antikörper gegen abstossungs führung molekül b (rgmb)
|
JP6290209B2
(ja)
|
2012-08-07 |
2018-03-07 |
ロシュ グリクアート アーゲー |
低下した及び増加したエフェクター機能を有するように操作された2つの抗体を含む組成物。
|
BR112015002085A2
(pt)
|
2012-08-08 |
2017-12-19 |
Roche Glycart Ag |
proteína, polinucleotídeo, vetor, célula hospedeira, método para produzir a proteína, composição farmacêutica, uso da proteína, método de tratamento e invenção
|
CN109705218B
(zh)
|
2012-08-09 |
2022-07-19 |
罗切格利卡特公司 |
Asgpr抗体及其用途
|
US20140044675A1
(en)
|
2012-08-10 |
2014-02-13 |
Roche Glycart Ag |
Interleukin-2 fusion proteins and uses thereof
|
WO2014028939A2
(en)
|
2012-08-17 |
2014-02-20 |
California Institute Of Technology |
Targeting phosphofructokinase and its glycosylation form for cancer
|
WO2014031566A1
(en)
|
2012-08-22 |
2014-02-27 |
Immunogen, Inc. |
Cytotoxic benzodiazepine derivatives
|
EA201990839A1
(ru)
|
2012-08-23 |
2019-08-30 |
Эдженсис, Инк. |
Конъюгаты антитело-лекарственное средство (adc), которые связываются с белками 158p1d7
|
DK2889377T3
(da)
|
2012-08-24 |
2020-03-30 |
Chugai Pharmaceutical Co Ltd |
Fc?RIIb-Specifik Fc-regionsvariant
|
WO2014030750A1
(ja)
|
2012-08-24 |
2014-02-27 |
中外製薬株式会社 |
マウスFcγRII特異的Fc抗体
|
PL3489261T3
(pl)
|
2012-08-24 |
2021-08-16 |
The Regents Of The University Of California |
Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu
|
EP2966088B1
(de)
|
2012-08-31 |
2019-10-16 |
The Scripps Research Institute |
Antikörper, die eukaryotische zellen modulieren
|
SG11201500938XA
(en)
|
2012-08-31 |
2015-04-29 |
Immunogen Inc |
Diagnostic assays and kits for detection of folate receptor 1
|
US9512214B2
(en)
|
2012-09-02 |
2016-12-06 |
Abbvie, Inc. |
Methods to control protein heterogeneity
|
WO2014035475A1
(en)
|
2012-09-02 |
2014-03-06 |
Abbvie Inc. |
Methods to control protein heterogeneity
|
US9737493B2
(en)
|
2012-09-07 |
2017-08-22 |
University Of Louisville Research Foundation, Inc. |
Compositions and methods for modulating DNMT1 inhibitor activity
|
JOP20200308A1
(ar)
|
2012-09-07 |
2017-06-16 |
Novartis Ag |
جزيئات إرتباط il-18
|
AU2013312211B2
(en)
|
2012-09-07 |
2018-03-29 |
King's College London |
VISTA modulators for diagnosis and treatment of cancer
|
DK2895621T3
(da)
|
2012-09-14 |
2020-11-30 |
Population Bio Inc |
Fremgangsmåder og sammensætning til diagnosticering, prognose og behandling af neurologiske tilstande
|
CN104797710A
(zh)
|
2012-09-27 |
2015-07-22 |
中外制药株式会社 |
Fgfr3融合基因和以其作为标靶的药物
|
CA2922005A1
(en)
|
2012-09-27 |
2014-04-03 |
Population Diagnostics, Inc. |
Methods and compositions for screening and treating developmental disorders
|
NO2760138T3
(de)
|
2012-10-01 |
2018-08-04 |
|
|
WO2014055561A1
(en)
|
2012-10-01 |
2014-04-10 |
Adaptive Biotechnologies Corporation |
Immunocompetence assessment by adaptive immune receptor diversity and clonality characterization
|
WO2014055442A2
(en)
|
2012-10-01 |
2014-04-10 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for targeting stromal cells for the treatment of cancer
|
EP2905335B1
(de)
*
|
2012-10-03 |
2018-01-31 |
Chiome Bioscience Inc. |
Antikörper gegen menschliches dlk-1 mit in-vivo-antitumorwirkung
|
ES2743423T3
(es)
|
2012-10-03 |
2020-02-19 |
Philogen Spa |
Conjugado de anticuerpos para su uso en el tratamiento de una enfermedad inflamatoria intestinal
|
RU2661083C2
(ru)
|
2012-10-04 |
2018-07-11 |
Иммуноджен, Инк. |
Использование пвдф-мембраны для очистки конъюгатов клеточно-связывающий агент - цитотоксический агент
|
KR20150064068A
(ko)
|
2012-10-08 |
2015-06-10 |
로슈 글리카트 아게 |
2개의 Fab 단편을 포함하는 FC-부재 항체 및 이용 방법
|
UA118441C2
(uk)
|
2012-10-08 |
2019-01-25 |
Протена Біосаєнсиз Лімітед |
Антитіло, що розпізнає альфа-синуклеїн
|
AU2013329421A1
(en)
|
2012-10-09 |
2015-04-30 |
Biogen Ma Inc. |
Combination therapies and uses for treatment of demyelinating disorders
|
KR102369419B1
(ko)
|
2012-10-11 |
2022-03-02 |
다이이찌 산쿄 가부시키가이샤 |
글리신아미드 화합물의 제조 방법
|
EP3679950A1
(de)
|
2012-10-12 |
2020-07-15 |
The Brigham and Women's Hospital, Inc. |
Verbesserung der immunreaktion
|
CN110294804B
(zh)
|
2012-10-15 |
2023-07-14 |
米迪缪尼有限公司 |
针对β淀粉样蛋白的抗体
|
WO2014062985A1
(en)
|
2012-10-17 |
2014-04-24 |
University Of Maryland, Office Of Technology Commercialization |
Device and methods of using device for detection of aminoacidopathies
|
EP2910573B1
(de)
|
2012-10-19 |
2020-02-19 |
Daiichi Sankyo Company, Limited |
Durch bindung über einen linker mit hydrophiler struktur hergestelltes antikörper-wirkstoff-konjugat
|
EP2912064B1
(de)
|
2012-10-24 |
2019-04-24 |
Research Development Foundation |
Jam-c-antikörper und verfahren zur behandlung von krebs
|
US9676861B2
(en)
|
2012-10-30 |
2017-06-13 |
Apexigen, Inc. |
Anti-CD40 antibodies and methods of use
|
SG11201503412RA
(en)
|
2012-11-01 |
2015-05-28 |
Abbvie Inc |
Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof
|
EP3508503B1
(de)
|
2012-11-01 |
2022-11-02 |
Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft |
Antikörper gegen cd269 (bcma)
|
EP2914621B1
(de)
|
2012-11-05 |
2023-06-07 |
Foundation Medicine, Inc. |
Neuartige ntrk1-fusionsmoleküle und verwendungen davon
|
WO2014071282A1
(en)
|
2012-11-05 |
2014-05-08 |
Genzyme Corporation |
Compositions and methods for treating proteinopathies
|
CN104903349B
(zh)
|
2012-11-08 |
2018-10-19 |
十一生物治疗股份有限公司 |
Il-6拮抗剂及其应用
|
JP6212497B2
(ja)
|
2012-11-08 |
2017-10-11 |
国立大学法人 宮崎大学 |
トランスフェリン受容体を特異的に認識できる抗体
|
WO2014074942A1
(en)
|
2012-11-08 |
2014-05-15 |
Illumina, Inc. |
Risk variants of alzheimer's disease
|
UY35148A
(es)
|
2012-11-21 |
2014-05-30 |
Amgen Inc |
Immunoglobulinas heterodiméricas
|
EA031184B1
(ru)
|
2012-11-21 |
2018-11-30 |
Янссен Байотек, Инк. |
БИСПЕЦИФИЧЕСКИЕ К EGFR/c-Met АНТИТЕЛА
|
CA2891280C
(en)
|
2012-11-24 |
2018-03-20 |
Hangzhou Dac Biotech Co., Ltd. |
Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
|
US20140154255A1
(en)
|
2012-11-30 |
2014-06-05 |
Abbvie Biotherapeutics Inc. |
Anti-vegf antibodies and their uses
|
WO2014084859A1
(en)
|
2012-11-30 |
2014-06-05 |
Novartis Ag |
Molecules and methods for modulating tmem16a activities
|
SG11201503567SA
(en)
|
2012-12-05 |
2015-06-29 |
Novartis Ag |
Compositions and methods for antibodies targeting epo
|
DK2928923T3
(da)
|
2012-12-10 |
2020-02-17 |
Biogen Ma Inc |
Antistoffer mod dendritisk celle-antigen 2 fra blod og anvendelser deraf
|
CN108641002A
(zh)
|
2012-12-18 |
2018-10-12 |
西奈山伊坎医学院 |
流感病毒疫苗及其用途
|
CA2891686A1
(en)
|
2012-12-18 |
2014-06-26 |
Novartis Ag |
Compositions and methods that utilize a peptide tag that binds to hyaluronan
|
GB201223276D0
(en)
|
2012-12-21 |
2013-02-06 |
Ucb Pharma Sa |
Antibodies and methods of producing same
|
KR20150100715A
(ko)
|
2012-12-21 |
2015-09-02 |
앰플리뮨, 인크. |
항-h7cr 항체
|
WO2014100542A1
(en)
|
2012-12-21 |
2014-06-26 |
Abbvie, Inc. |
High-throughput antibody humanization
|
AU2013202668B2
(en)
|
2012-12-24 |
2014-12-18 |
Adelaide Research & Innovation Pty Ltd |
Inhibition of cancer growth and metastasis
|
US10766960B2
(en)
|
2012-12-27 |
2020-09-08 |
Chugai Seiyaku Kabushiki Kaisha |
Heterodimerized polypeptide
|
WO2014106176A1
(en)
|
2012-12-28 |
2014-07-03 |
Precision Biologics, Inc. |
Humanized monoclonal antibodies and methods of use for the diagnosis and treatment of colon and pancreas cancer
|
US10717965B2
(en)
|
2013-01-10 |
2020-07-21 |
Gloriana Therapeutics, Inc. |
Mammalian cell culture-produced neublastin antibodies
|
EP3939614A1
(de)
|
2013-01-18 |
2022-01-19 |
Foundation Medicine, Inc. |
Verfahren zur behandlung cholangiokarzinom
|
WO2014120916A1
(en)
|
2013-02-01 |
2014-08-07 |
Bristol-Myers Squibb Company |
Pegylated domain antibodies monovalent for cd28 binding and methods of use
|
SG11201506132PA
(en)
|
2013-02-06 |
2015-09-29 |
Inhibrx Llc |
Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereof
|
WO2015198217A2
(en)
|
2013-02-08 |
2015-12-30 |
Novartis Ag |
Compositions and methods for long-acting antibodies targeting il-17
|
CA2897682C
(en)
|
2013-02-08 |
2023-03-14 |
Novartis Ag |
Anti-il-17a antibodies and their use in treating autoimmune and inflammatory disorders
|
GB201302447D0
(en)
|
2013-02-12 |
2013-03-27 |
Oxford Biotherapeutics Ltd |
Therapeutic and diagnostic target
|
WO2014129895A1
(en)
|
2013-02-19 |
2014-08-28 |
Stichting Vu-Vumc |
Means and method for increasing the sensitivity of cancers for radiotherapy
|
AU2014218730B2
(en)
|
2013-02-22 |
2018-12-13 |
Abbvie Stemcentrx Llc |
Novel antibody conjugates and uses thereof
|
EP2961771B1
(de)
|
2013-02-26 |
2020-01-01 |
Roche Glycart AG |
Bispezifische antigenbindende moleküle zur t-zellen-aktivierung spezifisch auf cd3 und cea
|
FR3004184B1
(fr)
|
2013-02-26 |
2016-03-18 |
Agronomique Inst Nat Rech |
Anticorps anti-gluten desamide et utilisations.
|
JP6499087B2
(ja)
|
2013-02-26 |
2019-04-10 |
ロシュ グリクアート アーゲー |
二重特異性t細胞活性化抗原結合分子
|
WO2014131711A1
(en)
|
2013-02-26 |
2014-09-04 |
Roche Glycart Ag |
Bispecific t cell activating antigen binding molecules
|
EP3566750A3
(de)
|
2013-02-28 |
2020-04-08 |
ImmunoGen, Inc. |
Konjugate aus zellbindenden und zytotoxischen verbindungen
|
CA2902068C
(en)
|
2013-02-28 |
2023-10-03 |
Caprion Proteomics Inc. |
Tuberculosis biomarkers and uses thereof
|
US9901647B2
(en)
|
2013-02-28 |
2018-02-27 |
Immunogen, Inc. |
Conjugates comprising cell-binding agents and cytotoxic agents
|
EP2830651A4
(de)
|
2013-03-12 |
2015-09-02 |
Abbvie Inc |
An humanes tnf-alpha bindende humane antikörper und verfahren zur herstellung davon
|
EP2970453B1
(de)
|
2013-03-13 |
2019-12-04 |
Prothena Biosciences Limited |
Tau-immuntherapie
|
WO2014142646A1
(en)
|
2013-03-13 |
2014-09-18 |
Stichting Katholieke Universiteit |
Q-fever diagnostic
|
CN105378099B
(zh)
|
2013-03-14 |
2021-05-11 |
雅培制药有限公司 |
Hcv核心脂质结合结构域单克隆抗体
|
US9302005B2
(en)
|
2013-03-14 |
2016-04-05 |
Mayo Foundation For Medical Education And Research |
Methods and materials for treating cancer
|
WO2014151878A2
(en)
|
2013-03-14 |
2014-09-25 |
Abbvie Inc. |
Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
|
CN105189551B
(zh)
|
2013-03-14 |
2021-03-05 |
埃派斯进有限公司 |
抗-rankl抗体及其使用方法
|
WO2014159960A1
(en)
|
2013-03-14 |
2014-10-02 |
Icahn School Of Medicine At Mount Sinai |
Antibodies against influenza virus hemagglutinin and uses thereof
|
US10093921B2
(en)
|
2013-03-14 |
2018-10-09 |
The Governing Council Of The University Of Toronto |
Scaffolded peptidic libraries and methods of making and screening the same
|
BR112015023212A2
(pt)
|
2013-03-14 |
2017-11-21 |
Gill Parkash |
tratamento do câncer utilizando anticorpos que se ligam à grp78 da superfície celular
|
US8921526B2
(en)
|
2013-03-14 |
2014-12-30 |
Abbvie, Inc. |
Mutated anti-TNFα antibodies and methods of their use
|
CA2906421C
(en)
|
2013-03-14 |
2022-08-16 |
George J. Dawson |
Hcv antigen-antibody combination assay and methods and compositions for use therein
|
US9790478B2
(en)
|
2013-03-14 |
2017-10-17 |
Abbott Laboratories |
HCV NS3 recombinant antigens and mutants thereof for improved antibody detection
|
WO2014159239A2
(en)
|
2013-03-14 |
2014-10-02 |
Novartis Ag |
Antibodies against notch 3
|
US9017687B1
(en)
|
2013-10-18 |
2015-04-28 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same using displacement chromatography
|
WO2014142882A1
(en)
|
2013-03-14 |
2014-09-18 |
Abbvie Inc. |
Protein purification using displacement chromatography
|
EP2970375A1
(de)
|
2013-03-14 |
2016-01-20 |
AbbVie Inc. |
Schwach saure zusammensetzungen und verfahren zu ihrer herstellung durch verdrängungschromatografie
|
CA2899308C
(en)
|
2013-03-14 |
2017-04-18 |
Abbvie Inc. |
Low acidic species adalimumab compositions and uses thereof
|
JP2016515524A
(ja)
|
2013-03-15 |
2016-05-30 |
アッヴィ バイオテクノロジー リミテッド |
抗cd25抗体およびそれらの使用
|
CN105143257B
(zh)
|
2013-03-15 |
2020-10-27 |
艾伯维生物医疗股份有限公司 |
Fc变体
|
JP6466904B2
(ja)
|
2013-03-15 |
2019-02-06 |
ヤンセン バイオテツク,インコーポレーテツド |
インターフェロンアルファ及びオメガ抗体アンタゴニスト
|
MX2015013166A
(es)
|
2013-03-15 |
2015-12-11 |
Abbvie Inc |
Proteinas de union especificas duales dirigidas contra il-1 beta y/o il-17.
|
WO2014144292A2
(en)
|
2013-03-15 |
2014-09-18 |
Sanofi Pasteur Biologics , Llc |
Antibodies against clostridium difficile toxins and methods of using the same
|
US20140286969A1
(en)
|
2013-03-15 |
2014-09-25 |
Abbvie Inc. |
Anti-egfr antibody drug conjugate formulations
|
EP3424530A1
(de)
|
2013-03-15 |
2019-01-09 |
Zyngenia, Inc. |
Multivalente und monovalente multispezifische komplexe und deren verwendungen
|
CN105705165B
(zh)
|
2013-03-15 |
2020-04-24 |
纪念斯隆-凯特琳癌症中心 |
高亲和力抗gd2抗体
|
AU2014228938B2
(en)
|
2013-03-15 |
2019-05-02 |
Bioverativ Therapeutics Inc. |
Factor IX polypeptide formulations
|
EP2968589A1
(de)
|
2013-03-15 |
2016-01-20 |
AbbVie Inc. |
Aufreinigung eins antikörper-wirkstoff-konjugats (adc)
|
US9469686B2
(en)
|
2013-03-15 |
2016-10-18 |
Abbott Laboratories |
Anti-GP73 monoclonal antibodies and methods of obtaining the same
|
CN105121470A
(zh)
|
2013-03-15 |
2015-12-02 |
艾伯维生物技术有限公司 |
抗cd25抗体及其用途
|
AU2014236986A1
(en)
|
2013-03-15 |
2015-09-03 |
Biogen Ma Inc. |
Treatment and prevention of acute kidney injury using anti-alpha v beta 5 antibodies
|
PL2976361T3
(pl)
|
2013-03-18 |
2018-12-31 |
Biocerox Products B.V. |
Humanizowane przeciwciała anty-CD134 (OX40) i ich zastosowania
|
ES2830036T3
(es)
|
2013-03-20 |
2021-06-02 |
Sphingotec Gmbh |
Adrenomedulina para guiar una terapia de disminución de la presión sanguínea
|
MX2015013703A
(es)
|
2013-03-27 |
2016-08-11 |
Cedars Sinai Medical Center |
Mitigacion e inversion de la fibrosis e inflamacion mediante la inhibicion de la funcion de tl1a y vias de señalizacion relacionadas.
|
WO2014163101A1
(ja)
|
2013-04-02 |
2014-10-09 |
中外製薬株式会社 |
Fc領域改変体
|
UA118028C2
(uk)
|
2013-04-03 |
2018-11-12 |
Рош Глікарт Аг |
Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
|
US9499621B2
(en)
|
2013-04-08 |
2016-11-22 |
Cytodyn, Inc. |
Felinized antibodies and methods of treating retroviral infections in felines
|
GB201307501D0
(en)
|
2013-04-25 |
2013-06-12 |
Univ Aberdeen |
Anti-fungal antibody molecules and uses thereof
|
WO2014178715A1
(en)
|
2013-05-02 |
2014-11-06 |
Stichting Katholieke Universiteit |
Personalised medicine
|
EP2981822B1
(de)
|
2013-05-06 |
2020-09-02 |
Scholar Rock, Inc. |
Zusammensetzungen und verfahren zur modulation von wachstumsfaktoren
|
EP2997378B1
(de)
|
2013-05-16 |
2018-08-08 |
Kyoto University |
Verfahren zur bestimmung der prognose von krebs
|
GB201309178D0
(en)
|
2013-05-21 |
2013-07-03 |
Ucl Business Plc |
Enzyme and uses thereof
|
KR20160129698A
(ko)
|
2013-05-24 |
2016-11-09 |
메디뮨 엘엘씨 |
항-b7-h5 항체 및 이의 용도
|
WO2014194030A2
(en)
|
2013-05-31 |
2014-12-04 |
Immunogen, Inc. |
Conjugates comprising cell-binding agents and cytotoxic agents
|
EP3293275B1
(de)
|
2013-06-06 |
2021-08-04 |
Dana-Farber Cancer Institute, Inc. |
Zusammensetzung und verfahren zur identifikation, beurteilung, vorbeugung und behandlung von krebs mit pd-l1-isoformen
|
AU2014274660B2
(en)
|
2013-06-06 |
2019-05-16 |
Pierre Fabre Médicament |
Anti-C10orf54 antibodies and uses thereof
|
WO2014197885A2
(en)
|
2013-06-07 |
2014-12-11 |
Duke University |
Inhibitors of complement factor h
|
US10782290B2
(en)
|
2013-06-11 |
2020-09-22 |
National Center Of Neurology And Psychiatry |
Method for predicting post-therapy prognosis of relapsing-remitting multiple sclerosis (RRMS) patient, and method for determining applicability of novel therapy
|
JP2016521744A
(ja)
|
2013-06-13 |
2016-07-25 |
ファスト フォワード ファーマスーティカルズ ベー.フェー. |
追加化合物が胆汁酸、胆汁酸誘導体、tgr5受容体作動物質、fxr作動物質またはそれらの組合せである、慢性炎症の治療および消化器癌または線維症の予防のためのcd40シグナル伝達阻害物質および追加化合物
|
AR096601A1
(es)
|
2013-06-21 |
2016-01-20 |
Novartis Ag |
Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
|
JPWO2014208482A1
(ja)
|
2013-06-24 |
2017-02-23 |
中外製薬株式会社 |
ヒト化抗Epiregulin抗体を有効成分として含む腺癌以外の非小細胞肺癌の治療剤
|
US9708657B2
(en)
|
2013-07-01 |
2017-07-18 |
Adaptive Biotechnologies Corp. |
Method for generating clonotype profiles using sequence tags
|
EP3708189B1
(de)
|
2013-07-05 |
2023-11-29 |
University of Washington through its Center for Commercialization |
Löslicher mic-neutralisierender monoklonaler antikörper zur behandlung von krebs
|
US9951131B2
(en)
|
2013-07-12 |
2018-04-24 |
Prothena Biosciences Limited |
Antibodies that recognize IAPP
|
US9850302B2
(en)
|
2013-07-12 |
2017-12-26 |
Prothena Biosciences Limited |
Antibodies that recognize IAPP
|
US10208125B2
(en)
|
2013-07-15 |
2019-02-19 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Anti-mucin 1 binding agents and uses thereof
|
EP4105236A1
(de)
|
2013-07-19 |
2022-12-21 |
Cedars-Sinai Medical Center |
Anti-tl1a (tnfsf15) antikörper zur behandlung von entzündlichen darmerkrankungen
|
EP3027225B1
(de)
|
2013-07-31 |
2021-03-24 |
Dana-Farber Cancer Institute, Inc. |
Zusammensetzungen und verfahren zur modulierung der thermogenese mit transformierender wachstumsfaktor alpha
|
MX2016001233A
(es)
|
2013-08-01 |
2016-10-28 |
Agensys Inc |
Conjugados de anticuerpo farmaco (adc) que enlazan a proteinas cd37.
|
CN113683695A
(zh)
|
2013-08-02 |
2021-11-23 |
辉瑞公司 |
抗cxcr4抗体及抗体-药物缀合物
|
US10227370B2
(en)
|
2013-08-02 |
2019-03-12 |
California Institute Of Technology |
Heparan sulfate/heparin mimetics with anti-chemokine and anti-inflammatory activity
|
US9770461B2
(en)
|
2013-08-02 |
2017-09-26 |
California Institute Of Technology |
Tailored glycopolymers as anticoagulant heparin mimetics
|
CN104341504B
(zh)
|
2013-08-06 |
2017-10-24 |
百奥泰生物科技(广州)有限公司 |
双特异性抗体
|
US20160178610A1
(en)
|
2013-08-07 |
2016-06-23 |
Friedrich Miescher Institute For Biomedical Research |
New screening method for the treatment Friedreich's ataxia
|
WO2015023851A1
(en)
|
2013-08-14 |
2015-02-19 |
The Governing Council Of The University Of Toronto |
Antibodies against frizzled proteins and methods of use thereof
|
TN2016000057A1
(en)
|
2013-08-14 |
2017-07-05 |
Novartis Ag |
Methods of treating sporadic inclusion body myositis
|
WO2015026846A1
(en)
|
2013-08-19 |
2015-02-26 |
Biogen Idec Ma Inc. |
Control of protein glycosylation by culture medium supplementation and cell culture process parameters
|
WO2015027120A1
(en)
|
2013-08-21 |
2015-02-26 |
Jiang Jean X |
Compositions and methods for targeting connexin hemichannels
|
CA2922478C
(en)
|
2013-08-26 |
2020-09-29 |
MabVax Therapeutics, Inc. |
Nucleic acids encoding human antibodies to sialyl-lewisa
|
WO2015031541A1
(en)
|
2013-08-28 |
2015-03-05 |
Stem Centrx, Inc. |
Novel sez6 modulators and methods of use
|
CA2922547C
(en)
|
2013-08-28 |
2020-03-10 |
Stemcentrx, Inc. |
Site-specific antibody conjugation methods and compositions
|
IL293871A
(en)
|
2013-08-30 |
2022-08-01 |
Immunogen Inc |
Antibodies and assays for the detection of folate receptor 1
|
WO2015035044A2
(en)
|
2013-09-04 |
2015-03-12 |
Abbvie Biotherapeutics Inc. |
Fc VARIANTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY
|
WO2015034052A1
(ja)
|
2013-09-05 |
2015-03-12 |
国立大学法人 宮崎大学 |
ヒトインテグリンa6b4と特異的に反応する抗体
|
US10702608B2
(en)
|
2013-09-08 |
2020-07-07 |
Kodiak Sciences Inc. |
Factor VIII zwitterionic polymer conjugates
|
US20160229922A1
(en)
|
2013-09-20 |
2016-08-11 |
Chugai Seiyaku Kabushiki Kaisha |
Treatment for hemorrhagic diseases by anti-protein-c antibody
|
US10611794B2
(en)
|
2013-09-25 |
2020-04-07 |
Bioverativ Therapeutics Inc. |
On-column viral inactivation methods
|
EP3049521B1
(de)
|
2013-09-25 |
2019-03-06 |
Cornell University |
Verbindungen zur induzierung von antitumorimmunität und verfahren dafür
|
WO2015048312A1
(en)
|
2013-09-26 |
2015-04-02 |
Costim Pharmaceuticals Inc. |
Methods for treating hematologic cancers
|
SG10201803449VA
(en)
|
2013-09-27 |
2018-05-30 |
Chugai Pharmaceutical Co Ltd |
Method for producing polypeptide heteromultimer
|
MX2016003617A
(es)
*
|
2013-09-30 |
2016-07-21 |
Chugai Pharmaceutical Co Ltd |
Metodo para producir molecula de enlace al antigeno usando fago auxiliar modificado.
|
EP3835422A1
(de)
|
2013-09-30 |
2021-06-16 |
Daiichi Sankyo Company, Limited |
Anti-lps-o11-antikörper
|
US10259875B2
(en)
|
2013-10-01 |
2019-04-16 |
Mayo Foundation For Medical Education And Research |
Methods for treating cancer in patients with elevated levels of BIM
|
WO2015050959A1
(en)
|
2013-10-01 |
2015-04-09 |
Yale University |
Anti-kit antibodies and methods of use thereof
|
SG11201602522VA
(en)
|
2013-10-02 |
2016-04-28 |
Medimmune Llc |
Neutralizing anti-influenza a antibodies and uses thereof
|
WO2015051293A2
(en)
|
2013-10-04 |
2015-04-09 |
Abbvie, Inc. |
Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
|
CN105792844B
(zh)
|
2013-10-08 |
2021-03-02 |
第一三共株式会社 |
抗fgfr2抗体和另一药剂的组合
|
MX2016004411A
(es)
|
2013-10-08 |
2016-07-05 |
Immunogen Inc |
Regimenes de dosificacion de inmunoconjugado anti-receptor 1 de folato (folr1).
|
US8946395B1
(en)
|
2013-10-18 |
2015-02-03 |
Abbvie Inc. |
Purification of proteins using hydrophobic interaction chromatography
|
WO2015057939A1
(en)
|
2013-10-18 |
2015-04-23 |
Biogen Idec Ma Inc. |
Anti-s1p4 antibodies and uses thereof
|
US9181337B2
(en)
|
2013-10-18 |
2015-11-10 |
Abbvie, Inc. |
Modulated lysine variant species compositions and methods for producing and using the same
|
US9085618B2
(en)
|
2013-10-18 |
2015-07-21 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same
|
EP3063317B1
(de)
|
2013-10-28 |
2020-06-03 |
DOTS Technology Corp. |
Allergennachweis
|
WO2015066190A1
(en)
|
2013-10-29 |
2015-05-07 |
President And Fellows Of Harvard College |
Methods and compositions for inhibting oxidative stress
|
GB201319374D0
(en)
|
2013-11-01 |
2013-12-18 |
Univ Nottingham |
Glycans as functional cancer targets abd antibodies thereto
|
US9840555B2
(en)
|
2013-11-04 |
2017-12-12 |
Li-Te Chin |
Method for producing human monoclonal antibodies that binds to at least one part of HMGB1
|
EP3065774B1
(de)
|
2013-11-06 |
2021-05-26 |
Janssen Biotech, Inc. |
Anti-ccl17-antikörper
|
US20160272674A1
(en)
|
2013-11-07 |
2016-09-22 |
Abbvie Inc. |
Isolation and purification of antibodies
|
WO2015068847A1
(ja)
|
2013-11-11 |
2015-05-14 |
中外製薬株式会社 |
改変された抗体可変領域を含む抗原結合分子
|
EP2891722B1
(de)
|
2013-11-12 |
2018-10-10 |
Population Bio, Inc. |
Verfahren und Zusammensetzungen zur Diagnose, Prognose und Behandlung von Endometriose
|
GB201320061D0
(en)
|
2013-11-13 |
2013-12-25 |
Electrophoretics Ltd |
Materials nad methods for diagnosis and prognosis of liver cancer
|
WO2015073884A2
(en)
|
2013-11-15 |
2015-05-21 |
Abbvie, Inc. |
Glycoengineered binding protein compositions
|
US10900093B2
(en)
|
2013-11-15 |
2021-01-26 |
Institut Pasteur |
Molecular marker of plasmodium falciparum artemisinin resistance
|
US9309314B2
(en)
|
2013-12-03 |
2016-04-12 |
Agency For Science, Technology And Research (A*Star) |
Polypeptides, nucleic acids and uses thereof
|
TWI702316B
(zh)
|
2013-12-04 |
2020-08-21 |
日商中外製藥股份有限公司 |
因應化合物濃度使抗原結合能力變化的抗原結合分子及其資料庫
|
AU2014359085B2
(en)
|
2013-12-08 |
2017-11-02 |
Peptcell Limited |
HIV antigens and antibodies and compositions, methods and uses thereof
|
US9045545B1
(en)
|
2014-07-15 |
2015-06-02 |
Kymab Limited |
Precision medicine by targeting PD-L1 variants for treatment of cancer
|
US9914769B2
(en)
|
2014-07-15 |
2018-03-13 |
Kymab Limited |
Precision medicine for cholesterol treatment
|
US8986691B1
(en)
|
2014-07-15 |
2015-03-24 |
Kymab Limited |
Method of treating atopic dermatitis or asthma using antibody to IL4RA
|
US8980273B1
(en)
|
2014-07-15 |
2015-03-17 |
Kymab Limited |
Method of treating atopic dermatitis or asthma using antibody to IL4RA
|
US8986694B1
(en)
|
2014-07-15 |
2015-03-24 |
Kymab Limited |
Targeting human nav1.7 variants for treatment of pain
|
US9067998B1
(en)
|
2014-07-15 |
2015-06-30 |
Kymab Limited |
Targeting PD-1 variants for treatment of cancer
|
US8992927B1
(en)
|
2014-07-15 |
2015-03-31 |
Kymab Limited |
Targeting human NAV1.7 variants for treatment of pain
|
CN109908017A
(zh)
|
2013-12-19 |
2019-06-21 |
高露洁-棕榄公司 |
口腔护理组合物
|
TWI672379B
(zh)
|
2013-12-19 |
2019-09-21 |
瑞士商諾華公司 |
人類間皮素嵌合性抗原受體及其用途
|
WO2015095809A1
(en)
|
2013-12-20 |
2015-06-25 |
Biogen Idec Ma Inc. |
Use of perfusion seed cultures to improve biopharmaceutical fed-batch production capacity and product quality
|
WO2015095868A1
(en)
|
2013-12-20 |
2015-06-25 |
Wake Forest University Health Sciences |
Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines
|
EP2960252A1
(de)
|
2014-06-26 |
2015-12-30 |
Institut Pasteur |
Phospholipase zur Behandlung von Immunosuppression
|
US11014987B2
(en)
|
2013-12-24 |
2021-05-25 |
Janssen Pharmaceutics Nv |
Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
|
CA2935378C
(en)
|
2013-12-24 |
2023-04-18 |
Janssen Pharmaceutica Nv |
Anti-vista antibodies and fragments
|
KR20230078820A
(ko)
|
2013-12-25 |
2023-06-02 |
다이이찌 산쿄 가부시키가이샤 |
항 trop2 항체-약물 컨쥬게이트
|
JP6722455B2
(ja)
|
2013-12-27 |
2020-07-15 |
中外製薬株式会社 |
等電点の低い抗体の精製方法
|
EP3581179A1
(de)
|
2013-12-27 |
2019-12-18 |
Chugai Seiyaku Kabushiki Kaisha |
Mutantes fgfr-gatekeeper-gen und dagegen gerichteter wirkstoff
|
CA2936488C
(en)
|
2014-01-14 |
2022-05-03 |
The Medical College Of Wisconsin, Inc. |
Targeting clptm1l for treatment and prevention of cancer
|
WO2015134121A2
(en)
|
2014-01-20 |
2015-09-11 |
President And Fellows Of Harvard College |
Negative selection and stringency modulation in continuous evolution systems
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
BR112016013482B1
(pt)
|
2014-01-31 |
2022-04-19 |
Daiichi Sankyo Company, Limited |
Conjugado de anticorpo anti-her2-fármaco, fármacos antitumor e/ou anticâncer e composição farmacêutica
|
US11648335B2
(en)
|
2014-01-31 |
2023-05-16 |
Wake Forest University Health Sciences |
Organ/tissue decellularization, framework maintenance and recellularization
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
WO2015120187A1
(en)
|
2014-02-05 |
2015-08-13 |
The University Of Chicago |
Chimeric antigen receptors recognizing cancer-spevific tn glycopeptide variants
|
CR20160333A
(es)
|
2014-02-06 |
2016-09-05 |
F Hoffman-La Roche Ag |
Proteinas de fusión de interleucina-2 y usos de las mismas
|
CA3212977A1
(en)
|
2014-02-11 |
2015-08-20 |
Visterra, Inc. |
Antibody molecules to dengue virus and uses thereof
|
EP3107576A4
(de)
|
2014-02-21 |
2017-09-06 |
Abbvie Stemcentrx LLC |
Anti-dll3-antikörper und arzneimittelkonjugate zur verwendung in melanomen
|
US9732154B2
(en)
|
2014-02-28 |
2017-08-15 |
Janssen Biotech, Inc. |
Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
|
CA2938919C
(en)
|
2014-02-28 |
2020-12-29 |
Hangzhou Dac Biotech Co., Ltd |
Charged linkers and their uses for conjugation
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
WO2015134787A2
(en)
|
2014-03-05 |
2015-09-11 |
Adaptive Biotechnologies Corporation |
Methods using randomer-containing synthetic molecules
|
US10059761B2
(en)
|
2014-03-12 |
2018-08-28 |
Prothena Biosciences Limited |
Anti-Laminin4 antibodies specific for LG4-5
|
CA2938931A1
(en)
|
2014-03-12 |
2015-09-17 |
Prothena Biosciences Limited |
Anti-laminin4 antibodies specific for lg1-3
|
PT3116911T
(pt)
|
2014-03-12 |
2019-09-04 |
Prothena Biosciences Ltd |
Anticorpos anti-mcam e métodos de utilização associados
|
TW201623331A
(zh)
|
2014-03-12 |
2016-07-01 |
普羅帝納生物科學公司 |
抗黑色素瘤細胞黏著分子(mcam)抗體類及使用彼等之相關方法
|
PT3116909T
(pt)
|
2014-03-14 |
2020-01-30 |
Novartis Ag |
Moléculas de anticorpos para lag-3 e suas utilizações
|
US9738702B2
(en)
|
2014-03-14 |
2017-08-22 |
Janssen Biotech, Inc. |
Antibodies with improved half-life in ferrets
|
DK3122869T3
(da)
|
2014-03-24 |
2019-09-09 |
Biogen Ma Inc |
Fremgangsmåder til afhjælpning af glutamindeprivation under pattedyrecellekultur
|
SG11201607772WA
(en)
|
2014-03-31 |
2016-10-28 |
Debiopharm Int Sa |
Fgfr fusions
|
US10066265B2
(en)
|
2014-04-01 |
2018-09-04 |
Adaptive Biotechnologies Corp. |
Determining antigen-specific t-cells
|
AU2015240599B2
(en)
|
2014-04-04 |
2020-11-19 |
Bionomics, Inc. |
Humanized antibodies that bind LGR5
|
HUE051676T2
(hu)
|
2014-04-08 |
2021-03-29 |
Boston Pharmaceuticals Inc |
Il-21-re specifikus kötõ molekulák és alkalmazásaik
|
JP6744856B2
(ja)
|
2014-04-08 |
2020-08-19 |
プロセナ・バイオサイエンシズ・リミテッド |
α−シヌクレインを認識する抗体を含む血液脳関門シャトル
|
IL311108A
(en)
|
2014-04-10 |
2024-04-01 |
Daiichi Sankyo Co Ltd |
Preparation method of drug conjugate - anti-HER3 antibody
|
JP2017512765A
(ja)
|
2014-04-11 |
2017-05-25 |
メディミューン,エルエルシー |
二重特異性her2抗体
|
GB201406767D0
(en)
|
2014-04-15 |
2014-05-28 |
Cancer Rec Tech Ltd |
Humanized anti-Tn-MUC1 antibodies anf their conjugates
|
ES2777529T3
(es)
|
2014-04-17 |
2020-08-05 |
Adaptive Biotechnologies Corp |
Cuantificación de genomas de células inmunitarias adaptativas en una mezcla compleja de células
|
EP3132049B1
(de)
*
|
2014-04-17 |
2021-08-25 |
University of Maryland, College Park |
Vorrichtung und verfahren zur verwendung der vorrichtung für den nachweis von aminoazidopathien
|
TW201622746A
(zh)
|
2014-04-24 |
2016-07-01 |
諾華公司 |
改善或加速髖部骨折術後身體復原之方法
|
WO2015164364A2
(en)
|
2014-04-25 |
2015-10-29 |
The Brigham And Women's Hospital, Inc. |
Methods to manipulate alpha-fetoprotein (afp)
|
US9753036B2
(en)
|
2014-04-29 |
2017-09-05 |
Edp Biotech Corporation |
Methods and compositions for screening and detecting biomarkers
|
CA2946669A1
(en)
|
2014-05-02 |
2015-11-05 |
Medimmune Limited |
Ion channel modulators & uses thereof
|
AU2015259516B2
(en)
|
2014-05-13 |
2020-05-28 |
Bavarian Nordic A/S |
Combination therapy for treating cancer with a poxvirus expressing a tumor antigen and a monoclonal antibody against TIM-3
|
CN106413750B
(zh)
|
2014-05-16 |
2022-04-29 |
免疫医疗有限责任公司 |
具有增强的治疗和诊断特性的带有改变的新生儿Fc受体结合的分子
|
WO2015179654A1
(en)
|
2014-05-22 |
2015-11-26 |
Mayo Foundation For Medical Education And Research |
Distinguishing antagonistic and agonistic anti b7-h1 antibodies
|
NZ726513A
(en)
|
2014-05-28 |
2023-07-28 |
Memorial Sloan Kettering Cancer Center |
Anti-gitr antibodies and methods of use thereof
|
GB201409558D0
(en)
|
2014-05-29 |
2014-07-16 |
Ucb Biopharma Sprl |
Method
|
RU2636780C1
(ru)
|
2014-06-03 |
2017-11-28 |
ИксБиотеч, Инк. |
КОМПОЗИЦИИ И СПОСОБЫ ЛЕЧЕНИЯ И ПРЕДУПРЕЖДЕНИЯ ИНФЕКЦИЙ, ВЫЗВАННЫХ Staphylococcus aureus
|
NZ764877A
(en)
|
2014-06-04 |
2023-12-22 |
Biontech Res And Development Inc |
Human monoclonal antibodies to ganglioside gd2
|
SG10201810507WA
(en)
|
2014-06-06 |
2018-12-28 |
Bristol Myers Squibb Co |
Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
|
JP6997619B2
(ja)
|
2014-06-11 |
2022-01-17 |
キャシー・エイ・グリーン |
液性免疫の抑制または増進のための、vistaアゴニスト及びvistaアンタゴニストの使用
|
WO2015189816A1
(en)
|
2014-06-13 |
2015-12-17 |
Friedrich Miescher Institute For Biomedical Research |
New treatment against influenza virus
|
TWI695011B
(zh)
|
2014-06-18 |
2020-06-01 |
美商梅爾莎納醫療公司 |
抗her2表位之單株抗體及其使用之方法
|
TWI713453B
(zh)
|
2014-06-23 |
2020-12-21 |
美商健生生物科技公司 |
干擾素α及ω抗體拮抗劑
|
US10308935B2
(en)
|
2014-06-23 |
2019-06-04 |
Friedrich Miescher Institute For Biomedical Research |
Methods for triggering de novo formation of heterochromatin and or epigenetic silencing with small RNAS
|
WO2015198240A2
(en)
|
2014-06-25 |
2015-12-30 |
Novartis Ag |
Compositions and methods for long acting proteins
|
GB201411320D0
(en)
|
2014-06-25 |
2014-08-06 |
Ucb Biopharma Sprl |
Antibody construct
|
WO2015198243A2
(en)
|
2014-06-25 |
2015-12-30 |
Novartis Ag |
Compositions and methods for long acting proteins
|
JP6791763B2
(ja)
|
2014-06-26 |
2020-11-25 |
イェール ユニバーシティーYale University |
疾患および障害の処置においてレナラーゼを制御する組成物および方法
|
US9840553B2
(en)
|
2014-06-28 |
2017-12-12 |
Kodiak Sciences Inc. |
Dual PDGF/VEGF antagonists
|
PE20170286A1
(es)
|
2014-07-01 |
2017-03-30 |
Pfizer |
Diacuerpos heterodimericos biespecificos y sus usos
|
EP3164129A1
(de)
|
2014-07-01 |
2017-05-10 |
Friedrich Miescher Institute for Biomedical Research |
Kombination eines brafv600e-hemmers und mertk-hemmers zur melanombehandlung
|
US9139648B1
(en)
|
2014-07-15 |
2015-09-22 |
Kymab Limited |
Precision medicine by targeting human NAV1.9 variants for treatment of pain
|
GB201412658D0
(en)
|
2014-07-16 |
2014-08-27 |
Ucb Biopharma Sprl |
Molecules
|
GB201412659D0
(en)
|
2014-07-16 |
2014-08-27 |
Ucb Biopharma Sprl |
Molecules
|
WO2016008112A1
(en)
|
2014-07-16 |
2016-01-21 |
Medshine Discovery Inc. |
Linkers and application towards adc thereof
|
EP3172232B1
(de)
|
2014-07-17 |
2023-12-27 |
Novo Nordisk A/S |
Ortsgerichtete mutagenese von trem-1 antikörpern zur reduktion der viskosität.
|
SG11201700416TA
(en)
|
2014-07-21 |
2017-02-27 |
Novartis Ag |
Treatment of cancer using a cd33 chimeric antigen receptor
|
EP3171896A4
(de)
|
2014-07-23 |
2018-03-21 |
Mayo Foundation for Medical Education and Research |
Abzielung auf dna-pkcs und b7-h1 zur behandlung von krebs
|
WO2016012623A1
(en)
|
2014-07-25 |
2016-01-28 |
Theravectys |
Lentiviral vectors for regulated expression of a chimeric antigen receptor molecule
|
KR102317315B1
(ko)
|
2014-08-04 |
2021-10-27 |
에프. 호프만-라 로슈 아게 |
이중특이적 t 세포 활성화 항원 결합 분자
|
WO2016020882A2
(en)
|
2014-08-07 |
2016-02-11 |
Novartis Ag |
Angiopoetin-like 4 (angptl4) antibodies and methods of use
|
DK3177642T3
(da)
|
2014-08-07 |
2022-02-21 |
Novartis Ag |
Angiopoietin-lignende 4-antistoffer og fremgangsmåder til anvendelse deraf
|
WO2016025880A1
(en)
|
2014-08-14 |
2016-02-18 |
Novartis Ag |
Treatment of cancer using gfr alpha-4 chimeric antigen receptor
|
EP3712171A1
(de)
|
2014-08-19 |
2020-09-23 |
Novartis AG |
Behandlung von krebs mit einem chimären cd123-antigenrezeptor
|
EP4056993A1
(de)
|
2014-08-20 |
2022-09-14 |
Chugai Seiyaku Kabushiki Kaisha |
Verfahren zur messung der viskosität einer proteinlösung
|
US10961298B2
(en)
|
2014-08-21 |
2021-03-30 |
The Government Of The United States, Represented By The Secretary Of The Army |
Monoclonal antibodies for treatment of microbial infections
|
CN116514903A
(zh)
|
2014-09-03 |
2023-08-01 |
伊缪诺金公司 |
细胞毒性苯并二氮杂䓬衍生物
|
JP2017527562A
(ja)
|
2014-09-03 |
2017-09-21 |
イミュノジェン・インコーポレーテッド |
細胞毒性ベンゾジアゼピン誘導体
|
CA2996445A1
(en)
|
2014-09-05 |
2016-03-10 |
Eli Hatchwell |
Methods and compositions for inhibiting and treating neurological conditions
|
WO2016037985A1
(en)
|
2014-09-08 |
2016-03-17 |
Ruprecht-Karls-Universität Heidelberg |
Construct for the delivery of a molecule into the cytoplasm of a cell
|
AU2015315396B2
(en)
|
2014-09-09 |
2020-10-08 |
Janssen Biotech, Inc. |
Combination therapies with anti-CD38 antibodies
|
US20160075772A1
(en)
|
2014-09-12 |
2016-03-17 |
Regeneron Pharmaceuticals, Inc. |
Treatment of Fibrodysplasia Ossificans Progressiva
|
WO2016040880A1
(en)
|
2014-09-13 |
2016-03-17 |
Novartis Ag |
Combination therapies of alk inhibitors
|
AR101875A1
(es)
|
2014-09-15 |
2017-01-18 |
Amgen Inc |
Proteína de unión a antígenos, bi-específicos del receptor anti-cgrp / receptor pac1 y usos de las mismas
|
AU2015316522B2
(en)
|
2014-09-16 |
2021-01-21 |
Symphogen A/S |
Anti-met antibodies and compositions
|
WO2016046768A1
(en)
|
2014-09-24 |
2016-03-31 |
Friedrich Miescher Institute For Biomedical Research |
Lats and breast cancer
|
MA40764A
(fr)
|
2014-09-26 |
2017-08-01 |
Chugai Pharmaceutical Co Ltd |
Agent thérapeutique induisant une cytotoxicité
|
US10400037B2
(en)
|
2014-09-30 |
2019-09-03 |
Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts |
Binding molecules, especially antibodies, binding to L1CAM (CD171)
|
KR20230153495A
(ko)
|
2014-10-01 |
2023-11-06 |
메디뮨 리미티드 |
티카그렐로에 대한 항체 및 이의 사용 방법
|
BR112017006664A2
(pt)
|
2014-10-03 |
2017-12-26 |
Novartis Ag |
terapias de combinação
|
JP2017531642A
(ja)
|
2014-10-03 |
2017-10-26 |
マサチューセッツ インスティテュート オブ テクノロジー |
エボラ糖タンパク質に結合する抗体およびその使用
|
TN2017000129A1
(en)
|
2014-10-14 |
2018-10-19 |
Dana Farber Cancer Inst Inc |
Antibody molecules to pd-l1 and uses thereof
|
JP6749898B2
(ja)
|
2014-10-15 |
2020-09-02 |
アムジエン・インコーポレーテツド |
宿主細胞における異種由来遺伝子の発現を改善するためのプロモーター及び調節エレメント
|
MA41685A
(fr)
|
2014-10-17 |
2017-08-22 |
Biogen Ma Inc |
Supplémentation en cuivre pour la régulation de la glycosylation dans un procédé de culture cellulaire de mammifère
|
KR20210013299A
(ko)
|
2014-10-17 |
2021-02-03 |
코디악 사이언시스 인코포레이티드 |
부티릴콜린에스테라제 양성이온성 중합체 컨쥬게이트
|
US10920208B2
(en)
|
2014-10-22 |
2021-02-16 |
President And Fellows Of Harvard College |
Evolution of proteases
|
CA2966201A1
(en)
|
2014-10-29 |
2016-05-06 |
Adaptive Biotechnologies Corp. |
Highly-multiplexed simultaneous detection of nucleic acids encoding paired adaptive immune receptor heterodimers from many samples
|
MA40864A
(fr)
|
2014-10-31 |
2017-09-05 |
Biogen Ma Inc |
Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
|
US10011657B2
(en)
|
2014-10-31 |
2018-07-03 |
Abbvie Biotherapeutics Inc. |
Anti-CS1 antibodies and antibody drug conjugates
|
WO2016073401A1
(en)
|
2014-11-03 |
2016-05-12 |
Bristol-Myers Squibb Company |
Use of caprylic acid precipitation for protein purification
|
WO2016073685A1
(en)
|
2014-11-05 |
2016-05-12 |
Annexon, Inc. |
Humanized anti-complement factor c1q antibodies and uses thereof
|
WO2016073157A1
(en)
|
2014-11-06 |
2016-05-12 |
Genentech, Inc. |
Anti-ang2 antibodies and methods of use thereof
|
WO2016073894A1
(en)
|
2014-11-07 |
2016-05-12 |
Eleven Biotherapeutics, Inc. |
Therapeutic agents with increased ocular retention
|
US11180543B2
(en)
|
2014-11-07 |
2021-11-23 |
Mayo Foundation For Medical Education And Research |
Treatment of neonatal hypoxia including impairments or effects thereof
|
SG10202103420PA
(en)
|
2014-11-07 |
2021-05-28 |
Eleven Biotherapeutics Inc |
Improved il-6 antibodies
|
LT3218406T
(lt)
|
2014-11-10 |
2021-06-25 |
Medimmune Limited |
Surišančios molekulės, specifiškos cd73 ir jų panaudojimas
|
EP3789403A1
(de)
|
2014-11-11 |
2021-03-10 |
MedImmune Limited |
Therapeutische kombinationen mit anti-cd73-antikörpern und a2a-rezeptorinhibitoren sowie verwendungen davon
|
US9879087B2
(en)
|
2014-11-12 |
2018-01-30 |
Siamab Therapeutics, Inc. |
Glycan-interacting compounds and methods of use
|
EP3218005B1
(de)
|
2014-11-12 |
2023-01-04 |
Seagen Inc. |
Glycaninteragierende verbindungen und verfahren zur verwendung
|
US10246701B2
(en)
|
2014-11-14 |
2019-04-02 |
Adaptive Biotechnologies Corp. |
Multiplexed digital quantitation of rearranged lymphoid receptors in a complex mixture
|
CN113372434A
(zh)
|
2014-11-14 |
2021-09-10 |
豪夫迈·罗氏有限公司 |
包含tnf家族配体三聚体的抗原结合分子
|
CN107406503B
(zh)
|
2014-11-18 |
2021-07-16 |
詹森药业有限公司 |
Cd47抗体、方法和用途
|
JP6788586B2
(ja)
|
2014-11-19 |
2020-11-25 |
コーニンクレッカ フィリップス エヌ ヴェKoninklijke Philips N.V. |
Hnlを用いる診断方法
|
CN107592813A
(zh)
|
2014-11-19 |
2018-01-16 |
伊缪诺金公司 |
用于制备细胞结合剂‑细胞毒性剂缀合物的方法
|
WO2016079081A1
(en)
|
2014-11-20 |
2016-05-26 |
F. Hoffmann-La Roche Ag |
Common light chains and methods of use
|
EP3725808A1
(de)
|
2014-11-21 |
2020-10-21 |
Bristol-Myers Squibb Company |
Antikörper gegen cd73 und verwendungen davon
|
EP3220900B1
(de)
|
2014-11-21 |
2020-09-23 |
University of Maryland, Baltimore |
Systeme zur gezielten strukturspezifischen partikelabgabe
|
ES2764111T3
(es)
|
2014-12-03 |
2020-06-02 |
Hoffmann La Roche |
Anticuerpos multiespecíficos
|
AU2015357463B2
(en)
|
2014-12-05 |
2021-10-07 |
Immunext, Inc. |
Identification of VSIG8 as the putative vista receptor and its use thereof to produce vista/VSIG8 modulators
|
WO2016094273A1
(en)
|
2014-12-08 |
2016-06-16 |
Dana-Farber Cancer Institute, Inc. |
Methods for upregulating immune responses using combinations of anti-rgmb and anti-pd-1 agents
|
JP2018506509A
(ja)
|
2014-12-09 |
2018-03-08 |
アッヴィ・インコーポレイテッド |
細胞透過性Bcl−xL阻害剤との抗体薬物コンジュゲート
|
JP2018508463A
(ja)
|
2014-12-09 |
2018-03-29 |
アッヴィ・インコーポレイテッド |
低細胞透過性を有するBcl−xL阻害性化合物およびこれを含む抗体薬物コンジュゲート
|
WO2016094837A2
(en)
|
2014-12-11 |
2016-06-16 |
Igenica Biotherapeutics, Inc. |
Anti-c10orf54 antibodies and uses thereof
|
KR20170093182A
(ko)
|
2014-12-11 |
2017-08-14 |
인바이오모션 에스.엘. |
인간 c-maf에 대한 결합 구성원
|
WO2016094881A2
(en)
|
2014-12-11 |
2016-06-16 |
Abbvie Inc. |
Lrp-8 binding proteins
|
MA41142A
(fr)
|
2014-12-12 |
2017-10-17 |
Amgen Inc |
Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement
|
AU2015365583B2
(en)
|
2014-12-19 |
2021-10-28 |
Regenesance B.V. |
Antibodies that bind human C6 and uses thereof
|
US20170340733A1
(en)
|
2014-12-19 |
2017-11-30 |
Novartis Ag |
Combination therapies
|
UY36449A
(es)
|
2014-12-19 |
2016-07-29 |
Novartis Ag |
Composiciones y métodos para anticuerpos dirigidos a bmp6
|
JP7211703B2
(ja)
|
2014-12-22 |
2023-01-24 |
ザ ロックフェラー ユニバーシティー |
抗mertkアゴニスト抗体及びその使用
|
BR112017013385A2
(pt)
|
2014-12-23 |
2018-02-06 |
Bristol-Myers Squibb Company |
anticorpos para tigit
|
US10435467B2
(en)
|
2015-01-08 |
2019-10-08 |
Biogen Ma Inc. |
LINGO-1 antagonists and uses for treatment of demyelinating disorders
|
JP7152156B2
(ja)
|
2015-01-14 |
2022-10-12 |
ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド |
抗lapモノクローナル抗体による癌の処置
|
AU2016209032A1
(en)
|
2015-01-23 |
2017-08-10 |
Icahn School Of Medicine At Mount Sinai |
Influenza virus vaccination regimens
|
EP3250609A4
(de)
|
2015-01-26 |
2018-07-11 |
The University of Chicago |
Il13ra-alpha-2-bindende wirkstoffe und verwendung davon bei der krebsbehandlung
|
US20180170992A1
(en)
|
2015-01-26 |
2018-06-21 |
The University Of Chicago |
CAR T CELLS RECOGNIZING CANCER-SPECIFIC IL 13Ra2
|
TWI769570B
(zh)
|
2015-01-28 |
2022-07-01 |
愛爾蘭商普羅佘納生物科技有限公司 |
抗甲狀腺素運送蛋白抗體
|
TWI718122B
(zh)
|
2015-01-28 |
2021-02-11 |
愛爾蘭商普羅佘納生物科技有限公司 |
抗甲狀腺素運送蛋白抗體
|
TWI781507B
(zh)
|
2015-01-28 |
2022-10-21 |
愛爾蘭商普羅佘納生物科技有限公司 |
抗甲狀腺素運送蛋白抗體
|
CA2975346A1
(en)
|
2015-02-02 |
2016-08-11 |
I2 Pharmaceuticals, Inc. |
Anti-surrogate light chain antibodies
|
EP3256164B1
(de)
|
2015-02-09 |
2020-03-25 |
Memorial Sloan Kettering Cancer Center |
Multispezifische antikörpern mit affinität für menschliches a33-antigen und dota-metallkomplex
|
WO2016128349A1
(en)
|
2015-02-09 |
2016-08-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antibodies specific to glycoprotein (gp) of ebolavirus and uses for the treatment and diagnosis of ebola virus infection
|
CA2977646A1
(en)
*
|
2015-02-24 |
2016-09-01 |
Rpeptide, Llc |
Anti-amyloid-beta antibodies
|
WO2016136933A1
(ja)
|
2015-02-27 |
2016-09-01 |
中外製薬株式会社 |
Il-6関連疾患治療用組成物
|
DE112016001013T5
(de)
|
2015-03-03 |
2017-12-21 |
Kymab Limited |
Antikörper, verwendungen und verfahren
|
US10711067B2
(en)
|
2015-03-03 |
2020-07-14 |
Xoma (Us) Llc |
Treatment of post-prandial hyperinsulinemia and hypoglycemia after bariatric surgery
|
BR112017018468A2
(pt)
|
2015-03-06 |
2018-04-17 |
Csl Behring Recombinant Facility Ag |
fator de von willebrand modificado com meia-vida aumentada
|
EP3735982A1
(de)
|
2015-03-10 |
2020-11-11 |
The University of Massachusetts |
Abzielung auf gdf6 und bmp-signalisierung für antimelanomtherapie
|
US10695693B2
(en)
|
2015-03-13 |
2020-06-30 |
Bristol-Myers Squibb Company |
Use of alkaline washes during chromatography to remove impurities
|
WO2016146833A1
(en)
|
2015-03-19 |
2016-09-22 |
F. Hoffmann-La Roche Ag |
Biomarkers for nad(+)-diphthamide adp ribosyltransferase resistance
|
US20180105555A1
(en)
|
2015-03-20 |
2018-04-19 |
Bristol-Myers Squibb Company |
Use of dextran for protein purification
|
WO2016153978A1
(en)
|
2015-03-20 |
2016-09-29 |
Bristol-Myers Squibb Company |
Use of dextran to enhance protein purification by affinity chromatography
|
WO2016151557A1
(en)
|
2015-03-25 |
2016-09-29 |
Alexion Pharmaceuticals, Inc. |
A method for measuring the protease activity of c5 convertase of the alternative complement pathway
|
US20180074077A1
(en)
|
2015-03-25 |
2018-03-15 |
Alexion Pharmaceuticals, Inc. |
A method for measuring the protease activity of factor d of the alternative complement pathway
|
ES2904573T3
(es)
|
2015-03-27 |
2022-04-05 |
Univ Southern California |
Terapia con células T dirigida a LHR para el tratamiento de tumores sólidos
|
KR102261618B1
(ko)
|
2015-03-31 |
2021-06-04 |
메디뮨 리미티드 |
신규한 il33 형태, il33의 돌연변이된 형태, 항체, 검정 및 이의 이용 방법
|
IL254577B2
(en)
|
2015-03-31 |
2023-11-01 |
Vhsquared Ltd |
polypeptides
|
WO2016156475A1
(en)
|
2015-03-31 |
2016-10-06 |
Vhsquared Limited |
Polypeptide comprising an immunoglobulin chain variable domain which binds to clostridium difficile toxin b
|
CN108136001B
(zh)
|
2015-04-03 |
2022-07-29 |
佐马技术有限公司 |
使用TGF-β抑制剂和PD-1抑制剂治疗癌症
|
US10125198B2
(en)
|
2015-04-17 |
2018-11-13 |
Distributed Bio, Inc. |
Method for mass humanization of non-human antibodies
|
WO2016168631A1
(en)
|
2015-04-17 |
2016-10-20 |
President And Fellows Of Harvard College |
Vector-based mutagenesis system
|
EP3875477A1
(de)
|
2015-04-17 |
2021-09-08 |
Alpine Immune Sciences, Inc. |
Immunmodulatorische proteine mit einstellbaren affinitäten
|
WO2016170022A1
(en)
|
2015-04-21 |
2016-10-27 |
Institut Gustave Roussy |
Therapeutic methods, products and compositions inhibiting znf555
|
GB201506870D0
(en)
|
2015-04-22 |
2015-06-03 |
Ucb Biopharma Sprl |
Method
|
GB201506869D0
(en)
|
2015-04-22 |
2015-06-03 |
Ucb Biopharma Sprl |
Method
|
CA2983293C
(en)
|
2015-04-24 |
2023-06-20 |
The Regents Of The University Of California |
Modulators of ror1-ror2 binding
|
AU2016256486B2
(en)
|
2015-04-29 |
2021-09-23 |
University Of South Australia |
Compositions and methods for administering antibodies
|
CA2984249A1
(en)
|
2015-04-29 |
2016-11-03 |
Regeneron Pharmaceuticals, Inc. |
Treatment of fibrodysplasia ossificans progressiva
|
US11685773B2
(en)
|
2015-04-30 |
2023-06-27 |
Abcheck S.R.O. |
Method for mass humanization of rabbit antibodies
|
WO2016179518A2
(en)
|
2015-05-06 |
2016-11-10 |
Janssen Biotech, Inc. |
Prostate specific membrane antigen (psma) bispecific binding agents and uses thereof
|
TWI820377B
(zh)
|
2015-05-07 |
2023-11-01 |
美商艾吉納斯公司 |
抗ox40抗體及其使用方法
|
US10900975B2
(en)
|
2015-05-12 |
2021-01-26 |
Arizona Board Of Regents On Behalf Of Arizona State University |
Systems and methods of epitope binning and antibody profiling
|
WO2016187068A1
(en)
|
2015-05-15 |
2016-11-24 |
The General Hospital Corporation |
Antagonistic anti-tumor necrosis factor receptor superfamily antibodies
|
EP3095465A1
(de)
|
2015-05-19 |
2016-11-23 |
U3 Pharma GmbH |
Kombination von fgfr4-inhibitor und gallensäurekomplexbildner
|
UA124143C2
(uk)
|
2015-05-20 |
2021-07-28 |
Янссен Байотек, Інк. |
Антитіла до cd38 для лікування амілоїдозу, викликаного відкладеннями легких ланцюгів імуноглобулінів, і інших cd38-позитивних злоякісних гематологічних новоутворень
|
EA039951B1
(ru)
|
2015-05-27 |
2022-03-31 |
Юсб Биофарма Спрл |
Ингибитор активности csf-1r, предназначенный для лечения или профилактики эпилепсии или болезни паркинсона, и фармацевтическая композиция на его основе
|
PE20180193A1
(es)
|
2015-05-29 |
2018-01-26 |
Abbvie Inc |
Anticuerpos anti-cd40 y sus usos
|
MA44594B1
(fr)
|
2015-05-29 |
2020-09-30 |
Memorial Sloan Kettering Cancer Center |
Anticorps anti-ctla-4 et méthodes d'utilisation de ceux-ci
|
UY36687A
(es)
|
2015-05-29 |
2016-11-30 |
Bristol Myers Squibb Company Una Corporación Del Estado De Delaware |
Anticuerpos contra ox40 y sus usos
|
US10711064B2
(en)
|
2015-06-04 |
2020-07-14 |
University Of Southern California |
Lym-1 and Lym-2 targeted CAR cell immunotherapy
|
EA201792561A1
(ru)
|
2015-06-05 |
2018-04-30 |
Новартис Аг |
Антитела, нацеленные на морфогенетический белок кости 9 (bmp9), и способы их применения
|
US10723793B2
(en)
|
2015-06-12 |
2020-07-28 |
Ludwig Institute For Cancer Research, Ltd. |
TGF-β3 specific antibodies and methods and uses thereof
|
TW201710286A
(zh)
|
2015-06-15 |
2017-03-16 |
艾伯維有限公司 |
抗vegf、pdgf及/或其受體之結合蛋白
|
GB201510758D0
(en)
|
2015-06-18 |
2015-08-05 |
Ucb Biopharma Sprl |
Novel TNFa structure for use in therapy
|
CA2990406A1
(en)
|
2015-06-22 |
2016-12-29 |
Janssen Biotech, Inc. |
Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors
|
PE20181090A1
(es)
|
2015-06-24 |
2018-07-09 |
Janssen Biotech Inc |
Modulacion y tratamiento inmunes de tumores solidos con anticuerpos que se unen especificamente a cd38
|
US11009509B2
(en)
|
2015-06-24 |
2021-05-18 |
Janssen Pharmaceutica Nv |
Anti-VISTA antibodies and fragments
|
JP2018526977A
(ja)
|
2015-06-29 |
2018-09-20 |
ザ ロックフェラー ユニヴァーシティ |
アゴニスト活性が増強されたcd40に対する抗体
|
DK3313884T3
(da)
|
2015-06-29 |
2021-02-22 |
Immunogen Inc |
Anti-cd123-antistoffer og konjugater og derivater deraf
|
KR20180021723A
(ko)
|
2015-06-29 |
2018-03-05 |
다이이찌 산쿄 가부시키가이샤 |
항체-약물 콘주게이트의 선택적 제조 방법
|
EP3319936A4
(de)
|
2015-07-12 |
2019-02-06 |
Suzhou M-conj Biotech Co., Ltd. |
Brückenlinker zur konjugation von zellbindenden molekülen
|
US9839687B2
(en)
|
2015-07-15 |
2017-12-12 |
Suzhou M-Conj Biotech Co., Ltd. |
Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
|
GB201601073D0
(en)
|
2016-01-20 |
2016-03-02 |
Ucb Biopharma Sprl |
Antibodies
|
GB201601077D0
(en)
|
2016-01-20 |
2016-03-02 |
Ucb Biopharma Sprl |
Antibody molecule
|
GB201601075D0
(en)
|
2016-01-20 |
2016-03-02 |
Ucb Biopharma Sprl |
Antibodies molecules
|
WO2017015545A1
(en)
|
2015-07-22 |
2017-01-26 |
President And Fellows Of Harvard College |
Evolution of site-specific recombinases
|
US11524983B2
(en)
|
2015-07-23 |
2022-12-13 |
President And Fellows Of Harvard College |
Evolution of Bt toxins
|
US20180207273A1
(en)
|
2015-07-29 |
2018-07-26 |
Novartis Ag |
Combination therapies comprising antibody molecules to tim-3
|
LT3317301T
(lt)
|
2015-07-29 |
2021-07-26 |
Novartis Ag |
Kombinuotos terapijos, apimančios antikūno molekules prieš lag-3
|
US10612011B2
(en)
|
2015-07-30 |
2020-04-07 |
President And Fellows Of Harvard College |
Evolution of TALENs
|
JP6940479B2
(ja)
|
2015-08-03 |
2021-09-29 |
ノバルティス アーゲー |
Fgf21関連障害を処置する方法
|
EA201890434A1
(ru)
|
2015-08-05 |
2018-10-31 |
Янссен Байотек, Инк. |
Антитела к cd154 и способы их применения
|
WO2017024285A2
(en)
|
2015-08-06 |
2017-02-09 |
Xoma (Us) Llc |
Antibody fragments against the insulin receptor and uses thereof to treat hypoglycemia
|
EP3152570A1
(de)
|
2015-08-06 |
2017-04-12 |
Yaya Diagnostics GmbH |
Vorrichtung und verfahren zur erkennung von zielen
|
JP2018528191A
(ja)
|
2015-08-19 |
2018-09-27 |
ラトガーズ, ザ ステイト ユニバーシティ オブ ニュー ジャージー |
抗体を生成する新規な方法
|
EP3341415B1
(de)
|
2015-08-28 |
2021-03-24 |
H. Hoffnabb-La Roche Ag |
Anti-hypusin-antikörper und verwendungen davon
|
CN107949573B
(zh)
|
2015-09-01 |
2022-05-03 |
艾吉纳斯公司 |
抗-pd-1抗体及其使用方法
|
AU2016315892B2
(en)
|
2015-09-02 |
2023-06-15 |
The Regents Of The University Of Colorado, A Body Corporate |
Compositions and methods for modulating T-cell mediated immune response
|
EA038332B1
(ru)
|
2015-09-09 |
2021-08-10 |
Новартис Аг |
Молекулы, связывающиеся с тимусным стромальным лимфопоэтином (tslp), и способы применения таких молекул
|
SI3347377T1
(sl)
|
2015-09-09 |
2021-06-30 |
Novartis Ag |
Protitelesa, ki vežejo timusni stromalni limfopoietin (tslp) in postopki uporabe protiteles
|
WO2017044453A1
(en)
|
2015-09-10 |
2017-03-16 |
Becton, Dickinson And Company |
Cyclophosphamide analogs for use as immunogens and assay conjugates for an immunoassay of cyclophosphamide and ifosfamide
|
CA3036652A1
(en)
|
2015-09-15 |
2017-03-23 |
Scholar Rock, Inc. |
Anti-pro/latent-myostatin antibodies and uses thereof
|
EP3350216A1
(de)
|
2015-09-15 |
2018-07-25 |
Amgen Inc. |
Tetravalente bispezifische und tetraspezifische antigenbindende proteine und verwendungen davon
|
WO2017046776A2
(en)
|
2015-09-16 |
2017-03-23 |
Prothena Biosciences Limited |
Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
|
WO2017046774A2
(en)
|
2015-09-16 |
2017-03-23 |
Prothena Biosciences Limited |
Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
|
JP6880006B2
(ja)
|
2015-09-17 |
2021-06-02 |
イミュノジェン, インコーポレイテッド |
抗folr1免疫複合体を含む治療組み合わせ
|
SG10201911226QA
(en)
|
2015-09-23 |
2020-01-30 |
Genentech Inc |
Optimized variants of anti-vegf antibodies
|
AU2016326721C1
(en)
|
2015-09-23 |
2021-06-03 |
Cytoimmune Therapeutics, Inc. |
FLT3 directed car cells for immunotherapy
|
SG11201802352VA
(en)
|
2015-09-24 |
2018-04-27 |
Daiichi Sankyo Co Ltd |
Anti-garp antibody
|
RU2638457C2
(ru)
|
2015-09-28 |
2017-12-13 |
Общество С Ограниченной Ответственностью "Онкомакс" |
Антитела, специфически связывающие рецептор 1 типа фактора роста фибробластов, применение антител для лечения онкологического заболевания, способ получения антител
|
CN108368510B
(zh)
|
2015-09-30 |
2023-09-01 |
詹森生物科技公司 |
特异性结合人cd40的激动性抗体和使用方法
|
AR106188A1
(es)
|
2015-10-01 |
2017-12-20 |
Hoffmann La Roche |
Anticuerpos anti-cd19 humano humanizados y métodos de utilización
|
CN107949574A
(zh)
|
2015-10-02 |
2018-04-20 |
豪夫迈·罗氏有限公司 |
双特异性t细胞活化性抗原结合分子
|
WO2017055392A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-cd3xcd44v6 bispecific t cell activating antigen binding molecules
|
WO2017055385A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-cd3xgd2 bispecific t cell activating antigen binding molecules
|
WO2017055395A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-cd3xrob04 bispecific t cell activating antigen binding molecules
|
US20170096485A1
(en)
|
2015-10-02 |
2017-04-06 |
Hoffmann-La Roche Inc. |
Bispecific t cell activating antigen binding molecules
|
WO2017055393A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-cd3xtim-3 bispecific t cell activating antigen binding molecules
|
EP3356410B1
(de)
|
2015-10-02 |
2021-10-20 |
F. Hoffmann-La Roche AG |
Bispezifische anti-ceaxcd3-t-zell-aktivierende antigenbindende moleküle
|
WO2017055314A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Bispecific anti-cd19xcd3 t cell activating antigen binding molecules
|
WO2017066561A2
(en)
|
2015-10-16 |
2017-04-20 |
President And Fellows Of Harvard College |
Regulatory t cell pd-1 modulation for regulating t cell effector immune responses
|
RU2754683C2
(ru)
|
2015-10-27 |
2021-09-06 |
Юсб Биофарма Срл |
Способы лечения с использованием анти-il-17a антител
|
US20180348224A1
(en)
|
2015-10-28 |
2018-12-06 |
Friedrich Miescher Institute For Biomedical Resear Ch |
Tenascin-w and biliary tract cancers
|
US20210106661A1
(en)
|
2015-10-29 |
2021-04-15 |
Dana-Farber Cancer Institute, Inc. |
Methods for identification, assessment, prevention, and treatment of metabolic disorders using pm20d1 and n-lipidated amino acids
|
WO2017075045A2
(en)
|
2015-10-30 |
2017-05-04 |
Mayo Foundation For Medical Education And Research |
Antibodies to b7-h1
|
EP3368076A4
(de)
|
2015-10-30 |
2019-08-28 |
Galaxy Biotech, LLC |
An death-rezeptor 4 und 5 bindende hochwirksame antikörper
|
ITUB20155272A1
(it)
|
2015-11-02 |
2017-05-02 |
Scuola Normale Superiore |
Intracellular antibody
|
MA43186B1
(fr)
|
2015-11-03 |
2022-03-31 |
Janssen Biotech Inc |
Anticorps se liant spécifiquement à pd-1 et leurs utilisations
|
SI3370770T1
(sl)
|
2015-11-03 |
2021-03-31 |
Janssen Biotech, Inc. |
Subkutane formulacije protiteles proti CD38 in njihove uporabe
|
WO2017079833A1
(en)
|
2015-11-09 |
2017-05-18 |
The University Of British Columbia |
Epitopes in amyloid beta mid-region and conformationally-selective antibodies thereto
|
EP3374379A4
(de)
|
2015-11-09 |
2019-05-15 |
The University Of British Columbia |
N-terminale epitope in amyloid-beta und konformationsselektive antikörper dagegen
|
WO2017079835A1
(en)
|
2015-11-09 |
2017-05-18 |
The University Of British Columbia |
Amyloid beta epitopes and antibodies thereto
|
CN108473559A
(zh)
|
2015-11-10 |
2018-08-31 |
威特拉公司 |
特异性结合脂多糖的抗体分子-药物共轭物及其应用
|
SG10202103712VA
(en)
|
2015-11-10 |
2021-05-28 |
Medimmune Llc |
Binding molecules specific for asct2 and uses thereof
|
CA3002097A1
(en)
|
2015-11-12 |
2017-05-18 |
Siamab Therapeutics, Inc. |
Glycan-interacting compounds and methods of use
|
WO2017086367A1
(ja)
|
2015-11-18 |
2017-05-26 |
中外製薬株式会社 |
免疫抑制機能を有する細胞に対するt細胞リダイレクト抗原結合分子を用いた併用療法
|
JP6925278B2
(ja)
|
2015-11-18 |
2021-08-25 |
中外製薬株式会社 |
液性免疫応答の増強方法
|
CN107406504B
(zh)
|
2015-11-19 |
2021-04-30 |
蔡则玲 |
Ctla-4抗体及其用途
|
US11213586B2
(en)
|
2015-11-19 |
2022-01-04 |
Bristol-Myers Squibb Company |
Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR)
|
FI3380522T3
(fi)
|
2015-11-25 |
2024-01-16 |
Visterra Inc |
Vasta-ainemolekyylejä april-proteiinille ja niiden käyttöjä
|
JP6983779B2
(ja)
|
2015-11-30 |
2021-12-17 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアThe Regents Of The University Of California |
非常に特異的な腫瘍細胞表面抗原を標的とするヒト抗体を用いた腫瘍特異的ペイロード送達及び免疫活性化
|
JP6849694B2
(ja)
|
2015-11-30 |
2021-03-24 |
ブリストル−マイヤーズ スクウィブ カンパニー |
抗ヒトip−10抗体およびそれらの使用
|
JP2019501124A
(ja)
|
2015-11-30 |
2019-01-17 |
アッヴィ・インコーポレイテッド |
抗huLRRC15抗体薬物コンジュゲート及びその使用方法
|
JP2019500327A
(ja)
|
2015-11-30 |
2019-01-10 |
アッヴィ・インコーポレイテッド |
抗huLRRC15抗体薬物コンジュゲート及びその使用方法
|
WO2017096051A1
(en)
|
2015-12-02 |
2017-06-08 |
Stcube & Co., Inc. |
Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
|
CN108925136B
(zh)
|
2015-12-02 |
2022-02-01 |
斯特赛恩斯公司 |
特异于糖基化的btla(b和t淋巴细胞衰减因子)的抗体
|
GB201521382D0
(en)
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl |
Antibodies
|
GB201521383D0
(en)
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl And Ucb Celltech |
Method
|
GB201521393D0
(en)
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl |
Antibodies
|
GB201521389D0
(en)
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl |
Method
|
GB201521391D0
(en)
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl |
Antibodies
|
WO2017097889A1
(en)
|
2015-12-10 |
2017-06-15 |
Katholieke Universiteit Leuven |
Anti adamts13 antibodies and their use for treatment or prevention of haemorrhagic disorders due to ventricular assist device
|
KR20180087430A
(ko)
|
2015-12-17 |
2018-08-01 |
얀센 바이오테크 인코포레이티드 |
Hla-dr에 특이적으로 결합하는 항체 및 이의 용도
|
KR20180094977A
(ko)
|
2015-12-17 |
2018-08-24 |
노파르티스 아게 |
c-Met 억제제와 PD-1에 대한 항체 분자의 조합물 및 그의 용도
|
CA3007671A1
(en)
|
2015-12-17 |
2017-06-22 |
Novartis Ag |
Antibody molecules to pd-1 and uses thereof
|
KR20180089510A
(ko)
|
2015-12-18 |
2018-08-08 |
노파르티스 아게 |
CD32b를 표적화하는 항체 및 그의 사용 방법
|
EP3184544A1
(de)
|
2015-12-23 |
2017-06-28 |
Julius-Maximilians-Universität Würzburg |
Glycoprotein-v-inhibitoren zur verwendung als koagulansien
|
SG11201803989WA
(en)
|
2015-12-28 |
2018-06-28 |
Chugai Pharmaceutical Co Ltd |
Method for promoting efficiency of purification of fc region-containing polypeptide
|
BR112018013407A2
(pt)
|
2015-12-30 |
2018-12-18 |
Kodiak Sciences Inc |
anticorpos e conjugados dos mesmos
|
WO2017118761A1
(en)
|
2016-01-08 |
2017-07-13 |
Iontas Ltd |
Binding members with altered diversity scaffold domains
|
WO2017120523A2
(en)
|
2016-01-08 |
2017-07-13 |
Scholar Rock, Inc. |
Anti-pro/latent myostatin antibodies and methods of use thereof
|
WO2017121880A1
(en)
|
2016-01-15 |
2017-07-20 |
Philogen S.P.A |
Intestinal antigens for pharmacodelivery applications
|
EP3405492B1
(de)
|
2016-01-21 |
2020-10-21 |
Novartis AG |
Gegen cll-1 gerichtete multispezifische moleküle
|
CA3013125A1
(en)
|
2016-02-05 |
2017-08-10 |
Immunogen, Inc. |
Efficient process for preparing cell-binding agent-cytotoxic agent conjugates
|
GB201602413D0
(en)
|
2016-02-10 |
2016-03-23 |
Nascient Ltd |
Method
|
CN116920085A
(zh)
|
2016-02-12 |
2023-10-24 |
詹森药业有限公司 |
抗-vista(b7h5)抗体
|
CN116672445A
(zh)
|
2016-02-26 |
2023-09-01 |
德克萨斯大学体系董事会 |
连接蛋白(Cx)43半通道结合抗体及其用途
|
EP3423488A4
(de)
|
2016-02-29 |
2019-11-06 |
Foundation Medicine, Inc. |
Verfahren zur behandlung von krebs
|
WO2017149513A1
(en)
|
2016-03-03 |
2017-09-08 |
Prothena Biosciences Limited |
Anti-mcam antibodies and associated methods of use
|
EA201891983A8
(ru)
|
2016-03-04 |
2020-05-28 |
Бристол-Майерс Сквибб Компани |
Комбинированная терапия антителами к cd73
|
EP3423489A1
(de)
|
2016-03-04 |
2019-01-09 |
The Rockefeller University |
Antikörper gegen cd40 mit erhöhter agonistischer aktivität
|
WO2017153953A1
(en)
|
2016-03-09 |
2017-09-14 |
Prothena Biosciences Limited |
Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases
|
WO2017153955A1
(en)
|
2016-03-09 |
2017-09-14 |
Prothena Biosciences Limited |
Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases
|
KR20230152153A
(ko)
|
2016-03-10 |
2023-11-02 |
악셀레론 파마 인코포레이티드 |
액티빈 타입 2 수용체 결합 단백질 및 이의 용도
|
AU2017231833B2
(en)
|
2016-03-10 |
2024-03-14 |
Viela Bio, Inc. |
ILT7 binding molecules and methods of using the same
|
GB201604124D0
(en)
|
2016-03-10 |
2016-04-27 |
Ucb Biopharma Sprl |
Pharmaceutical formulation
|
SG11201807176XA
(en)
|
2016-03-11 |
2018-09-27 |
Scholar Rock Inc |
TGFß1-BINDING IMMUNOGLOBULINS AND USE THEREOF
|
WO2017160599A1
(en)
|
2016-03-14 |
2017-09-21 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Use of cd300b antagonists to treat sepsis and septic shock
|
WO2017159287A1
(ja)
|
2016-03-14 |
2017-09-21 |
中外製薬株式会社 |
癌の治療に用いるための細胞傷害誘導治療剤
|
JP7137474B2
(ja)
|
2016-03-15 |
2022-09-14 |
メルサナ セラピューティクス,インコーポレイティド |
NaPi2b標的化抗体-薬物コンジュゲート及びその使用方法
|
WO2017158064A1
(en)
|
2016-03-15 |
2017-09-21 |
Astrazeneca Ab |
Combination of a bace inhibitor and an antibody or antigen-binding fragment for the treatment of a disorder associated with the accumulation of amyloid beta
|
CA3017776A1
(en)
|
2016-03-15 |
2017-09-21 |
Generon (Shanghai) Corporation Ltd. |
Multispecific fab fusion proteins and use thereof
|
WO2017161067A1
(en)
|
2016-03-16 |
2017-09-21 |
Merrimack Pharmaceuticals, Inc |
Ephrin receptor a2 (epha2)-targeted docetaxel-generating nano-liposome compositions
|
CA3016383A1
(en)
|
2016-03-16 |
2017-09-21 |
Merrimack Pharmaceuticals, Inc |
Treating ephrin receptor a2 (epha2) positive cancer with targeted docetaxel-generating nano-liposome compositions
|
DK3219727T3
(da)
|
2016-03-17 |
2021-01-04 |
Tillotts Pharma Ag |
Anti-THF-alpha-antistoffer og funktionelle fragmenter deraf
|
EP3430041B1
(de)
|
2016-03-17 |
2023-05-24 |
Numab Innovation AG |
Anti-tnf-alpha-antikörper und funktionale fragmente davon
|
JP7184746B2
(ja)
|
2016-03-17 |
2022-12-06 |
ヌマブ イノヴェイション アーゲー |
抗TNFα抗体およびそれらの機能的断片
|
KR20220153109A
(ko)
|
2016-03-17 |
2022-11-17 |
세다르스-신나이 메디칼 센터 |
Rnaset2를 통한 염증성 장 질환의 진단 방법
|
WO2017158436A1
(en)
|
2016-03-17 |
2017-09-21 |
Oslo Universitetssykehus Hf |
Fusion proteins targeting tumour associated macrophages for treating cancer
|
PT3219726T
(pt)
|
2016-03-17 |
2020-12-15 |
Tillotts Pharma Ag |
Alfa-anticorpos anti-tnf e fragmentos funcionais dos mesmos
|
WO2017158101A1
(en)
|
2016-03-17 |
2017-09-21 |
Numab Innovation Ag |
ANTI-TNFα-ANTIBODIES AND FUNCTIONAL FRAGMENTS THEREOF
|
AU2017238172A1
(en)
|
2016-03-21 |
2018-09-13 |
Marengo Therapeutics, Inc. |
Multispecific and multifunctional molecules and uses thereof
|
AU2017239038A1
(en)
|
2016-03-22 |
2018-10-04 |
Bionomics Inc |
Administration of an anti-LGR5 monoclonal antibody
|
CA3012422A1
(en)
|
2016-03-22 |
2017-09-28 |
F. Hoffmann-La Roche Ag |
Protease-activated t cell bispecific molecules
|
AU2017238651A1
(en)
|
2016-03-25 |
2018-10-04 |
Visterra, Inc. |
Formulation of antibody molecules to dengue virus
|
MX2018011939A
(es)
|
2016-03-29 |
2019-05-20 |
Stcube Inc |
Anticuerpos de funcion doble especificos para pd-l1 glicosilada y metodos de uso de los mismos.
|
EP3231813A1
(de)
|
2016-03-29 |
2017-10-18 |
F. Hoffmann-La Roche AG |
Trimere kostimulatorische tnf-familien-ligandenhaltige antigenbindende moleküle
|
US11046782B2
(en)
|
2016-03-30 |
2021-06-29 |
Musc Foundation For Research Development |
Methods for treatment and diagnosis of cancer by targeting glycoprotein A repetitions predominant (GARP) and for providing effective immunotherapy alone or in combination
|
CA3018936C
(en)
|
2016-04-06 |
2021-10-19 |
Zumutor Biologics, Inc. |
Vectors for cloning and expression of proteins, methods and applications thereof
|
EP3439692A4
(de)
|
2016-04-08 |
2020-01-22 |
ITI Health, Inc. |
Plectin-1-antikörper und verwendungen davon
|
JP7184751B2
(ja)
|
2016-04-15 |
2022-12-06 |
イミュネクスト インコーポレイテッド |
抗ヒトvista抗体およびその使用
|
WO2017181098A2
(en)
|
2016-04-15 |
2017-10-19 |
Visterra, Inc. |
Antibody molecules to zika virus and uses thereof
|
BR112018071307A2
(pt)
|
2016-04-18 |
2019-02-26 |
Celldex Therapeutics, Inc. |
anticorpos agonistas que ligam cd40 humana e usos dos mesmos
|
SG11201809252YA
(en)
|
2016-04-21 |
2018-11-29 |
Sphingotec Therapeutics Gmbh |
Methods for determining dpp3 and therapeutic methods
|
CU24538B1
(es)
|
2016-05-02 |
2021-08-06 |
Prothena Biosciences Ltd |
Anticuerpos monoclonales que compiten por unirse a tau humano con el anticuerpo 16g7
|
CU24537B1
(es)
|
2016-05-02 |
2021-07-02 |
Prothena Biosciences Ltd |
Anticuerpos monoclonales que compiten por unirse a tau humano con el anticuerpo 3d6
|
KR102417687B1
(ko)
|
2016-05-09 |
2022-07-07 |
브리스톨-마이어스 스큅 컴퍼니 |
Tl1a 항체 및 그의 용도
|
EP3243836A1
(de)
|
2016-05-11 |
2017-11-15 |
F. Hoffmann-La Roche AG |
C-terminal-fusionierte antigenbindende moleküle mit ligandentrimer der tnf-familie
|
WO2017194442A1
(en)
|
2016-05-11 |
2017-11-16 |
F. Hoffmann-La Roche Ag |
Antigen binding molecules comprising a tnf family ligand trimer and a tenascin binding moiety
|
EP3243832A1
(de)
|
2016-05-13 |
2017-11-15 |
F. Hoffmann-La Roche AG |
Antigenbindende moleküle mit einem ligandentrimer der tnf-familie und pd1-bindungsteil
|
JP7084878B2
(ja)
|
2016-05-16 |
2022-06-15 |
武田薬品工業株式会社 |
抗第IX因子Padua抗体
|
KR20230028574A
(ko)
|
2016-05-17 |
2023-02-28 |
애브비 바이오테라퓨틱스 인크. |
항-cMet 항체 약물 컨쥬게이트 및 그들의 이용 방법
|
WO2017205465A2
(en)
|
2016-05-24 |
2017-11-30 |
Griswold Karl Edwin |
Antibodies and methods of making same
|
UA123111C2
(uk)
|
2016-05-27 |
2021-02-17 |
Еббві Байотерапьютікс Інк. |
Антитіло до cd40 та його застосування
|
KR20230091191A
(ko)
|
2016-05-27 |
2023-06-22 |
아게누스 인코포레이티드 |
항-tim-3 항체 및 이의 사용 방법
|
WO2017205745A1
(en)
|
2016-05-27 |
2017-11-30 |
Abbvie Biotherapeutics Inc. |
Anti-4-1bb antibodies and their uses
|
RU2745748C2
(ru)
|
2016-06-02 |
2021-03-31 |
Эббви Инк. |
Агонист глюкокортикоидного рецептора и его иммуноконъюгаты
|
WO2017208210A1
(en)
|
2016-06-03 |
2017-12-07 |
Prothena Biosciences Limited |
Anti-mcam antibodies and associated methods of use
|
KR102356864B1
(ko)
|
2016-06-06 |
2022-02-04 |
시티 오브 호프 |
Baff-r 표적 키메라 항원 수용체-변형된 t 세포 및 그 용도
|
WO2017214170A2
(en)
|
2016-06-06 |
2017-12-14 |
City Of Hope |
Baff-r antibodies and uses thereof
|
KR102497013B1
(ko)
|
2016-06-07 |
2023-02-20 |
맥스-델브뤼크-센트럼 퓌어 몰레쿨라레 메디친 |
Bcma에 결합하는 키메라 항원 수용체 및 car-t 세포
|
PL3458479T3
(pl)
|
2016-06-08 |
2021-07-26 |
Abbvie Inc. |
Przeciwciała anty-b7-h3 i koniugaty przeciwciało-lek
|
AU2017283787B2
(en)
|
2016-06-15 |
2020-09-17 |
Novartis Ag |
Methods for treating disease using inhibitors of bone morphogenetic protein 6 (BMP6)
|
JP7237344B2
(ja)
|
2016-06-15 |
2023-03-13 |
アイカーン スクール オブ メディシン アット マウント サイナイ |
インフルエンザウイルス血球凝集素タンパク質及びその使用
|
JP6996821B2
(ja)
|
2016-06-26 |
2022-02-04 |
ジェノヴァ バイオファーマシューティカルズ リミテッド |
抗体ファージディスプレイライブラリー
|
MA45493A
(fr)
|
2016-06-27 |
2019-05-01 |
Aicuris Anti Infective Cures Gmbh |
Inhibiteurs d'entrée de hcmv.
|
EP3475446A1
(de)
|
2016-06-27 |
2019-05-01 |
Juno Therapeutics, Inc. |
Verfahren zur identifizierung von peptidepitopen, moleküle zur bindung derartiger epitope und verwendungen davon
|
MA45491A
(fr)
|
2016-06-27 |
2019-05-01 |
Juno Therapeutics Inc |
Épitopes à restriction cmh-e, molécules de liaison et procédés et utilisations associés
|
EP3474895A1
(de)
|
2016-06-28 |
2019-05-01 |
UMC Utrecht Holding B.V. |
Behandlung von ige-vermittelten erkrankungen mit spezifisch cd38 bindenden antikörpern
|
WO2018007922A2
(en)
|
2016-07-02 |
2018-01-11 |
Prothena Biosciences Limited |
Anti-transthyretin antibodies
|
EP3478715A2
(de)
|
2016-07-02 |
2019-05-08 |
Prothena Biosciences Limited |
Anti-transthyretin-antikörper
|
EP3478716A2
(de)
|
2016-07-02 |
2019-05-08 |
Prothena Biosciences Limited |
Anti-transthyretin-antikörper
|
EP3482210B1
(de)
|
2016-07-06 |
2021-06-23 |
Prothena Biosciences Limited |
Verfahren zum nachweis von gesamtem und s129 phosphoryliertem alpha-synuklein
|
EP3481864A1
(de)
|
2016-07-08 |
2019-05-15 |
Staten Biotechnology B.V. |
Anti-apoc3-antikörper und verfahren zur verwendung davon
|
MX2019000003A
(es)
|
2016-07-08 |
2019-08-29 |
Sphingotec Gmbh |
Adrenomodulina para evaluar la congestión en un individuo con insuficiencia cardiaca aguda.
|
CN109862911A
(zh)
|
2016-07-13 |
2019-06-07 |
比奥根Ma公司 |
Lingo-1拮抗剂的剂量方案和用于治疗脱髓鞘病症的用途
|
JP7027401B2
(ja)
|
2016-07-14 |
2022-03-01 |
ブリストル-マイヤーズ スクイブ カンパニー |
Tim3に対する抗体およびその使用
|
CN110461315A
(zh)
|
2016-07-15 |
2019-11-15 |
诺华股份有限公司 |
使用与激酶抑制剂组合的嵌合抗原受体治疗和预防细胞因子释放综合征
|
JP2019521171A
(ja)
|
2016-07-20 |
2019-07-25 |
ヒブリジェニクス・エスアー |
抗cd38薬剤とのイネカルシトールの組み合わせ、及び癌を治療するためのその使用
|
WO2018017673A1
(en)
|
2016-07-20 |
2018-01-25 |
Stcube, Inc. |
Methods of cancer treatment and therapy using a combination of antibodies that bind glycosylated pd-l1
|
AU2017300040A1
(en)
|
2016-07-22 |
2019-01-24 |
Deutsches Zentrum Für Neurodegenerative Erkrankungen E.V. (Dzne) |
TREM2 cleavage modulators and uses thereof
|
CA3218290A1
(en)
|
2016-07-22 |
2018-01-25 |
Amgen Inc. |
Methods of purifying fc-containing proteins
|
US20190330318A1
(en)
|
2016-07-25 |
2019-10-31 |
Biogen Ma Inc. |
Anti-hspa5 (grp78) antibodies and uses thereof
|
EP3491022A1
(de)
|
2016-07-29 |
2019-06-05 |
Institut National de la Sante et de la Recherche Medicale (INSERM) |
Antikörper gegen tumor-assoziierte makrophagen und verwendungen davon
|
US10519250B2
(en)
|
2016-08-01 |
2019-12-31 |
Xoma (Us) Llc |
Parathyroid hormone receptor 1 (PTH1R) antibodies and uses thereof
|
WO2018052556A1
(en)
|
2016-08-02 |
2018-03-22 |
Visterra, Inc. |
Engineered polypeptides and uses thereof
|
US11649285B2
(en)
|
2016-08-03 |
2023-05-16 |
Bio-Techne Corporation |
Identification of VSIG3/VISTA as a novel immune checkpoint and use thereof for immunotherapy
|
US20190352426A1
(en)
|
2016-08-03 |
2019-11-21 |
Achaogen, Inc. |
Plazomicin antibodies and methods of use
|
WO2018027124A1
(en)
|
2016-08-05 |
2018-02-08 |
Medimmune, Llc |
Anti-o2 antibodies and uses thereof
|
KR102587941B1
(ko)
|
2016-08-12 |
2023-10-11 |
얀센 바이오테크 인코포레이티드 |
향상된 효능작용 및 이펙터 기능을 갖는 조작된 항체 및 다른 Fc-도메인 함유 분자
|
JP2019530646A
(ja)
|
2016-08-12 |
2019-10-24 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
タンパク質精製法
|
WO2018031400A1
(en)
|
2016-08-12 |
2018-02-15 |
Janssen Biotech, Inc. |
Fc engineered anti-tnfr superfamily member antibodies having enhanced agonistic activity and methods of using them
|
US10981976B2
(en)
|
2016-08-31 |
2021-04-20 |
University Of Rochester |
Human monoclonal antibodies to human endogenous retrovirus K envelope (HERV-K) and use thereof
|
TW201825511A
(zh)
|
2016-09-09 |
2018-07-16 |
美商艾斯合顧問有限公司 |
表現免疫檢查點調節子的溶瘤病毒
|
AU2017326329B2
(en)
|
2016-09-14 |
2023-10-26 |
Abbvie Biotherapeutics Inc. |
Anti-pd-1 antibodies and their uses
|
JP2020501508A
(ja)
|
2016-09-15 |
2020-01-23 |
クアドルセプト バイオ リミテッド |
多量体、四量体および八量体
|
JP7274413B2
(ja)
|
2016-09-23 |
2023-05-16 |
マレンゴ・セラピューティクス,インコーポレーテッド |
ラムダ及びカッパ軽鎖を含む多重特異性抗体分子
|
CA3038679A1
(en)
|
2016-09-28 |
2018-04-05 |
Xoma (Us) Llc |
Antibodies that bind interleukin-2 and uses thereof
|
GB201616596D0
(en)
|
2016-09-29 |
2016-11-16 |
Nascient Limited |
Epitope and antibodies
|
WO2018060453A1
(en)
|
2016-09-30 |
2018-04-05 |
Vhsquared Limited |
Compositions
|
CN109843926B
(zh)
|
2016-09-30 |
2023-01-20 |
豪夫迈·罗氏有限公司 |
针对cd3的双特异性抗体
|
JP2019535015A
(ja)
|
2016-10-03 |
2019-12-05 |
アボット・ラボラトリーズAbbott Laboratories |
患者サンプルにおけるgfap状況を評価する改善された方法
|
US20190330368A1
(en)
|
2016-10-07 |
2019-10-31 |
Daiichi Sankyo Company, Limited |
Therapy for drug-resistant cancer by administration of anti-her2 antibody/drug conjugate
|
AU2017341047A1
(en)
|
2016-10-07 |
2019-05-02 |
Novartis Ag |
Chimeric antigen receptors for the treatment of cancer
|
WO2018071500A1
(en)
|
2016-10-11 |
2018-04-19 |
Agenus Inc. |
Anti-lag-3 antibodies and methods of use thereof
|
CN109996560A
(zh)
|
2016-10-13 |
2019-07-09 |
麻省理工学院 |
结合寨卡病毒包膜蛋白的抗体及其用途
|
WO2018071576A1
(en)
|
2016-10-14 |
2018-04-19 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Treatment of tumors by inhibition of cd300f
|
EP3312290A1
(de)
|
2016-10-18 |
2018-04-25 |
Ipsen Biopharm Limited |
Zellulärer vamp-spaltungstest
|
SG11201903063UA
(en)
|
2016-10-19 |
2019-05-30 |
Medimmune Llc |
Anti-o1 antibodies and uses thereof
|
CN110121509A
(zh)
|
2016-10-26 |
2019-08-13 |
西达-赛奈医疗中心 |
中和抗tl1a单克隆抗体
|
US11249082B2
(en)
|
2016-10-29 |
2022-02-15 |
University Of Miami |
Zika virus assay systems
|
SG11201903842YA
(en)
|
2016-11-02 |
2019-05-30 |
Immunogen Inc |
Combination treatment with antibody-drug conjugates and parp inhibitors
|
WO2018083237A1
(en)
|
2016-11-03 |
2018-05-11 |
Roche Diagnostics Operations Inc. |
Novel anti-py520-ddr1 antibodies
|
WO2018083238A1
(en)
|
2016-11-03 |
2018-05-11 |
Roche Diagnostics Gmbh |
Novel anti-py792-ddr1 antibodies
|
WO2018083248A1
(en)
|
2016-11-03 |
2018-05-11 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses & methods
|
WO2018083235A1
(en)
|
2016-11-03 |
2018-05-11 |
Roche Diagnostics Gmbh |
Novel anti-py513-ddr1 antibodies
|
WO2018083240A1
(en)
|
2016-11-03 |
2018-05-11 |
Roche Diagnostics Gmbh |
Novel anti-py796-ddr1 antibodies
|
US11332521B2
(en)
|
2016-11-07 |
2022-05-17 |
Neuracle Science Co., Ltd. |
Anti-family with sequence similarity 19, member A5 antibodies and method of use thereof
|
NZ754407A
(en)
|
2016-11-09 |
2023-01-27 |
Philogen Spa |
Il2 and tnf mutant immunoconjugates
|
US20180125920A1
(en)
|
2016-11-09 |
2018-05-10 |
The University Of British Columbia |
Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
|
EP3888691A1
(de)
|
2016-11-14 |
2021-10-06 |
Hangzhou Dac Biotech Co., Ltd. |
Konjugationslinker, zellbindende molekül-wirkstoffkonjugate mit den linkern, verfahren zur herstellung und verwendung solcher konjugate mit den linkern
|
AU2017356317A1
(en)
|
2016-11-14 |
2019-05-30 |
Amgen Inc. |
Bispecific or biparatopic antigen binding proteins and uses thereof
|
US11339209B2
(en)
|
2016-11-14 |
2022-05-24 |
Novartis Ag |
Compositions, methods, and therapeutic uses related to fusogenic protein minion
|
EP3541422A4
(de)
|
2016-11-16 |
2020-05-06 |
Janssen Biotech, Inc. |
Verfahren zur behandlung von schuppenflechte mit anti-il-23-spezifischem antikörper
|
US11401330B2
(en)
|
2016-11-17 |
2022-08-02 |
Seagen Inc. |
Glycan-interacting compounds and methods of use
|
EP4015532A1
(de)
|
2016-11-21 |
2022-06-22 |
cureab GmbH |
Anti-gp73-antikörper und immunkonjugate
|
CN108367075B
(zh)
|
2016-11-23 |
2022-08-09 |
免疫方舟医药技术股份有限公司 |
4-1bb结合蛋白及其用途
|
KR20190080949A
(ko)
|
2016-11-23 |
2019-07-08 |
바이오버라티브 테라퓨틱스 인크. |
응고 인자 ix 및 응고 인자 x에 결합하는 이중특이적 항체
|
AU2017364818A1
(en)
|
2016-11-28 |
2019-05-23 |
Chugai Seiyaku Kabushiki Kaisha |
Ligand-binding molecule having adjustable ligand binding activity
|
CN110300599A
(zh)
|
2016-12-07 |
2019-10-01 |
艾吉纳斯公司 |
抗体和其使用方法
|
BR112019011651A2
(pt)
|
2016-12-07 |
2020-01-07 |
Agenus Inc. |
Anticorpos anti-cttla-4 e métodos de uso dos mesmos
|
MY198059A
(en)
|
2016-12-15 |
2023-07-31 |
Abbvie Biotherapeutics Inc |
Anti-ox40 antibodies and their uses
|
AU2017375049A1
(en)
|
2016-12-16 |
2019-06-13 |
Adrenomed Ag |
Anti-Adrenomedullin (ADM) antibody or anti-ADM antibody fragment or anti-ADM non-Ig scaffold for use in intervention and therapy of congestion in a patient in need thereof
|
EP3339324A1
(de)
|
2016-12-22 |
2018-06-27 |
sphingotec GmbH |
Anti-adrenomedullin (adm)-antikörper oder anti-adm antikörperfragment oder anti-adm-nicht-ig-gerüst zur verwendung in einer intervention und therapie von verstopfung bei einem darauf angewiesenen patienten
|
WO2018114754A1
(en)
|
2016-12-19 |
2018-06-28 |
F. Hoffmann-La Roche Ag |
Combination therapy with targeted 4-1bb (cd137) agonists
|
GB201621635D0
(en)
|
2016-12-19 |
2017-02-01 |
Ucb Biopharma Sprl |
Crystal structure
|
BR112019007267A2
(pt)
|
2016-12-20 |
2019-07-09 |
Hoffmann La Roche |
anticorpo biespecífico anti-cd20/anti-cd3, produto farmacêutico, composição farmacêutica que compreende um anticorpo biespecífico anti-cd20/anti-cd3, uso de combinação de anticorpo biespecífico anti-cd20/anti-cd3 e um agonista de 4-1bb e método de tratamento ou retardamento da progressão de câncer em pacientes
|
JP7202185B2
(ja)
|
2016-12-22 |
2023-01-11 |
第一三共株式会社 |
抗cd3抗体及び該抗体を含む分子
|
KR20190111036A
(ko)
|
2016-12-23 |
2019-10-01 |
비스테라, 인크. |
결합 폴리펩타이드 및 이의 제조 방법
|
CA3048186A1
(en)
|
2016-12-23 |
2018-06-28 |
Cephalon, Inc. |
Anti-il-5 antibodies
|
DK3565592T3
(da)
|
2017-01-06 |
2023-05-01 |
Scholar Rock Inc |
Behandling af stofskiftesygdomme ved inhibering af myostatinaktivering
|
EP3565845A4
(de)
|
2017-01-06 |
2020-10-07 |
Biosion, Inc. |
Erbb2-antikörper und deren verwendungen
|
PT3565592T
(pt)
|
2017-01-06 |
2023-05-31 |
Scholar Rock Inc |
Tratamento de doenças metabólicas através da inibição da ativação da miostatina
|
WO2018129329A1
(en)
|
2017-01-06 |
2018-07-12 |
Scholar Rock, Inc. |
ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFβ1 INHIBITORS AND USE THEREOF
|
US20180244785A1
(en)
|
2017-01-09 |
2018-08-30 |
Merrimack Pharmaceuticals, Inc. |
Anti-fgfr antibodies and methods of use
|
TWI659750B
(zh)
|
2017-01-13 |
2019-05-21 |
中央研究院 |
用以治療心肌梗塞之可重複裝載之改良水膠系統
|
CN110290811A
(zh)
|
2017-01-13 |
2019-09-27 |
中央研究院 |
用以治疗脑部疾病的可重复装载的水胶系统
|
SG11201906554RA
(en)
|
2017-01-17 |
2019-08-27 |
Daiichi Sankyo Co Ltd |
Anti-gpr20 antibody and anti-gpr20 antibody-drug conjugate
|
CA3049449A1
(en)
|
2017-01-18 |
2018-07-26 |
Visterra, Inc. |
Antibody molecule-drug conjugates and uses thereof
|
CA3051512A1
(en)
|
2017-01-26 |
2018-08-02 |
Zlip Holding Limited |
Cd47 antigen binding unit and uses thereof
|
EP3574012A1
(de)
|
2017-01-27 |
2019-12-04 |
Memorial Sloan Kettering Cancer Center |
Bispezifische her2- und cd3-bindende moleküle
|
AU2017396503A1
(en)
|
2017-01-30 |
2019-07-11 |
Janssen Biotech, Inc. |
Anti-TNF antibodies, compositions, and methods for the treatment of active Psoriatic arthritis
|
US10240205B2
(en)
|
2017-02-03 |
2019-03-26 |
Population Bio, Inc. |
Methods for assessing risk of developing a viral disease using a genetic test
|
US11623945B2
(en)
|
2017-02-06 |
2023-04-11 |
The United States Of America, As Represented By The Secretary Of Agriculture |
Immunostimulating compositions and uses therefore
|
AU2017398101A1
(en)
|
2017-02-07 |
2019-08-01 |
Janssen Biotech, Inc. |
Anti-TNF antibodies, compositions, and methods for the treatment of active Ankylosing Spondylitis
|
CN110462038A
(zh)
|
2017-02-07 |
2019-11-15 |
第一三共株式会社 |
抗gprc5d抗体和包含所述抗体的分子
|
MX2019009498A
(es)
|
2017-02-08 |
2019-10-02 |
Novartis Ag |
Anticuerpos mimeticos de fgf21 y usos de los mismos.
|
US20200291089A1
(en)
|
2017-02-16 |
2020-09-17 |
Elstar Therapeutics, Inc. |
Multifunctional molecules comprising a trimeric ligand and uses thereof
|
BR112019016374A2
(pt)
|
2017-02-17 |
2020-04-07 |
Bristol-Myers Squibb Company |
anticorpos para alfa-sinucleína e usos dos mesmos
|
TWI781145B
(zh)
|
2017-02-28 |
2022-10-21 |
美商伊繆諾金公司 |
具有自分解肽連接子之類美登素衍生物及其結合物
|
CN110382529B
(zh)
|
2017-03-02 |
2024-03-08 |
诺华股份有限公司 |
工程化的异源二聚体蛋白质
|
WO2018158398A1
(en)
|
2017-03-02 |
2018-09-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antibodies having specificity to nectin-4 and uses thereof
|
SG11201907889YA
(en)
|
2017-03-03 |
2019-09-27 |
Seattle Genetics Inc |
Glycan-interacting compounds and methods of use
|
EP3589324A1
(de)
|
2017-03-03 |
2020-01-08 |
Janssen Biotech, Inc. |
Co-therapie mit einem inhibitor des kleinen moleküls csf-1r und einem agonistischen antikörper mit spezifischer cd40-bindung zur behandlung von krebs
|
JOP20180021A1
(ar)
|
2017-03-16 |
2019-01-30 |
Janssen Biotech Inc |
الأجسام المضادة لتكتلات خيوط بروتين تاو (tau) الحلزونية المزدوجة واستخداماتها
|
WO2018175942A1
(en)
|
2017-03-23 |
2018-09-27 |
Abbott Laboratories |
Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in a human subject using the early biomarker ubiquitin carboxy-terminal hydrolase l1
|
WO2018176019A1
(en)
|
2017-03-24 |
2018-09-27 |
The Regents Of The University Of California |
Proteoglycan irregularities in abnormal fibroblasts and therapies based therefrom
|
EP3604340A4
(de)
|
2017-03-24 |
2021-01-06 |
Zenyaku Kogyo Co., Ltd |
Anti-igm/b-zelloberflächenantigen-bispezifischer antikörper
|
WO2018175460A1
(en)
|
2017-03-24 |
2018-09-27 |
Novartis Ag |
Methods for preventing and treating heart disease
|
WO2018178074A1
(en)
|
2017-03-29 |
2018-10-04 |
F. Hoffmann-La Roche Ag |
Trimeric antigen binding molecules specific for a costimulatory tnf receptor
|
WO2018178055A1
(en)
|
2017-03-29 |
2018-10-04 |
F. Hoffmann-La Roche Ag |
Bispecific antigen binding molecule for a costimulatory tnf receptor
|
JP7205995B2
(ja)
|
2017-03-29 |
2023-01-17 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
共刺激性tnf受容体に対する二重特異性抗原結合分子
|
CN110741017B
(zh)
|
2017-03-30 |
2023-08-29 |
约翰霍普金斯大学 |
用于纯化生物大分子的超分子高亲和力蛋白结合系统
|
PE20200010A1
(es)
|
2017-04-03 |
2020-01-06 |
Hoffmann La Roche |
Anticuerpos que se unen a steap-1
|
CA3055769A1
(en)
|
2017-04-03 |
2018-10-11 |
Oncologie, Inc. |
Methods for treating cancer using ps-targeting antibodies with immuno-oncology agents
|
PE20191494A1
(es)
|
2017-04-03 |
2019-10-21 |
Hoffmann La Roche |
Inmunoconjugados de un anticuerpo anti-pd-1 con un il-2 mutante o con il-15
|
CN110382525B
(zh)
|
2017-04-03 |
2023-10-20 |
豪夫迈·罗氏有限公司 |
免疫缀合物
|
TWI788340B
(zh)
|
2017-04-07 |
2023-01-01 |
美商必治妥美雅史谷比公司 |
抗icos促效劑抗體及其用途
|
US11254733B2
(en)
|
2017-04-07 |
2022-02-22 |
Icahn School Of Medicine At Mount Sinai |
Anti-influenza B virus neuraminidase antibodies and uses thereof
|
WO2018189611A1
(en)
|
2017-04-12 |
2018-10-18 |
Pfizer Inc. |
Antibodies having conditional affinity and methods of use thereof
|
BR112019017241A2
(pt)
|
2017-04-13 |
2020-04-14 |
Agenus Inc |
anticorpos anti-cd137 e métodos de uso dos mesmos
|
CA3059938A1
(en)
|
2017-04-14 |
2018-10-18 |
Kodiak Sciences Inc. |
Complement factor d antagonist antibodies and conjugates thereof
|
US10877048B2
(en)
|
2017-04-15 |
2020-12-29 |
Abbott Laboratories |
Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury in a human subject using early biomarkers
|
EP3612563A1
(de)
|
2017-04-19 |
2020-02-26 |
Elstar Therapeutics, Inc. |
Multispezifische moleküle und verwendungen davon
|
WO2018195243A1
(en)
|
2017-04-20 |
2018-10-25 |
Immunogen, Inc. |
Cytotoxic benzodiazepine derivatives and conjugates thereof
|
EP3612560A1
(de)
|
2017-04-21 |
2020-02-26 |
Staten Biotechnology B.V. |
Anti-apoc3-antikörper und verfahren zur verwendung davon
|
KR102637960B1
(ko)
|
2017-04-22 |
2024-02-21 |
이뮤노믹 쎄라퓨틱스, 인크. |
개선된 lamp 구축물
|
JP7080899B2
(ja)
|
2017-04-28 |
2022-06-06 |
アボット・ラボラトリーズ |
同じヒト対象に由来する少なくとも2つの試料に対して早期バイオマーカーを使用する、外傷性脳損傷の超急性の診断及び決定の一助となるための方法
|
CA3059769A1
(en)
|
2017-04-28 |
2018-11-01 |
Elstar Therapeutics, Inc. |
Multispecific molecules comprising a non-immunoglobulin heterodimerization domain and uses thereof
|
US11021537B2
(en)
|
2017-05-01 |
2021-06-01 |
Agenus Inc. |
Anti-TIGIT antibodies and methods of use thereof
|
EP3620531A4
(de)
|
2017-05-02 |
2021-03-17 |
National Center of Neurology and Psychiatry |
Verfahren zur vorhersage und beurteilung der therapeutischen wirkung bei erkrankungen im zusammenhang mit il-6 und neutrophilen
|
JP7442790B2
(ja)
|
2017-05-02 |
2024-03-05 |
プロセナ バイオサイエンシーズ リミテッド |
タウ認識抗体
|
JP7222915B2
(ja)
|
2017-05-02 |
2023-02-15 |
イミュノミック セラピューティックス, インコーポレイテッド |
癌抗原を含む改善されたlamp構築物
|
US10865238B1
(en)
|
2017-05-05 |
2020-12-15 |
Duke University |
Complement factor H antibodies
|
JOP20190256A1
(ar)
|
2017-05-12 |
2019-10-28 |
Icahn School Med Mount Sinai |
فيروسات داء نيوكاسل واستخداماتها
|
TWI794230B
(zh)
|
2017-05-15 |
2023-03-01 |
日商第一三共股份有限公司 |
抗cdh6抗體及抗cdh6抗體-藥物結合物、以及其製造方法
|
US11530273B2
(en)
|
2017-05-23 |
2022-12-20 |
Helmholtz Zentrum München—Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) |
Anti-CD73 monoclonal antibody, encoding nucleic acids and method for producing
|
BR112019024701A2
(pt)
|
2017-05-25 |
2020-06-09 |
Abbott Lab |
métodos para auxiliar na determinação se um exame de imagem deve ser realizado em um indivíduo humano que sofreu ou pode ter sofrido uma lesão na cabeça com o uso de biomarcadores precoces
|
EP3933408A1
(de)
|
2017-05-30 |
2022-01-05 |
Nant Holdings IP LLC |
Zirkulierende tumorzellenanreicherung unter verwendung von neoepitopen
|
CA3059601A1
(en)
|
2017-05-30 |
2018-12-06 |
Abbott Laboratories |
Methods for aiding in diagnosing and evaluating a mild traumatic brain injury in a human subject using cardiac troponin i and early biomarkers
|
CA3065301A1
(en)
|
2017-05-31 |
2018-12-06 |
Stcube & Co., Inc. |
Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
|
WO2018222901A1
(en)
|
2017-05-31 |
2018-12-06 |
Elstar Therapeutics, Inc. |
Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
|
US20200131266A1
(en)
|
2017-05-31 |
2020-04-30 |
Stcube & Co., Inc. |
Methods of treating cancer using antibodies and molecules that immunospecifically bind to btn1a1
|
KR20200014379A
(ko)
|
2017-06-05 |
2020-02-10 |
얀센 바이오테크 인코포레이티드 |
비대칭 ch2-ch3 영역 돌연변이를 갖는 조작된 다중특이성 항체 및 다른 다량체 단백질
|
BR112019025574A2
(pt)
|
2017-06-05 |
2020-06-23 |
Janssen Biotech, Inc. |
Anticorpos que se ligam especificamente ao pd-1 e métodos de uso
|
WO2018226671A1
(en)
|
2017-06-06 |
2018-12-13 |
Stcube & Co., Inc. |
Methods of treating cancer using antibodies and molecules that bind to btn1a1 or btn1a1-ligands
|
CN110997718B
(zh)
|
2017-06-07 |
2023-11-10 |
菲洛根股份公司 |
血管内皮生长因子/抗纤连蛋白抗体融合蛋白
|
KR20200015717A
(ko)
|
2017-06-09 |
2020-02-12 |
프로비던스 헬스 앤드 서비시즈 - 오레곤 |
암 치료를 위한 인간 종양 반응성 t 세포의 확인을 위한 cd39 및 cd103의 활용
|
GB201709379D0
(en)
|
2017-06-13 |
2017-07-26 |
Univ Leuven Kath |
Humanised ADAMTS13 binding antibodies
|
WO2018229715A1
(en)
|
2017-06-16 |
2018-12-20 |
Novartis Ag |
Compositions comprising anti-cd32b antibodies and methods of use thereof
|
WO2018236904A1
(en)
|
2017-06-19 |
2018-12-27 |
Surface Oncology, Inc. |
COMBINATION OF ANTI-CD47 ANTIBODIES AND CELL DEATH INDUCING AGENTS, AND USES THEREOF
|
WO2018237173A1
(en)
|
2017-06-22 |
2018-12-27 |
Novartis Ag |
ANTIBODY MOLECULES DIRECTED AGAINST CD73 AND CORRESPONDING USES
|
WO2019005817A2
(en)
|
2017-06-26 |
2019-01-03 |
Bio-Techne Corporation |
HYBRIDOMIC CLONES, MONOCLONAL ANTIBODIES DIRECTED AGAINST VSIG-4, AND METHODS OF MAKING AND USING SAME
|
CA3066747A1
(en)
|
2017-06-27 |
2019-01-03 |
Novartis Ag |
Dosage regimens for anti-tim-3 antibodies and uses thereof
|
WO2019003104A1
(en)
|
2017-06-28 |
2019-01-03 |
Novartis Ag |
METHOD FOR PREVENTING AND TREATING URINARY INCONTINENCE
|
JP7181535B2
(ja)
|
2017-06-30 |
2022-12-01 |
国立大学法人北海道大学 |
成長障害を生じない小児骨粗鬆症治療薬
|
US11169159B2
(en)
|
2017-07-03 |
2021-11-09 |
Abbott Laboratories |
Methods for measuring ubiquitin carboxy-terminal hydrolase L1 levels in blood
|
WO2019010164A1
(en)
|
2017-07-06 |
2019-01-10 |
President And Fellows Of Harvard College |
EVOLUTION OF ARNT SYNTHÉTASES
|
SG10201913147WA
(en)
|
2017-07-11 |
2020-02-27 |
Compass Therapeutics Llc |
Agonist antibodies that bind human cd137 and uses thereof
|
WO2019012015A1
(en)
|
2017-07-12 |
2019-01-17 |
Iontas Limited |
POTASIC CHANNEL INHIBITORS
|
GB201711208D0
(en)
|
2017-07-12 |
2017-08-23 |
Iontas Ltd |
Ion channel inhibitors
|
KR20200027522A
(ko)
|
2017-07-13 |
2020-03-12 |
에프. 호프만-라 로슈 아게 |
Pivka에 대한 신규 결합제 및 어세이
|
EP3652211A1
(de)
|
2017-07-14 |
2020-05-20 |
Pfizer Inc. |
Antikörper gegen madcam
|
WO2019014768A1
(en)
|
2017-07-18 |
2019-01-24 |
The University Of British Columbia |
ANTI-BETA-AMYLOID ANTIBODY
|
EP3431496A1
(de)
|
2017-07-19 |
2019-01-23 |
Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. |
Anti-isoasp7-amyloid-beta-antikörper und verwendungen davon
|
US20200172617A1
(en)
|
2017-07-20 |
2020-06-04 |
Novartis Ag |
Dosage regimens of anti-lag-3 antibodies and uses thereof
|
WO2019020480A1
(en)
|
2017-07-24 |
2019-01-31 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
ANTIBODIES AND PEPTIDES FOR TREATING HCMV RELATED DISEASES
|
MX2020000966A
(es)
|
2017-07-27 |
2020-09-28 |
Daiichi Sankyo Co Ltd |
Anticuerpo anti-cd147.
|
MA49690A
(fr)
|
2017-07-28 |
2021-05-19 |
Scholar Rock Inc |
Inhibiteurs spécifiques du complexe ltbp de tgf-bêta 1 et leurs utilisations
|
CN117050176A
(zh)
|
2017-07-31 |
2023-11-14 |
豪夫迈·罗氏有限公司 |
基于三维结构的人源化方法
|
CN111164100B
(zh)
|
2017-08-03 |
2024-03-12 |
美国安进公司 |
白介素-21突变蛋白和治疗方法
|
WO2019030706A1
(en)
|
2017-08-10 |
2019-02-14 |
Janssen Pharmaceutica Nv |
ANTI-THROMBIN ANTIBODY MOLECULES AND METHODS OF USE IN ORTHOPEDIC SURGERY
|
CN107446050A
(zh)
|
2017-08-11 |
2017-12-08 |
百奥泰生物科技(广州)有限公司 |
Trop2阳性疾病治疗的化合物及方法
|
WO2019035938A1
(en)
|
2017-08-16 |
2019-02-21 |
Elstar Therapeutics, Inc. |
MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
|
WO2019035055A1
(en)
|
2017-08-16 |
2019-02-21 |
Janssen Pharmaceutica Nv |
ANTI-THROMBIN ANTIBODY MOLECULES AND METHODS OF USE WITH PLATELET ANTI-AGGREGATE AGENTS
|
EP3444275A1
(de)
|
2017-08-16 |
2019-02-20 |
Exiris S.r.l. |
Monoklonaler antikörper anti-fgfr4
|
WO2019036605A2
(en)
|
2017-08-17 |
2019-02-21 |
Massachusetts Institute Of Technology |
MULTIPLE SPECIFICITY BINDING AGENTS OF CXC CHEMOKINES AND USES THEREOF
|
EP3668640A4
(de)
|
2017-08-18 |
2021-07-14 |
The Johns Hopkins University |
Supramolekulare filamentöse anordnungen zur proteinreinigung
|
KR20200038303A
(ko)
|
2017-08-18 |
2020-04-10 |
캠브리지 엔터프라이즈 리미티드 |
모듈형 결합 단백질
|
AU2018321134A1
(en)
|
2017-08-23 |
2020-02-27 |
Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft |
Chimeric antigen receptor and CAR-T cells that bind CXCR5
|
US11078263B2
(en)
|
2017-08-25 |
2021-08-03 |
Janssen Biotech, Inc. |
Fc γ RIII binding fibronectin type III domains, their conjugates and multispecific molecules comprising them
|
SG11202000387YA
(en)
|
2017-08-25 |
2020-03-30 |
Five Prime Therapeutics Inc |
B7-h4 antibodies and methods of use thereof
|
UY37870A
(es)
|
2017-09-08 |
2019-03-29 |
Amgen Inc |
Inhibidores de kras g12c y métodos para utilizarlos campo de la invención
|
WO2019055825A1
(en)
|
2017-09-15 |
2019-03-21 |
The Regents Of The University Of California |
INHIBITION OF AMINOACYLASE 3 (AA3) IN THE TREATMENT OF CANCER
|
WO2019056002A1
(en)
|
2017-09-18 |
2019-03-21 |
President And Fellows Of Harvard College |
CONTINUOUS EVOLUTION FOR STABILIZED PROTEINS
|
WO2019060269A1
(en)
|
2017-09-21 |
2019-03-28 |
Becton, Dickinson And Company |
KIT FOR COLLECTING HAZARDOUS CONTAMINANTS AND RAPID ANALYSIS
|
TW201922780A
(zh)
|
2017-09-25 |
2019-06-16 |
美商健生生物科技公司 |
以抗il12/il23抗體治療狼瘡之安全且有效之方法
|
US20220227854A1
(en)
|
2017-09-25 |
2022-07-21 |
Adrenomed Ag |
Anti-adrenomedullin (adm) binder for use in therapy or prevention of symptoms of illness
|
KR20200061376A
(ko)
|
2017-09-29 |
2020-06-02 |
다이이찌 산쿄 가부시키가이샤 |
항체-피롤로벤조디아제핀 유도체 콘쥬게이트
|
CN111183157A
(zh)
|
2017-10-02 |
2020-05-19 |
威特拉公司 |
Cd138抗体分子及其用途
|
EP3461841B1
(de)
|
2017-10-02 |
2019-09-11 |
Certest Biotec, S.L. |
Antikörper gegen dps und testvorrichtungen zum nachweis von bakterien der gattung campylobacter
|
JP2020536115A
(ja)
|
2017-10-04 |
2020-12-10 |
オプコ ファーマシューティカルズ、エルエルシー |
癌の個別化療法に関する物品および方法
|
US20200262917A1
(en)
|
2017-10-05 |
2020-08-20 |
Daiichi Sankyo Company, Limited |
Composition for cytotoxic t cell depletion
|
JP7230819B2
(ja)
|
2017-10-06 |
2023-03-01 |
小野薬品工業株式会社 |
二重特異性抗体
|
WO2019075090A1
(en)
|
2017-10-10 |
2019-04-18 |
Tilos Therapeutics, Inc. |
ANTI-LAP ANTIBODIES AND USES THEREOF
|
WO2019073069A1
(en)
|
2017-10-13 |
2019-04-18 |
Boehringer Ingelheim International Gmbh |
HUMAN ANTIBODIES AGAINST THOMSEN-NEW ANTIGEN (TN)
|
AU2018350861A1
(en)
|
2017-10-18 |
2020-04-09 |
Adrenomed Ag |
Therapy monitoring under treatment with an anti-adrenomedullin (ADM) binder
|
US20210198365A1
(en)
|
2017-10-19 |
2021-07-01 |
Merck Patent Gmbh |
Combination product for the treatment of cancer
|
US20200331975A1
(en)
|
2017-10-20 |
2020-10-22 |
Institut Curie |
Dap10/12 based cars adapted for rush
|
JP7235249B2
(ja)
|
2017-10-20 |
2023-03-08 |
学校法人兵庫医科大学 |
抗il-6受容体抗体を含有する術後の癒着を抑制するための医薬組成物
|
WO2019081983A1
(en)
|
2017-10-25 |
2019-05-02 |
Novartis Ag |
CD32B TARGETING ANTIBODIES AND METHODS OF USE
|
CN111542548A
(zh)
|
2017-10-25 |
2020-08-14 |
4Teen4制药有限公司 |
针对并结合于特异性dpp3表位的dpp3结合剂及其在预防或治疗与氧化应激相关的疾病/急性病状中的用途
|
BR112020008514A2
(pt)
|
2017-10-31 |
2020-10-20 |
Staten Biotechnology B.V. |
anticorpos anti-apoc3 e métodos de uso dos mesmos
|
US11718679B2
(en)
|
2017-10-31 |
2023-08-08 |
Compass Therapeutics Llc |
CD137 antibodies and PD-1 antagonists and uses thereof
|
WO2019089832A1
(en)
|
2017-10-31 |
2019-05-09 |
Janssen Biotech, Inc. |
Methods of treating high risk multiple myeloma
|
TW201922294A
(zh)
|
2017-10-31 |
2019-06-16 |
美商伊繆諾金公司 |
抗體-藥物結合物與阿糖胞苷之組合治療
|
MA50505A
(fr)
|
2017-11-01 |
2020-09-09 |
Hoffmann La Roche |
Anticorps 2 + 1 bispécifiques (contorsbodies)
|
CN111315781A
(zh)
|
2017-11-01 |
2020-06-19 |
豪夫迈·罗氏有限公司 |
用靶向性ox40激动剂的组合疗法
|
AU2018358804A1
(en)
|
2017-11-02 |
2020-04-09 |
Bayer Aktiengesellschaft |
Bispecific antibodies binding ALK-1 and BMPR-2
|
WO2019094595A2
(en)
|
2017-11-09 |
2019-05-16 |
Pinteon Therapeutics Inc. |
Methods and compositions for the generation and use of humanized conformation-specific phosphorylated tau antibodies
|
CN111655288A
(zh)
|
2017-11-16 |
2020-09-11 |
诺华股份有限公司 |
组合疗法
|
WO2019100052A2
(en)
|
2017-11-20 |
2019-05-23 |
Compass Therapeutics Llc |
Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof
|
CA3083345A1
(en)
|
2017-11-27 |
2019-05-31 |
Purdue Pharma L.P. |
Humanized antibodies targeting human tissue factor
|
BR112020010248A2
(pt)
|
2017-11-28 |
2020-11-10 |
Chugai Seiyaku Kabushiki Kaisha |
molécula de ligação do ligante tendo atividade de ligação do ligante ajustável
|
WO2019106694A1
(en)
|
2017-11-30 |
2019-06-06 |
University Of Delhi South Campus |
An antibody fragment library, and uses thereof
|
JP2021505172A
(ja)
|
2017-12-06 |
2021-02-18 |
マジェンタ セラピューティクス インコーポレイテッドMagenta Therapeutics, Inc. |
造血幹細胞及び前駆細胞を動員させるための投薬レジメン
|
WO2019113464A1
(en)
|
2017-12-08 |
2019-06-13 |
Elstar Therapeutics, Inc. |
Multispecific molecules and uses thereof
|
WO2019113525A2
(en)
|
2017-12-09 |
2019-06-13 |
Abbott Laboratories |
Methods for aiding in the diagnosis and evaluation of a subject who has sustained an orthopedic injury and that has or may have sustained an injury to the head, such as mild traumatic brain injury (tbi), using glial fibrillary acidic protein (gfap) and/or ubiquitin carboxy-terminal hydrolase l1 (uch-l1)
|
JP7379165B2
(ja)
|
2017-12-09 |
2023-11-14 |
アボット・ラボラトリーズ |
Gfapとuch-l1との組合せを使用する、ヒト対象における外傷性脳損傷を診断及び査定する一助となるための方法
|
EP3502139A1
(de)
|
2017-12-19 |
2019-06-26 |
Philogen S.p.A. |
Antikörper gegen tumorantigene
|
GB201721600D0
(en)
|
2017-12-21 |
2018-02-07 |
Plant Bioscience Ltd |
Metabolic engineering
|
PE20201149A1
(es)
|
2017-12-21 |
2020-10-26 |
Hoffmann La Roche |
Anticuerpos de union a hla-a2/wt1
|
EP3502140A1
(de)
|
2017-12-21 |
2019-06-26 |
F. Hoffmann-La Roche AG |
Kombinationstherapie von tumorabgezielten icos-agonisten mit t-zellenbispezifischen molekülen
|
US11793885B2
(en)
|
2017-12-28 |
2023-10-24 |
Immunogen, Inc. |
Substituted benzo[5,6][1,4]diazepino[1,2-a]indoles for the treatment of proliferative disorders
|
JP7314146B2
(ja)
|
2017-12-28 |
2023-07-25 |
中外製薬株式会社 |
細胞傷害誘導治療剤
|
KR20200106525A
(ko)
|
2018-01-05 |
2020-09-14 |
에이씨 이뮨 에스.에이. |
미스폴딩된 tdp-43 결합 분자
|
TW201930344A
(zh)
|
2018-01-12 |
2019-08-01 |
美商安進公司 |
抗pd-1抗體及治療方法
|
AU2019207915A1
(en)
|
2018-01-12 |
2020-07-16 |
Amgen Inc. |
PAC1 antibodies and uses thereof
|
US20220089720A1
(en)
|
2018-01-12 |
2022-03-24 |
Bristol-Myers Squibb Company |
Antibodies against tim3 and uses thereof
|
US20190225689A1
(en)
|
2018-01-22 |
2019-07-25 |
Janssen Biotech, Inc. |
Methods of treating cancers with antagonistic anti-pd-1 antibodies
|
US20210363238A1
(en)
|
2018-01-31 |
2021-11-25 |
Motokazu Kato |
Therapeutic agent for asthma containing il-6 inhibitor
|
CN111868082A
(zh)
|
2018-02-02 |
2020-10-30 |
博奥泰克尼公司 |
调节vista和vsig3的相互作用的化合物及其制备和使用方法
|
WO2019150309A1
(en)
|
2018-02-02 |
2019-08-08 |
Hammack Scott |
Modulators of gpr68 and uses thereof for treating and preventing diseases
|
CA3090736A1
(en)
|
2018-02-08 |
2019-08-15 |
Sphingotec Gmbh |
Adrenomedullin (adm) for diagnosis and/or prediction of dementia and anti-adrenomedullin binder for use in therapy or prevention of dementia
|
TW202340257A
(zh)
|
2018-02-09 |
2023-10-16 |
日商小野藥品工業股份有限公司 |
雙特異性抗體
|
TWI829667B
(zh)
|
2018-02-09 |
2024-01-21 |
瑞士商赫孚孟拉羅股份公司 |
結合gprc5d之抗體
|
BR112020016400A2
(pt)
|
2018-02-14 |
2020-12-15 |
Viela Bio, Inc. |
Anticorpos para o ligante do receptor de tirosina cinase 3 similar ao sarcoma felino de mcdonough (fms) (flt3l) e suas utilizações para o tratamento de doenças autoimunes e inflamatórias
|
US11591399B2
(en)
|
2018-02-14 |
2023-02-28 |
Abba Therapeutics Ag |
Anti-human PD-L2 antibodies
|
GB201802486D0
(en)
|
2018-02-15 |
2018-04-04 |
Ucb Biopharma Sprl |
Methods
|
EP3530282A1
(de)
|
2018-02-27 |
2019-08-28 |
Diaccurate |
Therapeutische verfahren
|
CN111971308A
(zh)
|
2018-03-02 |
2020-11-20 |
戊瑞治疗有限公司 |
B7-h4抗体及其使用方法
|
AU2019232624A1
(en)
|
2018-03-05 |
2020-09-10 |
Janssen Biotech, Inc. |
Methods of treating Crohn's disease with anti-IL23 specific antibody
|
CA3093205A1
(en)
|
2018-03-05 |
2019-09-12 |
Saitama Medical University |
Pharmaceutical composition for treating or preventing heterotopic ossification
|
US20210002358A1
(en)
|
2018-03-05 |
2021-01-07 |
Linda Barone |
Anti-phf-tau antibodies and uses thereof
|
BR112020017701A2
(pt)
|
2018-03-12 |
2020-12-29 |
Zoetis Services Llc |
Anticorpos anti-ngf e métodos dos mesmos
|
BR112020015568A2
(pt)
|
2018-03-13 |
2020-12-29 |
F. Hoffmann-La Roche Ag |
Agonista de 4-1bb (cd137), produto farmacêutico, composição farmacêutica, uso de uma combinação de um agonista de 4-1bb e método para tratar ou retardar a progressão do câncer
|
TW202003561A
(zh)
|
2018-03-13 |
2020-01-16 |
瑞士商赫孚孟拉羅股份公司 |
使用靶向4-1bb (cd137)之促效劑的組合療法
|
EP3765497A1
(de)
|
2018-03-14 |
2021-01-20 |
F. Hoffmann-La Roche AG |
Neuartige anti-troponin-t-antikörper
|
WO2019178364A2
(en)
|
2018-03-14 |
2019-09-19 |
Elstar Therapeutics, Inc. |
Multifunctional molecules and uses thereof
|
WO2019178362A1
(en)
|
2018-03-14 |
2019-09-19 |
Elstar Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
MX2020009568A
(es)
|
2018-03-14 |
2022-03-28 |
Surface Oncology Inc |
Anticuerpos que se unen a cd39 y sus usos.
|
WO2019175131A1
(en)
|
2018-03-14 |
2019-09-19 |
F. Hoffmann-La Roche Ag |
Method for affinity maturation of antibodies
|
WO2019183499A1
(en)
|
2018-03-22 |
2019-09-26 |
Surface Oncology, Inc. |
Anti-il-27 antibodies and uses thereof
|
CN111886256A
(zh)
|
2018-03-23 |
2020-11-03 |
百时美施贵宝公司 |
抗mica和/或micb抗体及其用途
|
WO2019180272A1
(en)
|
2018-03-23 |
2019-09-26 |
Fundación Instituto De Investigación Sanitaria De Santiago De Compostela |
Anti-leptin affinity reagents for use in the treatment of obesity and other leptin-resistance associated diseases
|
PT3775909T
(pt)
|
2018-03-26 |
2023-07-19 |
Glycanostics S R O |
Meios e métodos para o glicoperfil de uma proteína
|
US20210009632A1
(en)
|
2018-03-29 |
2021-01-14 |
Bristol-Myers Squibb Company |
Methods of purifying monomeric monoclonal antibodies
|
AU2019243595A1
(en)
|
2018-03-30 |
2020-09-17 |
Amgen Inc. |
C-terminal antibody variants
|
PE20201343A1
(es)
|
2018-04-02 |
2020-11-25 |
Bristol Myers Squibb Co |
Anticuerpos anti-trem-1 y usos de los mismos
|
WO2019200357A1
(en)
|
2018-04-12 |
2019-10-17 |
Surface Oncology, Inc. |
Biomarker for cd47 targeting therapeutics and uses therefor
|
CN112004558A
(zh)
|
2018-04-12 |
2020-11-27 |
米迪亚制药有限责任公司 |
Lgals3bp抗体-药物-偶联物及其用于癌症的治疗的用途
|
US20210147547A1
(en)
|
2018-04-13 |
2021-05-20 |
Novartis Ag |
Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
|
CR20200459A
(es)
|
2018-04-13 |
2020-11-11 |
Hoffmann La Roche |
Moléculas de unión a antígeno dirigidas a her2 que comprendan 4-1bbl
|
EP3781590A1
(de)
|
2018-04-20 |
2021-02-24 |
Medizinische Hochschule Hannover |
Chimärer antigenrezeptor und car-t zellen, die ein herpesvirus-antigen binden
|
CN112585165A
(zh)
|
2018-04-25 |
2021-03-30 |
普罗米修斯生物科学公司 |
优化的抗tl1a抗体
|
WO2019207159A1
(en)
|
2018-04-27 |
2019-10-31 |
Fondazione Ebri Rita Levi-Montalcini |
Antibody directed against a tau-derived neurotoxic peptide and uses thereof
|
US11065336B2
(en)
|
2018-04-30 |
2021-07-20 |
Medimmune Limited |
Conjugates for targeting and clearing aggregates
|
TW202003048A
(zh)
|
2018-05-15 |
2020-01-16 |
美商伊繆諾金公司 |
用抗體-藥物偶聯物及flt3抑制劑之組合治療
|
US20210261647A1
(en)
|
2018-05-15 |
2021-08-26 |
Immunomic Therapeutics, Inc |
Lamp constructs comprising allergens
|
BR112020023187A2
(pt)
|
2018-05-16 |
2021-04-20 |
Janssen Biotech, Inc. |
métodos para tratamento de cânceres e de aumento da eficácia de agentes terapêuticos de redirecionamento de células t
|
EP3569614A1
(de)
|
2018-05-18 |
2019-11-20 |
Julius-Maximilians-Universität Würzburg |
Verbindungen und verfahren zur immobilisierung von myostatin-inhibitoren auf der extrazellulären matrix durch transglutaminase
|
WO2019226658A1
(en)
|
2018-05-21 |
2019-11-28 |
Compass Therapeutics Llc |
Multispecific antigen-binding compositions and methods of use
|
JP2021525243A
(ja)
|
2018-05-21 |
2021-09-24 |
コンパス セラピューティクス リミテッド ライアビリティ カンパニー |
Nk細胞による標的細胞の殺傷を増進するための組成物および方法
|
WO2019225568A1
(ja)
|
2018-05-21 |
2019-11-28 |
中外製薬株式会社 |
ガラス容器に封入された凍結乾燥製剤
|
BR112020023416A2
(pt)
|
2018-05-24 |
2021-02-17 |
Janssen Biotech, Inc. |
anticorpos anti-tmeff2 monoespecíficos e multiespecíficos e usos dos mesmos
|
SG11202011270QA
(en)
|
2018-05-24 |
2020-12-30 |
Janssen Biotech Inc |
Anti-cd3 antibodies and uses thereof
|
KR20210015902A
(ko)
|
2018-05-24 |
2021-02-10 |
얀센 바이오테크 인코포레이티드 |
Psma 결합제 및 이의 용도
|
GB201808617D0
(en)
|
2018-05-25 |
2018-07-11 |
Plant Bioscience Ltd |
Scaffold modification
|
UY38247A
(es)
|
2018-05-30 |
2019-12-31 |
Novartis Ag |
Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
|
US11830582B2
(en)
|
2018-06-14 |
2023-11-28 |
University Of Miami |
Methods of designing novel antibody mimetics for use in detecting antigens and as therapeutic agents
|
WO2019241649A1
(en)
|
2018-06-14 |
2019-12-19 |
President And Fellows Of Harvard College |
Evolution of cytidine deaminases
|
CA3102743A1
(en)
|
2018-06-18 |
2019-12-26 |
UCB Biopharma SRL |
Gremlin-1 antagonist for the prevention and treatment of cancer
|
BR112020026033A2
(pt)
|
2018-06-19 |
2021-03-23 |
Atarga, Llc |
moléculas de anticorpo para complementar o componente 5 e usos das mesmas
|
EP3810189A1
(de)
|
2018-06-19 |
2021-04-28 |
Armo Biosciences, Inc. |
Zusammensetzungen und verfahren zur verwendung von il-10-wirkstoffen in verbindung mit einer chimären antigen-rezeptor-zelltherapie
|
US20210277118A1
(en)
|
2018-06-21 |
2021-09-09 |
Daiichi Sankyo Company, Limited |
Compositions including cd3 antigen binding fragments and uses thereof
|
EP3586865A1
(de)
|
2018-06-21 |
2020-01-01 |
Charité - Universitätsmedizin Berlin |
Ergänzende anaphylatoxinbindemittel und deren verwendung in der behandlung einer person mit okularer wunde und/oder fibrose
|
WO2019246494A1
(en)
|
2018-06-21 |
2019-12-26 |
Yumanity Therapeutics, Inc. |
Compositions and methods for the treatment and prevention of neurological disorders
|
WO2020003077A1
(en)
|
2018-06-25 |
2020-01-02 |
Janssen Pharmaceutica Nv |
Anti-thrombin antibody molecules for use in patients at risk for gastrointestinal (gi) bleeding
|
CN112955465A
(zh)
|
2018-07-03 |
2021-06-11 |
马伦戈治疗公司 |
抗tcr抗体分子及其用途
|
WO2020008083A1
(es)
|
2018-07-05 |
2020-01-09 |
Consejo Superior De Investigaciones Científicas |
Diana terapéutica en receptores de quimiocinas para la selección de compuestos útiles para el tratamiento de procesos patológicos que implican la señalización de quimiocinas
|
WO2020014473A1
(en)
|
2018-07-11 |
2020-01-16 |
Scholar Rock, Inc. |
TGFβ1 INHIBITORS AND USE THEREOF
|
WO2020014460A1
(en)
|
2018-07-11 |
2020-01-16 |
Scholar Rock, Inc. |
HIGH-AFFINITY, ISOFORM-SELECTIVE TGFβ1 INHIBITORS AND USE THEREOF
|
ES2905160T3
(es)
|
2018-07-11 |
2022-04-07 |
Scholar Rock Inc |
Inhibidores selectivos de la isoforma TGFBeta1 y utilización de los mismos
|
WO2020016838A2
(en)
|
2018-07-18 |
2020-01-23 |
Janssen Biotech, Inc. |
Sustained response predictors after treatment with anti-il23 specific antibody
|
BR112021000934A2
(pt)
|
2018-07-20 |
2021-04-27 |
Pierre Fabre Medicament |
receptor para vista
|
CA3106833A1
(en)
|
2018-07-20 |
2020-01-23 |
Aicuris Gmbh & Co. Kg |
Methods for screening and identifying agents that inhibit or modulate the nuclear egress complex of herpesviruses
|
WO2020021465A1
(en)
|
2018-07-25 |
2020-01-30 |
Advanced Accelerator Applications (Italy) S.R.L. |
Method of treatment of neuroendocrine tumors
|
CA3108071A1
(en)
|
2018-08-01 |
2020-02-06 |
Cephalon, Inc. |
Anti-cxcr2 antibodies and uses thereof
|
EP4177356A1
(de)
|
2018-08-08 |
2023-05-10 |
PML Screening, LLC |
Verfahren zur beurteilung des risikos der entwicklung einer viruserkrankung unter verwendung eines genetischen tests
|
WO2020033925A2
(en)
|
2018-08-09 |
2020-02-13 |
Compass Therapeutics Llc |
Antibodies that bind cd277 and uses thereof
|
EP3833442A2
(de)
|
2018-08-09 |
2021-06-16 |
Compass Therapeutics LLC |
Antikörper zur bindung von cd277 und verwendungen davon
|
WO2020033923A1
(en)
|
2018-08-09 |
2020-02-13 |
Compass Therapeutics Llc |
Antigen binding agents that bind cd277 and uses thereof
|
WO2020041360A1
(en)
|
2018-08-21 |
2020-02-27 |
Quidel Corporation |
Dbpa antibodies and uses thereof
|
EP3849602A1
(de)
|
2018-09-10 |
2021-07-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Kombination eines her2/neu-antikörpers mit häm zur behandlung von krebs
|
EP3883606B9
(de)
|
2018-09-24 |
2023-10-04 |
Janssen Biotech, Inc. |
Sichere und wirksame methode zur behandlung von colitis ulcerosa mit anti-il12/il23-antikörper
|
JP7465272B2
(ja)
|
2018-09-27 |
2024-04-10 |
マレンゴ・セラピューティクス,インコーポレーテッド |
Csf1r/ccr2多特異性抗体
|
AU2019349958A1
(en)
|
2018-09-28 |
2021-05-06 |
Kyowa Kirin Co., Ltd. |
IL-36 antibodies and uses thereof
|
AU2019352017A1
(en)
|
2018-10-03 |
2021-05-06 |
Staten Biotechnology B.V. |
Antibodies specific for human and cynomolgus ApoC3 and methods of use thereof
|
CA3113818A1
(en)
|
2018-10-05 |
2020-04-09 |
Bavarian Nordic A/S |
Combination therapy for treating cancer with an intravenous administration of a recombinant mva and an immune checkpoint antagonist or agonist
|
JP2022504839A
(ja)
|
2018-10-10 |
2022-01-13 |
ティロス・セラピューティクス・インコーポレイテッド |
抗lap抗体変異体及びその使用
|
UY38407A
(es)
|
2018-10-15 |
2020-05-29 |
Novartis Ag |
Anticuerpos estabilizadores de trem2
|
JP2022512722A
(ja)
|
2018-10-17 |
2022-02-07 |
ヤンセン バイオテツク,インコーポレーテツド |
抗cd38抗体の皮下投与を提供する方法
|
SG11202101037QA
(en)
|
2018-10-23 |
2021-02-25 |
Regeneron Pharma |
Anti-npr1 antibodies and uses thereof
|
EA202191122A1
(ru)
|
2018-10-23 |
2021-07-19 |
Сколар Рок, Инк. |
СЕЛЕКТИВНЫЕ К RGMc ИНГИБИТОРЫ И ИХ ПРИМЕНЕНИЕ
|
GB201817311D0
(en)
|
2018-10-24 |
2018-12-05 |
Ucb Biopharma Sprl |
Antibodies
|
GB201817309D0
(en)
|
2018-10-24 |
2018-12-05 |
Ucb Biopharma Sprl |
Antibodies
|
WO2020086408A1
(en)
|
2018-10-26 |
2020-04-30 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
A high-yield perfusion-based transient gene expression bioprocess
|
US20210403546A1
(en)
|
2018-11-05 |
2021-12-30 |
Ludwig Institute For Cancer Research Ltd. |
Humanized and variant tgf-beta1 specific antibodies and methods and uses thereof
|
AU2019374496A1
(en)
|
2018-11-05 |
2021-05-27 |
Centre Hospitalier Universitaire Vaudois |
Humanized and variant TGF-β3 specific antibodies and methods and uses thereof
|
MX2021005594A
(es)
|
2018-11-13 |
2021-10-22 |
Compass Therapeutics Llc |
Constructos multiespecificos de union contra moleculas de puntos de control y usos de los mismos.
|
JP2022513018A
(ja)
|
2018-11-13 |
2022-02-07 |
ヤンセン バイオテツク,インコーポレーテツド |
抗cd38抗体の生成中の微量金属の制御
|
BR112021009251A2
(pt)
|
2018-11-14 |
2021-08-10 |
Daiichi Sankyo Company, Limited |
conjugado anticorpo-fármaco, anticorpo ou um fragmento funcional do mesmo, polinucleotídeo, vetor de expressão, célula hospedeira, composição farmacêutica, e, métodos para produção de um anticorpo com glicano remodelado, de um conjugado anticorpo-fármaco, do anticorpo ou um fragmento funcional do mesmo e para tratamento de um tumor.
|
EP3880708A1
(de)
|
2018-11-16 |
2021-09-22 |
Bristol-Myers Squibb Company |
Anti-nkg2a-antikörper und verwendungen davon
|
JP7463366B2
(ja)
|
2018-11-20 |
2024-04-08 |
タケダ ワクチン,インコーポレイテッド |
新規の抗ジカウイルス抗体及びその使用
|
CN113395979A
(zh)
|
2018-11-20 |
2021-09-14 |
詹森生物科技公司 |
用抗il-23特异性抗体治疗银屑病的安全且有效的方法
|
SG11202104918PA
(en)
|
2018-11-20 |
2021-06-29 |
Bavarian Nordic As |
Therapy for treating cancer with an intratumoral and/or intravenous administration of a recombinant mva encoding 4-1bbl (cd137l) and/or cd40l
|
KR20210093974A
(ko)
|
2018-11-20 |
2021-07-28 |
가부시키가이샤 페르세우스 프로테오믹스 |
세포내 철 흡수 억제제
|
CN113166727A
(zh)
|
2018-11-28 |
2021-07-23 |
四十七公司 |
对消融方案耐受的基因修饰的hspc
|
EP3897722A4
(de)
|
2018-12-18 |
2022-09-14 |
Janssen Biotech, Inc. |
Sichere und wirksame methode zur behandlung von lupus mit anti-il12/il23-antikörper
|
CA3124356A1
(en)
|
2018-12-20 |
2020-06-25 |
Kyowa Kirin Co., Ltd. |
Fn14 antibodies and uses thereof
|
KR20210106483A
(ko)
|
2018-12-20 |
2021-08-30 |
노파르티스 아게 |
Mdm2 억제제를 위한 확장된 저용량 요법
|
WO2020128039A2
(en)
|
2018-12-21 |
2020-06-25 |
4TEEN4 Pharmaceuticals GmbH |
Therapy guidance and/or therapy monitoring for a treatment with angiotensin-receptor-agonist and/or a precursor thereof
|
TW202030204A
(zh)
|
2018-12-21 |
2020-08-16 |
瑞士商赫孚孟拉羅股份公司 |
靶向腫瘤之超促效cd28抗原結合分子
|
AU2019410073A1
(en)
|
2018-12-21 |
2021-06-10 |
F. Hoffmann-La Roche Ag |
Tumor-targeted agonistic CD28 antigen binding molecules
|
CN113227135A
(zh)
|
2018-12-28 |
2021-08-06 |
斯帕克斯治疗公司 |
用于治疗癌症和其他疾病的对紧密连接蛋白18.2具有特异性的结合分子、其组合物和方法
|
TW202043256A
(zh)
|
2019-01-10 |
2020-12-01 |
美商健生生物科技公司 |
前列腺新抗原及其用途
|
EP3911363A1
(de)
|
2019-01-14 |
2021-11-24 |
University of Virginia Patent Foundation |
Verwendung von integrininhibitoren zur behandlung oder vorbeugung einer neurologischen immunitätsstörung und/oder nervensystemverletzung
|
MX2021008453A
(es)
|
2019-01-16 |
2021-08-19 |
Compass Therapeutics Llc |
Formulaciones de anticuerpos que se unen a cd137 humano y usos de los mismos.
|
GB201900732D0
(en)
|
2019-01-18 |
2019-03-06 |
Ucb Biopharma Sprl |
Antibodies
|
CA3127236A1
(en)
|
2019-01-22 |
2020-07-30 |
Bristol-Myers Squibb Company |
Antibodies against il-7r alpha subunit and uses thereof
|
WO2020153467A1
(ja)
|
2019-01-24 |
2020-07-30 |
中外製薬株式会社 |
新規がん抗原及びそれらの抗原に対する抗体
|
AU2020215639A1
(en)
|
2019-01-28 |
2021-08-05 |
Becton, Dickinson And Company |
Hazardous contaminant collection device with integrated swab and test device
|
CN116063505A
(zh)
|
2019-01-30 |
2023-05-05 |
真和制药有限公司 |
抗gal3抗体及其用途
|
BR112021015056A2
(pt)
|
2019-01-30 |
2022-01-11 |
Scholar Rock Inc |
Inibidores específicos de complexos ltbp de tgf-beta e usos dos mesmos
|
SG11202107720UA
(en)
|
2019-01-31 |
2021-08-30 |
Agency Science Tech & Res |
Cnx/erp57 inhibitor for use in the treatment or prevention of cancer
|
US11738050B2
(en)
|
2019-02-01 |
2023-08-29 |
Regents Of The University Of Minnesota |
Compounds binding to fibroblast activation protein alpha
|
EP3693063A1
(de)
|
2019-02-06 |
2020-08-12 |
Diaccurate |
Verfahren und zusammensetzungen zur behandlung von krebs
|
EP3696191A1
(de)
|
2019-02-14 |
2020-08-19 |
Fundación Instituto de Investigación contra la Leucemia Josep Carreras (IJC) |
Car-t-zellen zur behandlung von cd1a-positivem krebs
|
US10871640B2
(en)
|
2019-02-15 |
2020-12-22 |
Perkinelmer Cellular Technologies Germany Gmbh |
Methods and systems for automated imaging of three-dimensional objects
|
EP3927746A1
(de)
|
2019-02-21 |
2021-12-29 |
Marengo Therapeutics, Inc. |
An calreticulin bindende multifunktionsmoleküle und ihre verwendungen
|
CN114127112A
(zh)
|
2019-02-21 |
2022-03-01 |
马伦戈治疗公司 |
与t细胞结合的多功能分子及其治疗自身免疫性病症的用途
|
CA3131014A1
(en)
|
2019-02-21 |
2020-08-27 |
Andreas Loew |
Anti-tcr antibody molecules and uses thereof
|
WO2020169840A1
(en)
|
2019-02-21 |
2020-08-27 |
Cambridge Enterprise Limited |
Bispecific proteins with a chimeric scaffold
|
AU2020226893A1
(en)
|
2019-02-21 |
2021-09-23 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to T cell related cancer cells and uses thereof
|
GB2597851A
(en)
|
2019-02-21 |
2022-02-09 |
Marengo Therapeutics Inc |
Antibody molecules that bind to NKP30 and uses thereof
|
GB201902392D0
(en)
|
2019-02-21 |
2019-04-10 |
Cambridge Entpr Ltd |
Modular binding proteins
|
KR20210132117A
(ko)
|
2019-02-26 |
2021-11-03 |
얀센 바이오테크 인코포레이티드 |
이중특이성 항-EGFR/c-Met 항체를 사용한 병용 요법 및 환자 계층화
|
WO2020176497A1
(en)
|
2019-02-26 |
2020-09-03 |
Rgenix, Inc. |
High-affinity anti-mertk antibodies and uses thereof
|
CA3130909A1
(en)
|
2019-02-28 |
2020-09-03 |
Juntendo Educational Foundation |
Antibodies that bind to cleaved form of mutant calreticulin, and diagnostic, preventive, or therapeutic agent for myeloproliferative neoplasm
|
CA3131531A1
(en)
|
2019-03-03 |
2020-09-10 |
Prothena Biosciences Limited |
Antibodies recognizing tau
|
US20200291107A1
(en)
|
2019-03-14 |
2020-09-17 |
Janssen Biotech, Inc. |
Manufacturing Methods for Producing Anti-IL12/IL23 Antibody Compositions
|
CN113853385A
(zh)
|
2019-03-18 |
2021-12-28 |
詹森生物科技公司 |
用抗il12/il23抗体治疗儿科受试者的银屑病的方法
|
GB201903767D0
(en)
|
2019-03-19 |
2019-05-01 |
Quadrucept Bio Ltd |
Multimers, tetramers & octamers
|
EP3943108A4
(de)
|
2019-03-19 |
2023-01-04 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-bindendes molekül mit antigen-bindender domäne mit veränderlicher bindungsaktivität gegenüber antigen in abhängigkeit von mta und bibliothek zur gewinnung der antigen-bindenden domäne
|
EP3947446A1
(de)
|
2019-03-25 |
2022-02-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Behandlung von tauopathie-erkrankungen durch abzielen auf neue tau-spezies
|
US20220177601A1
(en)
|
2019-03-25 |
2022-06-09 |
Daiichi Sankyo Company, Limited |
Anti-her2 antibody-pyrrolobenzodiazepine derivative conjugate
|
KR20210143237A
(ko)
|
2019-03-25 |
2021-11-26 |
다이이찌 산쿄 가부시키가이샤 |
항체-피롤로벤조디아제핀 유도체 컨쥬게이트
|
WO2020193628A1
(en)
|
2019-03-25 |
2020-10-01 |
Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft |
Enhancement of cytolytic t-cell activity by inhibiting ebag9
|
WO2020196712A1
(ja)
|
2019-03-27 |
2020-10-01 |
第一三共株式会社 |
抗体-ピロロベンゾジアゼピン誘導体コンジュゲートとparp阻害剤の組み合わせ
|
WO2020193718A1
(en)
|
2019-03-27 |
2020-10-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Recombinant proteins with cd40 activating properties
|
US20220169706A1
(en)
|
2019-03-28 |
2022-06-02 |
Danisco Us Inc |
Engineered antibodies
|
WO2020205469A1
(en)
|
2019-03-29 |
2020-10-08 |
Bristol-Myers Squibb Company |
Methods of measuring hydrophobicity of chromatographic resins
|
CN113950355A
(zh)
|
2019-03-29 |
2022-01-18 |
阿塔盖有限责任公司 |
Fgf23的抗体分子和其用途
|
TW202102544A
(zh)
|
2019-04-04 |
2021-01-16 |
日商小野藥品工業股份有限公司 |
雙特異性抗體
|
EP3954696A4
(de)
|
2019-04-10 |
2023-07-26 |
Chugai Seiyaku Kabushiki Kaisha |
Verfahren zur reinigung von fc-region-modifiziertem antikörper
|
CN113677403A
(zh)
|
2019-04-12 |
2021-11-19 |
豪夫迈·罗氏有限公司 |
包含脂质运载蛋白突变蛋白的双特异性抗原结合分子
|
JP2022529943A
(ja)
|
2019-04-15 |
2022-06-27 |
クウィクセル セラピューティクス リミテッド ライアビリティ カンパニー |
がんの処置における使用のための、標的指向性のマスクされたi型インターフェロン(ifnaおよびifnb)と腫瘍抗原に対する抗体とを含む融合タンパク質組成物
|
TW202110477A
(zh)
|
2019-04-17 |
2021-03-16 |
國立大學法人廣島大學 |
以組合投予il-6 抑制劑與ccr2 抑制劑為特徵之泌尿器官癌的治療劑
|
MX2021012767A
(es)
|
2019-04-19 |
2021-11-18 |
Janssen Biotech Inc |
Metodos para tratar el cancer de prostata con un anticuerpo anti-psma/cd3.
|
AU2020259405A1
(en)
|
2019-04-19 |
2021-09-23 |
Janssen Biotech, Inc. |
Methods of treating renal cancer with an anti- PSMA/CD3 antibody
|
EP3958908A1
(de)
|
2019-04-24 |
2022-03-02 |
Heidelberg Pharma Research GmbH |
Amatoxin-antikörper-wirkstoff-konjugate und verwendungen davon
|
US11850248B2
(en)
|
2019-05-14 |
2023-12-26 |
Yuhan Corporation |
Therapies with 3rd generation EGFR tyrosine kinase inhibitors
|
US11879013B2
(en)
|
2019-05-14 |
2024-01-23 |
Janssen Biotech, Inc. |
Combination therapies with bispecific anti-EGFR/c-Met antibodies and third generation EGFR tyrosine kinase inhibitors
|
JP2022534020A
(ja)
|
2019-05-23 |
2022-07-27 |
ヤンセン バイオテツク,インコーポレーテツド |
Il-23及びtnfアルファに対する抗体の併用療法による炎症性腸疾患の治療方法
|
TW202110879A
(zh)
|
2019-05-23 |
2021-03-16 |
瑞士商Ac 免疫有限公司 |
抗tdp-43結合分子及其用途
|
CN114127269A
(zh)
|
2019-05-24 |
2022-03-01 |
乔奥洛博安图内斯分子医学研究院 |
Alt癌症的治疗
|
SG11202112429PA
(en)
|
2019-05-29 |
2021-12-30 |
Daiichi Sankyo Co Ltd |
Dosage of an antibody-drug conjugate
|
CA3141690A1
(en)
|
2019-05-30 |
2020-12-03 |
Amgen Inc. |
Engineering the hinge region to drive antibody dimerization
|
KR20220017430A
(ko)
|
2019-06-05 |
2022-02-11 |
추가이 세이야쿠 가부시키가이샤 |
항체 절단 부위 결합 분자
|
UY38747A
(es)
|
2019-06-12 |
2021-01-29 |
Novartis Ag |
Anticuerpos de receptor de péptido natriurético 1 y métodos de uso
|
GB201908431D0
(en)
|
2019-06-12 |
2019-07-24 |
Plant Bioscience Ltd |
Biosynthetic genes and polypeptides
|
US20200392241A1
(en)
|
2019-06-17 |
2020-12-17 |
Visterra, Inc. |
Humanized antibody molecules to cd138 and uses thereof
|
KR20220041080A
(ko)
|
2019-06-18 |
2022-03-31 |
얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 |
B형 간염 바이러스(hbv) 백신 및 항-pd-1 또는 항-pc-l1 항체의 조합
|
CN114206379A
(zh)
|
2019-06-18 |
2022-03-18 |
爱尔兰詹森科学公司 |
乙型肝炎病毒(hbv)疫苗和抗pd-1抗体的组合
|
WO2020254827A1
(en)
|
2019-06-21 |
2020-12-24 |
Vhsquared Limited |
Polypeptides
|
JP2022538083A
(ja)
|
2019-06-21 |
2022-08-31 |
ソリッソ ファーマシューティカルズ,インク. |
ポリペプチド
|
KR20220063148A
(ko)
|
2019-06-21 |
2022-05-17 |
소리소 파마슈티컬스 인크. |
조성물
|
GB201909104D0
(en)
|
2019-06-25 |
2019-08-07 |
Plant Bioscience Ltd |
Transferase enzymes
|
CN114127123A
(zh)
|
2019-06-26 |
2022-03-01 |
豪夫迈·罗氏有限公司 |
结合cea的抗体与4-1bbl的融合
|
CN114531878A
(zh)
|
2019-06-27 |
2022-05-24 |
豪夫迈·罗氏有限公司 |
新颖icos抗体及包含它们的肿瘤靶向抗原结合分子
|
US20220363770A1
(en)
|
2019-06-28 |
2022-11-17 |
Amgen Inc. |
Anti-cgrp receptor/anti-pac1 receptor bispecific antigen binding proteins
|
EP3994169A1
(de)
|
2019-07-02 |
2022-05-11 |
F. Hoffmann-La Roche AG |
Immunokonjugate mit einem mutierten interleukin-2 und einen anti-cd8-antikörper
|
TW202328206A
(zh)
|
2019-07-05 |
2023-07-16 |
日商小野藥品工業股份有限公司 |
以pd-1/cd3雙特異性蛋白質所進行之血液性癌症治療
|
CN114144436A
(zh)
|
2019-07-24 |
2022-03-04 |
H.隆德贝克有限公司 |
抗mGluR5抗体及其用途
|
WO2021021606A1
(en)
|
2019-07-26 |
2021-02-04 |
Visterra, Inc. |
Interleukin-2 agents and uses thereof
|
JPWO2021020282A1
(de)
|
2019-07-26 |
2021-02-04 |
|
|
EP4008348A4
(de)
|
2019-07-30 |
2023-11-15 |
ONO Pharmaceutical Co., Ltd. |
Bispezifische antikörper
|
SG11202112491WA
(en)
|
2019-07-31 |
2021-12-30 |
Hoffmann La Roche |
Antibodies binding to gprc5d
|
GB201910899D0
(en)
|
2019-07-31 |
2019-09-11 |
Scancell Ltd |
Binding members
|
EP4004045A1
(de)
|
2019-07-31 |
2022-06-01 |
F. Hoffmann-La Roche AG |
An gprc5d bindende antikörper
|
LT4007777T
(lt)
|
2019-08-02 |
2024-02-12 |
Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS) |
Car t ląstelės prieš bcma, skirtos dauginės mielomos gydymui
|
EP4031658A1
(de)
|
2019-08-07 |
2022-07-27 |
DB Biotech, AS |
Verbesserte meerrettichperoxidase-polypeptide
|
EP4011918A4
(de)
|
2019-08-08 |
2023-08-23 |
ONO Pharmaceutical Co., Ltd. |
Dual-spezifisches protein
|
AU2020329217A1
(en)
|
2019-08-12 |
2022-07-28 |
Aptevo Research And Development Llc |
4-1BB and OX40 binding proteins and related compositions and methods, antibodies against 4-1BB, antibodies against OX40
|
AU2020338818A1
(en)
|
2019-08-30 |
2022-03-31 |
4TEEN4 Pharmaceuticals GmbH |
Therapy guidance and/or therapy monitoring for treatment of shock
|
BR112022003740A2
(pt)
|
2019-08-30 |
2022-05-31 |
Agenus Inc |
Anticorpos anti-cd96 e métodos de uso dos mesmos
|
GB201912657D0
(en)
|
2019-09-03 |
2019-10-16 |
Scancell Ltd |
Binding members
|
EP4025303A1
(de)
|
2019-09-04 |
2022-07-13 |
Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) |
Herv-inhibitoren zur verwendung bei der behandlung von tauopathien
|
EP4026560A4
(de)
|
2019-09-04 |
2023-10-25 |
Perseus Proteomics Inc. |
Therapeutisches mittel für polyzythämie
|
CN114641501A
(zh)
|
2019-09-04 |
2022-06-17 |
Y生物股份有限公司 |
抗vsig4抗体或抗原结合片段及其用途
|
GB201912882D0
(en)
|
2019-09-06 |
2019-10-23 |
Scancell Ltd |
Ssea-4 binding members
|
CN114450024A
(zh)
|
2019-09-16 |
2022-05-06 |
表面肿瘤学公司 |
抗cd39抗体组合物和方法
|
EP4031578A1
(de)
|
2019-09-18 |
2022-07-27 |
Novartis AG |
Entpd2-antikörper, kombinationstherapien und verfahren zur verwendung der antikörper und kombinationstherapien
|
TW202124446A
(zh)
|
2019-09-18 |
2021-07-01 |
瑞士商諾華公司 |
與entpd2抗體之組合療法
|
US20210115127A1
(en)
|
2019-09-25 |
2021-04-22 |
Surface Oncology, Inc. |
Anti-il-27 antibodies and uses thereof
|
JP2022549504A
(ja)
|
2019-09-26 |
2022-11-25 |
エスティーキューブ アンド カンパニー |
グリコシル化ctla-4に対して特異的な抗体およびその使用方法
|
WO2021058729A1
(en)
|
2019-09-27 |
2021-04-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Anti-müllerian inhibiting substance type i receptor antibodies and uses thereof
|
WO2021059075A1
(en)
|
2019-09-27 |
2021-04-01 |
Janssen Biotech, Inc. |
Anti-ceacam antibodies and uses thereof
|
JP2022550325A
(ja)
|
2019-09-27 |
2022-12-01 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
抗ミュラー管抑制物質抗体およびその使用
|
WO2021066869A1
(en)
|
2019-10-04 |
2021-04-08 |
TAE Life Sciences |
Antibody compositions comprising fc mutations and site-specific conjugation properties
|
US20240050529A1
(en)
|
2019-10-07 |
2024-02-15 |
University Of Virginia Patent Foundation |
Modulating lymphatic vessels in neurological disease
|
WO2021072277A1
(en)
|
2019-10-09 |
2021-04-15 |
Stcube & Co. |
Antibodies specific to glycosylated lag3 and methods of use thereof
|
CA3157509A1
(en)
|
2019-10-10 |
2021-04-15 |
Kodiak Sciences Inc. |
Methods of treating an eye disorder
|
KR20220083773A
(ko)
|
2019-10-18 |
2022-06-20 |
이뮤노믹 쎄라퓨틱스, 인크. |
암 항원을 포함하는 개선된 lamp 구축물
|
TW202128166A
(zh)
|
2019-10-21 |
2021-08-01 |
瑞士商諾華公司 |
組合療法
|
BR112022007179A2
(pt)
|
2019-10-21 |
2022-08-23 |
Novartis Ag |
Inibidores de tim-3 e usos dos mesmos
|
JP2022553324A
(ja)
|
2019-10-24 |
2022-12-22 |
プロメテウス バイオサイエンシーズ,インク. |
Tnf様リガンド1a(tl1a)に対するヒト化抗体およびその使用
|
US11459389B2
(en)
|
2019-10-24 |
2022-10-04 |
Massachusetts Institute Of Technology |
Monoclonal antibodies that bind human CD161
|
CA3155172A1
(en)
|
2019-10-25 |
2021-04-29 |
Shinko HAYASHI |
Combination of anti-garp antibody and immunomodulator
|
WO2021087406A1
(en)
|
2019-11-01 |
2021-05-06 |
Magenta Therapeutics, Inc. |
Dosing regimens for the mobilization of hematopoietic stem and progentor cells
|
AU2020380379A1
(en)
|
2019-11-08 |
2022-05-26 |
Amgen Inc. |
Engineering charge pair mutations for pairing of hetero-IgG molecules
|
IL293051A
(en)
|
2019-11-18 |
2022-07-01 |
Janssen Biotech Inc |
calr and jak2 mutant-based vaccines and their uses
|
WO2021102049A1
(en)
|
2019-11-19 |
2021-05-27 |
Amgen Inc. |
Novel multispecific antibody format
|
JP2023503857A
(ja)
|
2019-11-20 |
2023-02-01 |
バヴァリアン・ノルディック・アクティーゼルスカブ |
がんを治療するための腫瘍内及び/または静脈内投与用組み換えmvaウイルス
|
WO2021099576A1
(en)
|
2019-11-21 |
2021-05-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Novel immunotherapies targeting pd-1 with anti-pd-1/il-15 immunocytokines
|
WO2021107082A1
(ja)
|
2019-11-27 |
2021-06-03 |
株式会社ペルセウスプロテオミクス |
癌性腹膜炎の治療薬
|
GB201917480D0
(en)
|
2019-11-29 |
2020-01-15 |
Univ Oxford Innovation Ltd |
Antibodies
|
EP4072682A1
(de)
|
2019-12-09 |
2022-10-19 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Antikörper mit spezifität gegen her4 und verwendungen davon
|
AU2020408213A1
(en)
|
2019-12-19 |
2022-06-23 |
Quidel Corporation |
Monoclonal antibody fusions
|
GB201919058D0
(en)
|
2019-12-20 |
2020-02-05 |
Ucb Biopharma Sprl |
Multi-specific antibodies
|
CN115052662A
(zh)
|
2019-12-20 |
2022-09-13 |
诺华股份有限公司 |
抗TGFβ抗体和检查点抑制剂用于治疗增殖性疾病的用途
|
GB201919061D0
(en)
|
2019-12-20 |
2020-02-05 |
Ucb Biopharma Sprl |
Multi-specific antibody
|
GB201919062D0
(en)
|
2019-12-20 |
2020-02-05 |
Ucb Biopharma Sprl |
Antibody
|
TW202138388A
(zh)
|
2019-12-30 |
2021-10-16 |
美商西根公司 |
以非海藻糖苷化抗-cd70抗體治療癌症之方法
|
WO2021138407A2
(en)
|
2020-01-03 |
2021-07-08 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to cd33 and uses thereof
|
BR112022011749A2
(pt)
|
2020-01-06 |
2022-08-30 |
Vaccinex Inc |
Anticorpos anti-ccr8 e seus usos
|
WO2021142191A1
(en)
|
2020-01-08 |
2021-07-15 |
Regeneron Pharmaceuticals, Inc. |
Treatment of fibrodysplasia ossificans progressiva
|
CN115052663A
(zh)
|
2020-01-08 |
2022-09-13 |
辛瑟斯治疗股份有限公司 |
Alk5抑制剂缀合物及其用途
|
CN114929734A
(zh)
|
2020-01-09 |
2022-08-19 |
豪夫迈·罗氏有限公司 |
新型含有4-1bbl三聚体的抗原结合分子
|
CA3166328A1
(en)
|
2020-01-11 |
2021-07-15 |
Scholar Rock, Inc. |
Tgf-beta inhibitors and use thereof
|
EP4087649A1
(de)
|
2020-01-11 |
2022-11-16 |
Scholar Rock, Inc. |
Tgfbeta-inhibitoren und verwendung davon
|
TW202140553A
(zh)
|
2020-01-13 |
2021-11-01 |
美商威特拉公司 |
C5ar1抗體分子及其用途
|
MX2022008772A
(es)
|
2020-01-14 |
2022-10-07 |
Synthekine Inc |
Ortologos de il2 y metodos de uso.
|
US20230058489A1
(en)
|
2020-01-17 |
2023-02-23 |
Novartis Ag |
Combination comprising a tim-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia
|
US20230067811A1
(en)
|
2020-01-24 |
2023-03-02 |
University Of Virginia Patent Foundation |
Modulating lymphatic vessels in neurological disease
|
CA3165713A1
(en)
|
2020-01-30 |
2021-08-05 |
Andrew Scharenberg |
Bispecific transduction enhancer
|
US20230061973A1
(en)
|
2020-02-05 |
2023-03-02 |
Larimar Therapeutics, Inc. |
Tat peptide binding proteins and uses thereof
|
TW202140012A
(zh)
|
2020-02-12 |
2021-11-01 |
比利時商健生藥品公司 |
用於治療尿路上皮癌的fgfr酪胺酸激酶抑制劑和抗pd1藥劑
|
EP4103611B1
(de)
|
2020-02-13 |
2024-03-27 |
UCB Biopharma SRL |
Bispezifische, an hvem und cd9 bindende antikörper
|
EP4103610A1
(de)
|
2020-02-13 |
2022-12-21 |
UCB Biopharma SRL |
Anti-cd4-ctla4 bispezifische antikörper
|
US20230151108A1
(en)
|
2020-02-13 |
2023-05-18 |
UCB Biopharma SRL |
Bispecific antibodies against cd9 and cd137
|
US20230151109A1
(en)
|
2020-02-13 |
2023-05-18 |
UCB Biopharma SRL |
Bispecific antibodies against cd9
|
WO2021160267A1
(en)
|
2020-02-13 |
2021-08-19 |
UCB Biopharma SRL |
Bispecific antibodies against cd9 and cd7
|
TW202144389A
(zh)
|
2020-02-14 |
2021-12-01 |
美商健生生物科技公司 |
在多發性骨髓瘤中表現之新抗原及其用途
|
TW202144388A
(zh)
|
2020-02-14 |
2021-12-01 |
美商健生生物科技公司 |
在卵巢癌中表現之新抗原及其用途
|
CA3168337A1
(en)
|
2020-02-17 |
2021-08-26 |
Marie-Andree Forget |
Methods for expansion of tumor infiltrating lymphocytes and use thereof
|
US20230220074A1
(en)
|
2020-02-18 |
2023-07-13 |
Alector Llc |
Pilra antibodies and methods of use thereof
|
EP3871689A1
(de)
|
2020-02-26 |
2021-09-01 |
sphingotec GmbH |
Anti-adm-antikörper, die an den freien n-terminus binden, für einen beschleunigten übergang von adm-gly zu bio-adm bei patienten mit einem adm-gly/bio-adm-verhältnis über einem schwellenwert und kombination mit vitamin c
|
CN115244080A
(zh)
|
2020-02-27 |
2022-10-25 |
艾德里诺医药公司 |
用于治疗或预防休克的抗肾上腺髓质素(ADM)抗体或抗ADM抗体片段或抗ADM非Ig支架
|
AU2021228207A1
(en)
|
2020-02-27 |
2022-10-20 |
4TEEN4 Pharmaceuticals GmbH |
DPP3 for therapy guidance, monitoring and stratification of nt-ADM antibodies in patients with shock
|
JP2023515985A
(ja)
|
2020-02-27 |
2023-04-17 |
アドレノメト アクチェンゲゼルシャフト |
ショック状態の患者の治療において使用するための抗アドレノメデュリン(adm)結合剤
|
WO2021178896A1
(en)
|
2020-03-06 |
2021-09-10 |
Go Therapeutics, Inc. |
Anti-glyco-cd44 antibodies and their uses
|
WO2021176424A1
(en)
|
2020-03-06 |
2021-09-10 |
Ona Therapeutics, S.L. |
Anti-cd36 antibodies and their use to treat cancer
|
AU2021232853A1
(en)
|
2020-03-10 |
2022-09-22 |
Massachusetts Institute Of Technology |
Compositions and methods for immunotherapy of NPM1c-positive cancer
|
CA3174638A1
(en)
|
2020-03-11 |
2021-09-16 |
Fundacio Institut De Recerca Contra La Leucemia Josep Carreras |
Cd22 targeting-moiety for the treatment of b-cell acute lymphoblastic leukemia (b-all)
|
AU2021237689A1
(en)
|
2020-03-16 |
2022-11-03 |
4TEEN4 Pharmaceuticals GmbH |
DPP3 in patients infected with coronavirus
|
EP3922993A1
(de)
|
2020-06-12 |
2021-12-15 |
4TEEN4 Pharmaceuticals GmbH |
Dpp3 bei patienten, die mit coronavirus infiziert sind
|
JP2023517717A
(ja)
|
2020-03-16 |
2023-04-26 |
シュピーンゴテック ゲゼルシャフト ミット ベシュレンクテル ハフツング |
コロナウイルスに感染した患者におけるプロアドレノメデュリンまたはそのフラグメント、およびアドレノメデュリンに対する結合剤による治療
|
WO2021190980A1
(en)
|
2020-03-22 |
2021-09-30 |
Quadrucept Bio Limited |
Multimers for viral strain evolution
|
EP4129333A1
(de)
|
2020-03-27 |
2023-02-08 |
PhotoQ3 Inc. |
Pharmazeutisches arzneimittel zur zerstörung von tumorzellen
|
IL296514A
(en)
|
2020-03-30 |
2022-11-01 |
Univ Mie |
Bispecific antibody
|
WO2021202473A2
(en)
|
2020-03-30 |
2021-10-07 |
Danisco Us Inc |
Engineered antibodies
|
EP4126064A1
(de)
|
2020-04-03 |
2023-02-08 |
Visterra, Inc. |
Antikörpermolekül-wirkstoff-konjugate und verwendungen davon
|
CN115379858A
(zh)
|
2020-04-06 |
2022-11-22 |
光爱科技公司 |
用于杀死肿瘤细胞的医药品
|
JP2023521178A
(ja)
|
2020-04-10 |
2023-05-23 |
バヌディス ゲーエムベーハー |
予防および治療における自然抗体
|
EP4136459A1
(de)
|
2020-04-13 |
2023-02-22 |
Abbott Laboratories |
Verfahren, komplexe und kits zum nachweis oder zur bestimmung einer menge eines ss-coronavirus-antikörpers in einer probe
|
US20230192795A1
(en)
|
2020-04-15 |
2023-06-22 |
Hoffmann-La Roche Inc. |
Immunoconjugates
|
KR20230028242A
(ko)
|
2020-04-24 |
2023-02-28 |
마렝고 테라퓨틱스, 인크. |
T 세포 관련 암 세포에 결합하는 다중기능성 분자 및 그것의 용도
|
EP4143302A1
(de)
|
2020-04-27 |
2023-03-08 |
Magenta Therapeutics, Inc. |
Verfahren und zusammensetzungen zur transduktion hämatopoetischer stamm- und vorläuferzellen in vivo
|
WO2021220218A1
(en)
|
2020-05-01 |
2021-11-04 |
Novartis Ag |
Immunoglobulin variants
|
JP2023523794A
(ja)
|
2020-05-01 |
2023-06-07 |
ノバルティス アーゲー |
人工操作免疫グロブリン
|
KR20230009450A
(ko)
|
2020-05-11 |
2023-01-17 |
얀센 바이오테크 인코포레이티드 |
다발성 골수종을 치료하기 위한 방법
|
CA3180683A1
(en)
|
2020-05-12 |
2021-11-18 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
New method to treat cutaneous t-cell lymphomas and tfh derived lymphomas
|
US20230183366A1
(en)
|
2020-05-13 |
2023-06-15 |
Inserm (Institut National De La Santé Et De La Recherch Médicale) |
Recombinant proteins with ox40 activating properties
|
WO2021231732A1
(en)
|
2020-05-15 |
2021-11-18 |
Bristol-Myers Squibb Company |
Antibodies to garp
|
WO2021233834A1
(en)
|
2020-05-17 |
2021-11-25 |
Astrazeneca Uk Limited |
Sars-cov-2 antibodies and methods of selecting and using the same
|
WO2021234560A1
(en)
|
2020-05-19 |
2021-11-25 |
Janssen Biotech, Inc. |
Compositions comprising a t cell redirection therapeutic and a vla-4 adhesion pathway inhibitor
|
EP4153232A1
(de)
|
2020-05-22 |
2023-03-29 |
Philogen S.p.A. |
Tnf immunkonjugattherapie zur behandlung von hirntumoren
|
WO2021239666A1
(en)
|
2020-05-26 |
2021-12-02 |
Diaccurate |
Therapeutic methods
|
EP4157875A1
(de)
|
2020-06-02 |
2023-04-05 |
Arcus Biosciences, Inc. |
Antikörper gegen tigit
|
WO2021247908A1
(en)
|
2020-06-03 |
2021-12-09 |
Bionecure Therapeutics, Inc. |
Trophoblast cell-surface antigen-2 (trop-2) antibodies
|
CA3176552A1
(en)
|
2020-06-19 |
2021-12-23 |
F. Hoffmann-La Roche Ag |
Immune activating fc domain binding molecules
|
AU2021291002A1
(en)
|
2020-06-19 |
2022-10-13 |
F. Hoffmann-La Roche Ag |
Protease-activated T cell bispecific antibodies
|
PE20231361A1
(es)
|
2020-06-23 |
2023-09-05 |
Hoffmann La Roche |
Moleculas agonistas de union al antigeno cd28 que se dirigen a her2
|
WO2021261546A1
(ja)
|
2020-06-24 |
2021-12-30 |
国立大学法人 東京大学 |
光増感色素
|
AU2021297315A1
(en)
|
2020-06-24 |
2023-02-02 |
Visterra, Inc. |
Antibody molecules to APRIL and uses thereof
|
JP2023531067A
(ja)
|
2020-06-25 |
2023-07-20 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
抗cd3/抗cd28二重特異性抗原結合分子
|
CN116390772A
(zh)
|
2020-07-07 |
2023-07-04 |
博泰康医药公司 |
新型美登素类似物作为adc有效载荷及其在癌症治疗中的用途
|
MX2023000547A
(es)
|
2020-07-16 |
2023-02-13 |
Novartis Ag |
Anticuerpos anti-betacelulina, fragmentos de los mismos, y moleculas de union multiespecificas.
|
IL299757A
(en)
|
2020-07-20 |
2023-03-01 |
Astrazeneca Uk Ltd |
SARS-COV-2 proteins, antibodies against SARS-COV-2, and methods of using them
|
EP4190354A1
(de)
|
2020-07-28 |
2023-06-07 |
Chugai Seiyaku Kabushiki Kaisha |
Vorgefüllte spritzenzubereitung mit nadel mit nadelschutz und mit neuartigem modifiziertem antikörper
|
WO2022026592A2
(en)
|
2020-07-28 |
2022-02-03 |
Celltas Bio, Inc. |
Antibody molecules to coronavirus and uses thereof
|
WO2022022662A1
(zh)
|
2020-07-31 |
2022-02-03 |
百奥泰生物制药股份有限公司 |
Cd47抗体及其应用
|
JPWO2022025220A1
(de)
|
2020-07-31 |
2022-02-03 |
|
|
WO2022031804A1
(en)
|
2020-08-04 |
2022-02-10 |
Abbott Laboratories |
Improved methods and kits for detecting sars-cov-2 protein in a sample
|
WO2022032020A1
(en)
|
2020-08-07 |
2022-02-10 |
Fortis Therapeutics, Inc. |
Immunoconjugates targeting cd46 and methods of use thereof
|
WO2022034228A1
(en)
|
2020-08-14 |
2022-02-17 |
Ac Immune Sa |
Humanized anti-tdp-43 binding molecules and uses thereof
|
CN116761821A
(zh)
|
2020-08-18 |
2023-09-15 |
赛福伦有限责任公司 |
抗par-2抗体及其使用方法
|
MX2023002125A
(es)
|
2020-08-20 |
2023-04-26 |
Amgen Inc |
Proteínas de unión a antígenos con disulfuro no canónico en la región fab.
|
US20240009310A1
(en)
|
2020-08-24 |
2024-01-11 |
Charité - Universitätsmedizin Berlin |
A CHIMERIC ANTIGEN RECEPTOR CONSTRUCT ENCODING A CHECKPOINT INHIBITORY MOLECULE AND AN IMMUNE STIMULATORY CYTOKINE AND CAR-EXPRESSING CELLS RECOGNIZING CD44v6
|
WO2022043312A1
(en)
|
2020-08-24 |
2022-03-03 |
Charité - Universitätsmedizin Berlin |
Chimeric antigen receptor (car)-expressing cells recognizing cea
|
US20230312689A1
(en)
|
2020-08-26 |
2023-10-05 |
National University Corporation Kumamoto University |
Human antibody or antigen-binding fragment thereof against coronavirus spike protein
|
CA3190755A1
(en)
|
2020-08-26 |
2022-03-03 |
Andreas Loew |
Multifunctional molecules that bind to calreticulin and uses thereof
|
CN116761818A
(zh)
|
2020-08-26 |
2023-09-15 |
马伦戈治疗公司 |
检测trbc1或trbc2的方法
|
KR20230074144A
(ko)
|
2020-08-26 |
2023-05-26 |
마렝고 테라퓨틱스, 인크. |
NKp30에 결합하는 항체 분자 및 이의 용도
|
EP4204448A2
(de)
|
2020-08-27 |
2023-07-05 |
cureab GmbH |
Anti-golph2-antikörper zur makrophagen- und dendritischen zelldifferenzierung
|
JPWO2022045247A1
(de)
|
2020-08-27 |
2022-03-03 |
|
|
US20230321285A1
(en)
|
2020-08-31 |
2023-10-12 |
Advanced Accelerator Applications International Sa |
Method of treating psma-expressing cancers
|
WO2022043558A1
(en)
|
2020-08-31 |
2022-03-03 |
Advanced Accelerator Applications International Sa |
Method of treating psma-expressing cancers
|
JP2023540082A
(ja)
|
2020-09-04 |
2023-09-21 |
ラトガース,ザ ステート ユニバーシティ オブ ニュー ジャージー |
SARS-CoV-2ワクチン及び抗体
|
AU2021339953A1
(en)
|
2020-09-11 |
2023-05-18 |
Medimmune Limited |
Therapeutic b7-h4 binding molecules
|
AU2021342349A1
(en)
|
2020-09-12 |
2023-05-25 |
Medimmune Limited |
A scoring method for an anti-b7h4 antibody-drug conjugate therapy
|
EP4210702A1
(de)
|
2020-09-14 |
2023-07-19 |
JANSSEN Pharmaceutica NV |
Fgfr-inhibitorkombinationstherapien
|
CA3194796A1
(en)
|
2020-09-16 |
2022-03-24 |
Janssen Biotech, Inc. |
Methods for treating multiple myeloma
|
EP4225786A2
(de)
|
2020-10-07 |
2023-08-16 |
Amgen Inc. |
Rationale auswahl von bausteinen zur anordnung multispezifischer antikörper
|
CN116472282A
(zh)
|
2020-10-08 |
2023-07-21 |
国立大学法人东海国立大学机构 |
抗转铁蛋白受体抗体的药效或感受性的判定方法
|
WO2022081718A1
(en)
|
2020-10-14 |
2022-04-21 |
Five Prime Therapeutics, Inc. |
Anti-c-c chemokine receptor 8 (ccr8) antibodies and methods of use thereof
|
AU2021359092A1
(en)
|
2020-10-15 |
2023-06-01 |
UCB Biopharma SRL |
Binding molecules that multimerise cd45
|
US20230382978A1
(en)
|
2020-10-15 |
2023-11-30 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Antibody specific for sars-cov-2 receptor binding domain and therapeutic methods
|
AU2021366287A1
(en)
|
2020-10-20 |
2023-04-13 |
Kantonsspital St. Gallen |
Antibodies or antigen-binding fragments specifically binding to Gremlin-1 and uses thereof
|
WO2022087274A1
(en)
|
2020-10-21 |
2022-04-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Antibodies that neutralize type-i interferon (ifn) activity
|
WO2022097065A2
(en)
|
2020-11-06 |
2022-05-12 |
Novartis Ag |
ANTIBODY Fc VARIANTS
|
EP4244246A1
(de)
|
2020-11-10 |
2023-09-20 |
Amgen Inc. |
Neue linker von multispezifischen antigenbindenden domänen
|
US20230406921A1
(en)
|
2020-11-12 |
2023-12-21 |
Mabwell (shanghai) Bioscience Co., Ltd. |
Antibody and preparation method therefor
|
EP4251647A1
(de)
|
2020-11-24 |
2023-10-04 |
Bio-Techne Corporation |
Anti-sever-antikörper des akuten atemwegssyndroms coronavirus
|
IL303328A
(en)
|
2020-12-01 |
2023-07-01 |
Aptevo Res & Development Llc |
CD3-binding bispecific and heterodimeric antibodies to PSMA
|
CA3198161A1
(en)
|
2020-12-01 |
2022-06-09 |
Beth MCQUISTON |
Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
|
WO2023102384A1
(en)
|
2021-11-30 |
2023-06-08 |
Abbott Laboratories |
Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
|
EP4023218A1
(de)
|
2020-12-02 |
2022-07-06 |
S-Form Pharma |
Kombinationstherapie für patienten mit akuter und/oder anhaltender dyspnoe
|
TW202237171A
(zh)
|
2020-12-04 |
2022-10-01 |
美商威特拉公司 |
使用介白素-2藥劑之方法
|
WO2022117692A2
(en)
|
2020-12-04 |
2022-06-09 |
F. Hoffmann-La Roche Ag |
Ph-dependent mutant interleukin-2 polypeptides
|
US20240052042A1
(en)
|
2020-12-14 |
2024-02-15 |
Novartis Ag |
Reversal binding agents for anti-natriuretic peptide receptor i (npri) antibodies and uses thereof
|
EP4263597A2
(de)
|
2020-12-18 |
2023-10-25 |
Kiniksa Pharmaceuticals, Ltd. |
Proteinzusammensetzungen und verfahren zur herstellung und verwendung davon
|
EP4271998A1
(de)
|
2020-12-30 |
2023-11-08 |
Abbott Laboratories |
Verfahren zur bestimmung des sars-cov-2-antigens und anti-sars-cov-2-antikörpers in einer probe
|
WO2022148853A1
(en)
|
2021-01-11 |
2022-07-14 |
F. Hoffmann-La Roche Ag |
Immunoconjugates
|
US20240115720A1
(en)
|
2021-01-13 |
2024-04-11 |
Memorial Sloan Kettering Cancer Center |
Antibody-pyrrolobenzodiazepine derivative conjugate
|
JP2024503658A
(ja)
|
2021-01-13 |
2024-01-26 |
メモリアル スローン-ケタリング キャンサー センター |
抗dll3抗体-薬物コンジュゲート
|
AR124681A1
(es)
|
2021-01-20 |
2023-04-26 |
Abbvie Inc |
Conjugados anticuerpo-fármaco anti-egfr
|
WO2022159590A1
(en)
|
2021-01-20 |
2022-07-28 |
Visterra, Inc. |
Interleukin-2 mutants and uses thereof
|
EP4281477A2
(de)
|
2021-01-22 |
2023-11-29 |
Bayer Aktiengesellschaft |
Lrrc15-antikörper und konjugate davon
|
EP4284838A2
(de)
|
2021-01-28 |
2023-12-06 |
Janssen Biotech, Inc. |
Psma-bindende proteine und verwendungen davon
|
JP2024505049A
(ja)
|
2021-01-29 |
2024-02-02 |
ノバルティス アーゲー |
抗cd73及び抗entpd2抗体のための投与方式並びにその使用
|
US20220275090A1
(en)
|
2021-02-22 |
2022-09-01 |
Janssen Biotech, Inc. |
Combination Therapies with Anti-CD38 Antibodies and PARP or Adenosine Receptor Inhibitors
|
WO2022182872A2
(en)
|
2021-02-24 |
2022-09-01 |
Alladapt Immunotherapeutics, Inc. |
Compositions and methods for identification of cross-reactive allergenic proteins and treatment of allergies
|
US20220378929A1
(en)
|
2021-02-25 |
2022-12-01 |
MediBoston Limted |
Anti-her2 antibody-drug conjugates and uses thereof
|
WO2022184659A1
(en)
|
2021-03-01 |
2022-09-09 |
Quadrucept Bio Limited |
Antibody domains & multimers
|
TW202302645A
(zh)
|
2021-03-03 |
2023-01-16 |
法商皮爾法伯製藥公司 |
抗vsig4抗體或抗原結合片段及其用途
|
WO2022187440A1
(en)
|
2021-03-03 |
2022-09-09 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
La protien as a novel regulator of osteoclastogenesis
|
WO2022187591A1
(en)
|
2021-03-05 |
2022-09-09 |
Go Therapeutics, Inc. |
Anti-glyco-cd44 antibodies and their uses
|
CN117083084A
(zh)
|
2021-03-09 |
2023-11-17 |
豪夫迈·罗氏有限公司 |
Pd-1靶向il-2变体免疫缀合物和fap/4-1bb结合分子的组合疗法
|
EP4304724A1
(de)
|
2021-03-09 |
2024-01-17 |
F. Hoffmann-La Roche AG |
Kombinationstherapie aus pd-1-gerichtetem il-2-varianten-immunkonjugat und bispezifischen anti-tyrp1/anti-cd3-antikörpern
|
AU2022233518A1
(en)
|
2021-03-09 |
2023-10-26 |
Janssen Biotech, Inc. |
Treatment of cancers lacking egfr-activating mutations
|
KR20230156368A
(ko)
|
2021-03-12 |
2023-11-14 |
추가이 세이야쿠 가부시키가이샤 |
중증 근무력증의 치료 또는 예방용의 의약 조성물
|
EP4308694A1
(de)
|
2021-03-16 |
2024-01-24 |
Magenta Therapeutics, Inc. |
Dosierschemata zur mobilisierung hämatopoetischer stammzellen für stammzelltransplantationen bei patienten mit multiplem myelom
|
AU2022236492A1
(en)
|
2021-03-18 |
2023-10-26 |
Medimmune Limited |
Therapeutic binding molecule that binds to ccr9
|
EP4308935A1
(de)
|
2021-03-18 |
2024-01-24 |
Novartis AG |
Biomarker für krebs und verfahren zur verwendung davon
|
KR20230141868A
(ko)
|
2021-03-24 |
2023-10-10 |
와커 헤미 아게 |
불포화된 기를 갖는 유기폴리실록산의 제조 방법
|
WO2022204581A2
(en)
|
2021-03-26 |
2022-09-29 |
Scholar Rock, Inc. |
Tgf-beta inhibitors and use thereof
|
EP4317435A1
(de)
|
2021-03-29 |
2024-02-07 |
Daiichi Sankyo Company, Limited |
Stabiles multispezifisches molekül und verwendung davon
|
CN117157312A
(zh)
|
2021-03-30 |
2023-12-01 |
豪夫迈·罗氏有限公司 |
蛋白酶活化的多肽
|
EP4067381A1
(de)
|
2021-04-01 |
2022-10-05 |
Julius-Maximilians-Universität Würzburg |
Neue tnfr2-bindende moleküle
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途
|
JP2024515591A
(ja)
|
2021-04-08 |
2024-04-10 |
マレンゴ・セラピューティクス,インコーポレーテッド |
Tcrに結合する多機能性分子およびその使用
|
CN117651714A
(zh)
|
2021-04-20 |
2024-03-05 |
美国安进公司 |
多特异性和单价IgG分子组装中链配对的静电转向中的平衡电荷分布
|
TW202308689A
(zh)
|
2021-04-21 |
2023-03-01 |
美商健生生物科技公司 |
高濃度的雙特異性抗體調配物
|
BR112023022878A2
(pt)
|
2021-05-04 |
2024-01-23 |
Regeneron Pharma |
Agonistas do receptor fgf21 multiespecíficos e seus usos
|
WO2022236134A1
(en)
|
2021-05-07 |
2022-11-10 |
Surface Oncology, Inc. |
Anti-il-27 antibodies and uses thereof
|
TW202309522A
(zh)
|
2021-05-11 |
2023-03-01 |
美商健生生物科技公司 |
用於監測復發性及/或難治性多發性骨髓瘤之治療的方法及組成物
|
AU2022279156A1
(en)
|
2021-05-18 |
2023-11-02 |
Abbott Laboratories |
Methods of evaluating brain injury in a pediatric subject
|
TW202309094A
(zh)
|
2021-05-18 |
2023-03-01 |
美商健生生物科技公司 |
用於識別癌症患者以進行組合治療之方法
|
EP4340942A1
(de)
|
2021-05-18 |
2024-03-27 |
Janssen Biotech, Inc. |
Zusammensetzungen mit einem t-zell-umleitungstherapeutikum und einem anti-cd44-therapeutikum
|
WO2022251853A1
(en)
|
2021-05-25 |
2022-12-01 |
Edelweiss Immune Inc |
C-x-c motif chemokine receptor 6 (cxcr6) binding molecules, and methods of using the same
|
WO2022251446A1
(en)
|
2021-05-28 |
2022-12-01 |
Alexion Pharmaceuticals, Inc. |
Methods for detecting cm-tma biomarkers
|
AR126009A1
(es)
|
2021-06-02 |
2023-08-30 |
Hoffmann La Roche |
Moléculas agonistas de unión al antígeno cd28 que se dirigen a epcam
|
WO2022256723A2
(en)
|
2021-06-03 |
2022-12-08 |
Scholar Rock, Inc. |
Tgf-beta inhibitors and therapeutic use thereof
|
BR112023022097A2
(pt)
|
2021-06-07 |
2023-12-19 |
Agonox Inc |
Cxcr5, pd-1 e icos expressando células t cd4 reativas de tumor e seu uso
|
WO2022261183A2
(en)
|
2021-06-08 |
2022-12-15 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for treating and/or identifying an agent for treating intestinal cancers
|
WO2022263357A1
(en)
|
2021-06-14 |
2022-12-22 |
Argenx Iip Bv |
Anti-il-9 antibodies and methods of use thereof
|
AU2022293389A1
(en)
|
2021-06-14 |
2024-01-04 |
Abbott Laboratories |
Methods of diagnosing or aiding in diagnosis of brain injury caused by acoustic energy, electromagnetic energy, an over pressurization wave, and/or blast wind
|
AU2022292462A1
(en)
|
2021-06-18 |
2023-12-07 |
Nammi Therapeutics, Inc. |
FUSION PROTEIN COMPOSITION(S) COMPRISING MASKED TYPE I INTERFERONS (IFNα AND IFNβ) FOR USE IN THE TREATMENT OF CANCER AND METHODS THEREOF
|
WO2022271867A1
(en)
|
2021-06-23 |
2022-12-29 |
Scholar Rock, Inc. |
A myostatin pathway inhibitor in combination with a glp-1 pathway activator for use in treating metabolic disorders
|
CA3221281A1
(en)
|
2021-06-29 |
2023-01-05 |
Seagen Inc. |
Methods of treating cancer with a combination of a nonfucosylated anti-cd70 antibody and a cd47 antagonist
|
WO2023285878A1
(en)
|
2021-07-13 |
2023-01-19 |
Aviation-Ophthalmology |
Methods for detecting, treating, and preventing gpr68-mediated ocular diseases, disorders, and conditions
|
WO2023288267A1
(en)
|
2021-07-14 |
2023-01-19 |
2Seventy Bio, Inc. |
Engineered t cell receptors fused to binding domains from antibodies
|
WO2023286854A1
(ja)
|
2021-07-16 |
2023-01-19 |
ブライトパス・バイオ株式会社 |
抗Tim-3抗原抗体または抗体誘導体およびその用途
|
CA3226281A1
(en)
|
2021-07-30 |
2023-02-02 |
ONA Therapeutics S.L. |
Anti-cd36 antibodies and their use to treat cancer
|
CA3226428A1
(en)
|
2021-08-02 |
2023-02-09 |
Hangzhou Unogen Biotech, Ltd |
Anti-cd38 antibodies, anti-cd3 antibodies, and bispecific antibodies, and uses thereof
|
WO2023015169A1
(en)
|
2021-08-02 |
2023-02-09 |
Tavotek Biotech (Suzhou) Ltd |
Anti-cdh17 monoclonal and bispecific antibodies and uses thereof
|
US11807685B2
(en)
|
2021-08-05 |
2023-11-07 |
The Uab Research Foundation |
Anti-CD47 antibody and uses thereof
|
CA3228178A1
(en)
|
2021-08-05 |
2023-02-09 |
Go Therapeutics, Inc. |
Anti-glyco-muc4 antibodies and their uses
|
IL310535A
(en)
|
2021-08-10 |
2024-03-01 |
Byomass Inc |
Anti-GDF15 antibodies, compositions and uses thereof
|
WO2023025927A1
(en)
|
2021-08-26 |
2023-03-02 |
Glycanostics S.R.O |
Glycoprotein biomarkers for diagnosing cancer
|
WO2023027164A1
(ja)
|
2021-08-26 |
2023-03-02 |
株式会社ペルセウスプロテオミクス |
Ros(活性酸素種)産生増強剤
|
TW202323289A
(zh)
|
2021-08-31 |
2023-06-16 |
日商大正製藥股份有限公司 |
抗生長激素抗體
|
WO2023034777A1
(en)
|
2021-08-31 |
2023-03-09 |
Abbott Laboratories |
Methods and systems of diagnosing brain injury
|
AU2022339667A1
(en)
|
2021-09-03 |
2024-04-11 |
Go Therapeutics, Inc. |
Anti-glyco-cmet antibodies and their uses
|
CA3230933A1
(en)
|
2021-09-03 |
2023-03-09 |
Go Therapeutics, Inc. |
Anti-glyco-lamp1 antibodies and their uses
|
WO2023031881A1
(en)
|
2021-09-03 |
2023-03-09 |
University Of Bern |
Compositions and methods for treating long qt syndrome
|
EP4144898A1
(de)
|
2021-09-07 |
2023-03-08 |
New/era/mabs GmbH |
Verfahren zur selektion oder screenen von antikörpern aus einer antikörperbibliothek
|
WO2023041565A1
(en)
|
2021-09-14 |
2023-03-23 |
Glycanostics S.R.O |
Use of lectins to determine mammaglobin-a glycoforms in breast cancer
|
WO2023042097A1
(en)
|
2021-09-15 |
2023-03-23 |
Daiichi Sankyo Company, Limited |
Antibody-drug conjugate for use in methods of treating chemotherapy-resistant cancer
|
WO2023044483A2
(en)
|
2021-09-20 |
2023-03-23 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
CA3232420A1
(en)
|
2021-09-20 |
2023-03-23 |
Alnylam Pharmaceuticals, Inc. |
Inhibin subunit beta e (inhbe) modulator compositions and methods of use thereof
|
WO2023056268A1
(en)
|
2021-09-30 |
2023-04-06 |
Abbott Laboratories |
Methods and systems of diagnosing brain injury
|
WO2023057871A1
(en)
|
2021-10-04 |
2023-04-13 |
Novartis Ag |
Surfactant stabilizers
|
TW202333781A
(zh)
|
2021-10-08 |
2023-09-01 |
日商中外製藥股份有限公司 |
抗hla-dq2﹒5抗體製劑
|
AU2022362681A1
(en)
|
2021-10-14 |
2024-04-04 |
F. Hoffmann-La Roche Ag |
New interleukin-7 immunoconjugates
|
WO2023062048A1
(en)
|
2021-10-14 |
2023-04-20 |
F. Hoffmann-La Roche Ag |
Alternative pd1-il7v immunoconjugates for the treatment of cancer
|
WO2023069888A1
(en)
|
2021-10-18 |
2023-04-27 |
Tavotek Biotherapeutics (Hong Kong) Limited |
ANTI-EGFR ANTIBODIES, ANTI-cMET ANTIBODIES, ANTI-VEGF ANTIBODIES, MULTISPECIFIC ANTIBODIES, AND USES THEREOF
|
WO2023069421A1
(en)
|
2021-10-18 |
2023-04-27 |
Byomass Inc. |
Anti-activin a antibodies, compositions and uses thereof
|
US20230134748A1
(en)
|
2021-11-03 |
2023-05-04 |
Janssen Biotech, Inc. |
Corticosteriod Reduction in Treatment with Anti-CD38 Antibody
|
EP4177266A1
(de)
|
2021-11-05 |
2023-05-10 |
Katholieke Universiteit Leuven |
Neutralisierende humane anti-sars-cov-2-antikörper
|
WO2023088959A1
(en)
|
2021-11-16 |
2023-05-25 |
Ac Immune Sa |
Novel molecules for therapy and diagnosis
|
WO2023090361A1
(ja)
|
2021-11-16 |
2023-05-25 |
国立大学法人鳥取大学 |
改変d領域を含むヒト免疫グロブリン重鎖遺伝子座を有する哺乳動物人工染色体ベクター、及びそのベクターを保持する細胞又は非ヒト動物
|
WO2023092004A1
(en)
|
2021-11-17 |
2023-05-25 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of tau-related disorders
|
US20230312743A1
(en)
|
2021-11-19 |
2023-10-05 |
Mirobio Limited |
Engineered pd-1 antibodies and uses thereof
|
US20230348614A1
(en)
|
2021-11-24 |
2023-11-02 |
Visterra, Inc. |
Engineered antibody molecules to cd138 and uses thereof
|
WO2023094569A1
(en)
|
2021-11-26 |
2023-06-01 |
F. Hoffmann-La Roche Ag |
Combination therapy of anti-tyrp1/anti-cd3 bispecific antibodies and tyrp1-specific antibodies
|
WO2023097119A2
(en)
|
2021-11-29 |
2023-06-01 |
Dana-Farber Cancer Institute, Inc. |
Methods and compositions to modulate riok2
|
TW202333772A
(zh)
|
2021-12-01 |
2023-09-01 |
美商威特拉公司 |
使用介白素-2藥劑之方法
|
US20230183360A1
(en)
|
2021-12-09 |
2023-06-15 |
Janssen Biotech, Inc. |
Use of Amivantamab to Treat Colorectal Cancer
|
GB202117928D0
(en)
|
2021-12-11 |
2022-01-26 |
Cancer Research Tech Ltd |
Immunotherapy for cancer
|
WO2023114978A1
(en)
|
2021-12-17 |
2023-06-22 |
Abbott Laboratories |
Systems and methods for determining uch-l1, gfap, and other biomarkers in blood samples
|
WO2023122213A1
(en)
|
2021-12-22 |
2023-06-29 |
Byomass Inc. |
Targeting gdf15-gfral pathway cross-reference to related applications
|
WO2023118508A1
(en)
|
2021-12-23 |
2023-06-29 |
Bavarian Nordic A/S |
Recombinant mva viruses for intraperitoneal administration for treating cancer
|
WO2023129942A1
(en)
|
2021-12-28 |
2023-07-06 |
Abbott Laboratories |
Use of biomarkers to determine sub-acute traumatic brain injury (tbi) in a subject having received a head computerized tomography (ct) scan that is negative for a tbi or no head ct scan
|
WO2023139293A1
(en)
|
2022-01-24 |
2023-07-27 |
Novimmune Sa |
Composition and methods for the selective activation of cytokine signaling pathways
|
WO2023144303A1
(en)
|
2022-01-31 |
2023-08-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Cd38 as a biomarker and biotarget in t-cell lymphomas
|
WO2023147107A1
(en)
|
2022-01-31 |
2023-08-03 |
Byomass Inc. |
Myeloproliferative conditions
|
WO2023150652A1
(en)
|
2022-02-04 |
2023-08-10 |
Abbott Laboratories |
Lateral flow methods, assays, and devices for detecting the presence or measuring the amount of ubiquitin carboxy-terminal hydrolase l1 and/or glial fibrillary acidic protein in a sample
|
US20230383010A1
(en)
|
2022-02-07 |
2023-11-30 |
Visterra, Inc. |
Anti-idiotype antibody molecules and uses thereof
|
TW202342057A
(zh)
|
2022-02-07 |
2023-11-01 |
美商健生生物科技公司 |
用於減少用egfr/met雙特異性抗體治療之患者的輸注相關反應之方法
|
WO2023154305A2
(en)
|
2022-02-10 |
2023-08-17 |
Amgen Inc. |
Antibody protein product expression constructs for high throughput sequencing
|
TW202342519A
(zh)
|
2022-02-16 |
2023-11-01 |
瑞士商Ac 免疫有限公司 |
人源化抗tdp-43結合分子及其用途
|
WO2023166081A1
(en)
|
2022-03-02 |
2023-09-07 |
Heidelberg Immunotherapeutics Gmbh |
Vaccine comprising an antibody or an fc-containing fusion protein comprising an fc part of an antibody
|
US20240002544A1
(en)
|
2022-03-07 |
2024-01-04 |
Novimmune Sa |
Cd28 bispecific antibodies for targeted t cell activation
|
WO2023169896A1
(en)
|
2022-03-09 |
2023-09-14 |
Astrazeneca Ab |
BINDING MOLECULES AGAINST FRα
|
WO2023170216A1
(en)
|
2022-03-11 |
2023-09-14 |
Astrazeneca Ab |
A SCORING METHOD FOR AN ANTI-FRα ANTIBODY-DRUG CONJUGATE THERAPY
|
WO2023175035A1
(en)
|
2022-03-15 |
2023-09-21 |
Adrenomed Ag |
Stable aqueous formulation of an anti-adrenomedullin (adm) antibody or anti-adm antibody fragment
|
WO2023175171A1
(en)
|
2022-03-18 |
2023-09-21 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Bk polyomavirus antibodies and uses thereof
|
TW202402794A
(zh)
|
2022-03-28 |
2024-01-16 |
瑞士商赫孚孟拉羅股份公司 |
經改良的folr1蛋白酶可活化之t細胞雙特異性抗體
|
WO2023192436A1
(en)
|
2022-03-31 |
2023-10-05 |
Alexion Pharmaceuticals, Inc. |
Singleplex or multiplexed assay for complement markers in fresh biological samples
|
US20230416361A1
(en)
|
2022-04-06 |
2023-12-28 |
Mirobio Limited |
Engineered cd200r antibodies and uses thereof
|
US20230355792A1
(en)
|
2022-04-07 |
2023-11-09 |
Heidelberg Pharma Research Gmbh |
Methods of improving the therapeutic index
|
GB202205203D0
(en)
|
2022-04-08 |
2022-05-25 |
UCB Biopharma SRL |
Combination with inhibitor
|
GB202205200D0
(en)
|
2022-04-08 |
2022-05-25 |
Ucb Biopharma Sprl |
Combination with chemotherapy
|
WO2023194565A1
(en)
|
2022-04-08 |
2023-10-12 |
Ac Immune Sa |
Anti-tdp-43 binding molecules
|
WO2023201201A1
(en)
|
2022-04-10 |
2023-10-19 |
Immunomic Therapeutics, Inc. |
Bicistronic lamp constructs comprising immune response enhancing genes and methods of use thereof
|
WO2023203177A1
(en)
|
2022-04-20 |
2023-10-26 |
Kantonsspital St. Gallen |
Antibodies or antigen-binding fragments pan-specifically binding to gremlin-1 and gremlin-2 and uses thereof
|
US20240092921A1
(en)
|
2022-04-25 |
2024-03-21 |
Visterra, Inc. |
Antibody molecules to april and uses thereof
|
TW202400658A
(zh)
|
2022-04-26 |
2024-01-01 |
瑞士商諾華公司 |
靶向il—13和il—18的多特異性抗體
|
WO2023209177A1
(en)
|
2022-04-29 |
2023-11-02 |
Astrazeneca Uk Limited |
Sars-cov-2 antibodies and methods of using the same
|
WO2023215498A2
(en)
|
2022-05-05 |
2023-11-09 |
Modernatx, Inc. |
Compositions and methods for cd28 antagonism
|
WO2023220695A2
(en)
|
2022-05-13 |
2023-11-16 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
WO2023228095A1
(en)
|
2022-05-24 |
2023-11-30 |
Daiichi Sankyo Company, Limited |
Dosage regimen of an anti-cdh6 antibody-drug conjugate
|
WO2023240124A1
(en)
|
2022-06-07 |
2023-12-14 |
Regeneron Pharmaceuticals, Inc. |
Pseudotyped viral particles for targeting tcr-expressing cells
|
WO2023245097A2
(en)
|
2022-06-16 |
2023-12-21 |
Cephalon Llc |
Anti-pd-1 antibody-attenuated il-2 immunoconjugates and uses thereof
|
EP4296279A1
(de)
|
2022-06-23 |
2023-12-27 |
Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. |
Anti-transthyretin(ttr)-bindende proteine und ihre verwendungen
|
GB202209501D0
(en)
|
2022-06-29 |
2022-08-10 |
Plant Bioscience Ltd |
Biosynthetic enzymes
|
WO2024006876A1
(en)
|
2022-06-29 |
2024-01-04 |
Abbott Laboratories |
Magnetic point-of-care systems and assays for determining gfap in biological samples
|
WO2024003837A1
(en)
|
2022-06-30 |
2024-01-04 |
Janssen Biotech, Inc. |
Use of anti-egfr/anti-met antibody to treat gastric or esophageal cancer
|
WO2024006961A1
(en)
|
2022-07-01 |
2024-01-04 |
Neoleukin Therapeutics, Inc. |
Neo-2/15 variants and uses thereof for preferentially stimulating t-regulatory cells
|
WO2024008891A1
(en)
|
2022-07-07 |
2024-01-11 |
Cambridge Enterprise Limited |
Methods for mapping binding sites of compounds
|
WO2024015953A1
(en)
|
2022-07-15 |
2024-01-18 |
Danisco Us Inc. |
Methods for producing monoclonal antibodies
|
WO2024013727A1
(en)
|
2022-07-15 |
2024-01-18 |
Janssen Biotech, Inc. |
Material and methods for improved bioengineered pairing of antigen-binding variable regions
|
WO2024023368A1
(en)
|
2022-07-29 |
2024-02-01 |
4TEEN4 Pharmaceuticals GmbH |
Prediction of an increase of dpp3 in a patient with septic shock
|
WO2024023369A1
(en)
|
2022-07-29 |
2024-02-01 |
Adrenomed Ag |
Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy or prevention of shock
|
WO2024030976A2
(en)
|
2022-08-03 |
2024-02-08 |
Voyager Therapeutics, Inc. |
Compositions and methods for crossing the blood brain barrier
|
WO2024050354A1
(en)
|
2022-08-31 |
2024-03-07 |
Washington University |
Alphavirus antigen binding antibodies and uses thereof
|
WO2024050524A1
(en)
|
2022-09-01 |
2024-03-07 |
University Of Georgia Research Foundation, Inc. |
Compositions and methods for directing apolipoprotein l1 to induce mammalian cell death
|
WO2024050526A1
(en)
|
2022-09-02 |
2024-03-07 |
Biomarin Pharmaceutical Inc. |
Compositions and methods for treating long qt syndrome
|
WO2024054436A1
(en)
|
2022-09-06 |
2024-03-14 |
Alexion Pharmaceuticals, Inc. |
Diagnostic and prognostic biomarker profiles in patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy (hsct-tma)
|
WO2024052503A1
(en)
|
2022-09-08 |
2024-03-14 |
Institut National de la Santé et de la Recherche Médicale |
Antibodies having specificity to ltbp2 and uses thereof
|
WO2024056668A1
(en)
|
2022-09-12 |
2024-03-21 |
Institut National de la Santé et de la Recherche Médicale |
New anti-itgb8 antibodies and its uses thereof
|
WO2024059708A1
(en)
|
2022-09-15 |
2024-03-21 |
Abbott Laboratories |
Biomarkers and methods for differentiating between mild and supermild traumatic brain injury
|
WO2024062038A1
(en)
|
2022-09-21 |
2024-03-28 |
Elthera Ag |
Novel binding molecules binding to l1cam
|
WO2024068572A1
(en)
|
2022-09-28 |
2024-04-04 |
F. Hoffmann-La Roche Ag |
Improved protease-activatable t cell bispecific antibodies
|
WO2024068705A1
(en)
|
2022-09-29 |
2024-04-04 |
F. Hoffmann-La Roche Ag |
Protease-activated polypeptides
|
EP4345109A1
(de)
|
2022-09-30 |
2024-04-03 |
AdrenoMed AG |
Anti-adrenomedullin (adm)-bindemittel zur verwendung bei der behandlung von pädiatrischen patienten mit angeborener herzerkrankung
|